"ID","URL","PDF","Country","Province","Date","Completion","Trial status","Design","Blinding","Arms","COVID-19 status","Severity","Patient setting","Outcome","Treatment","Size"
"JPRN-UMIN000040479","https://rctportal.niph.go.jp/en/detail?trial_id=UMIN000040479",NA,"Japan","Tokyo","2020-May",NA,"Recruiting","Unspecified","Open-Label",NA,"Healthy","None","Unclear",NA,"Other",30
"CTRI/2020/04/024773","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42897",NA,"Argentina","Buenos Aires","2020-Apr",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ, LPV/r, Remdesivir, SOC",7000
"CTRI/2020/04/024773","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42897",NA,"Brazil","Brasilia","2020-Apr",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ, LPV/r, Remdesivir, SOC",7000
"CTRI/2020/04/024773","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42897",NA,"Canada","Ottawa","2020-Apr",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ, LPV/r, Remdesivir, SOC",7000
"CTRI/2020/04/024773","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42897",NA,"Germany","Berlin","2020-Apr",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ, LPV/r, Remdesivir, SOC",7000
"CTRI/2020/04/024773","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42897",NA,"India","New Delhi","2020-Apr",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ, LPV/r, Remdesivir, SOC",7000
"CTRI/2020/04/024773","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42897",NA,"Indonesia","Jakarta","2020-Apr",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ, LPV/r, Remdesivir, SOC",7000
"CTRI/2020/04/024773","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42897",NA,"Iran","Tehran","2020-Apr",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ, LPV/r, Remdesivir, SOC",7000
"CTRI/2020/04/024773","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42897",NA,"Norway","Oslo","2020-Apr",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ, LPV/r, Remdesivir, SOC",7000
"CTRI/2020/04/024773","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42897",NA,"Peru","Lima","2020-Apr",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ, LPV/r, Remdesivir, SOC",7000
"CTRI/2020/04/024773","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42897",NA,"Qatar","Doha","2020-Apr",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ, LPV/r, Remdesivir, SOC",7000
"CTRI/2020/04/024773","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42897",NA,"South Africa","Pretoria","2020-Apr",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ, LPV/r, Remdesivir, SOC",7000
"CTRI/2020/04/024773","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42897",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ, LPV/r, Remdesivir, SOC",7000
"CTRI/2020/04/024773","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42897",NA,"Switzerland","Bern","2020-Apr",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ, LPV/r, Remdesivir, SOC",7000
"CTRI/2020/04/024773","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42897",NA,"Thailand","Nan","2020-Apr",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ, LPV/r, Remdesivir, SOC",7000
"IRCT20200418047126N1","http://en.irct.ir/trial/47707",NA,"Iran","Tehran","2020-May","2020-Jun","Recruiting","Randomised","Single",2,"Confirmed","Unclear","Hospital","Hospitalization, Fever","HCQ, HCQ + Colchicine",100
"IRCT20190810044500N5","http://en.irct.ir/trial/46867",NA,"Iran","Tehran","2020-May","2021-Feb","Recruiting","Randomised","Double",2,"Confirmed","Unclear","Outpatient, Hospital","Mortality, Hospitalization, Hospital Discharge, Cough, Fever, Dyspnea, C-Reactive Protein, Ferritin, Platelet Count, Erythrocyte Sedimentation Rate, D-Dimer, LDH, SpO2","Colchicine, HCQ + Colchicine",200
"NCT04381923","https://ClinicalTrials.gov/show/NCT04381923",NA,"United States","Pennsylvania","2020-May","2020-Aug","Not Recruiting","Randomised","Single",2,"Confirmed","Unclear","Hospital, ICU","Mortality, ICU Admission, Dyspnea, Renal Outcome (Unspecified)","Non-invasive respiratory support",200
"IRCT20200428047228N1","http://en.irct.ir/trial/47559",NA,"Iran","Tehran","2020-May","2020-Jun","Recruiting","Randomised","Double",2,"Confirmed","Unclear","Hospital","Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, SpO2","HCQ, HCQ + FPV",50
"IRCT20190418043307N1","http://en.irct.ir/trial/47209",NA,"Iran","Tehran","2020-May","2020-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Mortality, C-Reactive Protein, Ferritin, White Blood Cell Count, Platelet Count","HCQ, HCQ + Other",100
"IRCT20180425039414N2","http://en.irct.ir/trial/47516",NA,"Iran","Tehran","2020-May","2020-May","Completed","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Hospitalization, Cough, Fever, Dyspnea, SpO2","HCQ, HCQ + Zinc",80
"IRCT20200506047323N1","http://en.irct.ir/trial/48114",NA,"Iran","Tehran","2020-May","2020-Aug","Recruiting","Randomised","Double",2,"Confirmed","Moderate","Hospital","Fever, Serious Adverse Events, C-Reactive Protein, SpO2, Respiratory Rate","Alternative therapy + HCQ, HCQ",84
"EUCTR2020-001448-24-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001448-24",NA,"Ghana","Accra","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",4,"Healthy, Confirmed","Healthy, Asymptomatic","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Serious Adverse Events, ALT","HCQ, LPV/r, SOC",6400
"EUCTR2020-001448-24-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001448-24",NA,"Nigeria","Niger","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",4,"Healthy, Confirmed","Healthy, Asymptomatic","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Serious Adverse Events, ALT","HCQ, LPV/r, SOC",6400
"EUCTR2020-001448-24-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001448-24",NA,"South Africa","Pretoria","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",4,"Healthy, Confirmed","Healthy, Asymptomatic","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Serious Adverse Events, ALT","HCQ, LPV/r, SOC",6400
"EUCTR2020-001448-24-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001448-24",NA,"United Kingdom","London","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",4,"Healthy, Confirmed","Healthy, Asymptomatic","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Serious Adverse Events, ALT","HCQ, LPV/r, SOC",6400
"EUCTR2020-001448-24-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001448-24",NA,"India","New Delhi","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",4,"Healthy, Confirmed","Healthy, Asymptomatic","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Serious Adverse Events, ALT","HCQ, LPV/r, SOC",6400
"NL8523","https://trialregister.nl/trial/8523",NA,"Netherlands","Amsterdam","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed, Suspected","Severe","ICU","ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, PaO2-FiO2, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Anesthetic",20
"NCT04398147","https://ClinicalTrials.gov/show/NCT04398147",NA,"Canada","Ottawa","2020-May","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","None","Healthy Unexposed","Adverse Events, Serious Adverse Events, Anti SARS-COV-2 Titers, IL-2, Tumor Necrosis Factor (Any), Interferon (Any), Lymphocyte Count, IgG, IgM or IgA, Antibodies","SOC, Vaccine",696
"2020-001684-89","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001684-89/GB/",NA,"United Kingdom","London","2020-Apr",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Serious or Seconday Infections, Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, Neutrophils, D-Dimer, Triglycerides, LDH, PaO2-FiO2, SpO2, Respiratory Rate","mAb, Other",NA
"NCT04382729","https://ClinicalTrials.gov/show/NCT04382729",NA,"Italy","Rome","2020-May","2020-Jul","Recruiting","Randomised","Single",2,"Confirmed","Unclear","Hospital","Clinical Improvement Score (Any), Other Mild Symptoms, 6-Minute Walking Distance, Quality of Life","Exercise, Other",80
"2020-001354-22","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001354-22/GB/",NA,"United Kingdom","London","2020-Apr",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Unclear","Hospital","Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Renal Outcome (Unspecified)","JAKi, mAb, SOC",NA
"JPRN-JRCT2031200035","https://rctportal.niph.go.jp/en/detail?trial_id=JRCT2031200035",NA,"United States","Washington, Dc","2020-May",NA,"Not Recruiting","Randomised","Unspecified",NA,"Confirmed Or Suspected","Unclear","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",35
"JPRN-JRCT2031200035","https://rctportal.niph.go.jp/en/detail?trial_id=JRCT2031200035",NA,"Japan","Tokyo","2020-May",NA,"Not Recruiting","Randomised","Unspecified",NA,"Confirmed Or Suspected","Unclear","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",35
"JPRN-JRCT2031200035","https://rctportal.niph.go.jp/en/detail?trial_id=JRCT2031200035",NA,"Japan","Toyama","2020-May",NA,"Not Recruiting","Randomised","Unspecified",NA,"Confirmed Or Suspected","Unclear","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",35
"2020-001357-52","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001357-52/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Double",2,"Healthy","Healthy","Healthy Unexposed","Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Distress","HCQ, SOC",NA
"NCT04392128","https://ClinicalTrials.gov/show/NCT04392128",NA,"France","Paris","2020-May","2020-Dec","Not Recruiting","Randomised","Quadruple",4,"Confirmed","Non-severe","Outpatient","Mortality, Viral Load or Clearance, Cough, Fever, Dyspnea, Anti SARS-COV-2 Titers","HCQ + AZT, SOC",114
"2020-001700-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001700-42/FR/",NA,"France","Paris","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Cough, SpO2, Renal Outcome (Unspecified)","ACEi, SOC",NA
"NCT04395976","https://ClinicalTrials.gov/show/NCT04395976",NA,"United Kingdom","London","2020-May","2020-Sep","Not Recruiting","Randomised","Open-Label",2,"Suspected","None","Healthy Exposed","Viral Load or Clearance","Alternative therapy, SOC",120
"IRCT20080901001165N56","http://en.irct.ir/trial/48116",NA,"Iran","Tehran","2020-May","2020-Jul","Recruiting","Randomised","Open-Label",2,"Confirmed","Moderate","Hospital","Cough, Fever, Dyspnea, Adverse Events","Alternative therapy, SOC",60
"IRCT20200405046960N2","http://en.irct.ir/trial/48126",NA,"Iran","Tehran","2020-May","2020-Jul","Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Moderate/Severe","Hospital","Cough, Fever, C-Reactive Protein, White Blood Cell Count, Lymphocyte Count, SpO2, Respiratory Rate","Alternative therapy, SOC",60
"IRCT20200518047497N1","http://en.irct.ir/trial/48289",NA,"Iran","East Azarbaijan","2020-May","2020-Jul","Recruiting","Randomised","Triple",2,"Confirmed Or Suspected","Unclear","Hospital","Mortality, Hospitalization, Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein, White Blood Cell Count, SpO2, Respiratory Rate, Radiographic Findings","Alternative therapy, SOC",80
"IRCT20200506047319N1","http://en.irct.ir/trial/48095",NA,"Iran","Zanjan","2020-May","2020-Jul","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Cough, Fever, Dyspnea, Other Mild Symptoms","Alternative therapy, SOC",100
"IRCT20081019001369N6","http://en.irct.ir/trial/47188",NA,"Iran","Tehran","2020-May","2020-Oct","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Moderate/Severe","Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), PaO2-FiO2","Alternative therapy, SOC",30
"NCT04392453","https://clinicaltrials.gov/show/NCT04392453",NA,"Italy","Milano","2020-May",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Healthy","None","Hospital",NA,"Device",40
"2020-001994-66","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001994-66/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Double",2,"Confirmed, Healthy","Unclear, Healthy","Healthy Exposed, Outpatient","Mortality, Viral Load or Clearance, Household Members with CoViD-19, Anti SARS-COV-2 Titers","Ivermectin, SOC",NA
"2020-001474-29","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001474-29/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Double",2,"Confirmed","Unclear","Outpatient","Mortality, Viral Load or Clearance, Cough, Fever, Adverse Events, IgG, IgM or IgA","Ivermectin, SOC",NA
"NCT04377711","https://ClinicalTrials.gov/show/NCT04377711",NA,"Switzerland","Zug","2020-May","2020-Sep","Not Recruiting","Randomised","Double",2,"Confirmed","Unclear","Outpatient","Mortality, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events, SpO2","Corticosteroids, SOC",400
"CHICTR2000032769","http://www.chictr.org.cn/showproj.aspx?proj=53368",NA,"China","Beijing","2020-May",NA,"Recruiting","Randomised","Double",2,"Confirmed","Mild/Moderate/Severe","Unclear","Viral Load or Clearance, Non-invasive Ventilation, Cough, Fever, Other Mild Symptoms, Adverse Events, Radiographic Findings","DAA, SOC",342
"NCT04397718","https://ClinicalTrials.gov/show/NCT04397718",NA,"United States","California","2020-May","2020-Oct","Not Recruiting","Randomised","Double",2,"Confirmed","Moderate/Severe","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever","Hormone therapy, SOC",198
"NCT04397718","https://ClinicalTrials.gov/show/NCT04397718",NA,"United States","New York","2020-May","2020-Oct","Not Recruiting","Randomised","Double",2,"Confirmed","Moderate/Severe","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever","Hormone therapy, SOC",198
"NCT04397718","https://ClinicalTrials.gov/show/NCT04397718",NA,"United States","Washington","2020-May","2020-Oct","Not Recruiting","Randomised","Double",2,"Confirmed","Moderate/Severe","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever","Hormone therapy, SOC",198
"NCT04382131","https://clinicaltrials.gov/show/NCT04382131",NA,"United Kingdom","London","2020-Aug",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed, Suspected","Unclear","Outpatient","Hospitalization, Clinical Improvement Score (Any), Other Mild Symptoms, Adverse Events","Hygiene, SOC",405
"NCT04379271","https://ClinicalTrials.gov/show/NCT04379271",NA,"United States","New York","2020-May","2020-Oct","Not Recruiting","Randomised","Double",2,"Confirmed","Moderate","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, C-Reactive Protein, Tumor Necrosis Factor (Any), Interferon (Any), D-Dimer, Weight, Height or BMI, Troponin, Procalcitonin, LDH, IgG, IgM or IgA, Antibodies, Blood Pressure, Heart Rate, ECG, SpO2, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Immunomodulators, SOC",230
"NCT04391309","https://ClinicalTrials.gov/show/NCT04391309",NA,"United States","Washington","2020-May","2021-Jul","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear","Hospital","Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein","mAb, SOC",300
"NCT04397562","https://ClinicalTrials.gov/show/NCT04397562",NA,"Russia","Moscow","2020-May","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality","mAb, SOC",204
"NCT04397497","https://clinicaltrials.gov/show/NCT04397497",NA,"Italy","Rome","2020-May",NA,"Not Recruiting","Randomised","Quadruple",1,"Confirmed","Severe","Hospital","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Anti SARS-COV-2 Titers, IL-1, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Hemoglobin, PaO2-FiO2, SpO2, Radiographic Findings","mAb, SOC",50
"NCT04376684","https://ClinicalTrials.gov/show/NCT04376684",NA,"United Kingdom","London","2020-May","2020-Dec","Not Recruiting","Randomised","Double",3,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events","mAb, SOC",800
"2020-001759-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001759-42/ES/",NA,"France","Paris","2020-May",NA,"Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events","mAb, SOC",800
"2020-001759-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001759-42/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events","mAb, SOC",800
"2020-001759-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001759-42/ES/",NA,"United Kingdom","London","2020-May",NA,"Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events","mAb, SOC",800
"2020-001759-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001759-42/ES/",NA,"United States","Washington, Dc","2020-May",NA,"Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events","mAb, SOC",800
"NCT04398290","https://ClinicalTrials.gov/show/NCT04398290",NA,"United States","Florida","2020-May","2021-Jan","Not Recruiting","Randomised","Double",3,"Confirmed","Mild/Moderate","Hospital","Mortality, Hospitalization, Adverse Events, Hemoglobin, Hypoxemia","Non-invasive respiratory support, SOC",30
"NCT04397692","https://ClinicalTrials.gov/show/NCT04397692",NA,"United States","Arkansas","2020-May","2020-Aug","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, SpO2","Non-invasive respiratory support, SOC",20
"2020-001203-16","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001203-16/GB/",NA,"United Kingdom","London","2020-Apr",NA,"Recruiting","Randomised","Single",2,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, SpO2","NSAIDs, SOC",NA
"NL8578","https://trialregister.nl/trial/8578",NA,"Netherlands","Amsterdam","2020-Feb",NA,"Not Recruiting","Randomised","Double",2,"Confirmed, Suspected","Severe","ICU","Mortality, Invasive Mechanical Ventilation or ECMO, Adverse Events, IL-6, IL-8, IL-10, Tumor Necrosis Factor (Any), Renal Outcome (Unspecified)","Other, SOC",124
"NCT04396106","https://ClinicalTrials.gov/show/NCT04396106",NA,"United States","California","2020-May","2020-Jul","Not Recruiting","Randomised","Triple",2,"Confirmed","Moderate","Hospital","Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate","Other, SOC",180
"NCT04396106","https://ClinicalTrials.gov/show/NCT04396106",NA,"United States","Illinois","2020-May","2020-Jul","Not Recruiting","Randomised","Triple",2,"Confirmed","Moderate","Hospital","Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate","Other, SOC",180
"NCT04396106","https://ClinicalTrials.gov/show/NCT04396106",NA,"United States","Maryland","2020-May","2020-Jul","Not Recruiting","Randomised","Triple",2,"Confirmed","Moderate","Hospital","Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate","Other, SOC",180
"NCT04396106","https://ClinicalTrials.gov/show/NCT04396106",NA,"United States","Massachusetts","2020-May","2020-Jul","Not Recruiting","Randomised","Triple",2,"Confirmed","Moderate","Hospital","Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate","Other, SOC",180
"NCT04396106","https://ClinicalTrials.gov/show/NCT04396106",NA,"United States","Missouri","2020-May","2020-Jul","Not Recruiting","Randomised","Triple",2,"Confirmed","Moderate","Hospital","Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate","Other, SOC",180
"NCT04396106","https://ClinicalTrials.gov/show/NCT04396106",NA,"United States","Ohio","2020-May","2020-Jul","Not Recruiting","Randomised","Triple",2,"Confirmed","Moderate","Hospital","Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate","Other, SOC",180
"NCT04396106","https://ClinicalTrials.gov/show/NCT04396106",NA,"United States","South Carolina","2020-May","2020-Jul","Not Recruiting","Randomised","Triple",2,"Confirmed","Moderate","Hospital","Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate","Other, SOC",180
"2020-001502-38","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001502-38/GB/",NA,"United Kingdom","London","2020-Apr",NA,"Recruiting","Randomised","Double",2,"Confirmed","Unclear","Hospital","Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, C-Reactive Protein, Ferritin, IL-6, IL-10, Tumor Necrosis Factor (Any)","Other, SOC",NA
"2020-001493-29","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001493-29/DE/",NA,"Germany","Berlin","2020-Apr",NA,"Recruiting","Randomised","Double",2,"Confirmed","Unclear","Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, Monocyte Count, Neutrophils, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Glucose, ECG","Other, SOC",NA
"NCT04382053","https://ClinicalTrials.gov/show/NCT04382053",NA,"Denmark","Copenhagen","2020-May","2020-Jul","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Quality of Life","Other, SOC",120
"IRCT20200502047268N1","http://en.irct.ir/trial/47692",NA,"Iran","Tehran","2020-May","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Lymphocyte Count","Other, SOC",10
"NCT04382924","https://clinicaltrials.gov/show/NCT04382924",NA,"Canada","British Columbia","2020-Aug",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, SpO2, Quality of Life","Other, SOC",462
"NCT04382651","https://ClinicalTrials.gov/show/NCT04382651",NA,"United States","Massachusetts","2020-May","2020-Jul","Not Recruiting","Randomised","Double",2,"Confirmed","Unclear","Hospital","Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Ferritin, Quality of Life","Other, SOC",120
"IRCT20151226025699N3","http://en.irct.ir/trial/48213",NA,"Iran","Razavi Khorasan","2020-May","2020-Jun","Not Recruiting","Randomised","Triple",2,"Confirmed Or Suspected","Severe","ICU","C-Reactive Protein, White Blood Cell Count, Lymphocyte Count, Neutrophils, Creatinine Phosphokinase, LDH","Other, SOC",50
"2020-001598-66","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001598-66/FR/",NA,"France","Paris","2020-Apr",NA,"Recruiting","Randomised","Single",2,"Confirmed","Severe","ICU","Mortality, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, SpO2, Radiographic Findings","Other, SOC",20
"NCT04375046","https://ClinicalTrials.gov/show/NCT04375046",NA,"Egypt","Cairo","2020-May","2020-Sep","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Unclear","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Fever, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, IL-8, Tumor Necrosis Factor (Any), PAI-1, von Wildebrandt Factor, Lymphocyte Count, Angiotensins, ACE, ACE-II, Surfactant Factor Protein, SRAGE, PaO2-FiO2, Radiographic Findings","Other, SOC",24
"JPRN-JRCTS061200002","https://rctportal.niph.go.jp/en/detail?trial_id=JRCTS061200002",NA,"Japan","Okayama","2020-May",NA,"Recruiting","Randomised","Unspecified",NA,"Confirmed Or Suspected","Unclear","Unclear","Mortality, Fever, Adverse Events","Other, SOC",100
"NCT04382755","https://ClinicalTrials.gov/show/NCT04382755",NA,"Belgium","Brussels","2020-May","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, D-Dimer, PaO2-FiO2, Radiographic Findings, Hypoxia, Distress","Other, SOC",81
"NCT04383535","https://ClinicalTrials.gov/show/NCT04383535",NA,"Argentina","Ciudad De Buenos Aires","2020-May","2020-Jul","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Unclear","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, Ferritin, D-Dimer, Antibodies","Plasma based therapy, SOC",333
"NCT04380935","https://clinicaltrials.gov/show/NCT04380935",NA,"Indonesia","Jakarta","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",1,"Confirmed","Severe","ICU","Mortality, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, IL-6, D-Dimer, PaO2-FiO2","Plasma based therapy, SOC",60
"IRCT20091012002582N21","http://en.irct.ir/trial/47197",NA,"Iran","Tehran","2020-May","2019-Aug","Completed","Randomised","Double",2,"Confirmed","Moderate/Severe","ICU","Blood Gas","Plasma based therapy, SOC",30
"EUCTR2020-001162-12-FR","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001162-12",NA,"France","Paris","2020-Mar",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Evidence of pneumonia","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Serious Adverse Events, ALT","Sarilumab, SOC",460
"EUCTR2020-001162-12-FR","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001162-12",NA,"Canada","Ottawa","2020-Mar",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Evidence of pneumonia","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Serious Adverse Events, ALT","Sarilumab, SOC",460
"EUCTR2020-001162-12-FR","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001162-12",NA,"Spain","Madrid","2020-Mar",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Evidence of pneumonia","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Serious Adverse Events, ALT","Sarilumab, SOC",460
"EUCTR2020-001162-12-FR","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001162-12",NA,"Russia","Moscow","2020-Mar",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Evidence of pneumonia","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Serious Adverse Events, ALT","Sarilumab, SOC",460
"EUCTR2020-001162-12-FR","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001162-12",NA,"Israel","Jerusalem","2020-Mar",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Evidence of pneumonia","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Serious Adverse Events, ALT","Sarilumab, SOC",460
"EUCTR2020-001162-12-FR","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001162-12",NA,"Germany","Berlin","2020-Mar",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Evidence of pneumonia","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Serious Adverse Events, ALT","Sarilumab, SOC",460
"EUCTR2020-001162-12-FR","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001162-12",NA,"Japan","Tokyo","2020-Mar",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Evidence of pneumonia","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Serious Adverse Events, ALT","Sarilumab, SOC",460
"EUCTR2020-001162-12-FR","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001162-12",NA,"Italy","Rome","2020-Mar",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Evidence of pneumonia","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Serious Adverse Events, ALT","Sarilumab, SOC",460
"NCT04382547","https://ClinicalTrials.gov/show/NCT04382547",NA,"Belarus","Minsk","2020-May","2021-Jun","Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events","SOC, Stem cells",40
"2020-001450-22","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001450-22/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Unclear","Mortality, Invasive Mechanical Ventilation or ECMO, Adverse Events, Ferritin, Monocyte Count, Lymphocyte Count, Neutrophils, D-Dimer, Troponin, Radiographic Findings","SOC, Stem cells",NA
"IRCT20200411047019N1","http://en.irct.ir/trial/47279",NA,"Iran","Alborz","2020-May","2021-Jun","Not Recruiting","Randomised","Double",2,"Healthy (Exposed)","None","Healthcare Workers","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Anti SARS-COV-2 Titers","SOC, Vaccine",500
"CHICTR2000032635","http://www.chictr.org.cn/showproj.aspx?proj=52671",NA,"China","Hubei","2020-May","2021-Mar","Not Recruiting","Randomised","Double",2,"Confirmed","Unclear","Outpatient","Clinical Improvement Score (Any), Viral Load or Clearance, White Blood Cell Count, Lymphocyte Count, Neutrophils, Antibodies, Radiographic Findings","TCM",60
"2020-002032-69","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002032-69/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Mild/Moderate","Hospital","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-1, IL-6, IL-10, IL-12, IL-17, D-Dimer, Procalcitonin, PaO2-FiO2, SpO2, Radiographic Findings, Quality of Life","SOC, TCZ",NA
"CHICTR2000032717","http://www.chictr.org.cn/showproj.aspx?proj=53322",NA,"China","Shaanxi","2020-May","2021-Jan","Completed","Randomised","Unspecified",6,"Confirmed","Mild/Moderate/Severe","Hospital","Viral Load or Clearance, Other Mild Symptoms, Blood Gas, Radiographic Findings","SOC, TCM, TCM + Vitamins",60
"DRKS00021248","https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00021248",NA,"Germany","Baden-Wurttemberg","2020-May",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Severe","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, IL-6, D-Dimer, Urine Sample","ECMO, ECMO + Cytokine removal",80
"NCT04398004","https://ClinicalTrials.gov/show/NCT04398004",NA,"Greece","Athens","2020-May","2022-May","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear","Unclear","Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, IL-1, IL-6, IL-8, IL-10, Tumor Necrosis Factor (Any), Monocyte Count","Antibiotics",90
"2020-001768-27","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001768-27/FR/",NA,"France","Paris","2020-Apr",NA,"Recruiting","Unspecified","Open-Label",NA,"Confirmed","Moderate/Severe","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, C-Reactive Protein, Ferritin, Lymphocyte Count, Platelet Count, LDH","Igs",NA
"IRCT20200501047259N1","http://en.irct.ir/trial/47609",NA,"Iran","Tehran","2020-May","2020-Jun","Recruiting","Single-Arm","Triple",1,"Confirmed","Unclear","Hospital, ICU","SpO2, Radiographic Findings","Igs",40
"2020-001777-71","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001777-71/GB/",NA,"United Kingdom","London","2020-Apr",NA,"Recruiting","Unspecified","Open-Label",NA,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, D-Dimer, Radiographic Findings","JAKi",NA
"IRCT20150107020592N22","http://en.irct.ir/trial/48262",NA,"Iran","Tehran","2020-May","2020-Jun","Recruiting","Single-Arm","Open-Label",1,"Confirmed Or Suspected","Severe","ICU","SpO2, Radiographic Findings","Cyclosporine",60
"NCT04363814","https://ClinicalTrials.gov/show/NCT04363814",NA,"Spain","Cordoba","2020-Apr","2020-Jul","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Mild","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events, Blood Pressure, Heart Rate, SpO2, Cardiac Outcome (Unspecified)","Other, SOC",100
"2020-001364-29","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001364-29/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Severe","Hospital, ICU","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events, Serious Adverse Events, ACE","LPV/r + HCQ, Stem cells",NA
"IRCT20101219005416N2","http://en.irct.ir/trial/46775",NA,"Iran","Kerman","2020-Apr","2020-May","Completed","Randomised","Double",2,NA,NA,"Hospital","Mortality, Hospitalization, Cough, Fever, Dyspnea, Other Mild Symptoms, SpO2, Respiratory Rate","Alternative therapy, SOC",80
"NCT04332107","https://ClinicalTrials.gov/show/NCT04332107",NA,"United States","California","2020-Apr","2020-Sep","Recruiting","Randomised","Quadruple",2,"Confirmed",NA,"Outpatient","Mortality, Hospitalization, Visits or Returns to Emergency Department, Clinical Improvement Score (Any), Viral Load or Clearance, Household Members with CoViD-19, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events","AZT, SOC",2271
"DRKS00021626","https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00021626",NA,"Germany","Berlin","2020-May",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Severe","Unclear","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Non-invasive respiratory support, SOC",200
"2020-001618-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001618-39/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Ferritin, IL-1, IL-6, Lymphocyte Count, Neutrophils, Platelet Count, D-Dimer, LDH, SpO2","Other, SOC",NA
"2020-001052-18","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001052-18/ES/",NA,"Denmark","Copenhagen","2020-Apr",NA,"Recruiting","Randomised","Double",2,"Confirmed",NA,"Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose, Renal Outcome (Unspecified)","Remdesivir, SOC",440
"2020-001052-18","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001052-18/ES/",NA,"Germany","Berlin","2020-Apr",NA,"Recruiting","Randomised","Double",2,"Confirmed",NA,"Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose, Renal Outcome (Unspecified)","Remdesivir, SOC",440
"2020-001052-18","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001052-18/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Double",2,"Confirmed",NA,"Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose, Renal Outcome (Unspecified)","Remdesivir, SOC",440
"EUCTR2020-001303-16-FR","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001303-16",NA,"France","Paris","2020-Mar",NA,"Not Recruiting","Randomised","Double",4,NA,NA,"Hospital","Mortality, ICU Admission, Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, Serious or Seconday Infections, Serious Adverse Events, C-Reactive Protein, Blood Pressure, 6-Minute Walking Distance","Alternative therapy, ARBs, AZT, HCQ",1600
"NCT04343768","https://ClinicalTrials.gov/show/NCT04343768",NA,"Iran","Tehran","2020-Apr","2020-Apr","Completed","Randomised","Open-Label",4,"Yes","Mixed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, SpO2","HCQ + LPV/r, HCQ + LPV/r + IFN",60
"NCT04343989","https://ClinicalTrials.gov/show/NCT04343989",NA,"United States","New York","2020-Apr","2020-Jul","Recruiting","Randomised","Double",3,NA,NA,"ICU","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein","Clazakizumab, SOC",90
"NCT04341389","https://ClinicalTrials.gov/show/NCT04341389",NA,"China","Hubei","2020-Apr","2021-Jan","Not Recruiting","Randomised","Double",2,NA,NA,"Healthy Unexposed","Viral Load or Clearance, Adverse Events, Serious Adverse Events, Anti SARS-COV-2 Titers, Interferon (Any), IgG, IgM or IgA, Antibodies","SOC, Vaccine",508
"JPRN-JRCTS031200026","https://rctportal.niph.go.jp/en/detail?trial_id=JRCTS031200026",NA,"Japan","Tokyo","2020-Jan",NA,"Recruiting","Randomised","Unspecified",NA,"Confirmed","Mixed","Unclear","Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, Coagulation Test, ALT, Bilirubin, Glucose, SpO2, Radiographic Findings, Renal Outcome (Unspecified)","Anticoagulants, FPV",160
"NCT04342182","https://ClinicalTrials.gov/show/NCT04342182",NA,"Netherlands","Zuid-Holland","2020-Apr","2020-Jul","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings","Plasma based therapy, SOC",426
"NCT04342182","https://ClinicalTrials.gov/show/NCT04342182",NA,"Netherlands","Amsterdam","2020-Apr","2020-Jul","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings","Plasma based therapy, SOC",426
"NCT04342182","https://ClinicalTrials.gov/show/NCT04342182",NA,"Netherlands","Groningen","2020-Apr","2020-Jul","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings","Plasma based therapy, SOC",426
"NCT04346615","https://ClinicalTrials.gov/show/NCT04346615",NA,"United States","District Of Columbia","2020-Apr","2020-Jul","Recruiting","Randomised","Quadruple",2,"Yes","Mixed","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, SpO2, Respiratory Rate, Renal Outcome (Unspecified)","SOC, Vazegepant",120
"NCT04346615","https://ClinicalTrials.gov/show/NCT04346615",NA,"United States","Pennsylvania","2020-Apr","2020-Jul","Recruiting","Randomised","Quadruple",2,"Yes","Mixed","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, SpO2, Respiratory Rate, Renal Outcome (Unspecified)","SOC, Vazegepant",120
"NCT04344041","https://ClinicalTrials.gov/show/NCT04344041",NA,"France","Paris","2020-Apr","2020-Jul","Recruiting","Randomised","Open-Label",2,NA,NA,"Unclear","Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","Vitamins",260
"2020-001823-15","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001823-15/FR/",NA,"France","Paris","2020-Apr",NA,"Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","ICU","Deep Vein Thrombosis or Pulmonary Embolism, C-Reactive Protein, D-Dimer, Fibrinogen, Renal Outcome (Unspecified)","Anticoagulants",NA
"2020-001659-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001659-42/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Dyspnea, Other Mild Symptoms, Serious or Seconday Infections, Adverse Events, Ferritin, IL-6, D-Dimer, LDH, Blood Pressure, PaO2-FiO2, SpO2, Radiographic Findings","Other",NA
"IRCT20171122037571N2","http://en.irct.ir/trial/46660",NA,"Iran","Tehran","2020-Apr","2020-May","Completed","Single-Arm","Open-Label",1,"Confirmed","Unclear","Hospital","Mortality, Clinical Improvement Score (Any), Cough, Fever, Adverse Events, PaO2-FiO2, SpO2, Respiratory Rate, Radiographic Findings","Remdesivir + Chloroqines + LPV/r or Atazanavir",120
"IRCT20200217046526N1","http://en.irct.ir/trial/47030",NA,"Iran","Tehran","2020-Apr","2020-Mar","Completed","Single-Arm","Open-Label",1,NA,NA,"Hospital, ICU","Adverse Events, SpO2","Stem cells",6
"NCT04323527","https://ClinicalTrials.gov/show/NCT04323527",NA,"Brazil","Amazonas","2020-Mar","2020-Aug","Recruiting","Randomised","Quadruple",2,"Mixed",NA,"Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, Creatinine Phosphokinase, CK-MB, Troponin, AST, Renal Outcome (Unspecified)","HCQ",440
"2020-001262-11","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001262-11/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Ferritin, IL-6, Lymphocyte Count, D-Dimer, Creatinine Phosphokinase, LDH, CD4, Blood Pressure, Renal Outcome (Unspecified)","Cyclosporine, Darunavir, HCQ, IFN, LPV/r, Other, TCZ",NA
"CHICTR2000030841","http://www.chictr.org.cn/showproj.aspx?proj=51072",NA,"China","Hubei","2020-Mar","2020-May","Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Severe","ICU","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Anti SARS-COV-2 Titers, PaO2-FiO2, Respiratory Rate, Radiographic Findings","Igs, SOC",10
"NCT04321616","https://ClinicalTrials.gov/show/NCT04321616",NA,"Norway","Oslo","2020-Mar","2020-Aug","Recruiting","Randomised","Open-Label",3,"Confirmed","Severe","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA)","HCQ, Remdesivir, SOC",700
"CHICTR2000029740","http://www.chictr.org.cn/showproj.aspx?proj=49317",NA,"China","Beijing","2020-Feb","2020-Feb","Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Unclear","Viral Load or Clearance, Fever, Serious or Seconday Infections, Lymphocyte Count, IgG, IgM or IgA, Blood Pressure, Heart Rate, Respiratory Rate, Radiographic Findings","HCQ, SOC",78
"2020-001023-14","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB/",NA,"United Kingdom","London","2020-Mar",NA,"Recruiting","Randomised","Double",2,"Confirmed",NA,"Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, Blood Pressure, Heart Rate, SpO2, Respiratory Rate","IFN, SOC",400
"2020-001530-35","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001530-35/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Double",2,NA,NA,"Healthcare Workers","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, IgG, IgM or IgA, Radiographic Findings, Distress","Melatonin, SOC",NA
"CHICTR2000030102","http://www.chictr.org.cn/showproj.aspx?proj=49747",NA,"China","Tianjin","2020-Feb","2020-May","Recruiting","Randomised","Unspecified",6,"Confirmed","Mixed","Outpatient, Hospital","Viral Load or Clearance, Cough, Fever, Dyspnea, Treatment-emergent Adverse Events, C-Reactive Protein, Blood Gas, SpO2, Radiographic Findings, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Non-invasive respiratory support, SOC",180
"2020-001736-95","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001736-95/GB/",NA,"United Kingdom","London","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Unclear","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Blood Pressure, Heart Rate, Respiratory Rate, Quality of Life","Other, SOC",825
"NCT04344756","https://ClinicalTrials.gov/show/NCT04344756",NA,"France","Paris","2020-Apr","2020-Jul","Not Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital, ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Coagulation Test, Bicarbonates, Renal Outcome (Unspecified)","Anticoagulants, SOC",808
"2020-001541-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001541-39/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Unspecified","Open-Label",NA,"Confirmed","Severe","Hospital, ICU","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Anti SARS-COV-2 Titers, White Blood Cell Count, Neutrophils, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, PaO2-FiO2, SpO2, Radiographic Findings, Renal Outcome (Unspecified)","Bevacizumab",NA
"NCT04291729","https://ClinicalTrials.gov/show/NCT04291729",NA,"China","Jiangxi","2020-Mar","2020-Mar","Completed","Single-Arm","Open-Label",1,"Confirmed",NA,"Hospital","ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events, Serious Adverse Events","DAA + IFN",11
"NCT04331665","https://ClinicalTrials.gov/show/NCT04331665",NA,"Canada","Ontario","2020-Apr","2020-Oct","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed",NA,"Hospital","Mortality, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events","JAKi",64
"NCT04326452","https://ClinicalTrials.gov/show/NCT04326452",NA,"United States","Arizona","2020-Mar","2020-May","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","Blood Gas, Blood Pressure, Heart Rate, SpO2, Respiratory Rate","Non-invasive respiratory support",15
"NCT04326452","https://ClinicalTrials.gov/show/NCT04326452",NA,"United States","California","2020-Mar","2020-May","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","Blood Gas, Blood Pressure, Heart Rate, SpO2, Respiratory Rate","Non-invasive respiratory support",15
"NCT04326452","https://ClinicalTrials.gov/show/NCT04326452",NA,"United States","Georgia","2020-Mar","2020-May","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","Blood Gas, Blood Pressure, Heart Rate, SpO2, Respiratory Rate","Non-invasive respiratory support",15
"2020-001442-19","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001442-19/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Creatinine Phosphokinase, CK-MB, Troponin, Fibrinogen, ALT, AST, Bilirubin, Glucose, LDH","TCZ",NA
"CHICTR2000029432","http://www.chictr.org.cn/showproj.aspx?proj=48881",NA,"China","Guangdong","2020-Feb","2020-Apr","Not Recruiting","Single-Arm","Unspecified",1,"Confirmed Or Suspected","Mixed","Hospital","Fever, C-Reactive Protein, Creatinine Phosphokinase, CK-MB, eGFR, Myoglobin, Procalcitonin, ALT, Albumin, Bilirubin, Blood Gas, Radiographic Findings, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","TCM",72
"IRCT20200413047056N1","http://en.irct.ir/trial/47212",NA,"Iran","South Khorasan","2020-Apr","2020-Jun","Recruiting","Randomised","Open-Label",3,NA,NA,"Hospital","Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, White Blood Cell Count, Erythrocyte Sedimentation Rate, LDH, Blood Gas, SpO2, Radiographic Findings","Igs, Plasma based therapy, SOC",15
"IRCT20200408046992N1","http://en.irct.ir/trial/47006",NA,"Iran","Tehran","2020-Apr","2020-Jul","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Fever, C-Reactive Protein, Blood Pressure, Heart Rate, ECG, SpO2, Respiratory Rate, Radiographic Findings, Renal Outcome (Unspecified)","HCQ, HCQ + Other",70
"2020-000982-18","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000982-18/NO/",NA,"Norway","Oslo","2020-Mar",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Severe","Hospital, ICU","Mortality, ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, eGFR, Radiographic Findings, Quality of Life, Cardiac Outcome (Unspecified)","HCQ, Remdesivir",NA
"NCT04328493","https://ClinicalTrials.gov/show/NCT04328493",NA,"Vietnam","Hanoi","2020-Mar","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Fever, Adverse Events","HCQ, SOC",250
"NCT04328493","https://ClinicalTrials.gov/show/NCT04328493",NA,"Vietnam","Ho Chi Minh City","2020-Mar","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Fever, Adverse Events","HCQ, SOC",250
"NCT04322396","https://ClinicalTrials.gov/show/NCT04322396",NA,"Denmark","Copenhagen","2020-Mar","2020-Oct","Recruiting","Randomised","Quadruple",3,"Confirmed",NA,"Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Blood Gas, Blood pH","HCQ + AZT, SOC",226
"2020-001614-38","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001614-38/BE/",NA,"Belgium","Brussels","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital, ICU","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Creatinine Phosphokinase, eGFR, Troponin, ALT, AST, Bilirubin, Glucose, ECG, 6-Minute Walking Distance, Radiographic Findings, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","AZT, SOC",NA
"CHICTR2000030258","http://www.chictr.org.cn/showproj.aspx?proj=49887",NA,"China","Heilongjiang","2020-Feb","2020-Aug","Not Recruiting","Single-Arm","Open-Label",2,"Confirmed",NA,"Hospital","Mortality, Viral Load or Clearance, Cough, Fever, SpO2, Respiratory Rate, 6-Minute Walking Distance, Radiographic Findings, Quality of Life, Depression, Anxiety","Respiratory support, SOC",60
"CHICTR2000031430","http://www.chictr.org.cn/showproj.aspx?proj=49254",NA,"China","Beijing","2020-Mar","2021-Dec","Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Mixed","Hospital","Clinical Improvement Score (Any), C-Reactive Protein, Ferritin, IL-6, Interferon (Any), Lymphocyte Count, D-Dimer, Creatinine Phosphokinase, CK-MB, eGFR, Myoglobin, Troponin, Procalcitonin, Prothrombin, Coagulation Test, ALT, Albumin, Bilirubin, IgG, IgM or IgA, Blood Gas, ECG, SpO2, 6-Minute Walking Distance, Radiographic Findings, Quality of Life, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","SOC, Stem cells",200
"NCT04335305","https://ClinicalTrials.gov/show/NCT04335305",NA,"Spain","Barcelona","2020-Apr","2020-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, White Blood Cell Count, Lymphocyte Count, Platelet Count, Hemoglobin, Coagulation Test, ALT, AST, Albumin, Bilirubin, Glucose, SpO2, Radiographic Findings, Renal Outcome (Unspecified)","SOC, TCZ + mAb",24
"NCT04335305","https://ClinicalTrials.gov/show/NCT04335305",NA,"Spain","Madrid","2020-Apr","2020-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, White Blood Cell Count, Lymphocyte Count, Platelet Count, Hemoglobin, Coagulation Test, ALT, AST, Albumin, Bilirubin, Glucose, SpO2, Radiographic Findings, Renal Outcome (Unspecified)","SOC, TCZ + mAb",24
"NCT04335305","https://ClinicalTrials.gov/show/NCT04335305",NA,"Spain","Valencia","2020-Apr","2020-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, White Blood Cell Count, Lymphocyte Count, Platelet Count, Hemoglobin, Coagulation Test, ALT, AST, Albumin, Bilirubin, Glucose, SpO2, Radiographic Findings, Renal Outcome (Unspecified)","SOC, TCZ + mAb",24
"NCT04275414","https://ClinicalTrials.gov/show/NCT04275414",NA,"China","Hubei","2020-Feb","2020-Apr","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","Mortality, Dyspnea, C-Reactive Protein, PaO2-FiO2, SpO2, Radiographic Findings","mAb",20
"NCT04275414","https://ClinicalTrials.gov/show/NCT04275414",NA,"China","Shandong","2020-Feb","2020-Apr","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","Mortality, Dyspnea, C-Reactive Protein, PaO2-FiO2, SpO2, Radiographic Findings","mAb",20
"NCT04275414","https://ClinicalTrials.gov/show/NCT04275414",NA,"Italy","Rome","2020-Feb","2020-Apr","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","Mortality, Dyspnea, C-Reactive Protein, PaO2-FiO2, SpO2, Radiographic Findings","mAb",20
"NCT04349631","https://ClinicalTrials.gov/show/NCT04349631",NA,"United States","Texas","2020-Apr","2020-Dec","Recruiting","Single-Arm","Open-Label",1,"No","Healthy","Healthcare Workers","Hospitalization, Cough, Fever, Dyspnea, Serious or Seconday Infections, C-Reactive Protein, IL-6, IL-10, Tumor Necrosis Factor (Any), White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, Electrolytes, INR, ALT, AST, Albumin, Bilirubin, Glucose, Blood Urea Nitrogen, Blood Gas, Quality of Life, Depression, Renal Outcome (Unspecified)","Stem cells",56
"NCT04345601","https://ClinicalTrials.gov/show/NCT04345601",NA,"United States","Texas","2020-Apr","2022-Feb","Not Recruiting","Single-Arm","Open-Label",1,"Yes","Severe","ICU","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, SpO2","Stem cells",30
"2020-001302-30","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001302-30/AT/",NA,"Austria","Vienna","2020-Apr",NA,"Recruiting","Randomised","Open-Label",4,NA,NA,"Outpatient, Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Other Mild Symptoms, Serious or Seconday Infections, White Blood Cell Count, Hemoglobin, Creatinine Phosphokinase, Angiotensins, Bilirubin, Glucose, Quality of Life, Anxiety","Anticoagulants, ARBs, HCQ, LPV/r",NA
"NCT04331054","https://ClinicalTrials.gov/show/NCT04331054",NA,"France","Paris","2020-Apr","2020-Jul","Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, PaO2-FiO2","Corticosteroids, SOC",436
"NCT04341116","https://ClinicalTrials.gov/show/NCT04341116",NA,"United States","District Of Columbia","2020-Apr","2020-Sep","Recruiting","Randomised","Quadruple",2,"Yes","Severe","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2, SpO2","mAb, SOC",144
"NCT04341116","https://ClinicalTrials.gov/show/NCT04341116",NA,"United States","Illinois","2020-Apr","2020-Sep","Recruiting","Randomised","Quadruple",2,"Yes","Severe","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2, SpO2","mAb, SOC",144
"NCT04341116","https://ClinicalTrials.gov/show/NCT04341116",NA,"United States","Indiana","2020-Apr","2020-Sep","Recruiting","Randomised","Quadruple",2,"Yes","Severe","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2, SpO2","mAb, SOC",144
"NCT04341116","https://ClinicalTrials.gov/show/NCT04341116",NA,"United States","Louisiana","2020-Apr","2020-Sep","Recruiting","Randomised","Quadruple",2,"Yes","Severe","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2, SpO2","mAb, SOC",144
"NCT04341116","https://ClinicalTrials.gov/show/NCT04341116",NA,"United States","Mississippi","2020-Apr","2020-Sep","Recruiting","Randomised","Quadruple",2,"Yes","Severe","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2, SpO2","mAb, SOC",144
"NCT04341116","https://ClinicalTrials.gov/show/NCT04341116",NA,"United States","Oregon","2020-Apr","2020-Sep","Recruiting","Randomised","Quadruple",2,"Yes","Severe","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2, SpO2","mAb, SOC",144
"NCT04341116","https://ClinicalTrials.gov/show/NCT04341116",NA,"United States","Pennsylvania","2020-Apr","2020-Sep","Recruiting","Randomised","Quadruple",2,"Yes","Severe","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2, SpO2","mAb, SOC",144
"NCT04345614","https://ClinicalTrials.gov/show/NCT04345614",NA,"United States","Michigan","2020-Apr","2020-Jul","Recruiting","Randomised","Open-Label",2,"Yes","Severe","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, IL-6, IL-17, Tumor Necrosis Factor (Any), Procalcitonin, PaO2-FiO2, SpO2, Blood pH","CM4620-Injectable Emulsion, SOC",120
"NCT04345614","https://ClinicalTrials.gov/show/NCT04345614",NA,"United States","Minnesota","2020-Apr","2020-Jul","Recruiting","Randomised","Open-Label",2,"Yes","Severe","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, IL-6, IL-17, Tumor Necrosis Factor (Any), Procalcitonin, PaO2-FiO2, SpO2, Blood pH","CM4620-Injectable Emulsion, SOC",120
"NCT04327206","https://ClinicalTrials.gov/show/NCT04327206",NA,"Australia","New South Wales","2020-Mar","2020-Oct","Recruiting","Randomised","Double",2,"Healthy (Exposed)",NA,"Healthcare Workers","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Adverse Events","Vaccine",10078
"NCT04327206","https://ClinicalTrials.gov/show/NCT04327206",NA,"Australia","South Australia","2020-Mar","2020-Oct","Recruiting","Randomised","Double",2,"Healthy (Exposed)",NA,"Healthcare Workers","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Adverse Events","Vaccine",10078
"NCT04327206","https://ClinicalTrials.gov/show/NCT04327206",NA,"Australia","Victoria","2020-Mar","2020-Oct","Recruiting","Randomised","Double",2,"Healthy (Exposed)",NA,"Healthcare Workers","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Adverse Events","Vaccine",10078
"NCT04327206","https://ClinicalTrials.gov/show/NCT04327206",NA,"Australia","Western Australia","2020-Mar","2020-Oct","Recruiting","Randomised","Double",2,"Healthy (Exposed)",NA,"Healthcare Workers","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Adverse Events","Vaccine",10078
"NCT04362189","https://ClinicalTrials.gov/show/NCT04362189",NA,"United States","Texas","2020-Apr","2020-Oct","Not Recruiting","Randomised","Quadruple",2,NA,NA,"Hospital","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, IL-6, IL-10, Tumor Necrosis Factor (Any), White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, D-Dimer, Creatinine Phosphokinase, Myoglobin, Troponin, Prothrombin, Electrolytes, INR, ALT, Albumin, Bilirubin, Glucose, CD4, CD8, Blood Urea Nitrogen, Blood Gas, ECG, SpO2, Bicarbonates, Renal Outcome (Unspecified)","HCQ + AZT, HCQ + AZT + Stem cells, SOC, Stem cells",100
"NCT04343651","https://ClinicalTrials.gov/show/NCT04343651",NA,"United States","California","2020-Apr","2020-Dec","Recruiting","Randomised","Quadruple",2,NA,NA,"Unclear","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Natural Killer Cell Count, CD4, CD8, SpO2, Radiographic Findings","mAb, SOC",75
"NCT04343651","https://ClinicalTrials.gov/show/NCT04343651",NA,"United States","Connecticut","2020-Apr","2020-Dec","Recruiting","Randomised","Quadruple",2,NA,NA,"Unclear","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Natural Killer Cell Count, CD4, CD8, SpO2, Radiographic Findings","mAb, SOC",75
"NCT04343651","https://ClinicalTrials.gov/show/NCT04343651",NA,"United States","New Jersey","2020-Apr","2020-Dec","Recruiting","Randomised","Quadruple",2,NA,NA,"Unclear","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Natural Killer Cell Count, CD4, CD8, SpO2, Radiographic Findings","mAb, SOC",75
"NCT04343651","https://ClinicalTrials.gov/show/NCT04343651",NA,"United States","New York","2020-Apr","2020-Dec","Recruiting","Randomised","Quadruple",2,NA,NA,"Unclear","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Natural Killer Cell Count, CD4, CD8, SpO2, Radiographic Findings","mAb, SOC",75
"NCT04343651","https://ClinicalTrials.gov/show/NCT04343651",NA,"United States","North Carolina","2020-Apr","2020-Dec","Recruiting","Randomised","Quadruple",2,NA,NA,"Unclear","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Natural Killer Cell Count, CD4, CD8, SpO2, Radiographic Findings","mAb, SOC",75
"NCT04343651","https://ClinicalTrials.gov/show/NCT04343651",NA,"United States","Ohio","2020-Apr","2020-Dec","Recruiting","Randomised","Quadruple",2,NA,NA,"Unclear","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Natural Killer Cell Count, CD4, CD8, SpO2, Radiographic Findings","mAb, SOC",75
"NCT04343651","https://ClinicalTrials.gov/show/NCT04343651",NA,"United States","Oregon","2020-Apr","2020-Dec","Recruiting","Randomised","Quadruple",2,NA,NA,"Unclear","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Natural Killer Cell Count, CD4, CD8, SpO2, Radiographic Findings","mAb, SOC",75
"NCT04333368","https://ClinicalTrials.gov/show/NCT04333368",NA,"France","Paris","2020-Apr","2020-Aug","Recruiting","Randomised","Triple",2,"Confirmed","Severe","ICU","Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, IL-1, IL-6, IL-8, IL-10, Tumor Necrosis Factor (Any), Antibodies, SRAGE, PaO2-FiO2, Quality of Life","SOC, Stem cells",40
"NCT04344080","https://ClinicalTrials.gov/show/NCT04344080",NA,"Germany","Hamburg","2020-Apr","2020-Dec","Recruiting","Randomised","Open-Label",2,NA,NA,"ICU","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, IL-6, IL-10, Tumor Necrosis Factor (Any), Procalcitonin, Bicarbonates, Renal Outcome (Unspecified)","ECMO, SOC",24
"2020-001413-20","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001413-20/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Ferritin, White Blood Cell Count, Lymphocyte Count, Platelet Count, Hemoglobin, D-Dimer, ALT, Bilirubin, LDH, SpO2, Radiographic Findings, Hypoxemia, Renal Outcome (Unspecified)","Corticosteroids, Siltuximab",NA
"2020-001622-64","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001622-64/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,NA,"Outpatient","ICU Admission, Hospitalization, Blood Gas, ECG, SpO2, Radiographic Findings","Corticosteroids, SOC",NA
"2020-001321-31","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001321-31/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",3,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, Serious or Seconday Infections, Anti SARS-COV-2 Titers, Peak RC-Reactive Protein, Ferritin, IL-6, White Blood Cell Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Erythrocyte Sedimentation Rate, D-Dimer, Creatinine Phosphokinase, Troponin, Procalcitonin, Fibrinogen, Coagulation Test, ALT, AST, Albumin, Bilirubin, LDH, PaO2-FiO2, SpO2, Respiratory Rate, Radiographic Findings, Shock","HCQ, Imatinib, JAKi, LPV/r",NA
"NCT04317092","https://ClinicalTrials.gov/show/NCT04317092",NA,"Italy","Alessandria","2020-Mar","2020-Dec","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2, Radiographic Findings","TCZ",400
"NCT04317092","https://ClinicalTrials.gov/show/NCT04317092",NA,"Italy","Rome","2020-Mar","2020-Dec","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2, Radiographic Findings","TCZ",400
"NCT04317092","https://ClinicalTrials.gov/show/NCT04317092",NA,"Italy","Catania","2020-Mar","2020-Dec","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2, Radiographic Findings","TCZ",400
"NCT04317092","https://ClinicalTrials.gov/show/NCT04317092",NA,"Italy","Cosenza","2020-Mar","2020-Dec","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2, Radiographic Findings","TCZ",400
"NCT04317092","https://ClinicalTrials.gov/show/NCT04317092",NA,"Italy","Modena","2020-Mar","2020-Dec","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2, Radiographic Findings","TCZ",400
"NCT04317092","https://ClinicalTrials.gov/show/NCT04317092",NA,"Italy","Ravenna","2020-Mar","2020-Dec","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2, Radiographic Findings","TCZ",400
"NCT04317092","https://ClinicalTrials.gov/show/NCT04317092",NA,"Italy","Reggio Calabria","2020-Mar","2020-Dec","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2, Radiographic Findings","TCZ",400
"NCT04317092","https://ClinicalTrials.gov/show/NCT04317092",NA,"Italy","Rimini","2020-Mar","2020-Dec","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2, Radiographic Findings","TCZ",400
"NCT04317092","https://ClinicalTrials.gov/show/NCT04317092",NA,"Italy","Varese","2020-Mar","2020-Dec","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2, Radiographic Findings","TCZ",400
"NCT04317092","https://ClinicalTrials.gov/show/NCT04317092",NA,"Italy","Verona","2020-Mar","2020-Dec","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2, Radiographic Findings","TCZ",400
"NCT04340232","https://ClinicalTrials.gov/show/NCT04340232",NA,"United States","Colorado","2020-Apr","2020-Aug","Not Recruiting","Single-Arm","Open-Label",1,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose, Renal Outcome (Unspecified)",NA,80
"NCT04339660","https://ClinicalTrials.gov/show/NCT04339660",NA,"China","Hubei","2020-Apr","2020-Jun","Recruiting","Randomised","Triple",2,NA,NA,"Unclear","Mortality, Viral Load or Clearance, Cough, Fever, Dyspnea, C-Reactive Protein, IL-1, IL-6, IL-8, Tumor Necrosis Factor (Any), Procalcitonin, CD4, CD8, SpO2, Radiographic Findings",NA,30
"JPRN-JRCT2031190264","https://rctportal.niph.go.jp/en/detail?trial_id=JRCT2031190264",NA,"United States","Washington, Dc","2020-Mar",NA,"Not Recruiting","Randomised","Unspecified",NA,"Confirmed","Mixed","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose, Renal Outcome (Unspecified)",NA,100
"JPRN-JRCT2031190264","https://rctportal.niph.go.jp/en/detail?trial_id=JRCT2031190264",NA,"South Korea","Seoul","2020-Mar",NA,"Not Recruiting","Randomised","Unspecified",NA,"Confirmed","Mixed","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose, Renal Outcome (Unspecified)",NA,100
"JPRN-JRCT2031190264","https://rctportal.niph.go.jp/en/detail?trial_id=JRCT2031190264",NA,"Japan","Toyama","2020-Mar",NA,"Not Recruiting","Randomised","Unspecified",NA,"Confirmed","Mixed","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose, Renal Outcome (Unspecified)",NA,100
"2020-001244-26","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001244-26/AT/",NA,"Austria","Vienna","2020-Mar",NA,"Recruiting","Randomised","Double",2,NA,NA,"ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Urine Sample, Blood Gas, Blood Pressure, Heart Rate, ECG, PaO2-FiO2, Respiratory Rate, Radiographic Findings, Cardiac Outcome (Unspecified)","Other, SOC",40
"2020-001266-11","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001266-11/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Single",2,NA,NA,"ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, IL-1, IL-2, IL-4, IL-6, IL-8, IL-10, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Natural Killer Cell Count, Platelet Count, Hemoglobin, D-Dimer, Creatinine Phosphokinase, Procalcitonin, Prothrombin, Fibrinogen, Coagulation Test, Electrolytes, INR, ALT, AST, Bilirubin, Glucose, LDH, IgG, IgM or IgA, CD4, CD8, Blood Urea Nitrogen, PaO2-FiO2, SpO2, Radiographic Findings","Stem cells",NA
"2020-001531-27","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001531-27/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",3,NA,NA,"Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Adverse Events, C-Reactive Protein, IL-1, IL-6, IL-8, IL-10, IL-12, Tumor Necrosis Factor (Any), PAI-1, Interferon (Any), White Blood Cell Count, Neutrophils, Platelet Count, Hemoglobin, D-Dimer, ALT, AST, Bilirubin, Renal Outcome (Unspecified)","Sarilumab, SOC",NA
"2020-001254-22","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001254-22/BE/",NA,"Belgium","Brussels","2020-Mar",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Hospital","Mortality, Hospitalization, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, Ferritin, IL-2, IL-7, Tumor Necrosis Factor (Any), Granulocyte Stimulaiting Factor, Interferon (Any), MCP-1, MIP-1, White Blood Cell Count, Lymphocyte Count, PaO2-FiO2, SpO2, Radiographic Findings","Other, SOC",NA
"2020-000936-23","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000936-23/AT/",NA,"Austria","Vienna","2020-May",NA,"Recruiting","Randomised","Open-Label",4,"Confirmed",NA,"Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, Electrolytes, INR, ALT, AST, Bilirubin, Glucose, Renal Outcome (Unspecified)","HCQ, LPV/r, Remdesivir",3100
"CHICTR2000032400","http://www.chictr.org.cn/showproj.aspx?proj=52958",NA,"China","Shanghai","2020-Apr","2020-Jun","Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Unclear","Unclear","Clinical Improvement Score (Any), C-Reactive Protein, Lymphocyte Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, LDH, Urine Sample, CD4, PaO2-FiO2","SOC, TCM",120
"NCT04336332","https://ClinicalTrials.gov/show/NCT04336332",NA,"United States","New Jersey","2020-Apr","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Non-severe","Outpatient, Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Fever","HCQ, HCQ + AZT, SOC",160
"NCT04373733","https://ClinicalTrials.gov/show/NCT04373733",NA,"United Kingdom","Westminster","2020-May","2021-Mar","Not Recruiting","Randomised","Open-Label",5,"Suspected Or Confirmed","Unspecified","Hospital","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Adverse Events, SpO2, Respiratory Rate, Quality of Life","FPV, HCQ + AZT + Zinc, SOC",450
"NCT04373733","https://ClinicalTrials.gov/show/NCT04373733",NA,"United Kingdom","London","2020-May","2021-Mar","Not Recruiting","Randomised","Open-Label",5,"Suspected Or Confirmed","Unspecified","Hospital","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Adverse Events, SpO2, Respiratory Rate, Quality of Life","FPV, HCQ + AZT + Zinc, SOC",450
"NCT04341935","https://ClinicalTrials.gov/show/NCT04341935",NA,"United States","Florida","2020-Apr","2020-Oct","Not Recruiting","Randomised","Open-Label",2,NA,NA,"Outpatient, Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, IL-6, Glucose, SpO2","DPP-4i, SOC",20
"NCT04360356","https://ClinicalTrials.gov/show/NCT04360356",NA,"Egypt","Cairo","2020-Apr","2020-Oct","Not Recruiting","Randomised","Double",2,NA,NA,"Unclear","Mortality, Viral Load or Clearance, Ferritin, IL-6, Tumor Necrosis Factor (Any), INR, PaO2-FiO2, Respiratory Rate","Ivermectin + Antivirals, Non-invasive respiratory support",100
"NCT04329923","https://ClinicalTrials.gov/show/NCT04329923",NA,"United States","Pennsylvania","2020-Apr","2021-Apr","Recruiting","Randomised","Triple",4,"Confirmed And Healthy","Mixed","Healthcare Workers, Outpatient, Hospital","ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Pneumonia or ARDS, Dyspnea, Adverse Events","HCQ, SOC",400
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Arizona","2020-Apr","2021-Apr","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ, SOC",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","California","2020-Apr","2021-Apr","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ, SOC",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Colorado","2020-Apr","2021-Apr","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ, SOC",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Florida","2020-Apr","2021-Apr","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ, SOC",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Kentucky","2020-Apr","2021-Apr","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ, SOC",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Louisiana","2020-Apr","2021-Apr","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ, SOC",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Maine","2020-Apr","2021-Apr","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ, SOC",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Massachusetts","2020-Apr","2021-Apr","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ, SOC",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Michigan","2020-Apr","2021-Apr","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ, SOC",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Mississippi","2020-Apr","2021-Apr","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ, SOC",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","New York","2020-Apr","2021-Apr","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ, SOC",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","North Carolina","2020-Apr","2021-Apr","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ, SOC",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Ohio","2020-Apr","2021-Apr","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ, SOC",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Oregon","2020-Apr","2021-Apr","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ, SOC",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Pennsylvania","2020-Apr","2021-Apr","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ, SOC",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","South Carolina","2020-Apr","2021-Apr","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ, SOC",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Tennessee","2020-Apr","2021-Apr","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ, SOC",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Texas","2020-Apr","2021-Apr","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ, SOC",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Utah","2020-Apr","2021-Apr","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ, SOC",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Virginia","2020-Apr","2021-Apr","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ, SOC",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Washington","2020-Apr","2021-Apr","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ, SOC",510
"NCT04362085","https://ClinicalTrials.gov/show/NCT04362085",NA,"Canada","Ontario","2020-Apr","2020-Nov","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Platelet Count, D-Dimer, Prothrombin, Fibrinogen","Anticoagulants, SOC",462
"NCT04327401","https://ClinicalTrials.gov/show/NCT04327401",NA,"Brazil","Bahia","2020-Mar","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Mixed","Unclear","Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Corticosteroids, SOC",290
"NCT04327401","https://ClinicalTrials.gov/show/NCT04327401",NA,"Brazil","Distrito Federal","2020-Mar","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Mixed","Unclear","Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Corticosteroids, SOC",290
"NCT04327401","https://ClinicalTrials.gov/show/NCT04327401",NA,"Brazil","Brasilia","2020-Mar","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Mixed","Unclear","Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Corticosteroids, SOC",290
"NCT04327401","https://ClinicalTrials.gov/show/NCT04327401",NA,"Brazil","Minas Gerais","2020-Mar","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Mixed","Unclear","Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Corticosteroids, SOC",290
"NCT04327401","https://ClinicalTrials.gov/show/NCT04327401",NA,"Brazil","Para","2020-Mar","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Mixed","Unclear","Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Corticosteroids, SOC",290
"NCT04327401","https://ClinicalTrials.gov/show/NCT04327401",NA,"Brazil","Rio Grande Do Norte","2020-Mar","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Mixed","Unclear","Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Corticosteroids, SOC",290
"NCT04327401","https://ClinicalTrials.gov/show/NCT04327401",NA,"Brazil","Rio Grande Do Sul","2020-Mar","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Mixed","Unclear","Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Corticosteroids, SOC",290
"NCT04327401","https://ClinicalTrials.gov/show/NCT04327401",NA,"Brazil","Santa Catarina","2020-Mar","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Mixed","Unclear","Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Corticosteroids, SOC",290
"NCT04327401","https://ClinicalTrials.gov/show/NCT04327401",NA,"Israel","Jerusalem","2020-Mar","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Mixed","Unclear","Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Corticosteroids, SOC",290
"NCT04317040","https://ClinicalTrials.gov/show/NCT04317040",NA,"United States","Florida","2020-Mar","2020-Sep","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Lymphocyte Count","Immunomodulators, SOC",230
"NCT04317040","https://ClinicalTrials.gov/show/NCT04317040",NA,"United States","Georgia","2020-Mar","2020-Sep","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Lymphocyte Count","Immunomodulators, SOC",230
"NCT04317040","https://ClinicalTrials.gov/show/NCT04317040",NA,"United States","Maryland","2020-Mar","2020-Sep","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Lymphocyte Count","Immunomodulators, SOC",230
"NCT04317040","https://ClinicalTrials.gov/show/NCT04317040",NA,"United States","Michigan","2020-Mar","2020-Sep","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Lymphocyte Count","Immunomodulators, SOC",230
"NCT04317040","https://ClinicalTrials.gov/show/NCT04317040",NA,"United States","New Jersey","2020-Mar","2020-Sep","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Lymphocyte Count","Immunomodulators, SOC",230
"NCT04317040","https://ClinicalTrials.gov/show/NCT04317040",NA,"United States","Ohio","2020-Mar","2020-Sep","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Lymphocyte Count","Immunomodulators, SOC",230
"NCT04317040","https://ClinicalTrials.gov/show/NCT04317040",NA,"United States","Pennsylvania","2020-Mar","2020-Sep","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Lymphocyte Count","Immunomodulators, SOC",230
"NCT04362137","https://ClinicalTrials.gov/show/NCT04362137",NA,"United States","Connecticut","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Quality of Life, Renal Outcome (Unspecified)","JAKi, SOC",402
"NCT04362137","https://ClinicalTrials.gov/show/NCT04362137",NA,"United States","Massachusetts","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Quality of Life, Renal Outcome (Unspecified)","JAKi, SOC",402
"NCT04362137","https://ClinicalTrials.gov/show/NCT04362137",NA,"United States","Michigan","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Quality of Life, Renal Outcome (Unspecified)","JAKi, SOC",402
"NCT04362137","https://ClinicalTrials.gov/show/NCT04362137",NA,"United States","New Jersey","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Quality of Life, Renal Outcome (Unspecified)","JAKi, SOC",402
"NCT04362137","https://ClinicalTrials.gov/show/NCT04362137",NA,"United States","Washington","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Quality of Life, Renal Outcome (Unspecified)","JAKi, SOC",402
"NCT04362137","https://ClinicalTrials.gov/show/NCT04362137",NA,"United States","Wisconsin","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Quality of Life, Renal Outcome (Unspecified)","JAKi, SOC",402
"NCT04362137","https://ClinicalTrials.gov/show/NCT04362137",NA,"Germany","Berlin","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Quality of Life, Renal Outcome (Unspecified)","JAKi, SOC",402
"NCT04362137","https://ClinicalTrials.gov/show/NCT04362137",NA,"Spain","Salamanca","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Quality of Life, Renal Outcome (Unspecified)","JAKi, SOC",402
"NCT04362137","https://ClinicalTrials.gov/show/NCT04362137",NA,"Spain","Barcelona","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Quality of Life, Renal Outcome (Unspecified)","JAKi, SOC",402
"NCT04362137","https://ClinicalTrials.gov/show/NCT04362137",NA,"Spain","Madrid","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Quality of Life, Renal Outcome (Unspecified)","JAKi, SOC",402
"NCT04362137","https://ClinicalTrials.gov/show/NCT04362137",NA,"United Kingdom","Leeds","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Quality of Life, Renal Outcome (Unspecified)","JAKi, SOC",402
"NCT04362137","https://ClinicalTrials.gov/show/NCT04362137",NA,"United Kingdom","London","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Quality of Life, Renal Outcome (Unspecified)","JAKi, SOC",402
"NCT04362137","https://ClinicalTrials.gov/show/NCT04362137",NA,"United Kingdom","Manchester","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Quality of Life, Renal Outcome (Unspecified)","JAKi, SOC",402
"NCT04346797","https://ClinicalTrials.gov/show/NCT04346797",NA,"France","Paris","2020-Apr","2020-Sep","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital, ICU","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), PaO2-FiO2, Renal Outcome (Unspecified)","mAb, SOC",120
"CHICTR2000032242","http://www.chictr.org.cn/showproj.aspx?proj=52824",NA,"China","Heilongjiang","2020-Apr","2021-May","Not Recruiting","Randomised","Open-Label",2,NA,NA,"Unclear","Mortality, Hospitalization, Hospital Discharge, Viral Load or Clearance, C-Reactive Protein, White Blood Cell Count, Coagulation Test, IgG, IgM or IgA, Antibodies","Other, SOC",350
"NCT04347382","https://ClinicalTrials.gov/show/NCT04347382",NA,"Pakistan","Punjab","2020-Apr","2020-Jul","Recruiting","Randomised","Quadruple",3,NA,NA,"Hospital","Mortality, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Other Mild Symptoms, SpO2, Radiographic Findings","Alternative therapy, SOC",30
"NCT04335136","https://ClinicalTrials.gov/show/NCT04335136",NA,"Austria","Vienna","2020-Apr","2020-Sep","Recruiting","Randomised","Double",2,"Confirmed","Unspecified","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, LDH","Antihypertensive, SOC",200
"NCT04335136","https://ClinicalTrials.gov/show/NCT04335136",NA,"Austria","Wien","2020-Apr","2020-Sep","Recruiting","Randomised","Double",2,"Confirmed","Unspecified","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, LDH","Antihypertensive, SOC",200
"NCT04335136","https://ClinicalTrials.gov/show/NCT04335136",NA,"Denmark","Copenhagen","2020-Apr","2020-Sep","Recruiting","Randomised","Double",2,"Confirmed","Unspecified","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, LDH","Antihypertensive, SOC",200
"NCT04335136","https://ClinicalTrials.gov/show/NCT04335136",NA,"Germany","Hamburg","2020-Apr","2020-Sep","Recruiting","Randomised","Double",2,"Confirmed","Unspecified","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, LDH","Antihypertensive, SOC",200
"NCT04335136","https://ClinicalTrials.gov/show/NCT04335136",NA,"Germany","Berlin","2020-Apr","2020-Sep","Recruiting","Randomised","Double",2,"Confirmed","Unspecified","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, LDH","Antihypertensive, SOC",200
"NCT04341675","https://ClinicalTrials.gov/show/NCT04341675",NA,"United States","Illinois","2020-Apr","2020-Jul","Recruiting","Randomised","Quadruple",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Ferritin, Lymphocyte Count, D-Dimer, LDH","Sirolimus, SOC",30
"NCT04341675","https://ClinicalTrials.gov/show/NCT04341675",NA,"United States","Ohio","2020-Apr","2020-Jul","Recruiting","Randomised","Quadruple",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Ferritin, Lymphocyte Count, D-Dimer, LDH","Sirolimus, SOC",30
"NCT04339712","https://ClinicalTrials.gov/show/NCT04339712",NA,"Greece","Athens","2020-Apr","2022-Apr","Recruiting","Non-Randomised","Open-Label",2,"Yes","Severe","Unclear","Mortality, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), PaO2-FiO2","Anakinra, TCZ",40
"NCT04352608","https://ClinicalTrials.gov/show/NCT04352608",NA,"China","Jiangsu","2020-Apr","2020-Aug","Recruiting","Randomised","Quadruple",6,NA,NA,"Healthy Unexposed","Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Creatinine Phosphokinase, ALT, AST, Bilirubin, Glucose, Urine Sample, IgG, IgM or IgA, Antibodies, Bicarbonates","SOC, Vaccine",744
"NCT04352465","https://ClinicalTrials.gov/show/NCT04352465",NA,"Brazil","Brasilia","2020-Apr","2020-Jun","Not Recruiting","Non-Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Other Mild Symptoms, PaO2-FiO2, Respiratory Rate, Hypoxia","Methotrexate",42
"NCT04335032","https://ClinicalTrials.gov/show/NCT04335032",NA,"Switzerland","Bern","2020-Apr","2020-Jul","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Fever, IL-6, PaO2-FiO2","Nutrition",240
"NCT04343261","https://ClinicalTrials.gov/show/NCT04343261",NA,"United States","Connecticut","2020-Apr","2020-Dec","Recruiting","Single-Arm","Open-Label",1,NA,NA,"Hospital","Mortality, Viral Load or Clearance, Dyspnea, Antibodies, PaO2-FiO2, Patient Positioning","Plasma based therapy",45
"NCT04321993","https://ClinicalTrials.gov/show/NCT04321993",NA,"Canada","Nova Scotia","2020-Mar","2022-Feb","Recruiting","Non-Randomised","Open-Label",3,"Confirmed","Mixed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, SpO2","HCQ, JAKi, LPV/r, Sarilumab",1000
"NCT04341285","https://ClinicalTrials.gov/show/NCT04341285",NA,"Germany","Berlin","2020-Apr","2024-Jun","Not Recruiting","Randomised","Open-Label",2,"Yes","Severe","ICU","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","ECMO",200
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Argentina","Buenos Aires","2020-Mar","2020-Jul","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Respiratory Rate, Hypoxemia","Sarilumab, SOC",400
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Canada","Ottawa","2020-Mar","2020-Jul","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Respiratory Rate, Hypoxemia","Sarilumab, SOC",400
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Chile","Santiago","2020-Mar","2020-Jul","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Respiratory Rate, Hypoxemia","Sarilumab, SOC",400
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"France","Paris","2020-Mar","2020-Jul","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Respiratory Rate, Hypoxemia","Sarilumab, SOC",400
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Germany","Berlin","2020-Mar","2020-Jul","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Respiratory Rate, Hypoxemia","Sarilumab, SOC",400
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Israel","Jerusalem","2020-Mar","2020-Jul","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Respiratory Rate, Hypoxemia","Sarilumab, SOC",400
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Italy","Milano","2020-Mar","2020-Jul","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Respiratory Rate, Hypoxemia","Sarilumab, SOC",400
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Italy","Modena","2020-Mar","2020-Jul","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Respiratory Rate, Hypoxemia","Sarilumab, SOC",400
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Italy","Parma","2020-Mar","2020-Jul","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Respiratory Rate, Hypoxemia","Sarilumab, SOC",400
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Italy","Rome","2020-Mar","2020-Jul","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Respiratory Rate, Hypoxemia","Sarilumab, SOC",400
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Japan","Tokyo","2020-Mar","2020-Jul","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Respiratory Rate, Hypoxemia","Sarilumab, SOC",400
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Russia","Moscow","2020-Mar","2020-Jul","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Respiratory Rate, Hypoxemia","Sarilumab, SOC",400
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Spain","Barcelona","2020-Mar","2020-Jul","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Respiratory Rate, Hypoxemia","Sarilumab, SOC",400
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Spain","Madrid","2020-Mar","2020-Jul","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Respiratory Rate, Hypoxemia","Sarilumab, SOC",400
"NCT04357860","https://ClinicalTrials.gov/show/NCT04357860",NA,"Spain","Madrid","2020-Apr","2020-Jul","Not Recruiting","Randomised","Open-Label",3,NA,NA,"Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Adverse Events, Treatment-emergent Adverse Events, C-Reactive Protein, IL-1, IL-6, IL-8, IL-10, IL-12, Interferon (Any), White Blood Cell Count, Neutrophils, Platelet Count, Hemoglobin, ALT, AST, Bilirubin","Sarilumab, SOC",120
"NCT04354259","https://ClinicalTrials.gov/show/NCT04354259",NA,"Canada","Ontario","2020-Apr","2020-Aug","Recruiting","Randomised","Quadruple",2,NA,NA,"Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Clinical Improvement Score (Any), Viral Load or Clearance, Household Members with CoViD-19, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Other Mild Symptoms, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Anti SARS-COV-2 Titers, C-Reactive Protein, Ferritin, Interferon (Any), White Blood Cell Count, D-Dimer, Troponin, LDH, Antibodies","IFN, SOC",140
"NCT04346199","https://ClinicalTrials.gov/show/NCT04346199",NA,"France","Paris","2020-Apr","2020-Nov","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2","Acalabrutinib, SOC",140
"NCT04346199","https://ClinicalTrials.gov/show/NCT04346199",NA,"Italy","Bologna","2020-Apr","2020-Nov","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2","Acalabrutinib, SOC",140
"NCT04346199","https://ClinicalTrials.gov/show/NCT04346199",NA,"Italy","Firenze","2020-Apr","2020-Nov","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2","Acalabrutinib, SOC",140
"NCT04346199","https://ClinicalTrials.gov/show/NCT04346199",NA,"Italy","Milano","2020-Apr","2020-Nov","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2","Acalabrutinib, SOC",140
"NCT04346199","https://ClinicalTrials.gov/show/NCT04346199",NA,"Italy","Roma","2020-Apr","2020-Nov","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2","Acalabrutinib, SOC",140
"NCT04346199","https://ClinicalTrials.gov/show/NCT04346199",NA,"Spain","Madrid","2020-Apr","2020-Nov","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2","Acalabrutinib, SOC",140
"NCT04357444","https://ClinicalTrials.gov/show/NCT04357444",NA,"France","Paris","2020-Apr","2020-May","Not Recruiting","Randomised","Quadruple",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, IL-2, IL-8, IL-10, Tumor Necrosis Factor (Any), CD4, CD8, Surfactant Factor Protein, PaO2-FiO2, Patient Positioning","Immunomodulators, SOC",30
"NCT04330690","https://ClinicalTrials.gov/show/NCT04330690",NA,"Canada","Alberta","2020-Apr","2022-Mar","Recruiting","Randomised","Open-Label",3,"Confirmed","Mixed","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Dyspnea, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","LPV/r, SOC",440
"NCT04330690","https://ClinicalTrials.gov/show/NCT04330690",NA,"Canada","British Columbia","2020-Apr","2022-Mar","Recruiting","Randomised","Open-Label",3,"Confirmed","Mixed","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Dyspnea, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","LPV/r, SOC",440
"NCT04330690","https://ClinicalTrials.gov/show/NCT04330690",NA,"Canada","Ontario","2020-Apr","2022-Mar","Recruiting","Randomised","Open-Label",3,"Confirmed","Mixed","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Dyspnea, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","LPV/r, SOC",440
"NCT04330690","https://ClinicalTrials.gov/show/NCT04330690",NA,"Canada","Quebec","2020-Apr","2022-Mar","Recruiting","Randomised","Open-Label",3,"Confirmed","Mixed","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Dyspnea, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","LPV/r, SOC",440
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Rome","2020-Apr","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2","SOC, TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Reggio Emilia","2020-Apr","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2","SOC, TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Alessandria","2020-Apr","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2","SOC, TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Cremona","2020-Apr","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2","SOC, TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Cuneo","2020-Apr","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2","SOC, TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Ferrara","2020-Apr","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2","SOC, TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Firenze","2020-Apr","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2","SOC, TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Genova","2020-Apr","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2","SOC, TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Imperia","2020-Apr","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2","SOC, TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","La Spezia","2020-Apr","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2","SOC, TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Mantova","2020-Apr","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2","SOC, TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Milano","2020-Apr","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2","SOC, TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Novara","2020-Apr","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2","SOC, TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Padova","2020-Apr","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2","SOC, TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Parma","2020-Apr","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2","SOC, TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Piacenza","2020-Apr","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2","SOC, TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Pisa","2020-Apr","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2","SOC, TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Bergamo","2020-Apr","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2","SOC, TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Treviso","2020-Apr","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2","SOC, TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Venezia","2020-Apr","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2","SOC, TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Verona","2020-Apr","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2","SOC, TCZ",398
"NCT04278963","https://ClinicalTrials.gov/show/NCT04278963",NA,"China","Hubei","2020-Feb","2021-Jan","Suspended","Randomised","Double",4,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Adverse Events, PaO2-FiO2, Respiratory Rate","TCM",300
"NCT04348435","https://ClinicalTrials.gov/show/NCT04348435",NA,"United States","Texas","2020-Apr","2020-Dec","Recruiting","Randomised","Quadruple",2,"No","Healthy","Healthcare Workers","Hospitalization, Cough, Fever, Dyspnea, Serious or Seconday Infections, C-Reactive Protein, IL-6, IL-10, Tumor Necrosis Factor (Any), White Blood Cell Count, Monocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, Coagulation Test, INR, Albumin, Bilirubin, Glucose, Blood Urea Nitrogen, Bicarbonates, Quality of Life, Depression","SOC, Stem cells",100
"NCT04334980","https://ClinicalTrials.gov/show/NCT04334980",NA,"Canada","British Columbia","2020-Apr","2021-Aug","Not Recruiting","Randomised","Triple",2,"Healthy","Non-severe","Healthy Unexposed","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Creatinine Phosphokinase, Prothrombin, ALT, Bilirubin, Glucose, Stool Sample, IgG, IgM or IgA, Antibodies","SOC, Vaccine",84
"NCT04334980","https://ClinicalTrials.gov/show/NCT04334980",NA,"Canada","Nova Scotia","2020-Apr","2021-Aug","Not Recruiting","Randomised","Triple",2,"Healthy","Non-severe","Healthy Unexposed","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Creatinine Phosphokinase, Prothrombin, ALT, Bilirubin, Glucose, Stool Sample, IgG, IgM or IgA, Antibodies","SOC, Vaccine",84
"NCT04342728","https://ClinicalTrials.gov/show/NCT04342728",NA,"United States","Florida","2020-Apr","2020-Dec","Recruiting","Single-Arm","Open-Label",1,"Yes","Non-severe","Outpatient","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Cough, Fever, Dyspnea, Other Mild Symptoms","SOC, Vitamins, Vitamins + Zinc, Zinc",520
"NCT04342728","https://ClinicalTrials.gov/show/NCT04342728",NA,"United States","Ohio","2020-Apr","2020-Dec","Recruiting","Single-Arm","Open-Label",1,"Yes","Non-severe","Outpatient","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Cough, Fever, Dyspnea, Other Mild Symptoms","SOC, Vitamins, Vitamins + Zinc, Zinc",520
"IRCT20200401046909N2","http://en.irct.ir/trial/47010",NA,"Iran","Tehran","2020-Apr","2020-Oct","Recruiting","Randomised","Double",2,NA,NA,"Healthy Exposed, Healthcare Workers","Clinical Improvement Score (Any), Viral Load or Clearance","SOC, Vitamins",540
"2020-001290-74","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001290-74/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,NA,"Unclear","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, IL-6, D-Dimer","AZT, HCQ, Sarilumab",NA
"NCT04330300","https://ClinicalTrials.gov/show/NCT04330300",NA,"Ireland","Galway","2020-Apr","2021-Jan","Recruiting","Randomised","Open-Label",4,"Healthy",NA,"Healthy Unexposed","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Troponin","Antihypertensive",2414
"NCT04330638","https://ClinicalTrials.gov/show/NCT04330638",NA,"Belgium","Brussels","2020-Apr","2020-Sep","Recruiting","Randomised","Open-Label",4,"Confirmed Or Suspected","Severe","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-1, IL-6, White Blood Cell Count, Neutrophils, PaO2-FiO2, Radiographic Findings, Hypoxia","Anakinra, Anakinra + Siltuximab, Anakinra + TCZ, Siltuximab, SOC, TCZ",342
"NCT04330638","https://ClinicalTrials.gov/show/NCT04330638",NA,"Belgium","Antwerp","2020-Apr","2020-Sep","Recruiting","Randomised","Open-Label",4,"Confirmed Or Suspected","Severe","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-1, IL-6, White Blood Cell Count, Neutrophils, PaO2-FiO2, Radiographic Findings, Hypoxia","Anakinra, Anakinra + Siltuximab, Anakinra + TCZ, Siltuximab, SOC, TCZ",342
"CHICTR2000029741","http://www.chictr.org.cn/showproj.aspx?proj=49263",NA,"China","Guangdong","2020-Feb","2020-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Outpatient","Mortality, Hospitalization, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, IL-10, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Neutrophils, Platelet Count, D-Dimer, Myoglobin, Procalcitonin, Prothrombin, Fibrinogen, Coagulation Test, Renal Outcome (Unspecified)","HCQ, LPV/r",112
"2020-001437-12","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001437-12/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",4,NA,NA,"Hospital, ICU","Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-1, IL-2, IL-6, IL-10, IL-12, Tumor Necrosis Factor (Any), D-Dimer, Triglycerides, PaO2-FiO2, SpO2","Cyclosporine, TCZ",NA
"NCT04329195","https://ClinicalTrials.gov/show/NCT04329195",NA,"France","Paris","2020-Apr","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","Antihypertensive",554
"NCT04321278","https://ClinicalTrials.gov/show/NCT04321278",NA,"Brazil","Brasilia","2020-Mar","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Severe","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ, HCQ + AZT",440
"NCT04321278","https://ClinicalTrials.gov/show/NCT04321278",NA,"Brazil","Distrito Federal","2020-Mar","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Severe","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ, HCQ + AZT",440
"NCT04321278","https://ClinicalTrials.gov/show/NCT04321278",NA,"Brazil","Espirito Santo","2020-Mar","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Severe","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ, HCQ + AZT",440
"NCT04321278","https://ClinicalTrials.gov/show/NCT04321278",NA,"Brazil","Goias","2020-Mar","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Severe","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ, HCQ + AZT",440
"NCT04321278","https://ClinicalTrials.gov/show/NCT04321278",NA,"Brazil","Minas Gerais","2020-Mar","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Severe","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ, HCQ + AZT",440
"NCT04321278","https://ClinicalTrials.gov/show/NCT04321278",NA,"Brazil","Para","2020-Mar","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Severe","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ, HCQ + AZT",440
"NCT04321278","https://ClinicalTrials.gov/show/NCT04321278",NA,"Brazil","Parana","2020-Mar","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Severe","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ, HCQ + AZT",440
"NCT04321278","https://ClinicalTrials.gov/show/NCT04321278",NA,"Brazil","Rio Grande Do Norte","2020-Mar","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Severe","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ, HCQ + AZT",440
"NCT04321278","https://ClinicalTrials.gov/show/NCT04321278",NA,"Brazil","Rio Grande Do Sul","2020-Mar","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Severe","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ, HCQ + AZT",440
"NCT04321278","https://ClinicalTrials.gov/show/NCT04321278",NA,"Brazil","Rio De Janeiro","2020-Mar","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Severe","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ, HCQ + AZT",440
"NCT04321278","https://ClinicalTrials.gov/show/NCT04321278",NA,"Brazil","Santa Catarina","2020-Mar","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Severe","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ, HCQ + AZT",440
"NCT04321278","https://ClinicalTrials.gov/show/NCT04321278",NA,"Israel","Jerusalem","2020-Mar","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Severe","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ, HCQ + AZT",440
"CHICTR2000030750","http://www.chictr.org.cn/showproj.aspx?proj=50928",NA,"China","Guangdong","2020-Mar","2021-Feb","Not Recruiting","Randomised","Unspecified",4,"Confirmed","Non-severe","Unclear","Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, C-Reactive Protein, IL-17, Lymphocyte Count, Blood Gas, Radiographic Findings","SOC, Vaccine",120
"NCT04315948","https://ClinicalTrials.gov/show/NCT04315948",NA,"France","Paris","2020-Mar","2023-Mar","Recruiting","Randomised","Open-Label",5,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Creatinine Phosphokinase, CK-MB, Prothrombin, Electrolytes, INR, ALT, AST, Bilirubin, Glucose","HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC",3100
"NCT04315948","https://ClinicalTrials.gov/show/NCT04315948",NA,"France","Martinique","2020-Mar","2023-Mar","Recruiting","Randomised","Open-Label",5,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Creatinine Phosphokinase, CK-MB, Prothrombin, Electrolytes, INR, ALT, AST, Bilirubin, Glucose","HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC",3100
"NCT04315948","https://ClinicalTrials.gov/show/NCT04315948",NA,"Luxembourg","Luxembourg","2020-Mar","2023-Mar","Recruiting","Randomised","Open-Label",5,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Creatinine Phosphokinase, CK-MB, Prothrombin, Electrolytes, INR, ALT, AST, Bilirubin, Glucose","HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC",3100
"CHICTR2000029999","http://www.chictr.org.cn/showproj.aspx?proj=49717",NA,"China","Shanghai","2020-Feb",NA,"Not Recruiting","Randomised","Unspecified",2,"Confirmed","Mixed","Unclear","Fever, C-Reactive Protein, IL-2, IL-4, IL-6, IL-10, IL-12, Tumor Necrosis Factor (Any), Interferon (Any), Erythrocyte Sedimentation Rate, D-Dimer, Weight, Height or BMI, ALT, AST, Albumin, IgG, IgM or IgA, Blood Urea Nitrogen, Blood Pressure, Heart Rate, ECG, Respiratory Rate, Radiographic Findings","Nutrition",60
"NCT04361435","https://ClinicalTrials.gov/show/NCT04361435",NA,"Canada","Quebec","2020-Apr","2020-Jul","Not Recruiting","Randomised","Open-Label",2,NA,NA,"ICU","Clinical Improvement Score (Any), Fever, Blood Pressure, Heart Rate, PaO2-FiO2, Respiratory Rate","Respiratory support",50
"CHICTR2000030398","http://www.chictr.org.cn/showproj.aspx?proj=50173",NA,"China","Hubei","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed",NA,"Hospital","Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, PaO2-FiO2, SpO2","Other, SOC",340
"NCT04343001","https://ClinicalTrials.gov/show/NCT04343001",NA,"Nigeria","Niger","2020-Apr","2021-Apr","Not Recruiting","Randomised","Open-Label",3,"Presumed","Mixed","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Lung Inflamation, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Losartan, Losartan + Simvastatin, NSAIDs, NSAIDs + Losartan, NSAIDs + Losartan + Simvastatin, NSAIDs + Simvastatin, Simvastatin",10000
"NCT04343001","https://ClinicalTrials.gov/show/NCT04343001",NA,"Pakistan","Islamabad","2020-Apr","2021-Apr","Not Recruiting","Randomised","Open-Label",3,"Presumed","Mixed","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Lung Inflamation, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Losartan, Losartan + Simvastatin, NSAIDs, NSAIDs + Losartan, NSAIDs + Losartan + Simvastatin, NSAIDs + Simvastatin, Simvastatin",10000
"NCT04360759","https://ClinicalTrials.gov/show/NCT04360759",NA,"South Africa","Western Cape","2020-Apr","2021-May","Not Recruiting","Randomised","Open-Label",2,NA,NA,"Outpatient","Mortality, ICU Admission, Pneumonia or ARDS, Adverse Events","HCQ, SOC",560
"2020-001500-41","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001500-41/BE/",NA,"Belgium","Brussels","2020-Apr",NA,"Recruiting","Randomised","Open-Label",6,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-1, IL-6, Triglycerides, PaO2-FiO2, Respiratory Rate, Radiographic Findings, Hypoxia","Siltuximab, TCZ",NA
"NCT04344782","https://ClinicalTrials.gov/show/NCT04344782",NA,"France","Paris","2020-Apr","2020-Sep","Not Recruiting","Randomised","Open-Label",2,"Yes","Mixed","Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Dyspnea, Adverse Events, Blood Pressure, Heart Rate, PaO2-FiO2","Bevacizumab, SOC",130
"NCT04331366","https://ClinicalTrials.gov/show/NCT04331366",NA,"United States","Georgia","2020-Apr","2020-May","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Mixed","Hospital","Blood Gas, Blood Pressure, Heart Rate, PaO2-FiO2, SpO2, Respiratory Rate, Blood pH, Bicarbonates","Bidirectional oxygen valve, SOC",5
"NCT04358835","https://ClinicalTrials.gov/show/NCT04358835",NA,"United States","Maryland","2020-Apr","2020-Aug","Not Recruiting","Single-Arm","Open-Label",1,NA,NA,"ICU","ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Ferritin, IL-1, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Platelet Count, Hemoglobin, Albumin, Glucose, Blood Urea Nitrogen, Heart Rate, PaO2-FiO2, Blood pH, Bicarbonates, Renal Outcome (Unspecified)","Nutrition",15
"2020-001420-34","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001420-34/DK/",NA,"Denmark","Copenhagen","2020-Apr",NA,"Recruiting","Randomised","Open-Label",1,NA,NA,"ICU","Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), PaO2-FiO2","Other",NA
"NCT04315987","https://ClinicalTrials.gov/show/NCT04315987",NA,"Brazil","Brasilia","2020-Mar","2020-Aug","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, Clinical Improvement Score (Any), Non-invasive Ventilation, White Blood Cell Count, Creatinine Phosphokinase, CK-MB, ALT, CD4, CD8, PaO2-FiO2, Hypoxia","Stem cells",90
"2020-001717-20","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001717-20/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Unclear","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Dyspnea, Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, IL-1, IL-2, IL-4, IL-6, IL-8, IL-12, Tumor Necrosis Factor (Any), Granulocyte Stimulaiting Factor, Interferon (Any), PaO2-FiO2, Respiratory Rate, Radiographic Findings","Vitamins",NA
"NCT04341038","https://ClinicalTrials.gov/show/NCT04341038",NA,"Spain","Barcelona","2020-Apr","2020-Jun","Recruiting","Randomised","Single",2,"Confirmed","Severe","ICU","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Ferritin, D-Dimer, PaO2-FiO2",NA,84
"NCT04324021","https://ClinicalTrials.gov/show/NCT04324021",NA,"Italy","Brescia","2020-Mar","2020-Jul","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Healthcare Workers, Unclear","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Platelet Count, Hemoglobin, D-Dimer, Troponin, Prothrombin, Fibrinogen, ALT, AST, Bilirubin, LDH, PaO2-FiO2, SpO2, Blood pH","Anakinra, mAb",54
"NCT04324021","https://ClinicalTrials.gov/show/NCT04324021",NA,"Italy","Milano","2020-Mar","2020-Jul","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Healthcare Workers, Unclear","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Platelet Count, Hemoglobin, D-Dimer, Troponin, Prothrombin, Fibrinogen, ALT, AST, Bilirubin, LDH, PaO2-FiO2, SpO2, Blood pH","Anakinra, mAb",54
"NCT04324021","https://ClinicalTrials.gov/show/NCT04324021",NA,"Italy","Parma","2020-Mar","2020-Jul","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Healthcare Workers, Unclear","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Platelet Count, Hemoglobin, D-Dimer, Troponin, Prothrombin, Fibrinogen, ALT, AST, Bilirubin, LDH, PaO2-FiO2, SpO2, Blood pH","Anakinra, mAb",54
"NCT04324021","https://ClinicalTrials.gov/show/NCT04324021",NA,"Italy","Roma","2020-Mar","2020-Jul","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Healthcare Workers, Unclear","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Platelet Count, Hemoglobin, D-Dimer, Troponin, Prothrombin, Fibrinogen, ALT, AST, Bilirubin, LDH, PaO2-FiO2, SpO2, Blood pH","Anakinra, mAb",54
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Alabama","2020-Feb","2023-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, SOC",800
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","California","2020-Feb","2023-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, SOC",800
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Colorado","2020-Feb","2023-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, SOC",800
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Georgia","2020-Feb","2023-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, SOC",800
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Illinois","2020-Feb","2023-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, SOC",800
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Louisiana","2020-Feb","2023-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, SOC",800
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Maryland","2020-Feb","2023-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, SOC",800
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Massachusetts","2020-Feb","2023-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, SOC",800
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Minnesota","2020-Feb","2023-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, SOC",800
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Missouri","2020-Feb","2023-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, SOC",800
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Nebraska","2020-Feb","2023-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, SOC",800
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","New York","2020-Feb","2023-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, SOC",800
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","North Carolina","2020-Feb","2023-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, SOC",800
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Pennsylvania","2020-Feb","2023-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, SOC",800
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Tennessee","2020-Feb","2023-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, SOC",800
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Texas","2020-Feb","2023-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, SOC",800
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Virginia","2020-Feb","2023-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, SOC",800
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Washington","2020-Feb","2023-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, SOC",800
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"Denmark","Copenhagen","2020-Feb","2023-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, SOC",800
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"Germany","Nordrhein-Westfalen","2020-Feb","2023-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, SOC",800
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"Germany","Berlin","2020-Feb","2023-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, SOC",800
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"Macedonia","Skopje","2020-Feb","2023-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, SOC",800
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"Greece","Athens","2020-Feb","2023-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, SOC",800
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"Japan","Tokyo","2020-Feb","2023-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, SOC",800
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"South Korea","Gyeonggi","2020-Feb","2023-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, SOC",800
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"South Korea","Seoul","2020-Feb","2023-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, SOC",800
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"Mexico","Mexico","2020-Feb","2023-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, SOC",800
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"Singapore","Singapore","2020-Feb","2023-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, SOC",800
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"Spain","Barcelona","2020-Feb","2023-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, SOC",800
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United Kingdom","East Sussex","2020-Feb","2023-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, SOC",800
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United Kingdom","City","2020-Feb","2023-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, SOC",800
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United Kingdom","Newcastle Upon Tyne","2020-Feb","2023-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, SOC",800
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United Kingdom","Leeds","2020-Feb","2023-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, SOC",800
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United Kingdom","London","2020-Feb","2023-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, SOC",800
"NCT04329650","https://ClinicalTrials.gov/show/NCT04329650",NA,"Spain","Madrid","2020-Apr","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, Ferritin, Lymphocyte Count, Platelet Count, Hemoglobin, D-Dimer, ALT, Bilirubin, LDH, SpO2, Hypoxemia","Corticosteroids, Siltuximab",200
"NCT04329650","https://ClinicalTrials.gov/show/NCT04329650",NA,"Spain","Barcelona","2020-Apr","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, Ferritin, Lymphocyte Count, Platelet Count, Hemoglobin, D-Dimer, ALT, Bilirubin, LDH, SpO2, Hypoxemia","Corticosteroids, Siltuximab",200
"NCT04329650","https://ClinicalTrials.gov/show/NCT04329650",NA,"Spain","Salamanca","2020-Apr","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, Ferritin, Lymphocyte Count, Platelet Count, Hemoglobin, D-Dimer, ALT, Bilirubin, LDH, SpO2, Hypoxemia","Corticosteroids, Siltuximab",200
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","California","2020-Mar","2021-Mar","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, Creatinine Phosphokinase, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, SOC",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Colorado","2020-Mar","2021-Mar","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, Creatinine Phosphokinase, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, SOC",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Connecticut","2020-Mar","2021-Mar","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, Creatinine Phosphokinase, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, SOC",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","District Of Columbia","2020-Mar","2021-Mar","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, Creatinine Phosphokinase, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, SOC",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Florida","2020-Mar","2021-Mar","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, Creatinine Phosphokinase, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, SOC",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Georgia","2020-Mar","2021-Mar","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, Creatinine Phosphokinase, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, SOC",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Illinois","2020-Mar","2021-Mar","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, Creatinine Phosphokinase, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, SOC",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Louisiana","2020-Mar","2021-Mar","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, Creatinine Phosphokinase, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, SOC",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Maryland","2020-Mar","2021-Mar","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, Creatinine Phosphokinase, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, SOC",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Massachusetts","2020-Mar","2021-Mar","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, Creatinine Phosphokinase, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, SOC",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Michigan","2020-Mar","2021-Mar","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, Creatinine Phosphokinase, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, SOC",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Minnesota","2020-Mar","2021-Mar","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, Creatinine Phosphokinase, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, SOC",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","New Jersey","2020-Mar","2021-Mar","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, Creatinine Phosphokinase, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, SOC",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","New York","2020-Mar","2021-Mar","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, Creatinine Phosphokinase, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, SOC",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Oklahoma","2020-Mar","2021-Mar","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, Creatinine Phosphokinase, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, SOC",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Oregon","2020-Mar","2021-Mar","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, Creatinine Phosphokinase, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, SOC",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Pennsylvania","2020-Mar","2021-Mar","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, Creatinine Phosphokinase, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, SOC",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Texas","2020-Mar","2021-Mar","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, Creatinine Phosphokinase, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, SOC",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Utah","2020-Mar","2021-Mar","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, Creatinine Phosphokinase, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, SOC",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Virginia","2020-Mar","2021-Mar","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, Creatinine Phosphokinase, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, SOC",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Washington","2020-Mar","2021-Mar","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, Creatinine Phosphokinase, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, SOC",400
"2020-001255-40","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001255-40/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Unspecified","Open-Label",NA,NA,NA,"Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, C-Reactive Protein, Ferritin, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Troponin, ALT, AST, LDH, Blood Urea Nitrogen, PaO2-FiO2, SpO2","Sarilumab",NA
"NCT04393948","https://ClinicalTrials.gov/show/NCT04393948",NA,"United States","Washington, Dc","2020-May","2020-Oct","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Radiographic Findings","Radiation therapy, SOC",48
"NCT04394169","https://ClinicalTrials.gov/show/NCT04394169",NA,"Spain","Barcelona","2020-May","2020-Sep","Not Recruiting","Randomised","Single",2,"Resolved","Unclear","Resolved Discharged","Quality of Life, Depression, Anxiety","Rehabilitation, SOC",102
"NCT04394377","https://ClinicalTrials.gov/show/NCT04394377",NA,"Brazil","Brasilia","2020-May","2020-Dec","Not Recruiting","Randomised","Single",2,"Confirmed","Unclear","Hospital","Mortality, D-Dimer, Troponin","Anticoagulants",600
"NCT04394416","https://ClinicalTrials.gov/show/NCT04394416",NA,"United States","Maryland","2020-May","2022-Jun","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","ICU","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Imatinib, SOC",204
"NCT04395170","https://ClinicalTrials.gov/show/NCT04395170",NA,"Colombia","Antioquia","2020-May","2020-Dec","Not Recruiting","Randomised","Open-Label",3,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events, IgG, IgM or IgA, Antibodies","Igs, Plasma based therapy, SOC",75
"NCT04395456","https://ClinicalTrials.gov/show/NCT04395456",NA,"United States","Pennsylvania","2020-May","2021-Jan","Not Recruiting","Randomised","Single",2,"Confirmed","Severe","Hospital","ICU Admission, Hospital Discharge, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, Ferritin, IL-1, IL-6, IL-12, Platelet Count, D-Dimer, Procalcitonin, LDH, Antibodies, Blood Pressure, Heart Rate, PaO2-FiO2, Respiratory Rate, Cardiac Outcome (Unspecified)","Other, SOC",144
"NCT04395768","https://ClinicalTrials.gov/show/NCT04395768",NA,"Australia","Victoria","2020-May","2021-May","Not Recruiting","Randomised","Double",6,"Confirmed","Unclear","Unclear","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Renal Outcome (Unspecified)","HCQ + AZT + Zinc + Vitamins",200
"NCT04395911","https://clinicaltrials.gov/show/NCT04395911",NA,"United States","Colorado","2020-May",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear","Unclear","Mortality, Renal Outcome (Unspecified)","Device",35
"NCT04396067","https://clinicaltrials.gov/show/NCT04396067",NA,"Egypt","Cairo","2020-May",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Moderate/Severe","Hospital",NA,"Other, SOC",360
"NCT04397328","https://ClinicalTrials.gov/show/NCT04397328",NA,"Canada","Ontario","2020-May","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Healthy","None","Healthy Unexposed, Healthy Exposed, Hospital","Mortality, ICU Admission, Cough, Fever, Dyspnea","HCQ, SOC",336
"NCT04397510","https://ClinicalTrials.gov/show/NCT04397510",NA,"United States","Maryland","2020-May","2020-Dec","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","ICU","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Adverse Events, PaO2-FiO2","Anticoagulants, SOC",50
"NCT04398303","https://ClinicalTrials.gov/show/NCT04398303",NA,"United States","Florida","2020-May","2020-Oct","Not Recruiting","Randomised","Double",3,"Confirmed","Moderate/Severe","Hospital","Mortality, ICU Admission","SOC, Stem cells",70
"NCT04399317","https://ClinicalTrials.gov/show/NCT04399317",NA,"Qatar","Doha","2020-May","2020-Jul","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","ICU","PaO2-FiO2","Device, SOC",20
"NCT04399356","https://ClinicalTrials.gov/show/NCT04399356",NA,"United States","Massachusetts","2020-May","2020-Oct","Not Recruiting","Randomised","Triple",3,"Confirmed","Unclear","Outpatient","Viral Load or Clearance","Other, SOC",100
"NCT04399798","https://ClinicalTrials.gov/show/NCT04399798",NA,"Italy","Pavia","2020-May","2020-Sep","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear","Unclear","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Adverse Events, IL-2, IL-6, IL-8, IL-10, IL-17, Tumor Necrosis Factor (Any), Interferon (Any), PaO2-FiO2, SpO2","JAKi",13
"NCT04399889","https://ClinicalTrials.gov/show/NCT04399889",NA,"United States","Colorado","2020-May","2021-Apr","Not Recruiting","Single-Arm","Quadruple",1,"Confirmed","Unclear","Unclear",NA,"SOC, Stem cells",30
"NCT04400019","https://ClinicalTrials.gov/show/NCT04400019",NA,"Spain","Malaga","2020-May","2020-Dec","Not Recruiting","Randomised","Double",2,"Healthy","None","Healthy Unexposed, Healthcare Workers","Mortality, Hospitalization, Adverse Events","HCQ, SOC",1930
"NCT04400058","https://ClinicalTrials.gov/show/NCT04400058",NA,"United States","Washington, Dc","2020-May","2020-Sep","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Dyspnea, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Albumin, Bilirubin, Glucose, LDH, IgG, IgM or IgA, Blood Urea Nitrogen, SpO2, Radiographic Findings, Quality of Life","Plasma based therapy, SOC",54
"NCT04357730","https://ClinicalTrials.gov/show/NCT04357730",NA,"United States","Colorado","2020-Apr","2020-Sep","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2","SOC, Thrombolytic agent",60
"EUCTR2020-001367-88-DK","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001367-88",NA,"Denmark","Copenhagen","2020-Jan",NA,"Not Recruiting","Randomised","Double",6,NA,NA,"Unclear","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events","HCQ, JAKi, Sarilumab, SOC",1500
"NCT04362813","https://ClinicalTrials.gov/show/NCT04362813",NA,"United States","California","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,"Confirmed","Mixed","Hospital","Mortality, Clinical Improvement Score (Any), Adverse Events, C-Reactive Protein, Ferritin, D-Dimer","mAb, SOC",450
"NCT04362813","https://ClinicalTrials.gov/show/NCT04362813",NA,"United States","Illinois","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,"Confirmed","Mixed","Hospital","Mortality, Clinical Improvement Score (Any), Adverse Events, C-Reactive Protein, Ferritin, D-Dimer","mAb, SOC",450
"NCT04362813","https://ClinicalTrials.gov/show/NCT04362813",NA,"United States","Maryland","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,"Confirmed","Mixed","Hospital","Mortality, Clinical Improvement Score (Any), Adverse Events, C-Reactive Protein, Ferritin, D-Dimer","mAb, SOC",450
"NCT04362813","https://ClinicalTrials.gov/show/NCT04362813",NA,"United States","Massachusetts","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,"Confirmed","Mixed","Hospital","Mortality, Clinical Improvement Score (Any), Adverse Events, C-Reactive Protein, Ferritin, D-Dimer","mAb, SOC",450
"NCT04362813","https://ClinicalTrials.gov/show/NCT04362813",NA,"United States","New York","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,"Confirmed","Mixed","Hospital","Mortality, Clinical Improvement Score (Any), Adverse Events, C-Reactive Protein, Ferritin, D-Dimer","mAb, SOC",450
"NCT04362813","https://ClinicalTrials.gov/show/NCT04362813",NA,"United States","North Carolina","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,"Confirmed","Mixed","Hospital","Mortality, Clinical Improvement Score (Any), Adverse Events, C-Reactive Protein, Ferritin, D-Dimer","mAb, SOC",450
"NCT04362813","https://ClinicalTrials.gov/show/NCT04362813",NA,"United States","Pennsylvania","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,"Confirmed","Mixed","Hospital","Mortality, Clinical Improvement Score (Any), Adverse Events, C-Reactive Protein, Ferritin, D-Dimer","mAb, SOC",450
"NCT04362813","https://ClinicalTrials.gov/show/NCT04362813",NA,"United States","Texas","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,"Confirmed","Mixed","Hospital","Mortality, Clinical Improvement Score (Any), Adverse Events, C-Reactive Protein, Ferritin, D-Dimer","mAb, SOC",450
"NCT04362813","https://ClinicalTrials.gov/show/NCT04362813",NA,"United States","Virginia","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,"Confirmed","Mixed","Hospital","Mortality, Clinical Improvement Score (Any), Adverse Events, C-Reactive Protein, Ferritin, D-Dimer","mAb, SOC",450
"NCT04362813","https://ClinicalTrials.gov/show/NCT04362813",NA,"Germany","Berlin","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,"Confirmed","Mixed","Hospital","Mortality, Clinical Improvement Score (Any), Adverse Events, C-Reactive Protein, Ferritin, D-Dimer","mAb, SOC",450
"NCT04362813","https://ClinicalTrials.gov/show/NCT04362813",NA,"Spain","Barcelona","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,"Confirmed","Mixed","Hospital","Mortality, Clinical Improvement Score (Any), Adverse Events, C-Reactive Protein, Ferritin, D-Dimer","mAb, SOC",450
"NCT04362813","https://ClinicalTrials.gov/show/NCT04362813",NA,"Spain","Madrid","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,"Confirmed","Mixed","Hospital","Mortality, Clinical Improvement Score (Any), Adverse Events, C-Reactive Protein, Ferritin, D-Dimer","mAb, SOC",450
"NCT04362813","https://ClinicalTrials.gov/show/NCT04362813",NA,"United Kingdom","Barnet","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,"Confirmed","Mixed","Hospital","Mortality, Clinical Improvement Score (Any), Adverse Events, C-Reactive Protein, Ferritin, D-Dimer","mAb, SOC",450
"NCT04362813","https://ClinicalTrials.gov/show/NCT04362813",NA,"United Kingdom","Leeds","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,"Confirmed","Mixed","Hospital","Mortality, Clinical Improvement Score (Any), Adverse Events, C-Reactive Protein, Ferritin, D-Dimer","mAb, SOC",450
"NCT04362813","https://ClinicalTrials.gov/show/NCT04362813",NA,"United Kingdom","London","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,"Confirmed","Mixed","Hospital","Mortality, Clinical Improvement Score (Any), Adverse Events, C-Reactive Protein, Ferritin, D-Dimer","mAb, SOC",450
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Indonesia","Jakarta","2020-Mar",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed",NA,"Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Iran","Tehran","2020-Mar",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed",NA,"Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Ireland","Dublin","2020-Mar",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed",NA,"Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Israel","Jerusalem","2020-Mar",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed",NA,"Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Italy","Rome","2020-Mar",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed",NA,"Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Kenya","Nairobi","2020-Mar",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed",NA,"Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Lebanon","Beirut","2020-Mar",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed",NA,"Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Malaysia","Kuala Lumpur","2020-Mar",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed",NA,"Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Norway","Oslo","2020-Mar",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed",NA,"Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Peru","Lima","2020-Mar",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed",NA,"Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Philippines","Manila","2020-Mar",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed",NA,"Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Qatar","Doha","2020-Mar",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed",NA,"Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Saudi Arabia","Riyadh","2020-Mar",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed",NA,"Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"South Africa","Pretoria","2020-Mar",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed",NA,"Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Spain","Madrid","2020-Mar",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed",NA,"Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Switzerland","Bern","2020-Mar",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed",NA,"Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Thailand","Nan","2020-Mar",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed",NA,"Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Argentina","Buenos Aires","2020-Mar",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed",NA,"Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Brazil","Brasilia","2020-Mar",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed",NA,"Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Canada","Ottawa","2020-Mar",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed",NA,"Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Germany","Berlin","2020-Mar",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed",NA,"Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Honduras","Tegucigalpa","2020-Mar",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed",NA,"Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"India","New Delhi","2020-Mar",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed",NA,"Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC",10000
"NCT04322123","https://ClinicalTrials.gov/show/NCT04322123",NA,"Brazil","Brasilia","2020-Mar","2020-Aug","Not Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected",NA,"Hospital, ICU","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2","HCQ, SOC",630
"NCT04322123","https://ClinicalTrials.gov/show/NCT04322123",NA,"Brazil","Distrito Federal","2020-Mar","2020-Aug","Not Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected",NA,"Hospital, ICU","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2","HCQ, SOC",630
"NCT04322123","https://ClinicalTrials.gov/show/NCT04322123",NA,"Brazil","Rio De Janeiro","2020-Mar","2020-Aug","Not Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected",NA,"Hospital, ICU","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2","HCQ, SOC",630
"NCT04366063","https://ClinicalTrials.gov/show/NCT04366063",NA,"Iran","Tehran","2020-Apr","2020-Jun","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","ICU Admission, Pneumonia or ARDS, Adverse Events, Serious Adverse Events","SOC, Stem cells",60
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","California","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Colorado","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Connecticut","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Hawaii","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Illinois","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Indiana","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Iowa","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Louisiana","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Maine","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Maryland","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Massachusetts","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Michigan","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Minnesota","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Montana","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","New Hampshire","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","New Jersey","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","New York","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","North Carolina","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Ohio","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Oregon","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Pennsylvania","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Rhode Island","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","South Carolina","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Texas","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Utah","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Virginia","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Washington","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"China","Beijing","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"France","Paris","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Germany","Berlin","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Germany","Hamburg","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Germany","Schleswig-Holstein","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"China","Hong Kong","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Italy","Bergamo","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Italy","Brescia","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Italy","Cremona","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Italy","Milano","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Italy","Rome","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Italy","Padova","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Italy","Parma","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Italy","Pavia","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Italy","Piacenza","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Italy","Roma","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Japan","Kanagawa","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Japan","Tokyo","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"South Korea","Daegu","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"South Korea","Seoul","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Netherlands","Amsterdam","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Singapore","Singapore","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Spain","Asturias","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Spain","Madrid","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Spain","Barcelona","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Spain","Bizkaia","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Spain","Sevilla","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Spain","Valencia","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Sweden","Stockholm","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Switzerland","Bern","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Taiwan","Taipei","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Taiwan","Taipei City","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United Kingdom","London","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United Kingdom","Edinburgh","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United Kingdom","Glasgow","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United Kingdom","Liverpool","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United Kingdom","Manchester","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United Kingdom","Plymouth","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United Kingdom","Sheffield","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, SOC",1600
"CTRI/2020/04/024479","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42713",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Open-Label",NA,NA,NA,"Hospital","Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events, Heart Rate","HCQ, SOC",32
"NCT04326790","https://ClinicalTrials.gov/show/NCT04326790",NA,"Gibraltar","Gibraltar","2020-Mar","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Unclear","Clinical Improvement Score (Any), C-Reactive Protein, Troponin","Colchicine, SOC",180
"EUCTR2020-001570-30-FR","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001570-30",NA,"France","Paris","2020-Jun",NA,"Not Recruiting","Randomised","Double",2,NA,NA,"ICU","Mortality, Secondary CoViD-19 Re-infection, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, C-Reactive Protein, Lymphocyte Count, D-Dimer, Fibrinogen, CD4, CD8, Renal Outcome (Unspecified)","Other, SOC",126
"2020-001591-15","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001591-15/NL/",NA,"Netherlands","Amsterdam","2020-Apr",NA,"Recruiting","Randomised","Single",2,NA,NA,"Healthy Unexposed","Mortality, ICU Admission, Hospitalization, Secondary CoViD-19 Re-infection, Fever, Other Mild Symptoms","SOC, Vaccine",NA
"NCT04312997","https://ClinicalTrials.gov/show/NCT04312997",NA,"United States","Kentucky","2020-Mar","2020-Sep","Recruiting","Randomised","Quadruple",2,"Confirmed","Unspecified","Unclear","Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation","Other, SOC",100
"NCT04312997","https://ClinicalTrials.gov/show/NCT04312997",NA,"United States","Oklahoma","2020-Mar","2020-Sep","Recruiting","Randomised","Quadruple",2,"Confirmed","Unspecified","Unclear","Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation","Other, SOC",100
"NCT04312997","https://ClinicalTrials.gov/show/NCT04312997",NA,"United States","Texas","2020-Mar","2020-Sep","Recruiting","Randomised","Quadruple",2,"Confirmed","Unspecified","Unclear","Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation","Other, SOC",100
"CHICTR2000029589","http://www.chictr.org.cn/showproj.aspx?proj=49104",NA,"China","Beijing","2020-Feb","2021-Dec","Recruiting","Non-Randomised","Open-Label",2,"Confirmed",NA,"Outpatient","Viral Load or Clearance, Cough, Fever, Dyspnea","SOC, TCM",60
"EUCTR2020-001039-29-GR","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001039-29",NA,"Greece","Athens","2020-Mar",NA,"Not Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), PaO2-FiO2, Radiographic Findings","Anakinra, TCZ",40
"NCT04342689","https://ClinicalTrials.gov/show/NCT04342689",NA,"United States","Massachusetts","2020-Apr","2021-Jun","Not Recruiting","Randomised","Quadruple",2,"Yes","Non-severe","Outpatient","Mortality, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Nutrition, SOC",1500
"NCT04345991","https://ClinicalTrials.gov/show/NCT04345991",NA,"France","Paris","2020-Apr","2020-May","Recruiting","Randomised","Open-Label",2,NA,NA,"Outpatient","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Ferritin, IL-6, D-Dimer, Creatinine Phosphokinase, Myoglobin, Troponin, Procalcitonin, Fibrinogen, Coagulation Test, Triglycerides, Electrolytes, Albumin, LDH, Urine Sample, PaO2-FiO2, Respiratory Rate","Plasma based therapy, SOC",120
"RPCEC00000306","http://rpcec.sld.cu/en/trials/RPCEC00000306-En",NA,"Cuba","Havana","2020-Apr",NA,"Recruiting","Randomised","Unspecified",NA,NA,NA,"Healthy Exposed","Viral Load or Clearance, Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, Tumor Necrosis Factor (Any), Interferon (Any), Prothrombin, Triglycerides, ALT, Albumin, Bilirubin, Glucose","SOC, Vaccine",80
"NCT04333355","https://ClinicalTrials.gov/show/NCT04333355",NA,"Mexico","Nuevo Leon","2020-Apr","2020-Dec","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","Viral Load or Clearance, Organ Failure or Dysfunction (SOFA), Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","Plasma based therapy",20
"IRCT20150303021315N17","http://en.irct.ir/trial/46550",NA,"Iran","Tehran","2020-Apr","2020-Jul","Recruiting","Single-Arm","Open-Label",1,NA,NA,"Unclear","Mortality, Non-invasive Ventilation, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, PaO2-FiO2, Radiographic Findings","TCZ",85
"NCT04338074","https://ClinicalTrials.gov/show/NCT04338074",NA,"United States","Alabama","2020-Apr","2020-Oct","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Mixed","Outpatient","Viral Load or Clearance, Treatment-emergent Adverse Events",NA,100
"NCT04334460","https://ClinicalTrials.gov/show/NCT04334460",NA,"United States","California","2020-Apr","2020-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Fever, Treatment-emergent Adverse Events, Serious Adverse Events, IL-6, PaO2-FiO2",NA,120
"NCT04334460","https://ClinicalTrials.gov/show/NCT04334460",NA,"United States","District Of Columbia","2020-Apr","2020-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Fever, Treatment-emergent Adverse Events, Serious Adverse Events, IL-6, PaO2-FiO2",NA,120
"NCT04334460","https://ClinicalTrials.gov/show/NCT04334460",NA,"United States","Florida","2020-Apr","2020-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Fever, Treatment-emergent Adverse Events, Serious Adverse Events, IL-6, PaO2-FiO2",NA,120
"NCT04334460","https://ClinicalTrials.gov/show/NCT04334460",NA,"United States","Illinois","2020-Apr","2020-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Fever, Treatment-emergent Adverse Events, Serious Adverse Events, IL-6, PaO2-FiO2",NA,120
"NCT04334460","https://ClinicalTrials.gov/show/NCT04334460",NA,"United States","Louisiana","2020-Apr","2020-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Fever, Treatment-emergent Adverse Events, Serious Adverse Events, IL-6, PaO2-FiO2",NA,120
"NCT04334460","https://ClinicalTrials.gov/show/NCT04334460",NA,"United States","Maryland","2020-Apr","2020-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Fever, Treatment-emergent Adverse Events, Serious Adverse Events, IL-6, PaO2-FiO2",NA,120
"NCT04334460","https://ClinicalTrials.gov/show/NCT04334460",NA,"United States","Michigan","2020-Apr","2020-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Fever, Treatment-emergent Adverse Events, Serious Adverse Events, IL-6, PaO2-FiO2",NA,120
"NCT04334460","https://ClinicalTrials.gov/show/NCT04334460",NA,"United States","Missouri","2020-Apr","2020-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Fever, Treatment-emergent Adverse Events, Serious Adverse Events, IL-6, PaO2-FiO2",NA,120
"NCT04334460","https://ClinicalTrials.gov/show/NCT04334460",NA,"United States","Nevada","2020-Apr","2020-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Fever, Treatment-emergent Adverse Events, Serious Adverse Events, IL-6, PaO2-FiO2",NA,120
"NCT04334460","https://ClinicalTrials.gov/show/NCT04334460",NA,"United States","North Carolina","2020-Apr","2020-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Fever, Treatment-emergent Adverse Events, Serious Adverse Events, IL-6, PaO2-FiO2",NA,120
"NCT04334460","https://ClinicalTrials.gov/show/NCT04334460",NA,"United States","Pennsylvania","2020-Apr","2020-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Fever, Treatment-emergent Adverse Events, Serious Adverse Events, IL-6, PaO2-FiO2",NA,120
"NCT04334460","https://ClinicalTrials.gov/show/NCT04334460",NA,"United States","Tennessee","2020-Apr","2020-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Fever, Treatment-emergent Adverse Events, Serious Adverse Events, IL-6, PaO2-FiO2",NA,120
"NCT04332081","https://ClinicalTrials.gov/show/NCT04332081",NA,"United States","New York","2020-Apr","2020-Jul","Recruiting","Single-Arm","Open-Label",1,"Confirmed",NA,"Hospital","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6",NA,40
"NCT04338906","https://clinicaltrials.gov/show/NCT04338906",NA,"Germany","Berlin","2020-Mar",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), C-Reactive Protein, Troponin",NA,334
"NCT04345419","https://clinicaltrials.gov/show/NCT04345419",NA,"Egypt","Cairo","2020-Nov",NA,"Not Recruiting","Randomised","Single",5,NA,NA,"Unclear","Hospitalization, Cough, Fever, Dyspnea, Other Mild Symptoms, Treatment-emergent Adverse Events",NA,120
"NCT04344561","https://clinicaltrials.gov/show/NCT04344561",NA,"United States","Maryland","2020-Oct",NA,"Not Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance",NA,70
"NCT04340349","https://clinicaltrials.gov/show/NCT04340349",NA,"Mexico","Mexico","2020-Feb",NA,"Recruiting","Randomised","Triple",1,NA,NA,"Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6",NA,140
"NCT04359316","https://ClinicalTrials.gov/show/NCT04359316",NA,"Iran","Tehran","2020-Apr","2020-May","Not Recruiting","Randomised","Triple",2,NA,NA,"Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","AZT, HCQ",40
"NL8521","https://trialregister.nl/trial/8521",NA,"Netherlands","Amsterdam","2020-Apr",NA,"Not Recruiting","Single-Arm","Open-Label",1,NA,NA,"Hospital","Clinical Improvement Score (Any), Dyspnea, Adverse Events, Heart Rate, PaO2-FiO2, Quality of Life","Device, SOC",13
"CHICTR2000031781","http://www.chictr.org.cn/showproj.aspx?proj=52006",NA,"China","Jiangsu","2020-Apr",NA,"Not Recruiting","Randomised","Double",3,NA,NA,"Unclear","Serious or Seconday Infections, Adverse Events, Anti SARS-COV-2 Titers","SOC, Vaccine",500
"CHICTR2000030054","http://www.chictr.org.cn/showproj.aspx?proj=49869",NA,"China","Fujian","2020-Feb","2020-May","Not Recruiting","Randomised","Unspecified",3,"Confirmed","Non-severe","Outpatient","Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Serious Adverse Events, Heart Rate, Respiratory Rate","HCQ, SOC",100
"CHICTR2000029939","http://www.chictr.org.cn/showproj.aspx?proj=49612",NA,"China","Zhejiang","2020-Feb","2021-Feb","Recruiting","Randomised","Unspecified",2,"Confirmed",NA,"Unclear","Mortality, Hospitalization, Clinical Improvement Score (Any), Secondary CoViD-19 Re-infection, Fever, Serious Adverse Events, C-Reactive Protein, IL-2, IL-4, IL-6, IL-10, Tumor Necrosis Factor (Any), ALT, Bilirubin, Radiographic Findings","HCQ, SOC",100
"NCT04360824","https://ClinicalTrials.gov/show/NCT04360824",NA,"United States","Iowa","2020-Apr","2021-Apr","Not Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Cardiac Outcome (Unspecified)","Anticoagulants",170
"NCT04310228","https://ClinicalTrials.gov/show/NCT04310228",NA,"China","Beijing","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",3,"Confirmed",NA,"Unclear","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","FPV, FPV + TCZ, TCZ",150
"NCT04310228","https://ClinicalTrials.gov/show/NCT04310228",NA,"China","Hubei","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",3,"Confirmed",NA,"Unclear","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","FPV, FPV + TCZ, TCZ",150
"CHICTR2000029996","http://www.chictr.org.cn/showproj.aspx?proj=49510",NA,"China","Beijing","2020-Feb","2020-Apr","Recruiting","Randomised","Open-Label",3,"Confirmed",NA,"Hospital","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Other Mild Symptoms","FPV",60
"IRCT20170207032444N3","http://en.irct.ir/trial/47119",NA,"Iran","Tehran","2020-Apr","2020-Jun","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, Blood Pressure","HCQ, HCQ + Immunomodulators",60
"NCT04328467","https://ClinicalTrials.gov/show/NCT04328467",NA,"United States","Minnesota","2020-Mar","2020-Aug","Not Recruiting","Randomised","Quadruple",2,"Healthy (Exposed)",NA,"Healthcare Workers",NA,"HCQ, SOC",1500
"IRCT20200411047025N1","http://en.irct.ir/trial/47078",NA,"Iran","Tehran","2020-Apr","2020-May","Completed","Randomised","Open-Label",2,NA,NA,"Hospital","Fever, C-Reactive Protein, Respiratory Rate","HCQ + Antiretroviral, HCQ + Antiretroviral + Vitamins",110
"IRCT20180725040596N2","http://en.irct.ir/trial/46897",NA,"Iran","Tehran","2020-Apr","2020-Sep","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Fever, C-Reactive Protein, Erythrocyte Sedimentation Rate, Radiographic Findings","HCQ + LPV/r, HCQ + Umifenovir",100
"NCT04328012","https://ClinicalTrials.gov/show/NCT04328012",NA,"United States","New York","2020-Mar","2021-Jan","Recruiting","Randomised","Quadruple",4,"Confirmed",NA,"Hospital","Clinical Improvement Score (Any), C-Reactive Protein, D-Dimer","ARBs, HCQ, LPV/r, SOC",4000
"2020-001072-15","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001072-15/GB/",NA,"United Kingdom","London","2020-Mar",NA,"Recruiting","Randomised","Single",4,NA,NA,"Healthy Unexposed","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Other Mild Symptoms, Serious or Seconday Infections, Adverse Events, Anti SARS-COV-2 Titers","Vaccine",1112
"NCT04363372","https://ClinicalTrials.gov/show/NCT04363372",NA,"United Kingdom","Leeds","2020-Apr","2020-Aug","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Mixed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events","Other, SOC",90
"CHICTR2000030929","http://www.chictr.org.cn/showproj.aspx?proj=50696",NA,"China","Hubei","2020-Mar","2020-Jun","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Cough, Fever, Other Mild Symptoms","Plasma based therapy, SOC",60
"CHICTR2000030010","http://www.chictr.org.cn/showproj.aspx?proj=49777",NA,"China","Hubei","2020-Feb","2020-May","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Cough, Fever, Dyspnea, Other Mild Symptoms","Plasma based therapy, SOC",100
"CHICTR2000032165","http://www.chictr.org.cn/showproj.aspx?proj=52679",NA,"China","Hubei","2020-Apr","2021-Mar","Not Recruiting","Randomised","Double",2,NA,NA,"Unclear","6-Minute Walking Distance, Radiographic Findings, Quality of Life","Education, TCM + Education",60
"NCT04261517","https://ClinicalTrials.gov/show/NCT04261517","http://www.zjujournals.com/med/EN/10.3785/j.issn.1008-9292.2020.03.03#1","China","Shanghai","2020-Feb","2020-Feb","Completed w. Results","Randomised","Open-Label",2,"Confirmed",NA,"Unclear","Mortality","HCQ, SOC",30
"NCT04361318","https://ClinicalTrials.gov/show/NCT04361318",NA,"Egypt","Cairo","2020-Apr","2020-Oct","Not Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, Viral Load or Clearance, Ferritin, IL-6, Tumor Necrosis Factor (Any), Prothrombin, PaO2-FiO2, Respiratory Rate","HCQ + Antivirals, SOC",100
"IRCT20151228025732N51","http://en.irct.ir/trial/46828",NA,"Iran","Semnan","2020-Apr","2020-Jun","Recruiting","Non-Randomised","Open-Label",2,NA,NA,"Hospital","Cough, Fever, Dyspnea, Other Mild Symptoms","Alternative therapy, SOC",60
"NCT04311177","https://ClinicalTrials.gov/show/NCT04311177",NA,"United States","Minnesota","2020-Mar","2021-Apr","Recruiting","Randomised","Quadruple",2,"Confirmed Or Suspected Or Exposed","Non-severe","Outpatient","Visits or Returns to Emergency Department","ARBs, SOC",580
"EUCTR2020-001320-34-NL","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001320-34",NA,"Netherlands","Amsterdam","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO","ARBs, SOC",641
"2020-001327-13","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001327-13/AT/",NA,"Austria","Vienna","2020-Mar",NA,"Recruiting","Randomised","Single",2,NA,NA,"Healthy Unexposed","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance","AZT, SOC",NA
"2020-001511-25","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001511-25/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, Ferritin, IL-1, IL-6, Tumor Necrosis Factor (Any), D-Dimer, LDH","Colchicine, SOC",NA
"NCT04252274","https://ClinicalTrials.gov/show/NCT04252274",NA,"China","Shanghai","2020-Feb","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Unclear","Mortality, Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO","DAA, SOC",30
"2020-001686-36","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001686-36/FR/",NA,"France","Paris","2020-Apr",NA,"Recruiting","Randomised","Double",4,"Confirmed","Severe","ICU","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), PaO2-FiO2","mAb, SOC",NA
"NCT04356508","https://ClinicalTrials.gov/show/NCT04356508",NA,"China","Hong Kong","2020-Apr","2020-Jun","Not Recruiting","Non-Randomised","Open-Label",2,NA,NA,"Outpatient, Hospital","Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, IL-1, IL-2, IL-6, Tumor Necrosis Factor (Any)","mAb, SOC",15
"IRCT20151228025732N52","http://en.irct.ir/trial/46963",NA,"Iran","Semnan","2020-Apr","2020-Jun","Recruiting","Randomised","Open-Label",2,NA,NA,"ICU","Organ Failure or Dysfunction (SOFA), Respiratory Rate, Radiographic Findings","Melatonin + Vitamins + Sulfate, SOC",30
"NCT04320056","https://ClinicalTrials.gov/show/NCT04320056",NA,"Canada","Quebec","2020-Mar","2021-Apr","Recruiting","Randomised","Open-Label",2,"Suspected","Severe","Hospital","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Non-invasive respiratory support, SOC",216
"NCT04323228","https://ClinicalTrials.gov/show/NCT04323228",NA,"Saudi Arabia","Riyadh","2020-Mar","2020-Oct","Not Recruiting","Randomised","Double",2,"Confirmed","Non-severe","Hospital","Non-invasive Ventilation, Fever, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), MCP-1, White Blood Cell Count, Neutrophils, Weight, Height or BMI","Nutrition, SOC",30
"CHICTR2000030260","http://www.chictr.org.cn/showproj.aspx?proj=50130",NA,"China","Sichuan","2020-Feb","2021-Feb","Not Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Hospital","C-Reactive Protein, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Albumin","Nutrition, SOC",20
"IRCT20160313027033N2","http://en.irct.ir/trial/46762",NA,"Iran","Tehran","2020-Apr","2020-May","Completed","Randomised","Open-Label",2,NA,NA,"Outpatient","Mortality, Hospitalization, Cough, Fever, Other Mild Symptoms, Respiratory Rate","Nutrition, SOC",120
"2020-001640-26","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001640-26/GB/",NA,"United Kingdom","London","2020-Apr",NA,"Recruiting","Single-Arm","Unspecified",1,NA,NA,"ICU","Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Fibrinogen, PaO2-FiO2","Other, SOC",24
"NCT04333472","https://ClinicalTrials.gov/show/NCT04333472",NA,"Israel","Jerusalem","2020-Apr","2020-Jun","Not Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Hospital","Mortality, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, PaO2-FiO2","Other, SOC",40
"NCT04282902","https://ClinicalTrials.gov/show/NCT04282902",NA,"China","Hubei","2020-Feb","2020-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Hospital","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, PaO2-FiO2, Radiographic Findings","Other, SOC",294
"CHICTR2000030779","http://www.chictr.org.cn/showproj.aspx?proj=50973",NA,"China","Shanghai","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Serious Adverse Events","Other, SOC",100
"CHICTR2000030039","http://www.chictr.org.cn/showproj.aspx?proj=49544",NA,"China","Jiangsu","2020-Feb","2020-Feb","Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Mixed","Outpatient, Hospital","Viral Load or Clearance, C-Reactive Protein, IL-6, LDH, Respiratory Rate, Renal Outcome (Unspecified)","Plasma based therapy, SOC",90
"IRCT20200404046948N1","http://en.irct.ir/trial/46973",NA,"Iran","Tehran","2020-Apr","2020-Jun","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever, PaO2-FiO2, Respiratory Rate","Plasma based therapy, SOC",60
"2020-001632-10","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001632-10/DE/",NA,"Germany","Berlin","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","Plasma based therapy, SOC",NA
"NCT04358406","https://ClinicalTrials.gov/show/NCT04358406",NA,"United States","New Jersey","2020-Apr","2020-Aug","Not Recruiting","Single-Arm","Quadruple",1,NA,NA,"Hospital","Mortality, Hospitalization, Hospital Discharge, Visits or Returns to Emergency Department, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Antibodies","Plasma based therapy, SOC",60
"NCT04347941","https://ClinicalTrials.gov/show/NCT04347941",NA,"Ireland","Galway","2020-Apr","2021-Mar","Not Recruiting","Randomised","Double",2,NA,NA,"ICU","Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Respiratory Rate, Patient Positioning","Positioning, SOC",200
"NCT04355728","https://ClinicalTrials.gov/show/NCT04355728",NA,"United States","Florida","2020-Apr","2020-Dec","Recruiting","Randomised","Single",2,NA,NA,"Hospital, ICU","Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, D-Dimer, Troponin, Antibodies","SOC, Stem cells",24
"NCT04273646","https://ClinicalTrials.gov/show/NCT04273646",NA,"China","Hubei","2020-Feb","2020-Jun","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Mortality, Clinical Improvement Score (Any), Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, C-Reactive Protein, Procalcitonin, CD4, CD8, PaO2-FiO2","SOC, Stem cells",48
"NCT04331808","https://ClinicalTrials.gov/show/NCT04331808",NA,"France","Paris","2020-Apr","2021-Mar","Not Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Hospital","Mortality, ICU Admission, PaO2-FiO2, Radiographic Findings, Blood pH","SOC, TCZ",228
"2020-001770-30","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001770-30/BE/",NA,"Belgium","Brussels","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, C-Reactive Protein, Respiratory Rate, Radiographic Findings","SOC, TCZ",60
"2020-001408-41","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001408-41/DE/",NA,"Germany","Berlin","2020-Apr",NA,"Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, Ferritin, IL-6, D-Dimer, Procalcitonin, Shock, Quality of Life, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","SOC, TCZ",NA
"NCT04285190","https://ClinicalTrials.gov/show/NCT04285190",NA,"China","Beijing","2020-Feb","2020-Jun","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Non-severe","Unclear","Mortality, Hospitalization, Fever, Dyspnea, Other Mild Symptoms, White Blood Cell Count, Neutrophils, Erythrocyte Sedimentation Rate, Creatinine Phosphokinase, Troponin, LDH","SOC, TCM",120
"CHICTR2000030255","http://www.chictr.org.cn/showproj.aspx?proj=50089",NA,"China","Shanghai","2020-Feb","2020-Jul","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Mixed","Outpatient, Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Respiratory Rate, Radiographic Findings","SOC, TCM",300
"CHICTR2000031089","http://www.chictr.org.cn/showproj.aspx?proj=51136",NA,"China","Guangdong","2020-Mar","2020-Apr","Not Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Mixed","Unclear","Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, White Blood Cell Count, Erythrocyte Sedimentation Rate, Creatinine Phosphokinase, CK-MB, eGFR, Myoglobin, Troponin, Procalcitonin, Prothrombin, Fibrinogen, Coagulation Test, ALT, Albumin, Bilirubin, Radiographic Findings","SOC, TCM",300
"CHICTR2000030188","http://www.chictr.org.cn/showproj.aspx?proj=50025",NA,"China","Guangdong","2020-Feb","2020-Mar","Recruiting","Randomised","Unspecified",2,"Confirmed","Severe","Unclear","Mortality, Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein, Erythrocyte Sedimentation Rate","SOC, TCM",120
"2020-000919-69","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000919-69/NL/",NA,"Netherlands","Amsterdam","2020-Mar",NA,"Recruiting","Randomised","Double",2,"Healthy (Exposed)","Healthy","Healthcare Workers","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS","SOC, Vaccine",NA
"NCT04357028","https://ClinicalTrials.gov/show/NCT04357028",NA,"Egypt","Cairo","2020-Apr","2020-Oct","Not Recruiting","Randomised","Single",2,NA,NA,"Healthy Unexposed",NA,"SOC, Vaccine",200
"IRCT20190917044805N2","http://en.irct.ir/trial/46804",NA,"Iran","Tehran","2020-Mar","2020-Oct","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Ferritin, Erythrocyte Sedimentation Rate","SOC, Vitamins",60
"CHICTR2000029435","http://www.chictr.org.cn/showproj.aspx?proj=48827",NA,"China","Hubei","2020-Feb","2020-Mar","Not Recruiting","Randomised","Unspecified",8,"Healthy (Exposed) Or Suspected",NA,"Outpatient","Viral Load or Clearance, Fever, Weight, Height or BMI, Creatinine Phosphokinase, CK-MB, eGFR, ALT, Albumin, Bilirubin, Blood Pressure, Heart Rate, Radiographic Findings","SOC, TCM",160
"CHICTR2000030484","http://www.chictr.org.cn/showproj.aspx?proj=50263",NA,"China","Hubei","2020-Mar","2021-Jan","Not Recruiting","Randomised","Unspecified",3,"Confirmed",NA,"Unclear","Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Dyspnea, Serious Adverse Events, C-Reactive Protein, PaO2-FiO2, Radiographic Findings","SOC, Stem cells",90
"CHICTR2000029778","http://www.chictr.org.cn/showproj.aspx?proj=49422",NA,"China","Shanghai","2020-Feb","2020-May","Recruiting","Non-Randomised","Unspecified",4,"Confirmed",NA,"Unclear","Hospitalization, Viral Load or Clearance, Fever","SOC, TCM",600
"CHICTR2000032135","http://www.chictr.org.cn/showproj.aspx?proj=52506",NA,"China","Shanghai","2020-Apr","2020-Dec","Not Recruiting","Randomised","Unspecified",4,NA,NA,"Unclear","Viral Load or Clearance, Adverse Events, Serious Adverse Events, Anti SARS-COV-2 Titers, CD4, PaO2-FiO2, Radiographic Findings","Other, SOC",50
"DRKS00021300","https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00021300",NA,"Germany","Baden-Wurttemberg","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, IL-6","ECMO, ECMO + Cytokine removal",30
"NCT04335552","https://ClinicalTrials.gov/show/NCT04335552",NA,"United States","North Carolina","2020-Apr","2020-Aug","Recruiting","Randomised","Open-Label",3,"Presumed","Mixed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2","AZT, HCQ, SOC",500
"ACTRN12620000445976","https://anzctr.org.au/ACTRN12620000445976.aspx",NA,"Australia","Canberra","2020-Jun",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed","Mixed","Hospital",NA,"HCQ, LPV/r, LPV/r + HCQ",2500
"ACTRN12620000445976","https://anzctr.org.au/ACTRN12620000445976.aspx",NA,"New Zealand","Wellington","2020-Jun",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed","Mixed","Hospital",NA,"HCQ, LPV/r, LPV/r + HCQ",2500
"NCT04344730","https://ClinicalTrials.gov/show/NCT04344730",NA,"France","Paris","2020-Apr","2020-Dec","Recruiting","Randomised","Quadruple",6,NA,NA,"ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Hypoxemia, Cardiac Outcome (Unspecified)","Corticosteroids, Mechanical Ventilation, Non-invasive respiratory support, Non-invasive respiratory support + Corticosteroids, SOC",550
"NCT04351724","https://ClinicalTrials.gov/show/NCT04351724",NA,"Austria","Tirol","2020-Apr","2020-Dec","Recruiting","Randomised","Open-Label",9,"Yes","Mixed","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events","Clazakizumab, HCQ, LPV/r, RAS blockade, Rivaroxiban, SOC",500
"NCT04351724","https://ClinicalTrials.gov/show/NCT04351724",NA,"Austria","Vienna","2020-Apr","2020-Dec","Recruiting","Randomised","Open-Label",9,"Yes","Mixed","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events","Clazakizumab, HCQ, LPV/r, RAS blockade, Rivaroxiban, SOC",500
"NCT04347980","https://ClinicalTrials.gov/show/NCT04347980",NA,"France","Paris","2020-Apr","2020-Jun","Recruiting","Randomised","Single",2,"Yes","Severe","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Patient Positioning","Corticosteroids + HCQ, HCQ",122
"NCT04350684","https://ClinicalTrials.gov/show/NCT04350684",NA,"Iran","Tehran","2020-Apr","2020-Apr","Recruiting","Randomised","Triple",5,"Confirmed","Mixed","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","HCQ + LPV/r + IFN, Umifenovir + HCQ + LPV/r + IFN",40
"NCT04350671","https://ClinicalTrials.gov/show/NCT04350671",NA,"Iran","Tehran","2020-Apr","2020-Apr","Recruiting","Randomised","Triple",3,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","LPV/r + HCQ, LPV/r + IFN + HCQ",40
"NCT04334265","https://ClinicalTrials.gov/show/NCT04334265",NA,"China","Anhui","2020-Apr","2020-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Unspecified","Unclear",NA,"Alternative therapy, SOC",750
"NCT04334265","https://ClinicalTrials.gov/show/NCT04334265",NA,"China","Hubei","2020-Apr","2020-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Unspecified","Unclear",NA,"Alternative therapy, SOC",750
"NCT04334265","https://ClinicalTrials.gov/show/NCT04334265",NA,"China","Zhejiang","2020-Apr","2020-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Unspecified","Unclear",NA,"Alternative therapy, SOC",750
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"United States","Missouri","2020-Apr","2020-Oct","Recruiting","Randomised","Quadruple",2,"Confirmed","Mixed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","Dapagliflozin, SOC",900
"NCT04348383","https://ClinicalTrials.gov/show/NCT04348383",NA,"Spain","Murcia","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Non-invasive Ventilation, C-Reactive Protein, IL-6, D-Dimer, Creatinine Phosphokinase, LDH, Radiographic Findings","Defibrotide, SOC",120
"CHICTR2000030028","http://www.chictr.org.cn/showproj.aspx?proj=49840",NA,"China","Sichuan","2020-Feb","2020-Aug","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Severe","Hospital, ICU","PD-1, Monocyte Count, Natural Killer Cell Count, Dendritic Cell Count, Neutrophils, CD4, CD8","mAb, SOC",40
"2020-001492-33","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001492-33/FR/",NA,"France","Paris","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,NA,"ICU","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events","Pulmozyme, SOC",NA
"2020-001160-28","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001160-28/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Cough, Fever, Dyspnea, Other Mild Symptoms, Organ Failure or Dysfunction (SOFA), Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings","SOC, TCZ + Pembrolizumab",NA
"2020-001275-32","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001275-32/DK/",NA,"Denmark","Copenhagen","2020-Mar",NA,"Recruiting","Randomised","Open-Label",4,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, C-Reactive Protein","Sarilumab, TCZ",NA
"NCT04336410","https://ClinicalTrials.gov/show/NCT04336410",NA,"United States","Missouri","2020-Apr","2021-Apr","Recruiting","Non-Randomised","Open-Label",2,"Healthy","Healthy","Healthy Unexposed","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Vaccine",40
"NCT04336410","https://ClinicalTrials.gov/show/NCT04336410",NA,"United States","Pennsylvania","2020-Apr","2021-Apr","Recruiting","Non-Randomised","Open-Label",2,"Healthy","Healthy","Healthy Unexposed","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Vaccine",40
"2020-001536-98","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001536-98/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Status Unclear","Non-Randomised","Unspecified",3,NA,NA,"Healthcare Workers","Viral Load or Clearance, Other Mild Symptoms","HCQ",NA
"2020-001765-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001765-37/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Single-Arm","Open-Label",1,NA,NA,"Unclear","Clinical Improvement Score (Any), Cough, Fever, Dyspnea, Other Mild Symptoms, Serious or Seconday Infections, Adverse Events","HCQ",NA
"NCT04339426","https://ClinicalTrials.gov/show/NCT04339426",NA,"United States","Arizona","2020-Apr","2020-Oct","Recruiting","Single-Arm","Open-Label",1,NA,NA,"Unclear","ICU Admission, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, Serious Adverse Events, PaO2-FiO2, Respiratory Rate","AZT + Atovaquone",25
"NCT04359615","https://ClinicalTrials.gov/show/NCT04359615",NA,"Iran","Tehran","2020-Apr","2020-May","Not Recruiting","Randomised","Triple",2,NA,NA,"Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","FPV + HCQ",40
"NCT04335123","https://ClinicalTrials.gov/show/NCT04335123",NA,"United States","Kansas","2020-Apr","2020-Sep","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Non-invasive Ventilation, Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Bicarbonates","Losartan",50
"CHICTR2000030853","http://www.chictr.org.cn/showproj.aspx?proj=51081",NA,"China","Guizhou","2020-Mar","2020-May","Not Recruiting","Single-Arm","Unspecified",1,"Confirmed","Severe","Hospital","CK-MB, LDH","Other",200
"NCT04372602","https://ClinicalTrials.gov/show/NCT04372602",NA,"United States","Missouri","2020-May","2021-Jul","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed",NA,"Hospital","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Renal Outcome (Unspecified)","Other",25
"NCT04326920","https://ClinicalTrials.gov/show/NCT04326920",NA,"Belgium","Brussels","2020-Mar","2020-Oct","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Adverse Events, Serious Adverse Events, PaO2-FiO2","Other",80
"NCT04327349","https://ClinicalTrials.gov/show/NCT04327349",NA,"Iran","Mazandaran","2020-Mar","2020-May","Recruiting","Single-Arm","Open-Label",1,"Confirmed",NA,"Unclear","Mortality, Hospitalization, Non-invasive Ventilation, C-Reactive Protein, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Creatinine Phosphokinase, CK-MB, ALT, LDH, IgG, IgM or IgA, CD4, CD8, PaO2-FiO2","Plasma based therapy",30
"NCT04345679","https://ClinicalTrials.gov/show/NCT04345679",NA,"Hungary","Budapest","2020-Apr","2020-Jun","Not Recruiting","Single-Arm","Open-Label",1,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Other Mild Symptoms, Bilirubin","Plasma based therapy",20
"NCT04348071","https://ClinicalTrials.gov/show/NCT04348071",NA,"United States","Colorado","2020-Apr","2020-Aug","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Mixed","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Hemoglobin, Creatinine Phosphokinase, Prothrombin, ALT, Bilirubin, Glucose","Ruxolitinib",80
"CHICTR2000031139","http://www.chictr.org.cn/showproj.aspx?proj=51404",NA,"China","Hubei","2020-Mar","2021-Mar","Recruiting","Single-Arm","Unspecified",1,"Confirmed",NA,"Unclear","Pneumonia or ARDS, Radiographic Findings, Quality of Life, Depression, Anxiety, Distress","Stem cells",20
"NCT04269525","https://ClinicalTrials.gov/show/NCT04269525",NA,"China","Hubei","2020-Feb","2020-Apr","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","ICU","Mortality, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, Tumor Necrosis Factor (Any), White Blood Cell Count, Procalcitonin, PaO2-FiO2, Radiographic Findings","Stem cells",10
"2020-001375-32","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001375-32/NL/",NA,"Netherlands","Amsterdam","2020-Apr",NA,"Recruiting","Randomised","Open-Label",NA,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Anti SARS-COV-2 Titers, C-Reactive Protein, IL-2, IL-6, IL-8, LDH, Radiographic Findings","TCZ",NA
"CHICTR2000029578","http://www.chictr.org.cn/showproj.aspx?proj=49080",NA,"China","Zhejiang","2020-Feb","2020-Apr","Recruiting","Single-Arm","Unspecified",1,"Confirmed",NA,"Unclear","Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Other Mild Symptoms, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","TCM",1000
"CHICTR2000029558","http://www.chictr.org.cn/showproj.aspx?proj=48792",NA,"China","Sichuan","2020-Feb","2020-May","Recruiting","Single-Arm","Unspecified",1,"Confirmed Or Suspected",NA,"Unclear","Viral Load or Clearance, C-Reactive Protein, Erythrocyte Sedimentation Rate, D-Dimer, Myoglobin, Troponin, Radiographic Findings","TCM",200
"NCT04339816","https://ClinicalTrials.gov/show/NCT04339816",NA,"Czechia","Prague","2020-Apr","2021-Dec","Not Recruiting","Randomised","Triple",3,NA,NA,"ICU","Mortality, Viral Load or Clearance, Treatment-emergent Adverse Events",NA,240
"CHICTR2000031888","http://www.chictr.org.cn/showproj.aspx?proj=52106",NA,"China","Guangdong","2020-Apr","2020-Nov","Recruiting","Randomised","Unspecified",2,NA,NA,"Unclear","Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Fever, Dyspnea, C-Reactive Protein, White Blood Cell Count, CD4, CD8, Renal Outcome (Unspecified)",NA,300
"2020-001236-10","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001236-10/NL/",NA,"Netherlands","Amsterdam","2020-Mar",NA,"Recruiting","Randomised","Single",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Erythrocyte Sedimentation Rate, Creatinine Phosphokinase, CK-MB, eGFR, Myoglobin, Troponin, Procalcitonin, Prothrombin, Fibrinogen, Coagulation Test, ALT, Albumin, Bilirubin, PaO2-FiO2",NA,304
"2020-001270-29","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001270-29/DK/",NA,"Denmark","Copenhagen","2020-Mar",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Fever, Adverse Events, Serious Adverse Events, PaO2-FiO2",NA,350
"NCT04303299","https://ClinicalTrials.gov/show/NCT04303299",NA,"Thailand","Nan","2020-Mar","2020-Oct","Not Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Outpatient","ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","DRV/r + FPV + HCQ, DRV/r + Oseltamivir, DRV/r + Oseltamivir + HCQ, HCQ + Oseltamivir, LPV/r + FPV, LPV/r + Oseltamivir, SOC",320
"CHICTR2000029992","http://www.chictr.org.cn/showproj.aspx?proj=49574",NA,"China","Fujian","2020-Feb","2020-May","Not Recruiting","Randomised","Open-Label",3,"Confirmed","Severe","Hospital","Hospital Discharge, Viral Load or Clearance, Fever, Serious Adverse Events, Respiratory Rate","HCQ, SOC",100
"NCT04321928","https://ClinicalTrials.gov/show/NCT04321928",NA,"China","Beijing","2020-Mar","2021-Apr","Not Recruiting","Randomised","Double",2,"Healthy","Healthy","Healthy Unexposed","ICU Admission, Hospitalization, Other Mild Symptoms","Education, Psychological therapy",7576
"CHICTR2000030718","http://www.chictr.org.cn/showproj.aspx?proj=50843",NA,"China","Hubei","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Dyspnea, Serious Adverse Events, Granulocyte Stimulaiting Factor, White Blood Cell Count, Monocyte Count, Natural Killer Cell Count, Neutrophils, ALT, Albumin, Bilirubin, IgG, IgM or IgA","Cyclosporine, HCQ, SOC",80
"NCT04280224","https://ClinicalTrials.gov/show/NCT04280224",NA,"China","Henan","2020-Feb","2020-Sep","Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Unclear","Viral Load or Clearance, Treatment-emergent Adverse Events, CD4, CD8, Radiographic Findings","Natural Killer Cells, SOC",30
"CHICTR2000030265","http://www.chictr.org.cn/showproj.aspx?proj=49691",NA,"China","Heilongjiang","2020-Feb","2021-Feb","Not Recruiting","Randomised","Unspecified",3,"Confirmed","Severe","Hospital","Mortality, Clinical Improvement Score (Any), Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO","Other, SOC",30
"CHICTR2000030333","http://www.chictr.org.cn/showproj.aspx?proj=48801",NA,"China","Hubei","2020-Feb","2020-Jul","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital, ICU","Mortality, Viral Load or Clearance, Cough, Dyspnea, IL-8","Other, SOC",292
"NCT04288102","https://ClinicalTrials.gov/show/NCT04288102",NA,"China","Hubei","2020-Feb","2020-Jul","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, CD4, PaO2-FiO2, Radiographic Findings","SOC, Stem cells",90
"CHICTR2000030759","http://www.chictr.org.cn/showproj.aspx?proj=49284",NA,"China","Zhejiang","2020-Mar","2020-May","Not Recruiting","Randomised","Unspecified",2,"Confirmed",NA,"Hospital","Viral Load or Clearance, Pneumonia or ARDS, Fever, C-Reactive Protein, IL-1, IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, Tumor Necrosis Factor (Any), Interferon (Any), Myoglobin, Troponin, Procalcitonin, Prothrombin, Coagulation Test, Triglycerides, ALT, Albumin, Bilirubin, Glucose, Urine Sample, Radiographic Findings","SOC, TCM",70
"CHICTR2000030479","http://www.chictr.org.cn/showproj.aspx?proj=50450",NA,"China","Jiangsu","2020-Mar","2021-Feb","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Viral Load or Clearance, Pneumonia or ARDS, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein, White Blood Cell Count, Erythrocyte Sedimentation Rate, Procalcitonin","SOC, TCM",100
"CHICTR2000029935","http://www.chictr.org.cn/showproj.aspx?proj=49607",NA,"China","Zhejiang","2020-Feb","2021-Feb","Recruiting","Single-Arm","Unspecified",1,"Confirmed",NA,"Unclear","Mortality, Hospitalization, Clinical Improvement Score (Any), Secondary CoViD-19 Re-infection, Serious Adverse Events, C-Reactive Protein","HCQ",100
"NCT04341584","https://ClinicalTrials.gov/show/NCT04341584",NA,"France","Paris","2020-Apr","2020-May","Not Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Anakinra",240
"2020-001391-15","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001391-15/IE/",NA,"Ireland","Dublin","2020-Mar",NA,"Recruiting","Randomised","Double",3,NA,NA,"Hospital","Mortality, ICU Admission, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, IL-1, IL-6, IL-8, IL-10, Tumor Necrosis Factor (Any), PaO2-FiO2, Shock, Renal Outcome (Unspecified)","Other",36
"CHICTR2000030046","http://www.chictr.org.cn/showproj.aspx?proj=49861",NA,"China","Jiangxi","2020-Feb","2020-Apr","Recruiting","Single-Arm","Unspecified",1,"Confirmed","Mixed","Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Dyspnea, C-Reactive Protein, ALT, Bilirubin, Antibodies","Plasma based therapy",10
"NCT04345289","https://ClinicalTrials.gov/show/NCT04345289",NA,"Denmark","Copenhagen","2020-Apr","2021-Jun","Recruiting","Randomised","Quadruple",6,NA,NA,"Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO",NA,1500
"NCT04344106","https://ClinicalTrials.gov/show/NCT04344106",NA,"France","Paris","2020-Apr","2020-Apr","Recruiting","Single-Arm","Open-Label",1,NA,NA,"Hospital, ICU","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Serious Adverse Events",NA,25
"NCT04342650","https://ClinicalTrials.gov/show/NCT04342650",NA,"Brazil","Amazonas","2020-Apr","2020-Sep","Recruiting","Randomised","Quadruple",2,NA,NA,"Unclear","Adverse Events, Natural Killer Cell Count",NA,210
"NCT04336904","https://ClinicalTrials.gov/show/NCT04336904",NA,"Italy","Milano","2020-Apr","2020-Jul","Not Recruiting","Randomised","Double",2,"Confirmed","Mixed","Outpatient, Hospital","Mortality, ICU Admission",NA,100
"NCT04336462","https://ClinicalTrials.gov/show/NCT04336462",NA,"China","Guangdong","2020-Apr","2020-Feb","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Dyspnea, C-Reactive Protein, White Blood Cell Count, Neutrophils, Hemoglobin, Urine Sample, IgG, IgM or IgA, Blood Urea Nitrogen",NA,100
"NCT04255017","https://clinicaltrials.gov/show/NCT04255017",NA,"China","Beijing","2020-Feb",NA,"Recruiting","Randomised","Single",2,"Confirmed",NA,"Unclear","Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein, Erythrocyte Sedimentation Rate, CK-MB, ALT, PaO2-FiO2, Radiographic Findings","LPV/r, Oseltamivir, SOC, Umifenovir",400
"NCT04261270","https://clinicaltrials.gov/show/NCT04261270",NA,"China","Beijing","2020-Apr",NA,"Recruiting","Randomised","Single",2,"Confirmed","Mixed","Hospital","ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events, C-Reactive Protein, Erythrocyte Sedimentation Rate, Creatinine Phosphokinase, CK-MB, ALT, PaO2-FiO2, Respiratory Rate","Oseltamivir, Oseltamivir + Antivirals, Other + Oseltamivir",60
"NCT04330495","https://clinicaltrials.gov/show/NCT04330495",NA,"Spain","Madrid","2020-Mar",NA,"Not Recruiting","Randomised","Double",1,"Confirmed",NA,"Unclear","Mortality, ICU Admission","HCQ, SOC",800
"NCT04268537","https://clinicaltrials.gov/show/NCT04268537",NA,"China","Beijing","2020-Aug",NA,"Not Recruiting","Randomised","Single",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, IL-6, Procalcitonin, Radiographic Findings","mAb, Other",120
"NCT04254874","https://clinicaltrials.gov/show/NCT04254874",NA,"China","Beijing","2020-Feb",NA,"Recruiting","Randomised","Single",1,"Confirmed","Mixed","Unclear","Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein, Erythrocyte Sedimentation Rate, CK-MB, ALT, PaO2-FiO2, Radiographic Findings","Umifenovir, Umifenovir + IFN",100
"NCT04310865","https://clinicaltrials.gov/show/NCT04310865",NA,"China","Beijing","2020-Mar",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, PaO2-FiO2","TCM",116
"NCT04331613","https://clinicaltrials.gov/show/NCT04331613",NA,"China","Beijing","2020-Jun",NA,"Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","ICU","Mortality, Viral Load or Clearance, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-1, IL-2, IL-6, IL-8, CK-MB, Procalcitonin",NA,9
"CHICTR2000030703","http://www.chictr.org.cn/showproj.aspx?proj=50251",NA,"China","Hunan","2020-Mar","2020-May","Recruiting","Randomised","Unspecified",2,"Confirmed","Mixed","Unclear","PaO2-FiO2, Respiratory Rate, Radiographic Findings","Antivirals, TCM + Antiviral",40
"NCT04371406","https://ClinicalTrials.gov/show/NCT04371406",NA,"France","Paris","2020-May","2020-Aug","Not Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Other Mild Symptoms, Adverse Events, Serious Adverse Events, Quality of Life","HCQ + AZT, Nutrition",2770
"NCT04359095","https://ClinicalTrials.gov/show/NCT04359095",NA,"Colombia","Huila","2020-Apr","2020-Oct","Not Recruiting","Randomised","Open-Label",4,NA,NA,"Hospital","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Serious Adverse Events","AZT, HCQ, LPV/r, SOC",1600
"NCT04359095","https://ClinicalTrials.gov/show/NCT04359095",NA,"Colombia","Bogota","2020-Apr","2020-Oct","Not Recruiting","Randomised","Open-Label",4,NA,NA,"Hospital","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Serious Adverse Events","AZT, HCQ, LPV/r, SOC",1600
"CHICTR2000029658","http://www.chictr.org.cn/showproj.aspx?proj=49074",NA,"China","Hubei","2020-Feb","2020-Apr","Suspended","Randomised","Unspecified",2,"Confirmed","Severe","ICU","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Hypoxia","Non-invasive respiratory support",60
"CHICTR2000030920","http://www.chictr.org.cn/showproj.aspx?proj=50476",NA,"China","Zhejiang","2020-Mar","2021-May","Recruiting","Randomised","Unspecified",4,"Resolved",NA,"Resolved Discharged","Viral Load or Clearance, Secondary CoViD-19 Re-infection, C-Reactive Protein, IL-2, IL-4, IL-6, IL-10, Tumor Necrosis Factor (Any), Weight, Height or BMI, Albumin, IgG, IgM or IgA, Antibodies, CD4, CD8","SOC, TCM",100
"CHICTR2000029542","http://www.chictr.org.cn/showproj.aspx?proj=48968",NA,"China","Guangdong","2020-Feb","2020-Jul","Recruiting","Non-Randomised","Unspecified",2,"Confirmed",NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein","HCQ, SOC",20
"CHICTR2000029550","http://www.chictr.org.cn/showproj.aspx?proj=48775",NA,"China","Sichuan","2020-Feb","2020-May","Recruiting","Randomised","Unspecified",2,"Confirmed",NA,"Unclear","C-Reactive Protein, White Blood Cell Count, Monocyte Count, Natural Killer Cell Count, Erythrocyte Sedimentation Rate, D-Dimer, Weight, Height or BMI, Creatinine Phosphokinase, Troponin, Procalcitonin, Radiographic Findings","TCM",300
"IRCT20120225009124N4","http://en.irct.ir/trial/46810",NA,"Iran","Fars","2020-Apr","2020-Jun","Recruiting","Randomised","Open-Label",3,NA,NA,"Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO","Corticosteroids + Igs + IFN, HCQ + Antivirals",105
"2020-001333-13","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001333-13/FR/",NA,"France","Paris","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,NA,"Unclear","Mortality, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections","Corticosteroids, HCQ",NA
"CHICTR2000029602","http://www.chictr.org.cn/showproj.aspx?proj=48985",NA,"China","Hubei","2020-Feb","2020-Aug","Recruiting","Randomised","Open-Label",2,"Healthy (Exposed)",NA,"Healthy Exposed","Clinical Improvement Score (Any), Viral Load or Clearance, Fever","Education + Monitoring + TCM, Psychological therapy",600
"NCT04345848","https://ClinicalTrials.gov/show/NCT04345848",NA,"Switzerland","Bern","2020-Apr","2020-Nov","Recruiting","Randomised","Single",2,NA,NA,"Hospital, ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Coagulation Test","Anticoagulants",200
"NCT04356690","https://ClinicalTrials.gov/show/NCT04356690",NA,"United States","Massachusetts","2020-Apr","2020-Dec","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital, ICU","Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, White Blood Cell Count, D-Dimer, PaO2-FiO2","Other, SOC",64
"CHICTR2000029544","http://www.chictr.org.cn/showproj.aspx?proj=49013",NA,"China","Zhejiang","2020-Feb","2020-May","Not Recruiting","Randomised","Unspecified",3,"Confirmed",NA,"Unclear","Mortality, ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","Antivirals, FPV, SOC",30
"CHICTR2000029548","http://www.chictr.org.cn/showproj.aspx?proj=49015",NA,"China","Zhejiang","2020-Feb","2020-Jun","Not Recruiting","Randomised","Open-Label",3,"Confirmed","Non-severe","Unclear","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events","FPV, LPV/r, Other",30
"NCT04319900","https://ClinicalTrials.gov/show/NCT04319900",NA,"China","Beijing","2020-Mar","2020-Apr","Recruiting","Randomised","Double",3,"Confirmed",NA,"Unclear","Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Serious or Seconday Infections, C-Reactive Protein, Radiographic Findings","FPV, HCQ + FPV, SOC",150
"CHICTR2000030894","http://www.chictr.org.cn/showproj.aspx?proj=51126",NA,"China","Beijing","2020-Mar","2020-May","Recruiting","Randomised","Unspecified",3,"Confirmed",NA,"Hospital","Mortality, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever, C-Reactive Protein, Radiographic Findings","FPV, FPV + TCZ, TCZ",150
"CHICTR2000030113","http://www.chictr.org.cn/showproj.aspx?proj=49988",NA,"China","Guangdong","2020-Feb","2020-May","Recruiting","Randomised","Unspecified",2,"Confirmed",NA,"Unclear","Radiographic Findings, Renal Outcome (Unspecified)","DAA, FPV",30
"NCT04332094","https://ClinicalTrials.gov/show/NCT04332094",NA,"Spain","Barcelona","2020-Apr","2020-Sep","Recruiting","Randomised","Open-Label",3,"Confirmed","Non-severe","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, TCZ + AZT + HCQ",276
"2020-001331-26","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001331-26/GB/",NA,"United Kingdom","London","2020-Apr",NA,"Recruiting","Randomised","Double",3,NA,NA,"Healthcare Workers","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Other Mild Symptoms, Adverse Events","HCQ, SOC",NA
"NCT04328961","https://ClinicalTrials.gov/show/NCT04328961",NA,"United States","California","2020-Apr","2020-Sep","Recruiting","Randomised","Double",2,"Healthy (Exposed)","Healthy","Healthy Exposed",NA,"HCQ, Vitamins",2000
"NCT04328961","https://ClinicalTrials.gov/show/NCT04328961",NA,"United States","Louisiana","2020-Apr","2020-Sep","Recruiting","Randomised","Double",2,"Healthy (Exposed)","Healthy","Healthy Exposed",NA,"HCQ, Vitamins",2000
"NCT04328961","https://ClinicalTrials.gov/show/NCT04328961",NA,"United States","Maryland","2020-Apr","2020-Sep","Recruiting","Randomised","Double",2,"Healthy (Exposed)","Healthy","Healthy Exposed",NA,"HCQ, Vitamins",2000
"NCT04328961","https://ClinicalTrials.gov/show/NCT04328961",NA,"United States","Massachusetts","2020-Apr","2020-Sep","Recruiting","Randomised","Double",2,"Healthy (Exposed)","Healthy","Healthy Exposed",NA,"HCQ, Vitamins",2000
"NCT04328961","https://ClinicalTrials.gov/show/NCT04328961",NA,"United States","New York","2020-Apr","2020-Sep","Recruiting","Randomised","Double",2,"Healthy (Exposed)","Healthy","Healthy Exposed",NA,"HCQ, Vitamins",2000
"NCT04328961","https://ClinicalTrials.gov/show/NCT04328961",NA,"United States","Washington","2020-Apr","2020-Sep","Recruiting","Randomised","Double",2,"Healthy (Exposed)","Healthy","Healthy Exposed",NA,"HCQ, Vitamins",2000
"NCT04328272","https://ClinicalTrials.gov/show/NCT04328272",NA,"Pakistan","Islamabad","2020-Mar","2020-May","Not Recruiting","Randomised","Single",3,"Confirmed","Mixed","Hospital","Clinical Improvement Score (Any), C-Reactive Protein, D-Dimer","HCQ, HCQ + AZT, SOC",75
"NCT04345861","https://ClinicalTrials.gov/show/NCT04345861",NA,"France","Paris","2020-Apr","2020-Sep","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Radiographic Findings","HCQ, HCQ + AZT",150
"2020-001527-14","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001527-14/NL/",NA,"Netherlands","Amsterdam","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Fever, Adverse Events, C-Reactive Protein, Respiratory Rate","HCQ, HCQ + AZT",60
"NCT04332835","https://ClinicalTrials.gov/show/NCT04332835",NA,"Colombia","Cundinamarca","2020-Apr","2020-Aug","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, IgG, IgM or IgA","HCQ + AZT, Plasma based therapy + HCQ + AZT",80
"IRCT20130812014333N145","http://en.irct.ir/trial/46790",NA,"Iran","Tehran","2020-Mar","2020-Jul","Recruiting","Randomised","Single",2,NA,NA,"Hospital","Clinical Improvement Score (Any)","HCQ + LPV/r, HCQ + LPV/r + DAA",80
"IRCT20150808023559N20","http://en.irct.ir/trial/47022",NA,"Iran","Tehran","2020-Apr","2020-Jul","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, Hospitalization","FPV + HCQ, HCQ + LPV/r",100
"IRCT20200317046797N3","http://en.irct.ir/trial/47014",NA,"Iran","East Azarbaijan","2020-Apr","2020-Jul","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Radiographic Findings","HCQ + LPV/r + Antivirals, Igs + HCQ + LPV/r + Antivirals",100
"IRCT20161204031229N3","http://en.irct.ir/trial/46814",NA,"Iran","Tehran","2020-Apr","2020-Jun","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Fever, Other Mild Symptoms, C-Reactive Protein, White Blood Cell Count, Erythrocyte Sedimentation Rate, Blood Pressure, Respiratory Rate, Radiographic Findings","HCQ + DAA, HCQ + LPV/r (or + DAA + Antibiotics)",40
"CHICTR2000030016","http://www.chictr.org.cn/showproj.aspx?proj=49799",NA,"China","Guangxi","2020-Feb","2022-Dec","Recruiting","Randomised","Double",2,"Confirmed",NA,"Unclear","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events","SOC, Vaccine",60
"IRCT20200408046987N1","http://en.irct.ir/trial/47012",NA,"Iran","Tehran","2020-Apr","2020-Jun","Recruiting","Randomised","Double",4,"Confirmed","Unclear","Unclear","Hospitalization, C-Reactive Protein, Radiographic Findings","Ivermectin, SOC",100
"CHICTR2000030215","http://www.chictr.org.cn/showproj.aspx?proj=50107",NA,"China","Jiangxi","2020-Feb",NA,"Not Recruiting","Randomised","Unspecified",6,"Confirmed","Mixed","Outpatient, Hospital","Viral Load or Clearance, Fever, C-Reactive Protein, Erythrocyte Sedimentation Rate, CD4, Respiratory Rate, Radiographic Findings","SOC, TCM",120
"CHICTR2000029991","http://www.chictr.org.cn/showproj.aspx?proj=49666",NA,"China","Jiangxi","2020-Feb","2020-Jul","Recruiting","Randomised","Open-Label",3,"Confirmed","Mixed","Unclear","Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever","SOC, TCM",72
"CHICTR2000029400","http://www.chictr.org.cn/showproj.aspx?proj=48824",NA,"China","Beijing","2020-Jan","2020-Dec","Recruiting","Non-Randomised","Unspecified",3,"Confirmed",NA,"Unclear","Viral Load or Clearance, Fever, White Blood Cell Count, Monocyte Count, Hemoglobin, Erythrocyte Sedimentation Rate, Radiographic Findings","LPV/r, LPV/r + TCM, TCM",60
"CHICTR2000030187","http://www.chictr.org.cn/showproj.aspx?proj=50057",NA,"China","Hubei","2020-Feb","2020-Mar","Recruiting","Randomised","Unspecified",2,"Confirmed",NA,"Unclear","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein, Tumor Necrosis Factor (Any), Granulocyte Stimulaiting Factor, Erythrocyte Sedimentation Rate, Creatinine Phosphokinase, CK-MB, eGFR, Procalcitonin, ALT, Albumin, Bilirubin","LPV/r, SOC",60
"IRCT20200314046764N1","http://en.irct.ir/trial/46533",NA,"Iran","Tehran","2020-Apr","2020-May","Completed","Randomised","Single",2,NA,NA,"Unclear","Cough, Dyspnea, Other Mild Symptoms","LPV/r + HCQ + Oseltamivir + Antivirals, LPV/r + HCQ + Oseltamivir + Pirfenidone",40
"IRCT20200404046935N1","http://en.irct.ir/trial/46940",NA,"Iran","Tehran","2020-Apr","2020-Jun","Recruiting","Randomised","Open-Label",2,NA,NA,"Unclear","Pneumonia or ARDS, Fever, Erythrocyte Sedimentation Rate","HCQ + LPV/r, HCQ + LPV/r + Alternative therapy",40
"IRCT20200420047147N1","http://en.irct.ir/trial/47334",NA,"Iran","Tehran","2020-Apr","2020-Aug","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Adverse Events, Radiographic Findings","DPP-4i, HCQ + LPV/r",84
"NCT04331470","https://ClinicalTrials.gov/show/NCT04331470",NA,"Iran","Fars","2020-Apr","2020-Apr","Recruiting","Randomised","Double",2,"Confirmed",NA,"Unclear","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, IL-6, PaO2-FiO2","HCQ + LPV/r, LPV/r + HCQ + Other",30
"CHICTR2000030166","http://www.chictr.org.cn/showproj.aspx?proj=49696",NA,"China","Beijing","2020-Feb","2020-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Outpatient, Hospital","Viral Load or Clearance, Fever, 3CL Mpro, White Blood Cell Count, Monocyte Count, Natural Killer Cell Count, Dendritic Cell Count, Neutrophils, Creatinine Phosphokinase, CK-MB, ALT, Urine Sample, Stool Sample, Radiographic Findings","LPV/r + IFN, LPV/r + IFN + TCM",20
"CHICTR2000030835","http://www.chictr.org.cn/showproj.aspx?proj=51050",NA,"China","Henan","2020-Mar","2021-Feb","Recruiting","Single-Arm","Open-Label",2,"Confirmed","Severe","Hospital","C-Reactive Protein, IL-1, IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, Tumor Necrosis Factor (Any), Granulocyte Stimulaiting Factor, IP-10, White Blood Cell Count, Monocyte Count, Natural Killer Cell Count, Procalcitonin, ALT, Albumin, Bilirubin, Glucose, Urine Sample, Radiographic Findings, Depression, Anxiety, Distress","Stem cells",20
"NCT04283461","https://ClinicalTrials.gov/show/NCT04283461",NA,"United States","Georgia","2020-Feb","2021-Nov","Recruiting","Non-Randomised","Open-Label",2,"Healthy","Healthy","Healthy Unexposed","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Anti SARS-COV-2 Titers, Ferritin, IL-6, D-Dimer, Glucose, Antibodies, PaO2-FiO2","Vaccine",155
"NCT04283461","https://ClinicalTrials.gov/show/NCT04283461",NA,"United States","Maryland","2020-Feb","2021-Nov","Recruiting","Non-Randomised","Open-Label",2,"Healthy","Healthy","Healthy Unexposed","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Anti SARS-COV-2 Titers, Ferritin, IL-6, D-Dimer, Glucose, Antibodies, PaO2-FiO2","Vaccine",155
"NCT04283461","https://ClinicalTrials.gov/show/NCT04283461",NA,"United States","Washington","2020-Feb","2021-Nov","Recruiting","Non-Randomised","Open-Label",2,"Healthy","Healthy","Healthy Unexposed","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Anti SARS-COV-2 Titers, Ferritin, IL-6, D-Dimer, Glucose, Antibodies, PaO2-FiO2","Vaccine",155
"IRCT20200417047113N1","http://en.irct.ir/trial/47264",NA,"Iran","Tehran","2020-Apr","2020-Dec","Recruiting","Randomised","Double",7,NA,NA,"Hospital","Cough, Respiratory Rate, Lung Inflamation","Natural Killer Cells, SOC",70
"NCT04358926","https://ClinicalTrials.gov/show/NCT04358926",NA,"Israel","Jerusalem","2020-Apr","2020-Jun","Recruiting","Randomised","Double",2,NA,NA,"Unclear","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Cough, Dyspnea, Other Mild Symptoms, Adverse Events, Anti SARS-COV-2 Titers, C-Reactive Protein, Ferritin, IL-1, IL-2, IL-6, IL-10, Tumor Necrosis Factor (Any), White Blood Cell Count, Erythrocyte Sedimentation Rate, Procalcitonin, IgG, IgM or IgA, Antibodies, PaO2-FiO2","Non-invasive respiratory support",30
"CHICTR2000029851","http://www.chictr.org.cn/showproj.aspx?proj=49534",NA,"China","Shanghai","2020-Feb","2020-Mar","Recruiting","Randomised","Unspecified",2,"Confirmed","Severe","Hospital","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance","Other, SOC",68
"CHICTR2000029867","http://www.chictr.org.cn/showproj.aspx?proj=49514",NA,"China","Beijing","2020-Feb","2021-Feb","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Outpatient, Hospital, ICU","Viral Load or Clearance, Fever","Carrimycin, LPV/r",520
"CHICTR2000029768","http://www.chictr.org.cn/showproj.aspx?proj=49131",NA,"China","Hubei","2020-Feb","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Hospital","Hospitalization, Hospital Discharge, Viral Load or Clearance","Other, SOC",60
"CHICTR2000029739","http://www.chictr.org.cn/showproj.aspx?proj=49283",NA,"China","Guangdong","2020-Feb","2021-Aug","Recruiting","Randomised","Unspecified",2,"Confirmed","Mixed","Hospital","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein, Creatinine Phosphokinase, CK-MB, eGFR, Myoglobin, Troponin, Procalcitonin, Prothrombin, Fibrinogen, ALT, Albumin, Bilirubin, Quality of Life","Non-invasive respiratory support",440
"CHICTR2000030000","http://www.chictr.org.cn/showproj.aspx?proj=49748",NA,"China","Jiangxi","2020-Feb",NA,"Recruiting","Non-Randomised","Unspecified",5,"Confirmed",NA,"Hospital","Viral Load or Clearance, Adverse Events, PaO2-FiO2, Respiratory Rate","DAA, IFN, TCM",50
"CHICTR2000029899","http://www.chictr.org.cn/showproj.aspx?proj=49536",NA,"China","Beijing","2020-Feb","2020-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Non-severe","Outpatient","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, IgG, IgM or IgA","HCQ",100
"IRCT20200413047063N1","http://en.irct.ir/trial/47156",NA,"Iran","Tehran","2020-May","2020-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Mild/moderate","Unclear","ICU Admission, Clinical Improvement Score (Any), Pneumonia or ARDS, Adverse Events, Serious Adverse Events, PaO2-FiO2","SOC, Stem cells",20
"NCT04313127","https://ClinicalTrials.gov/show/NCT04313127",NA,"China","Hubei","2020-Mar","2020-Dec","Not Recruiting","Non-Randomised","Open-Label",2,"Healthy","Healthy","Healthy Unexposed","Treatment-emergent Adverse Events, Serious Adverse Events, Antibodies","Vaccine",108
"CHICTR2000030933","http://www.chictr.org.cn/showproj.aspx?proj=51184",NA,"China","Jiangxi","2020-Mar","2020-Dec","Not Recruiting","Randomised","Open-Label",3,"Resolved",NA,"Resolved Discharged","Fever, Respiratory Rate, 6-Minute Walking Distance, Quality of Life, Depression, Anxiety, Distress","Exercise, Exercise + Respiratory support, Respiratory support",108
"NCT04356677","https://ClinicalTrials.gov/show/NCT04356677",NA,"United States","New Jersey","2020-Apr","2021-Apr","Not Recruiting","Non-Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2","Antivirals",50
"NCT04328285","https://ClinicalTrials.gov/show/NCT04328285",NA,"France","Paris","2020-Mar","2020-Nov","Not Recruiting","Randomised","Triple",4,"Healthy",NA,"Healthcare Workers","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Treatment-emergent Adverse Events","HCQ, LPV/r, SOC",1200
"CHICTR2000030923","http://www.chictr.org.cn/showproj.aspx?proj=51139",NA,"China","Shaanxi","2020-Mar","2020-Apr","Recruiting","Randomised","Open-Label",4,"Confirmed Or Suspected",NA,"Unclear","Clinical Improvement Score (Any), Viral Load or Clearance","SOC, TCM",400
"2020-001469-35","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001469-35/PL/",NA,"Poland","Warsaw","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,NA,"Outpatient","Mortality, Hospitalization, Fever, Dyspnea, Other Mild Symptoms, Adverse Events, Heart Rate","HCQ, SOC",400
"CHICTR2000031204","http://www.chictr.org.cn/showproj.aspx?proj=49420",NA,"China","Beijing","2020-Mar","2020-Apr","Recruiting","Randomised","Single",2,"Confirmed",NA,"Unclear","Viral Load or Clearance, Fever, Serious or Seconday Infections, C-Reactive Protein, Radiographic Findings","HCQ, SOC",300
"NCT04325893","https://ClinicalTrials.gov/show/NCT04325893",NA,"France","Paris","2020-Mar","2020-Sep","Recruiting","Randomised","Double",2,"Confirmed",NA,"Unclear","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, CK-MB, Procalcitonin, Radiographic Findings","HCQ, SOC",1300
"NCT04325893","https://ClinicalTrials.gov/show/NCT04325893",NA,"France","Cher","2020-Mar","2020-Sep","Recruiting","Randomised","Double",2,"Confirmed",NA,"Unclear","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, CK-MB, Procalcitonin, Radiographic Findings","HCQ, SOC",1300
"NCT04325893","https://ClinicalTrials.gov/show/NCT04325893",NA,"Monaco","Monaco","2020-Mar","2020-Sep","Recruiting","Randomised","Double",2,"Confirmed",NA,"Unclear","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, CK-MB, Procalcitonin, Radiographic Findings","HCQ, SOC",1300
"NCT04331834","https://ClinicalTrials.gov/show/NCT04331834",NA,"Spain","Barcelona","2020-Apr","2020-Oct","Recruiting","Randomised","Quadruple",2,"Negative","Healthy","Healthcare Workers","Viral Load or Clearance, Treatment-emergent Adverse Events, Serious Adverse Events","HCQ, SOC",440
"2020-001440-26","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001440-26/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Double",2,NA,NA,"Healthcare Workers","Adverse Events, Anti SARS-COV-2 Titers","HCQ, SOC",NA
"2020-001363-85","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001363-85/DK/",NA,"Denmark","Copenhagen","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance","HCQ, SOC",NA
"IRCT20130306012728N8","http://en.irct.ir/trial/46932",NA,"Iran","East Azarbaijan","2020-Apr","2021-Mar","Recruiting","Randomised","Double",2,NA,NA,"Healthy Exposed, Healthcare Workers","Mortality, Hospitalization, Viral Load or Clearance","HCQ, SOC",500
"NCT04304053","https://ClinicalTrials.gov/show/NCT04304053",NA,"Spain","Barcelona","2020-Mar","2020-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Non-severe","Outpatient","Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Treatment-emergent Adverse Events, CD4, PaO2-FiO2, Radiographic Findings","HCQ + Antivirals, SOC",3040
"NCT04380688","https://ClinicalTrials.gov/show/NCT04380688",NA,"United States","District Of Columbia","2020-May","2020-Sep","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2","Acalabrutinib, SOC",60
"NCT04380688","https://ClinicalTrials.gov/show/NCT04380688",NA,"United States","Kentucky","2020-May","2020-Sep","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2","Acalabrutinib, SOC",60
"NCT04380688","https://ClinicalTrials.gov/show/NCT04380688",NA,"United States","Maryland","2020-May","2020-Sep","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2","Acalabrutinib, SOC",60
"NCT04380688","https://ClinicalTrials.gov/show/NCT04380688",NA,"United States","New Jersey","2020-May","2020-Sep","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2","Acalabrutinib, SOC",60
"NCT04380688","https://ClinicalTrials.gov/show/NCT04380688",NA,"United States","New York","2020-May","2020-Sep","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2","Acalabrutinib, SOC",60
"IRCT20200415047082N1","http://en.irct.ir/trial/47193",NA,"Iran","East Azarbaijan","2020-Apr","2020-Jun","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Fever, Other Mild Symptoms, C-Reactive Protein, Blood Pressure, Heart Rate, Respiratory Rate, Radiographic Findings","Alternative therapy, SOC",10
"IRCT20160131026298N2","http://en.irct.ir/trial/46733",NA,"Iran","Tehran","2020-Apr","2020-Mar","Completed","Randomised","Open-Label",2,NA,NA,"Hospital","Cough, Dyspnea, Radiographic Findings","Alternative therapy, SOC",64
"IRCT20080901001157N16","http://en.irct.ir/trial/46907",NA,"Iran","Tehran","2020-Apr","2020-May","Completed","Randomised","Triple",2,NA,NA,"Unclear","Cough, Fever, C-Reactive Protein, Erythrocyte Sedimentation Rate, ALT, Blood Urea Nitrogen, Respiratory Rate, Lung Inflamation","Alternative therapy, SOC",60
"IRCT20180610040049N3","http://en.irct.ir/trial/46697",NA,"Iran","Markazi","2020-Mar","2020-May","Completed","Randomised","Triple",2,"Confirmed","Unclear","Hospital","C-Reactive Protein, Lung Inflamation","Alternative therapy, SOC",60
"IRCT20180712040449N2","http://en.irct.ir/trial/46782",NA,"Iran","Tehran","2020-Apr","2020-Jun","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Lung Inflamation","Alternative therapy, SOC",68
"IRCT20200402046923N1","http://en.irct.ir/trial/46879",NA,"Iran","East Azarbaijan","2020-Apr","2020-May","Completed","Randomised","Open-Label",2,NA,NA,"Hospital","ICU Admission, Hospitalization, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events, Serious Adverse Events, ALT","Alternative therapy, SOC",110
"NCT04367168","https://ClinicalTrials.gov/show/NCT04367168",NA,"Mexico","Mexico","2020-Apr","2021-Apr","Recruiting","Randomised","Quadruple",2,NA,NA,"Hospital","Fever, Other Mild Symptoms, Ferritin, D-Dimer, Fibrinogen, PaO2-FiO2, Respiratory Rate","Colchicine, SOC",174
"NCT04360980","https://ClinicalTrials.gov/show/NCT04360980",NA,"Iran","Tehran","2020-Apr","2020-May","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Fever, C-Reactive Protein, LDH","Colchicine, SOC",80
"NCT04325061","https://ClinicalTrials.gov/show/NCT04325061",NA,"Spain","Barcelona","2020-Mar","2020-Oct","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Corticosteroids, SOC",200
"NCT04325061","https://ClinicalTrials.gov/show/NCT04325061",NA,"Spain","Las Palmas","2020-Mar","2020-Oct","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Corticosteroids, SOC",200
"NCT04325061","https://ClinicalTrials.gov/show/NCT04325061",NA,"Spain","Madrid","2020-Mar","2020-Oct","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Corticosteroids, SOC",200
"NCT04325061","https://ClinicalTrials.gov/show/NCT04325061",NA,"Spain","Ciudad Real","2020-Mar","2020-Oct","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Corticosteroids, SOC",200
"NCT04325061","https://ClinicalTrials.gov/show/NCT04325061",NA,"Spain","Murcia","2020-Mar","2020-Oct","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Corticosteroids, SOC",200
"NCT04325061","https://ClinicalTrials.gov/show/NCT04325061",NA,"Spain","Pontevedra","2020-Mar","2020-Oct","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Corticosteroids, SOC",200
"NCT04325061","https://ClinicalTrials.gov/show/NCT04325061",NA,"Spain","Valencia","2020-Mar","2020-Oct","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Corticosteroids, SOC",200
"NCT04325061","https://ClinicalTrials.gov/show/NCT04325061",NA,"Spain","Valladolid","2020-Mar","2020-Oct","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Corticosteroids, SOC",200
"NCT04244591","https://ClinicalTrials.gov/show/NCT04244591",NA,"China","Beijing","2020-Jan","2020-Apr","Completed","Randomised","Open-Label",2,"Confirmed","Severe","ICU","Mortality, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Radiographic Findings","Corticosteroids, SOC",80
"CHICTR2000029656","http://www.chictr.org.cn/showproj.aspx?proj=49086",NA,"China","Hubei","2020-Feb","2020-Apr","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Radiographic Findings","Corticosteroids, SOC",100
"CHICTR2000029386","http://www.chictr.org.cn/showproj.aspx?proj=48777",NA,"China","Chongqing","2020-Jan",NA,"Recruiting","Randomised","Unspecified",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO","Corticosteroids, SOC",48
"IRCT20200404046947N1","http://en.irct.ir/trial/46904",NA,"Iran","Tehran","2020-Apr","2020-May","Completed","Randomised","Single",2,NA,NA,"Hospital","Mortality, Non-invasive Ventilation, Radiographic Findings","Corticosteroids, SOC",68
"NCT04361526","https://ClinicalTrials.gov/show/NCT04361526",NA,"Spain","Barcelona","2020-Apr","2020-Jul","Recruiting","Randomised","Open-Label",2,NA,NA,"ICU","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Cytokine removal, SOC",40
"DRKS00021447","https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00021447",NA,"Germany","Berlin","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Unclear","Mortality, ICU Admission, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, IL-6, Renal Outcome (Unspecified)","Cytokine removal, SOC",100
"CHICTR2000030259","http://www.chictr.org.cn/showproj.aspx?proj=49918",NA,"China","Shanghai","2020-Feb","2020-Apr","Recruiting","Randomised","Unspecified",2,"Confirmed","Mixed","Hospital","Viral Load or Clearance, PaO2-FiO2, Respiratory Rate","DAA, SOC",60
"IRCT20200128046294N2","http://en.irct.ir/trial/46463",NA,"Iran","Tehran","2020-Mar","2020-Jun","Recruiting","Randomised","Single",2,"Confirmed","Mixed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Respiratory Rate","DAA, SOC",70
"IRCT20100228003449N29","http://en.irct.ir/trial/46567",NA,"Iran","Tehran","2020-Mar","2020-May","Completed","Randomised","Open-Label",2,"Confirmed Or Suspected",NA,"Hospital","Radiographic Findings, Renal Outcome (Unspecified)","DAA, SOC",50
"NCT04353674","https://ClinicalTrials.gov/show/NCT04353674",NA,"Canada","Ontario","2020-Apr","2020-Jul","Recruiting","Randomised","Open-Label",2,NA,NA,"ICU","ICU Admission, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), White Blood Cell Count, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Dialysis, SOC",40
"CHICTR2000030058","http://www.chictr.org.cn/showproj.aspx?proj=49831",NA,"China","Hubei","2020-Feb","2020-May","Not Recruiting","Randomised","Double",2,"Confirmed","Mixed","Unclear","Viral Load or Clearance, Fever, C-Reactive Protein, Radiographic Findings","DMARD, SOC",200
"NCT04357613","https://clinicaltrials.gov/show/NCT04357613",NA,"France","Paris","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events","Imatinib, SOC",99
"CHICTR2000029989","http://www.chictr.org.cn/showproj.aspx?proj=49720",NA,"China","Beijing","2020-Feb","2020-May","Not Recruiting","Randomised","Unspecified",2,"Confirmed",NA,"Hospital","Viral Load or Clearance, Cough, Fever, Dyspnea, Respiratory Rate, Radiographic Findings","IFN, SOC",300
"CHICTR2000030167","http://www.chictr.org.cn/showproj.aspx?proj=49567",NA,"China","Hubei","2020-Feb","2020-Sep","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Mixed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, C-Reactive Protein, Natural Killer Cell Count, CD4, CD8","IFN, SOC",80
"CHICTR2000030013","http://www.chictr.org.cn/showproj.aspx?proj=49796",NA,"China","Beijing","2020-Feb","2020-Jun","Not Recruiting","Non-Randomised","Unspecified",2,"Healthy (Exposed)","Healthy","Healthcare Workers","Pneumonia or ARDS, Cough, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings","IFN, SOC",450
"CHICTR2000029539","http://www.chictr.org.cn/showproj.aspx?proj=48991",NA,"China","Hubei","2020-Feb","2021-Feb","Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Outpatient","ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Cough, Fever, Dyspnea, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Respiratory Rate","LPV/r, SOC",328
"CHICTR2000030089","http://www.chictr.org.cn/showproj.aspx?proj=49889",NA,"China","Shanghai","2020-Feb","2020-Aug","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events","mAb, SOC",60
"NCT04305457","https://ClinicalTrials.gov/show/NCT04305457",NA,"United States","Louisiana","2020-Mar","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Non-invasive respiratory support, SOC",240
"NCT04305457","https://ClinicalTrials.gov/show/NCT04305457",NA,"United States","Massachusetts","2020-Mar","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Non-invasive respiratory support, SOC",240
"2020-001490-68","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001490-68/SE/",NA,"Sweden","Stockholm","2020-Apr",NA,"Recruiting","Randomised","Single",2,NA,NA,"ICU","Mortality, PaO2-FiO2","Non-invasive respiratory support, SOC",NA
"NCT04359303","https://ClinicalTrials.gov/show/NCT04359303",NA,"Spain","Valencia","2020-Apr","2020-Nov","Not Recruiting","Randomised","Double",2,NA,NA,"Hospital","Hospitalization, Clinical Improvement Score (Any), Serious or Seconday Infections, Radiographic Findings","Non-invasive respiratory support, SOC",50
"2020-001301-23","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001301-23/FR/",NA,"France","Paris","2020-Mar",NA,"Recruiting","Randomised","Open-Label",2,NA,NA,"Unclear","Mortality, Viral Load or Clearance, Organ Failure or Dysfunction (SOFA)","NSAIDs, SOC",NA
"NCT04323345","https://ClinicalTrials.gov/show/NCT04323345",NA,"Egypt","Cairo","2020-Mar","2020-Dec","Recruiting","Randomised","Single",2,"Confirmed",NA,"Unclear","Mortality, Viral Load or Clearance, Fever, Radiographic Findings","Nutrition, SOC",1000
"CHICTR2000030897","http://www.chictr.org.cn/showproj.aspx?proj=50462",NA,"China","Zhejiang","2020-Mar","2021-May","Recruiting","Randomised","Unspecified",2,"Resolved",NA,"Resolved Discharged","Hospitalization, Hospital Discharge, Viral Load or Clearance, Fever, C-Reactive Protein, IL-2, IL-4, IL-6, IL-8, IL-10, Tumor Necrosis Factor (Any), Interferon (Any), White Blood Cell Count, Monocyte Count, Weight, Height or BMI, Albumin, IgG, IgM or IgA, Antibodies, CD4, Radiographic Findings","Nutrition, SOC",20
"CHICTR2000030261","http://www.chictr.org.cn/showproj.aspx?proj=49963",NA,"China","Jiangsu","2020-Feb","2020-May","Not Recruiting","Randomised","Unspecified",2,"Confirmed Or Suspected",NA,"Unclear","Viral Load or Clearance, White Blood Cell Count, Radiographic Findings","Other, SOC",26
"NCT04321096","https://ClinicalTrials.gov/show/NCT04321096",NA,"Denmark","Copenhagen","2020-Mar","2020-Dec","Recruiting","Randomised","Quadruple",2,"Confirmed",NA,"Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, SOC",580
"NCT04333550","https://ClinicalTrials.gov/show/NCT04333550",NA,"Iran","Kermanshah","2020-Apr","2020-Sep","Recruiting","Randomised","Double",2,"Confirmed","Mixed","Hospital, Unclear","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), C-Reactive Protein, PaO2-FiO2","Other, SOC",50
"NCT04313023","https://ClinicalTrials.gov/show/NCT04313023",NA,"United States","Oklahoma","2020-Mar","2020-Sep","Not Recruiting","Randomised","Quadruple",2,"Healthy (Exposed)","Healthy","Healthy Exposed","Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation","Other, SOC",200
"NCT04313023","https://ClinicalTrials.gov/show/NCT04313023",NA,"United States","Texas","2020-Mar","2020-Sep","Not Recruiting","Randomised","Quadruple",2,"Healthy (Exposed)","Healthy","Healthy Exposed","Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation","Other, SOC",200
"NCT04358783","https://ClinicalTrials.gov/show/NCT04358783",NA,"Mexico","Nuevo Leon","2020-Apr","2021-Feb","Recruiting","Randomised","Quadruple",2,NA,NA,"Hospital","Mortality, Viral Load or Clearance, Anti SARS-COV-2 Titers","Plasma based therapy, SOC",30
"2020-001310-38","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001310-38/DE/",NA,"Germany","Berlin","2020-Mar",NA,"Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital, ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Anti SARS-COV-2 Titers, C-Reactive Protein, IL-6, Tumor Necrosis Factor (Any)","Plasma based therapy, SOC",NA
"IRCT20200409047007N1","http://en.irct.ir/trial/47058",NA,"Iran","Razavi Khorasan","2020-Apr","2020-Aug","Recruiting","Randomised","Open-Label",2,NA,NA,"ICU","Mortality, ICU Admission","Plasma based therapy, SOC",32
"CHICTR2000029976","http://www.chictr.org.cn/showproj.aspx?proj=49631",NA,"China","Shanghai","2020-Feb","2022-Feb","Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Non-severe","Unclear","Non-invasive Ventilation, Cough, Dyspnea, Other Mild Symptoms, Radiographic Findings, Quality of Life","Psychological therapy, SOC",160
"NCT04252664","https://ClinicalTrials.gov/show/NCT04252664",NA,"China","Hubei","2020-Feb","2020-Apr","Suspended","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, Serious Adverse Events, PaO2-FiO2, Respiratory Rate","Remdesivir, SOC",308
"NCT04257656","https://ClinicalTrials.gov/show/NCT04257656",NA,"China","Beijing","2020-Feb","2020-Mar","Status Unclear","Randomised","Quadruple",2,"Confirmed",NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Treatment-emergent Adverse Events, Serious Adverse Events, PaO2-FiO2, Respiratory Rate","Remdesivir, SOC",237
"NCT04325633","https://ClinicalTrials.gov/show/NCT04325633",NA,"France","Paris","2020-Mar","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, Clinical Improvement Score (Any)","NSAIDs, SOC",584
"EUCTR2020-001634-36-ES","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001634-36",NA,"Spain","Madrid","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","Sarilumab, SOC",30
"NCT04252118","https://ClinicalTrials.gov/show/NCT04252118",NA,"China","Beijing","2020-Feb","2020-Dec","Recruiting","Non-Randomised","Open-Label",2,"Confirmed",NA,"Unclear","Mortality, Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Dyspnea, Treatment-emergent Adverse Events, C-Reactive Protein, Creatinine Phosphokinase, ALT, CD4, CD8","SOC, Stem cells",20
"NCT04346368","https://ClinicalTrials.gov/show/NCT04346368",NA,"China","Guangdong","2020-Apr","2020-Dec","Not Recruiting","Randomised","Single",2,NA,NA,"ICU","Mortality, Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Dyspnea, Adverse Events, C-Reactive Protein, CD4, CD8, PaO2-FiO2, Radiographic Findings","SOC, Stem cells",20
"CHICTR2000029990","http://www.chictr.org.cn/showproj.aspx?proj=49674",NA,"China","Beijing","2020-Feb","2020-Mar","Recruiting","Randomised","Unspecified",2,"Confirmed","Mixed","Hospital",NA,"SOC, Stem cells",120
"CHICTR2000029572","http://www.chictr.org.cn/showproj.aspx?proj=41760",NA,"China","Hubei","2020-Feb","2021-Apr","Recruiting","Randomised","Unspecified",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Pneumonia or ARDS, Non-invasive Ventilation, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings","SOC, Stem cells",30
"CHICTR2000029569","http://www.chictr.org.cn/showproj.aspx?proj=49062",NA,"China","Hubei","2020-Feb","2021-Apr","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Pneumonia or ARDS, Non-invasive Ventilation, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings","SOC, Stem cells",30
"NCT04335071","https://ClinicalTrials.gov/show/NCT04335071",NA,"Switzerland","Bern","2020-Apr","2020-Oct","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism","SOC, TCZ",100
"NCT04335071","https://ClinicalTrials.gov/show/NCT04335071",NA,"Switzerland","Vaud","2020-Apr","2020-Oct","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism","SOC, TCZ",100
"NCT04335071","https://ClinicalTrials.gov/show/NCT04335071",NA,"Switzerland","Zurich","2020-Apr","2020-Oct","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism","SOC, TCZ",100
"DRKS00021238","https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00021238",NA,"Germany","Baden-Wurttemberg","2020-Apr",NA,"Recruiting","Randomised","Triple",2,NA,NA,"ICU","Mortality, ICU Admission, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, PaO2-FiO2","SOC, TCZ",200
"CHICTR2000032573","http://www.chictr.org.cn/showproj.aspx?proj=53225",NA,"China","Guangdong","2020-May","2021-May","Not Recruiting","Randomised","Double",2,"Recovery",NA,"Resolved Discharged","Clinical Improvement Score (Any), 6-Minute Walking Distance, Quality of Life","SOC, TCM",120
"CHICTR2000030988","http://www.chictr.org.cn/showproj.aspx?proj=51317",NA,"China","Guangdong","2020-Mar","2020-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Unclear","Hospitalization, Hospital Discharge, Pneumonia or ARDS, Treatment-emergent Adverse Events","SOC, TCM",204
"CHICTR2000030522","http://www.chictr.org.cn/showproj.aspx?proj=44213",NA,"China","Sichuan","2020-Mar","2020-Sep","Recruiting","Randomised","Double",2,"Confirmed","Mixed","Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Fever, C-Reactive Protein, White Blood Cell Count, Erythrocyte Sedimentation Rate, Radiographic Findings","SOC, TCM",100
"CHICTR2000030022","http://www.chictr.org.cn/showproj.aspx?proj=49797",NA,"China","Anhui","2020-Feb","2020-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Lung Inflamation","SOC, TCM",100
"NCT04323332","https://ClinicalTrials.gov/show/NCT04323332",NA,"China","Beijing","2020-Mar","2020-Mar","Not Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Adverse Events, C-Reactive Protein, Ferritin, IL-6, White Blood Cell Count, Neutrophils, Erythrocyte Sedimentation Rate, D-Dimer, Creatinine Phosphokinase, CK-MB, LDH, Antibodies, Radiographic Findings","SOC, TCM",50
"CHICTR2000030810","http://www.chictr.org.cn/showproj.aspx?proj=50986",NA,"China","Hubei","2020-Mar","2020-Mar","Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Non-severe","Unclear","Hospital Discharge, Creatinine Phosphokinase, CK-MB, ALT, Blood Urea Nitrogen","SOC, TCM",100
"CHICTR2000029789","http://www.chictr.org.cn/showproj.aspx?proj=49348",NA,"China","Henan","2020-Feb","2021-Jun","Recruiting","Randomised","Unspecified",2,"Resolved","Mixed","Resolved Discharged","Visits or Returns to Emergency Department, Pneumonia or ARDS, Radiographic Findings, Quality of Life","SOC, TCM",100
"CHICTR2000029788","http://www.chictr.org.cn/showproj.aspx?proj=49452",NA,"China","Beijing","2020-Feb","2020-Dec","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Non-severe","Unclear","Clinical Improvement Score (Any), Viral Load or Clearance, Fever","SOC, TCM",60
"CHICTR2000029747","http://www.chictr.org.cn/showproj.aspx?proj=49287",NA,"China","Anhui","2020-Feb","2021-Feb","Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Unclear","Radiographic Findings","SOC, TCM",200
"CHICTR2000029518","http://www.chictr.org.cn/showproj.aspx?proj=48860",NA,"China","Zhejiang","2020-Feb","2020-Apr","Recruiting","Randomised","Double",4,"Confirmed","Mixed","Outpatient, Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Other Mild Symptoms, Adverse Events, Serious Adverse Events, Quality of Life","SOC, TCM",140
"CHICTR2000029438","http://www.chictr.org.cn/showproj.aspx?proj=48911",NA,"China","Beijing","2020-Feb","2021-Dec","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism","SOC, TCM",100
"CHICTR2000029436","http://www.chictr.org.cn/showproj.aspx?proj=48884",NA,"China","Henan","2020-Feb","2020-Dec","Not Recruiting","Non-Randomised","Unspecified",2,"Confirmed",NA,"Unclear","Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Radiographic Findings, Quality of Life","SOC, TCM",100
"CHICTR2000029869","http://www.chictr.org.cn/showproj.aspx?proj=49486",NA,"China","Hubei","2020-Feb","2020-Jun","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Non-severe","Unclear","Mortality, ICU Admission, Pneumonia or ARDS, C-Reactive Protein, Tumor Necrosis Factor (Any), Interferon (Any), Creatinine Phosphokinase, CK-MB, eGFR, ALT, Albumin, Bilirubin, Radiographic Findings","SOC, TCM",300
"CHICTR2000030836","http://www.chictr.org.cn/showproj.aspx?proj=51054",NA,"China","Shanghai","2020-Mar","2020-Jun","Not Recruiting","Non-Randomised","Unspecified",2,"Confirmed",NA,"Unclear","Mortality, ICU Admission, Clinical Improvement Score (Any), Pneumonia or ARDS, Dyspnea, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, IL-6, Interferon (Any), eGFR, Coagulation Test, ALT, Albumin, Bilirubin, PaO2-FiO2, Respiratory Rate","SOC, TCM",300
"CHICTR2000032237","http://www.chictr.org.cn/showproj.aspx?proj=52699",NA,"China","Hubei","2020-Apr","2020-Jun","Recruiting","Randomised","Double",2,NA,NA,"Unclear","Other Mild Symptoms","SOC, TCM",200
"CHICTR2000030518","http://www.chictr.org.cn/showproj.aspx?proj=50586",NA,"China","Zhejiang","2020-Mar","2020-May","Recruiting","Randomised","Unspecified",2,"Confirmed","Mixed","Unclear","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, IL-2, IL-4, IL-6, IL-10, Tumor Necrosis Factor (Any), Interferon (Any), CD4, CD8, Radiographic Findings","SOC, TCM",60
"NCT04260594","https://ClinicalTrials.gov/show/NCT04260594",NA,"China","Shanghai","2020-Feb","2020-Jul","Not Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Hospital, ICU","Mortality, Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Treatment-emergent Adverse Events, Serious Adverse Events, PaO2-FiO2","SOC, Umifenovir",380
"2020-001678-31","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001678-31/FR/",NA,"France","Paris","2020-Apr",NA,"Recruiting","Randomised","Single",2,"Negative","Healthy","Healthy Unexposed, Healthy Exposed, Healthcare Workers","ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Anti SARS-COV-2 Titers","SOC, Vaccine",NA
"NCT04324606","https://ClinicalTrials.gov/show/NCT04324606",NA,"United Kingdom","Southampton","2020-Mar","2021-May","Not Recruiting","Randomised","Single",4,"Healthy","Healthy","Healthy Unexposed",NA,"SOC, Vaccine",1090
"NCT04324606","https://ClinicalTrials.gov/show/NCT04324606",NA,"United Kingdom","Bristol","2020-Mar","2021-May","Not Recruiting","Randomised","Single",4,"Healthy","Healthy","Healthy Unexposed",NA,"SOC, Vaccine",1090
"NCT04324606","https://ClinicalTrials.gov/show/NCT04324606",NA,"United Kingdom","London","2020-Mar","2021-May","Not Recruiting","Randomised","Single",4,"Healthy","Healthy","Healthy Unexposed",NA,"SOC, Vaccine",1090
"NCT04264533","https://ClinicalTrials.gov/show/NCT04264533",NA,"China","Hubei","2020-Feb","2020-Sep","Recruiting","Randomised","Triple",2,"Confirmed","Severe","ICU","Mortality, ICU Admission, Clinical Improvement Score (Any), PaO2-FiO2, Respiratory Rate, Hypoxia, Hypoxemia","SOC, Vitamins",140
"IRCT20170117032004N3","http://en.irct.ir/trial/46564",NA,"Iran","East Azarbaijan","2020-Mar","2020-Jul","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Hospitalization","SOC, Vitamins",30
"ACTRN12620000454976","https://anzctr.org.au/ACTRN12620000454976.aspx",NA,"Australia","Canberra","2020-Aug",NA,"Not Recruiting","Randomised","Unspecified",NA,NA,NA,"Hospital","Mortality, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2","SOC, Zinc",160
"IRCT20180610040049N4","http://en.irct.ir/trial/46850",NA,"Iran","Qom","2020-Apr","2020-May","Completed","Randomised","Triple",2,NA,NA,"Unclear","C-Reactive Protein, Lung Inflamation","Alternative therapy, SOC",60
"NCT04372979","https://ClinicalTrials.gov/show/NCT04372979",NA,"France","Paris","2020-May","2020-Oct","Not Recruiting","Randomised","Triple",2,"Confirmed","Unspecified","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Anti SARS-COV-2 Titers, Quality of Life","Plasma based therapy, SOC",80
"NCT04358939","https://ClinicalTrials.gov/show/NCT04358939",NA,"France","Paris","2020-Apr","2020-Nov","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Patient Positioning","Positioning",248
"CHICTR2000029418","http://www.chictr.org.cn/showproj.aspx?proj=48886",NA,"China","Beijing","2020-Jan","2020-Aug","Recruiting","Randomised","Unspecified",2,"Confirmed","Severe","Hospital","ICU Admission, PaO2-FiO2, Respiratory Rate","SOC, TCM",42
"CHICTR2000029606","http://www.chictr.org.cn/showproj.aspx?proj=49146",NA,"China","Zhejiang","2020-Feb","2022-Dec","Recruiting","Randomised","Open-Label",5,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","SOC, TCM",63
"CHICTR2000030469","http://www.chictr.org.cn/showproj.aspx?proj=50082",NA,"China","Shanghai","2020-Mar","2020-May","Recruiting","Randomised","Unspecified",2,"Confirmed","Mixed","Hospital","Hospitalization, Pneumonia or ARDS, Fever, Radiographic Findings","SOC, TCM",96
"CHICTR2000029813","http://www.chictr.org.cn/showproj.aspx?proj=49425",NA,"China","Shanghai","2020-Feb","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Viral Load or Clearance, Cough, Fever, C-Reactive Protein","SOC, TCM",72
"CHICTR2000029756","http://www.chictr.org.cn/showproj.aspx?proj=49222",NA,"China","Hubei","2020-Feb","2022-Feb","Recruiting","Randomised","Unspecified",2,"Confirmed",NA,"Unclear","ICU Admission, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Blood Pressure, Heart Rate, Surfactant Factor Protein, PaO2-FiO2, Respiratory Rate, Radiographic Findings","IFN, TCM",238
"NCT04322773","https://ClinicalTrials.gov/show/NCT04322773",NA,"Denmark","Copenhagen","2020-Mar","2021-Jun","Recruiting","Randomised","Open-Label",4,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein","Sarilumab, SOC, TCZ",200
"CHICTR2000030420","http://www.chictr.org.cn/showproj.aspx?proj=50286",NA,"China","Liaoning","2020-Mar","2020-Aug","Not Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected",NA,"Unclear","Depression, Anxiety, Distress","TCM",60
"CHICTR2000030467","http://www.chictr.org.cn/showproj.aspx?proj=50378",NA,"China","Liaoning","2020-Mar","2020-Aug","Not Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected",NA,"Unclear","Quality of Life","TCM, TCM + Psychological therapy",60
"CHICTR2000029621","http://www.chictr.org.cn/showproj.aspx?proj=49165",NA,"China","Shanghai","2020-Feb","2020-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed","Non-severe","Outpatient","Mortality, Viral Load or Clearance, Fever","SOC, Umifenovir",380
"2020-001431-27","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001431-27/DE/",NA,"Germany","Berlin","2020-Apr",NA,"Recruiting","Randomised","Unspecified",3,"Confirmed","Unclear","Unclear","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","ARBs, SOC",NA
"NCT04357782","https://ClinicalTrials.gov/show/NCT04357782",NA,"United States","Virginia","2020-Apr","2020-Jun","Recruiting","Single-Arm","Open-Label",1,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, Neutrophils, D-Dimer, LDH","Vitamins",20
"CHICTR2000030388","http://www.chictr.org.cn/showproj.aspx?proj=50306",NA,"China","Hubei","2020-Mar",NA,"Recruiting","Randomised","Unspecified",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Treatment-emergent Adverse Events, C-Reactive Protein, IL-6, IL-8, Tumor Necrosis Factor (Any), White Blood Cell Count, Shock","SOC, TCM",60
"NCT04344457","https://ClinicalTrials.gov/show/NCT04344457",NA,"United States","Arizona","2020-Apr","2020-Jun","Recruiting","Single-Arm","Open-Label",1,"Yes","Non-severe","Outpatient","Clinical Improvement Score (Any), Cough, Fever, Treatment-emergent Adverse Events","AZT, HCQ, Indomethacin/NSAID",80
"NCT04344457","https://ClinicalTrials.gov/show/NCT04344457",NA,"United States","Louisiana","2020-Apr","2020-Jun","Recruiting","Single-Arm","Open-Label",1,"Yes","Non-severe","Outpatient","Clinical Improvement Score (Any), Cough, Fever, Treatment-emergent Adverse Events","AZT, HCQ, Indomethacin/NSAID",80
"CHICTR2000030481","http://www.chictr.org.cn/showproj.aspx?proj=50453",NA,"China","Hubei","2020-Mar","2020-Apr","Recruiting","Randomised","Unspecified",3,"Confirmed",NA,"Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, Radiographic Findings, Renal Outcome (Unspecified)","Corticosteroids, SOC",200
"NCT04341688","https://ClinicalTrials.gov/show/NCT04341688",NA,"Pakistan","Sind","2020-Apr","2020-Dec","Not Recruiting","Randomised","Quadruple",2,"Yes","Unspecified","Hospital","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, C-Reactive Protein","Hygiene, SOC",50
"NCT04344236","https://ClinicalTrials.gov/show/NCT04344236",NA,"United States","New York","2020-Apr","2020-May","Recruiting","Randomised","Open-Label",3,NA,NA,"Unclear","Viral Load or Clearance, Pneumonia or ARDS, Heart Rate","Hygiene, SOC",48
"NCT04359537","https://ClinicalTrials.gov/show/NCT04359537",NA,"Pakistan","Islamabad","2020-Apr","2020-Aug","Recruiting","Randomised","Single",2,NA,NA,"Healthcare Workers","Mortality, ICU Admission, Hospitalization, Other Mild Symptoms, Treatment-emergent Adverse Events","HCQ, SOC",200
"NCT04353037","https://ClinicalTrials.gov/show/NCT04353037",NA,"United States","New York","2020-Apr","2021-Apr","Recruiting","Randomised","Double",2,NA,NA,"Healthcare Workers, Outpatient","Hospitalization, Viral Load or Clearance, Household Members with CoViD-19, Labor Absenteeism, Adverse Events","HCQ, SOC",850
"NCT04354441","https://ClinicalTrials.gov/show/NCT04354441",NA,"Canada","Quebec","2020-Apr","2020-Nov","Not Recruiting","Randomised","Quadruple",2,NA,NA,"Outpatient","Hospitalization, Clinical Improvement Score (Any), Cough, Other Mild Symptoms, Treatment-emergent Adverse Events","HCQ, SOC",600
"NCT04343092","https://ClinicalTrials.gov/show/NCT04343092",NA,"Iraq","Baghdad","2020-Apr","2020-Aug","Recruiting","Randomised","Double",4,"Yes","Mixed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Serious Adverse Events","HCQ + Avermectin + AZT, HCQ + AZT",50
"NCT04341493","https://ClinicalTrials.gov/show/NCT04341493",NA,"Mexico","Mexico","2020-Apr","2020-Aug","Recruiting","Randomised","Single",2,NA,NA,"Unclear","Hospitalization","HCQ, HCQ + Nitazoxanide",86
"NCT04359277","https://ClinicalTrials.gov/show/NCT04359277",NA,"United States","New York","2020-Apr","2021-Apr","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, D-Dimer, Troponin, Fibrinogen, Lung Inflamation, Hypoxemia, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Anticoagulants",1000
"NCT04345445","https://ClinicalTrials.gov/show/NCT04345445",NA,"Malaysia","Kuala Lumpur","2020-Apr","2020-Oct","Not Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation","Corticosteroids, TCZ",310
"NCT04349371","https://ClinicalTrials.gov/show/NCT04349371",NA,"United States","New York","2020-Apr","2021-Apr","Recruiting","Randomised","Quadruple",2,"No","Healthy","Healthcare Workers","Viral Load or Clearance, Serious Adverse Events","HCQ, SOC",350
"NCT04342169","https://ClinicalTrials.gov/show/NCT04342169",NA,"United States","Utah","2020-Apr","2022-Apr","Recruiting","Randomised","Open-Label",2,"Yes","Non-severe","Outpatient","ICU Admission, Depression, Anxiety","HCQ, SOC",400
"NCT04345692","https://ClinicalTrials.gov/show/NCT04345692",NA,"United States","Hawaii","2020-Apr","2021-Dec","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Heart Rate","HCQ, SOC",350
"NCT04344288","https://ClinicalTrials.gov/show/NCT04344288",NA,"France","Paris","2020-Apr","2020-Nov","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events","Corticosteroids, SOC",304
"NCT04344288","https://ClinicalTrials.gov/show/NCT04344288",NA,"France","Nord","2020-Apr","2020-Nov","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events","Corticosteroids, SOC",304
"NCT04344288","https://ClinicalTrials.gov/show/NCT04344288",NA,"France","Vienne","2020-Apr","2020-Nov","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events","Corticosteroids, SOC",304
"NCT04349241","https://ClinicalTrials.gov/show/NCT04349241",NA,"Egypt","Cairo","2020-Apr","2020-Oct","Not Recruiting","Randomised","Open-Label",2,"Yes","Non-severe","Outpatient","Viral Load or Clearance, Fever, Radiographic Findings","FPV, SOC",100
"JPRN-JAPICCTI-205238","https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-205238",NA,"Japan","Tokyo","2020-Mar",NA,"Recruiting","Randomised","Unspecified",NA,"Confirmed","Mixed","Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Adverse Events, Serious Adverse Events, Radiographic Findings","FPV, SOC",96
"NCT04350580","https://ClinicalTrials.gov/show/NCT04350580",NA,"France","Paris","2020-Apr","2020-Jun","Recruiting","Randomised","Double",2,"Yes","Severe","ICU","Mortality, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, C-Reactive Protein, Procalcitonin, PaO2-FiO2, Radiographic Findings, Renal Outcome (Unspecified)","Igs, SOC",138
"IRCT20150914024017N1","http://en.irct.ir/trial/46665",NA,"Iran","Tehran","2020-Apr","2021-Feb","Recruiting","Randomised","Triple",2,"Confirmed","Unspecified","Hospital","ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Fever, Treatment-emergent Adverse Events","IFN, SOC",40
"NCT04344431","https://ClinicalTrials.gov/show/NCT04344431",NA,"France","Paris","2020-Apr","2021-Apr","Recruiting","Randomised","Single",2,NA,NA,"Hospital","Mortality, Hospitalization, Non-invasive Ventilation","Non-invasive respiratory support, SOC",100
"NCT04346693","https://ClinicalTrials.gov/show/NCT04346693",NA,"Russia","Moscow","2020-Apr","2020-Dec","Not Recruiting","Randomised","Open-Label",4,NA,NA,"Hospital","Mortality, Hospitalization, Hospital Discharge, Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, SOC",320
"NCT04345523","https://ClinicalTrials.gov/show/NCT04345523",NA,"Spain","Zaragoza","2020-Apr","2020-Jul","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, C-Reactive Protein, IL-6, MCP-1, Dendritic Cell Count, D-Dimer, Coagulation Test, ALT, Glucose, LDH","Plasma based therapy, SOC",278
"NCT04345523","https://ClinicalTrials.gov/show/NCT04345523",NA,"Spain","Madrid","2020-Apr","2020-Jul","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, C-Reactive Protein, IL-6, MCP-1, Dendritic Cell Count, D-Dimer, Coagulation Test, ALT, Glucose, LDH","Plasma based therapy, SOC",278
"NCT04345523","https://ClinicalTrials.gov/show/NCT04345523",NA,"Spain","Asturias","2020-Apr","2020-Jul","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, C-Reactive Protein, IL-6, MCP-1, Dendritic Cell Count, D-Dimer, Coagulation Test, ALT, Glucose, LDH","Plasma based therapy, SOC",278
"NCT04344184","https://ClinicalTrials.gov/show/NCT04344184",NA,"United States","Virginia","2020-Apr","2021-May","Not Recruiting","Randomised","Quadruple",2,NA,NA,"Hospital","Clinical Improvement Score (Any), Fever","SOC, Vitamins",200
"CHICTR2000029975","http://www.chictr.org.cn/showproj.aspx?proj=49592",NA,"China","Jilin","2020-Feb","2020-May","Not Recruiting","Single-Arm","Unspecified",1,"Confirmed",NA,"Hospital","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","HCQ",10
"NCT04329572","https://ClinicalTrials.gov/show/NCT04329572",NA,"Brazil","Brasilia","2020-Apr","2020-May","Suspended","Single-Arm","Open-Label",1,"Confirmed","Mixed","Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea","HCQ + AZT",400
"IRCT20200411047030N1","http://en.irct.ir/trial/47099",NA,"Iran","Tehran","2020-Apr","2020-Jun","Recruiting","Unspecified","Open-Label",2,NA,NA,"Hospital","Mortality, ICU Admission, Fever, Other Mild Symptoms, C-Reactive Protein","HCQ + AZT + Melatonin",82
"NCT04335084","https://ClinicalTrials.gov/show/NCT04335084",NA,"United States","California","2020-Apr","2021-May","Not Recruiting","Single-Arm","Double",1,"Healthy","Healthy","Healthcare Workers","Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events, Serious Adverse Events","HCQ + Vitamins + Zinc",600
"2020-001723-13","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001723-13/FR/",NA,"France","Paris","2020-Apr",NA,"Recruiting","Randomised","Open-Label",4,"Confirmed","Mild","Outpatient","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Other Mild Symptoms, Adverse Events, Serious Adverse Events","AZT",NA
"CHICTR2000030475","http://www.chictr.org.cn/showproj.aspx?proj=50452",NA,"China","Beijing","2020-Mar","2020-Jun","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, IL-6, IL-10, Tumor Necrosis Factor (Any)","Cytokine removal",19
"CHICTR2000030487","http://www.chictr.org.cn/showproj.aspx?proj=50507",NA,"China","Henan","2020-Mar","2020-May","Recruiting","Single-Arm","Unspecified",1,"Confirmed","Mixed","Unclear","Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, CD4, CD8","DAA",10
"CHICTR2000030424","http://www.chictr.org.cn/showproj.aspx?proj=50174",NA,"China","Henan","2020-Mar","2022-May","Not Recruiting","Single-Arm","Unspecified",1,"Confirmed","Mixed","Unclear","Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Other Mild Symptoms, CD4, CD8","DAA",30
"IRCT20200317046797N5","http://en.irct.ir/trial/47015",NA,"Iran","East Azarbaijan","2020-Apr","2020-Jul","Recruiting","Single-Arm","Open-Label",1,NA,NA,"ICU","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Radiographic Findings","Dialysis",10
"IRCT20200325046859N1","http://en.irct.ir/trial/46811",NA,"Iran","Tehran","2020-Apr","2020-May","Completed","Single-Arm","Open-Label",1,NA,NA,"Hospital","Fever, White Blood Cell Count, Respiratory Rate, Radiographic Findings","Igs",50
"NCT04334044","https://ClinicalTrials.gov/show/NCT04334044",NA,"Mexico","Mexico","2020-Apr","2020-Jun","Recruiting","Single-Arm","Open-Label",1,"Confirmed",NA,"Unclear","Mortality, ICU Admission, Pneumonia or ARDS, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, D-Dimer","JAKi",20
"NCT04370288","https://ClinicalTrials.gov/show/NCT04370288",NA,"Iran","Razavi Khorasan","2020-Apr","2020-Sep","Recruiting","Randomised","Single",2,"Confirmed",NA,"ICU","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, White Blood Cell Count, PaO2-FiO2","Other",20
"CHICTR2000031138","http://www.chictr.org.cn/showproj.aspx?proj=51416",NA,"China","Hunan","2020-Mar","2020-Dec","Recruiting","Randomised","Unspecified",2,"Confirmed",NA,"Unclear","Clinical Improvement Score (Any), Pneumonia or ARDS, PaO2-FiO2, Respiratory Rate","Other",40
"NCT04304313","https://ClinicalTrials.gov/show/NCT04304313",NA,"China","Hubei","2020-Mar","2020-Mar","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Mixed","Unclear","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, CK-MB, ALT, PaO2-FiO2, Radiographic Findings","Other",10
"NCT04353206","https://ClinicalTrials.gov/show/NCT04353206",NA,"United States","California","2020-Apr","2021-May","Recruiting","Single-Arm","Open-Label",1,NA,NA,"ICU","Mortality","Plasma based therapy",60
"NCT04353206","https://ClinicalTrials.gov/show/NCT04353206",NA,"United States","Maryland","2020-Apr","2021-May","Recruiting","Single-Arm","Open-Label",1,NA,NA,"ICU","Mortality","Plasma based therapy",60
"NCT04332380","https://ClinicalTrials.gov/show/NCT04332380",NA,"Colombia","Cundinamarca","2020-Apr","2020-Aug","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, IgG, IgM or IgA","Plasma based therapy",10
"IRCT20200416047099N1","http://en.irct.ir/trial/47266",NA,"Iran","Tehran","2020-Apr","2020-May","Completed","Single-Arm","Open-Label",1,NA,NA,"ICU","Fever, PaO2-FiO2, Respiratory Rate, Radiographic Findings","Plasma based therapy",10
"NCT04348877","https://ClinicalTrials.gov/show/NCT04348877",NA,"Egypt","Cairo","2020-Apr","2020-Oct","Not Recruiting","Single-Arm","Open-Label",1,"Yes","Severe","Hospital","Viral Load or Clearance, Fever, Radiographic Findings","Plasma based therapy",20
"NCT04343755","https://ClinicalTrials.gov/show/NCT04343755",NA,"United States","New Jersey","2020-Apr","2021-Apr","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation","Plasma based therapy",55
"CHICTR2000030855","http://www.chictr.org.cn/showproj.aspx?proj=51090",NA,"China","Guizhou","2020-Mar","2020-May","Not Recruiting","Single-Arm","Unspecified",1,"Confirmed","Severe","Hospital","ICU Admission, PaO2-FiO2, Respiratory Rate","Respiratory support",200
"CHICTR2000030020","http://www.chictr.org.cn/showproj.aspx?proj=49812",NA,"China","Hunan","2020-Feb","2022-Feb","Recruiting","Single-Arm","Open-Label",1,"Confirmed Or Suspected",NA,"Unclear","Viral Load or Clearance, Radiographic Findings","Stem cells",20
"IRCT20200325046860N2","http://en.irct.ir/trial/46789",NA,"Iran","Tehran","2020-Apr","2020-Apr","Completed","Non-Randomised","Open-Label",0,NA,NA,"Hospital","Respiratory Rate","Stem cells",5
"NCT04276987","https://ClinicalTrials.gov/show/NCT04276987",NA,"China","Beijing","2020-Feb","2020-May","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, IL-1, IL-2, IL-6, IL-8, D-Dimer, LDH, Radiographic Findings","Stem cells",30
"NCT04331795","https://ClinicalTrials.gov/show/NCT04331795",NA,"United States","Illinois","2020-Apr","2020-Jul","Recruiting","Single-Arm","Open-Label",1,"Confirmed",NA,"Hospital","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","TCZ",50
"NCT04363853","https://ClinicalTrials.gov/show/NCT04363853",NA,"Mexico","Distrito Federal","2020-Apr","2020-Jun","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital, ICU","Pneumonia or ARDS, White Blood Cell Count, Hemoglobin, Glucose, Blood Urea Nitrogen, Radiographic Findings","TCZ",200
"CHICTR2000030196","http://www.chictr.org.cn/showproj.aspx?proj=49883",NA,"China","Hubei","2020-Feb","2020-May","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Mixed","Outpatient, Hospital","Adverse Events, Serious Adverse Events, IL-1, IL-6, Tumor Necrosis Factor (Any), Interferon (Any)","TCZ",60
"CHICTR2000030027","http://www.chictr.org.cn/showproj.aspx?proj=49852",NA,"China","Beijing","2020-Feb","2021-Feb","Recruiting","Single-Arm","Unspecified",1,"Confirmed","Severe","Unclear","Clinical Improvement Score (Any)","TCM",60
"CHICTR2000030751","http://www.chictr.org.cn/showproj.aspx?proj=50941",NA,"China","Inner Mongol","2020-Mar","2020-Dec","Not Recruiting","Single-Arm","Unspecified",1,"Confirmed",NA,"Unclear","Viral Load or Clearance, White Blood Cell Count, Monocyte Count, Natural Killer Cell Count, Neutrophils, Creatinine Phosphokinase, CK-MB, eGFR, ALT, Albumin, Bilirubin, Urine Sample, Radiographic Findings","TCM",60
"NCT04345276","https://ClinicalTrials.gov/show/NCT04345276",NA,"China","Hubei","2020-Apr","2020-Apr","Recruiting","Single-Arm","Open-Label",1,NA,NA,"Hospital","ICU Admission, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Serious Adverse Events",NA,40
"NCT04343183","https://ClinicalTrials.gov/show/NCT04343183",NA,"United States","Louisiana","2020-Apr","2020-Jun","Not Recruiting","Randomised","Single",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation",NA,48
"NCT04342221","https://ClinicalTrials.gov/show/NCT04342221",NA,"Germany","Berlin","2020-Apr","2021-Mar","Recruiting","Randomised","Quadruple",2,NA,NA,"Hospital","Mortality, Invasive Mechanical Ventilation or ECMO",NA,220
"NCT04341727","https://ClinicalTrials.gov/show/NCT04341727",NA,"United States","Missouri","2020-Apr","2021-Apr","Recruiting","Randomised","Open-Label",3,NA,NA,"Hospital",NA,NA,500
"NCT04334382","https://ClinicalTrials.gov/show/NCT04334382",NA,"United States","Utah","2020-Apr","2020-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed","Non-severe","Outpatient","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6",NA,1550
"2020-001409-21","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001409-21/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Double",2,NA,NA,"Hospital, ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events",NA,NA
"IRCT20200310046736N1","http://en.irct.ir/trial/46424",NA,"Iran","Golestan","2020-Apr","2020-Jul","Not Recruiting","Randomised","Single",3,"Confirmed","Severe","Hospital, ICU","Clinical Improvement Score (Any), Viral Load or Clearance",NA,45
"IRCT20200317046797N1","http://en.irct.ir/trial/46573",NA,"Iran","Tehran","2020-Apr","2020-May","Completed","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Radiographic Findings",NA,40
"IRCT20160310026998N11","http://en.irct.ir/trial/46690",NA,"Iran","East Azarbaijan","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",2,"Mixed","Mixed","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO",NA,200
"NCT04364009","https://ClinicalTrials.gov/show/NCT04364009",NA,"France","Paris","2020-Apr","2020-Sep","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed",NA,"Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, White Blood Cell Count, D-Dimer, Fibrinogen, LDH, PaO2-FiO2, Respiratory Rate, Quality of Life","Anakinra, SOC",240
"NCT04380701","https://ClinicalTrials.gov/show/NCT04380701",NA,"Germany","Berlin","2020-May","2020-Aug","Recruiting","Non-Randomised","Open-Label",4,NA,NA,"Healthy Unexposed","Adverse Events, Treatment-emergent Adverse Events, Anti SARS-COV-2 Titers","Vaccine",200
"NCT04366960","https://ClinicalTrials.gov/show/NCT04366960",NA,"Italy","Milano","2020-Apr","2020-Aug","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, C-Reactive Protein, IL-6, D-Dimer, Radiographic Findings, Cardiac Outcome (Unspecified)","Anticoagulants",2712
"NCT04353180","https://ClinicalTrials.gov/show/NCT04353180",NA,"Egypt","Cairo","2020-Apr","2020-Jun","Not Recruiting","Randomised","Open-Label",3,NA,NA,"ICU","Mortality, ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Anti SARS-COV-2 Titers, C-Reactive Protein, IL-1, IL-6, Interferon (Any), Erythrocyte Sedimentation Rate, D-Dimer","Other, SOC",360
"NCT04312009","https://ClinicalTrials.gov/show/NCT04312009",NA,"United States","Minnesota","2020-Mar","2021-Apr","Recruiting","Randomised","Quadruple",2,"Confirmed Or Suspected","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Dyspnea, Organ Failure or Dysfunction (SOFA), PaO2-FiO2","ARBs",200
"NCT04251871","https://ClinicalTrials.gov/show/NCT04251871",NA,"China","Beijing","2020-Feb","2021-Jan","Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Unclear","Mortality, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Dyspnea, Radiographic Findings","LPV/r + IFN + TCM + Non-invasive respiratory support, LPV/r + Non-invasive respiratory support + IFN",150
"CHICTR2000029638","http://www.chictr.org.cn/showproj.aspx?proj=49224",NA,"China","Sichuan","2020-Feb",NA,"Recruiting","Randomised","Unspecified",2,"Confirmed","Mixed","Unclear","Cough, Fever, Dyspnea, Other Mild Symptoms, Treatment-emergent Adverse Events, C-Reactive Protein, IL-1, IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, Tumor Necrosis Factor (Any), Granulocyte Stimulaiting Factor, White Blood Cell Count, Hemoglobin, Erythrocyte Sedimentation Rate, Creatinine Phosphokinase, CK-MB, Myoglobin, Troponin, Procalcitonin, Coagulation Test, Urine Sample, Blood Pressure, Heart Rate, Respiratory Rate, Radiographic Findings","IFN",100
"NCT04333914","https://ClinicalTrials.gov/show/NCT04333914",NA,"France","Paris","2020-Apr","2020-Jun","Recruiting","Randomised","Open-Label",4,"Confirmed Or Suspected",NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, Neutrophils, Hemoglobin","HCQ, mAb, SOC, TCZ",273
"NCT04333654","https://ClinicalTrials.gov/show/NCT04333654",NA,"United States","Massachusetts","2020-Apr","2020-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed","Non-severe","Outpatient","Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, IL-6, Tumor Necrosis Factor (Any), D-Dimer, Antibodies, PaO2-FiO2","HCQ, SOC",210
"NCT04333654","https://ClinicalTrials.gov/show/NCT04333654",NA,"Belgium","Brussels","2020-Apr","2020-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed","Non-severe","Outpatient","Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, IL-6, Tumor Necrosis Factor (Any), D-Dimer, Antibodies, PaO2-FiO2","HCQ, SOC",210
"NCT04333654","https://ClinicalTrials.gov/show/NCT04333654",NA,"France","Paris","2020-Apr","2020-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed","Non-severe","Outpatient","Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, IL-6, Tumor Necrosis Factor (Any), D-Dimer, Antibodies, PaO2-FiO2","HCQ, SOC",210
"NCT04333654","https://ClinicalTrials.gov/show/NCT04333654",NA,"Netherlands","Groningen","2020-Apr","2020-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed","Non-severe","Outpatient","Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, IL-6, Tumor Necrosis Factor (Any), D-Dimer, Antibodies, PaO2-FiO2","HCQ, SOC",210
"NCT04333654","https://ClinicalTrials.gov/show/NCT04333654",NA,"Netherlands","Amsterdam","2020-Apr","2020-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed","Non-severe","Outpatient","Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, IL-6, Tumor Necrosis Factor (Any), D-Dimer, Antibodies, PaO2-FiO2","HCQ, SOC",210
"EUCTR2020-001224-33-DE","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001224-33",NA,"Germany","Berlin","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ, SOC",220
"NCT04358068","https://ClinicalTrials.gov/show/NCT04358068",NA,"United States","Alabama","2020-Apr","2020-Oct","Recruiting","Randomised","Double",4,NA,NA,"Outpatient","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Other Mild Symptoms, Treatment-emergent Adverse Events, Cardiac Outcome (Unspecified)","HCQ + AZT, SOC",2000
"NCT04358068","https://ClinicalTrials.gov/show/NCT04358068",NA,"United States","California","2020-Apr","2020-Oct","Recruiting","Randomised","Double",4,NA,NA,"Outpatient","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Other Mild Symptoms, Treatment-emergent Adverse Events, Cardiac Outcome (Unspecified)","HCQ + AZT, SOC",2000
"NCT04358068","https://ClinicalTrials.gov/show/NCT04358068",NA,"United States","Colorado","2020-Apr","2020-Oct","Recruiting","Randomised","Double",4,NA,NA,"Outpatient","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Other Mild Symptoms, Treatment-emergent Adverse Events, Cardiac Outcome (Unspecified)","HCQ + AZT, SOC",2000
"NCT04358068","https://ClinicalTrials.gov/show/NCT04358068",NA,"United States","District Of Columbia","2020-Apr","2020-Oct","Recruiting","Randomised","Double",4,NA,NA,"Outpatient","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Other Mild Symptoms, Treatment-emergent Adverse Events, Cardiac Outcome (Unspecified)","HCQ + AZT, SOC",2000
"NCT04358068","https://ClinicalTrials.gov/show/NCT04358068",NA,"United States","Illinois","2020-Apr","2020-Oct","Recruiting","Randomised","Double",4,NA,NA,"Outpatient","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Other Mild Symptoms, Treatment-emergent Adverse Events, Cardiac Outcome (Unspecified)","HCQ + AZT, SOC",2000
"NCT04358068","https://ClinicalTrials.gov/show/NCT04358068",NA,"United States","Massachusetts","2020-Apr","2020-Oct","Recruiting","Randomised","Double",4,NA,NA,"Outpatient","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Other Mild Symptoms, Treatment-emergent Adverse Events, Cardiac Outcome (Unspecified)","HCQ + AZT, SOC",2000
"NCT04358068","https://ClinicalTrials.gov/show/NCT04358068",NA,"United States","New Jersey","2020-Apr","2020-Oct","Recruiting","Randomised","Double",4,NA,NA,"Outpatient","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Other Mild Symptoms, Treatment-emergent Adverse Events, Cardiac Outcome (Unspecified)","HCQ + AZT, SOC",2000
"NCT04358068","https://ClinicalTrials.gov/show/NCT04358068",NA,"United States","New York","2020-Apr","2020-Oct","Recruiting","Randomised","Double",4,NA,NA,"Outpatient","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Other Mild Symptoms, Treatment-emergent Adverse Events, Cardiac Outcome (Unspecified)","HCQ + AZT, SOC",2000
"NCT04358068","https://ClinicalTrials.gov/show/NCT04358068",NA,"United States","North Carolina","2020-Apr","2020-Oct","Recruiting","Randomised","Double",4,NA,NA,"Outpatient","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Other Mild Symptoms, Treatment-emergent Adverse Events, Cardiac Outcome (Unspecified)","HCQ + AZT, SOC",2000
"NCT04358068","https://ClinicalTrials.gov/show/NCT04358068",NA,"United States","Ohio","2020-Apr","2020-Oct","Recruiting","Randomised","Double",4,NA,NA,"Outpatient","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Other Mild Symptoms, Treatment-emergent Adverse Events, Cardiac Outcome (Unspecified)","HCQ + AZT, SOC",2000
"NCT04358068","https://ClinicalTrials.gov/show/NCT04358068",NA,"United States","Pennsylvania","2020-Apr","2020-Oct","Recruiting","Randomised","Double",4,NA,NA,"Outpatient","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Other Mild Symptoms, Treatment-emergent Adverse Events, Cardiac Outcome (Unspecified)","HCQ + AZT, SOC",2000
"NCT04358068","https://ClinicalTrials.gov/show/NCT04358068",NA,"United States","Tennessee","2020-Apr","2020-Oct","Recruiting","Randomised","Double",4,NA,NA,"Outpatient","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Other Mild Symptoms, Treatment-emergent Adverse Events, Cardiac Outcome (Unspecified)","HCQ + AZT, SOC",2000
"NCT04358068","https://ClinicalTrials.gov/show/NCT04358068",NA,"United States","Texas","2020-Apr","2020-Oct","Recruiting","Randomised","Double",4,NA,NA,"Outpatient","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Other Mild Symptoms, Treatment-emergent Adverse Events, Cardiac Outcome (Unspecified)","HCQ + AZT, SOC",2000
"NCT04358068","https://ClinicalTrials.gov/show/NCT04358068",NA,"United States","Washington","2020-Apr","2020-Oct","Recruiting","Randomised","Double",4,NA,NA,"Outpatient","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Other Mild Symptoms, Treatment-emergent Adverse Events, Cardiac Outcome (Unspecified)","HCQ + AZT, SOC",2000
"NCT04358068","https://ClinicalTrials.gov/show/NCT04358068",NA,"Puerto Rico","Puerto Rico","2020-Apr","2020-Oct","Recruiting","Randomised","Double",4,NA,NA,"Outpatient","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Other Mild Symptoms, Treatment-emergent Adverse Events, Cardiac Outcome (Unspecified)","HCQ + AZT, SOC",2000
"NCT04273321","https://ClinicalTrials.gov/show/NCT04273321",NA,"China","Hubei","2020-Feb","2020-Apr","Completed","Single-Arm","Open-Label",1,"Confirmed",NA,"Hospital",NA,"Corticosteroids, SOC",86
"NCT04273321","https://ClinicalTrials.gov/show/NCT04273321",NA,"China","Beijing","2020-Feb","2020-Apr","Completed","Single-Arm","Open-Label",1,"Confirmed",NA,"Hospital",NA,"Corticosteroids, SOC",86
"NCT04311697","https://ClinicalTrials.gov/show/NCT04311697",NA,"United States","California","2020-Mar","2020-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2, Radiographic Findings, Hypoxia","Inhaled solution, SOC",144
"NCT04311697","https://ClinicalTrials.gov/show/NCT04311697",NA,"United States","Florida","2020-Mar","2020-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2, Radiographic Findings, Hypoxia","Inhaled solution, SOC",144
"NCT04311697","https://ClinicalTrials.gov/show/NCT04311697",NA,"United States","New York","2020-Mar","2020-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2, Radiographic Findings, Hypoxia","Inhaled solution, SOC",144
"NCT04311697","https://ClinicalTrials.gov/show/NCT04311697",NA,"United States","Pennsylvania","2020-Mar","2020-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2, Radiographic Findings, Hypoxia","Inhaled solution, SOC",144
"NCT04311697","https://ClinicalTrials.gov/show/NCT04311697",NA,"Israel","Haifa","2020-Mar","2020-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2, Radiographic Findings, Hypoxia","Inhaled solution, SOC",144
"EUCTR2020-001324-33-FR","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001324-33",NA,"France","Aude","2020-Mar",NA,"Not Recruiting","Randomised","Open-Label",2,NA,NA,"ICU","Mortality, ICU Admission, Hospitalization, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Quality of Life","Other, SOC",194
"EUCTR2020-001682-36-ES","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001682-36",NA,"Spain","Madrid","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,NA,NA,"ICU","Mortality, Invasive Mechanical Ventilation or ECMO, Other Mild Symptoms, Radiographic Findings","SOC, Stem cells",24
"NCT04386850","https://ClinicalTrials.gov/show/NCT04386850",NA,"Iran","Tehran","2020-May","2020-Nov","Recruiting","Randomised","Quadruple",2,NA,NA,"Hospital","Viral Load or Clearance, Dyspnea","SOC, Vitamins",1500
"NCT04351152","https://ClinicalTrials.gov/show/NCT04351152",NA,"United States","Arizona","2020-Apr","2020-Sep","Recruiting","Randomised","Double",2,"Yes","Mixed","Hospital","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, PaO2-FiO2","Lenzilumab, SOC",238
"NCT04351152","https://ClinicalTrials.gov/show/NCT04351152",NA,"United States","California","2020-Apr","2020-Sep","Recruiting","Randomised","Double",2,"Yes","Mixed","Hospital","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, PaO2-FiO2","Lenzilumab, SOC",238
"NCT04351152","https://ClinicalTrials.gov/show/NCT04351152",NA,"United States","Florida","2020-Apr","2020-Sep","Recruiting","Randomised","Double",2,"Yes","Mixed","Hospital","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, PaO2-FiO2","Lenzilumab, SOC",238
"NCT04351152","https://ClinicalTrials.gov/show/NCT04351152",NA,"United States","Georgia","2020-Apr","2020-Sep","Recruiting","Randomised","Double",2,"Yes","Mixed","Hospital","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, PaO2-FiO2","Lenzilumab, SOC",238
"NCT04351152","https://ClinicalTrials.gov/show/NCT04351152",NA,"United States","Minnesota","2020-Apr","2020-Sep","Recruiting","Randomised","Double",2,"Yes","Mixed","Hospital","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, PaO2-FiO2","Lenzilumab, SOC",238
"NCT04351152","https://ClinicalTrials.gov/show/NCT04351152",NA,"United States","New Hampshire","2020-Apr","2020-Sep","Recruiting","Randomised","Double",2,"Yes","Mixed","Hospital","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, PaO2-FiO2","Lenzilumab, SOC",238
"NCT04351152","https://ClinicalTrials.gov/show/NCT04351152",NA,"United States","North Carolina","2020-Apr","2020-Sep","Recruiting","Randomised","Double",2,"Yes","Mixed","Hospital","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, PaO2-FiO2","Lenzilumab, SOC",238
"NCT04351152","https://ClinicalTrials.gov/show/NCT04351152",NA,"United States","Texas","2020-Apr","2020-Sep","Recruiting","Randomised","Double",2,"Yes","Mixed","Hospital","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, PaO2-FiO2","Lenzilumab, SOC",238
"NCT04347174","https://ClinicalTrials.gov/show/NCT04347174",NA,"India","Madhya Pradesh","2020-Apr","2020-Jun","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA)","SOC, Treated mycobacterium",40
"NCT04347174","https://ClinicalTrials.gov/show/NCT04347174",NA,"India","Chandigarh","2020-Apr","2020-Jun","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA)","SOC, Treated mycobacterium",40
"NCT04335786","https://ClinicalTrials.gov/show/NCT04335786",NA,"Netherlands","Amsterdam","2020-Apr","2020-Dec","Recruiting","Randomised","Quadruple",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation","SOC, Valsartan",651
"NCT04373044","https://ClinicalTrials.gov/show/NCT04373044",NA,"United States","California","2020-May","2021-Apr","Recruiting","Randomised","Double",3,"Confirmed","Moderate/Severe","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, C-Reactive Protein, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Hemoglobin, Blood Pressure, Respiratory Rate, Radiographic Findings, Cardiac Outcome (Unspecified)","JAKi + Antivirals",144
"NCT04342897","https://ClinicalTrials.gov/show/NCT04342897",NA,"United States","Illinois","2020-Apr","2020-Jun","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Serious Adverse Events","mAb",200
"NCT04342897","https://ClinicalTrials.gov/show/NCT04342897",NA,"United States","Indiana","2020-Apr","2020-Jun","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Serious Adverse Events","mAb",200
"NCT04346589","https://ClinicalTrials.gov/show/NCT04346589",NA,"Italy","Rome","2020-Apr","2020-Jul","Recruiting","Single-Arm","Open-Label",1,"Yes","Severe","Hospital","Mortality, Hospital Discharge, Non-invasive Ventilation","Plasma based therapy",10
"NCT04346589","https://ClinicalTrials.gov/show/NCT04346589",NA,"Italy","Bergamo","2020-Apr","2020-Jul","Recruiting","Single-Arm","Open-Label",1,"Yes","Severe","Hospital","Mortality, Hospital Discharge, Non-invasive Ventilation","Plasma based therapy",10
"ACTRN12620000478910","https://anzctr.org.au/ACTRN12620000478910.aspx",NA,"Australia","Canberra","2020-Apr",NA,"Not Recruiting","Randomised","Unspecified",NA,NA,NA,"Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Secondary CoViD-19 Re-infection, Invasive Mechanical Ventilation or ECMO, Other Mild Symptoms, Adverse Events, Anti SARS-COV-2 Titers","Stem cells",24
"NCT04340050","https://ClinicalTrials.gov/show/NCT04340050",NA,"United States","Illinois","2020-Apr","2020-Dec","Not Recruiting","Single-Arm","Open-Label",1,NA,NA,"Hospital","Mortality, Invasive Mechanical Ventilation or ECMO",NA,10
"NCT04334512","https://ClinicalTrials.gov/show/NCT04334512",NA,"United States","California","2020-Apr","2021-May","Not Recruiting","Randomised","Double",5,"Confirmed","Mixed","Unclear","Viral Load or Clearance, Radiographic Findings",NA,600
"NCT04340544","https://ClinicalTrials.gov/show/NCT04340544",NA,"Germany","Berlin","2020-Apr","2021-Nov","Recruiting","Randomised","Quadruple",2,NA,NA,"Outpatient","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6",NA,2700
"NCT04402866","https://ClinicalTrials.gov/show/NCT04402866",NA,"United Kingdom","Manchester","2020-May","2020-Oct","Not Recruiting","Randomised","Triple",2,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Hospital Discharge, Dyspnea, PaO2-FiO2","Other, SOC",159
"NCT04410562","https://ClinicalTrials.gov/show/NCT04410562",NA,"Spain","Barcelona","2020-Jun","2021-May","Recruiting","Randomised","Quadruple",2,NA,NA,"Unclear","Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Hemoglobin, Pregnancy or Birth Outcomes","HCQ, SOC",714
"NCT04410562","https://ClinicalTrials.gov/show/NCT04410562",NA,"Spain","Madrid","2020-Jun","2021-May","Recruiting","Randomised","Quadruple",2,NA,NA,"Unclear","Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Hemoglobin, Pregnancy or Birth Outcomes","HCQ, SOC",714
"NCT04279197","https://clinicaltrials.gov/show/NCT04279197",NA,"China","Beijing","2020-Feb",NA,"Recruiting","Randomised","Double",1,"Negative(?)",NA,"Unclear","Pneumonia or ARDS, Dyspnea, 6-Minute Walking Distance, Radiographic Findings","SOC, TCM",136
"NCT04386252","https://ClinicalTrials.gov/show/NCT04386252",NA,"United States","California","2020-May","2020-Oct","Not Recruiting","Randomised","Quadruple",2,"Healthy","Healthy","Healthcare Workers","IgG, IgM or IgA","Vaccine",180
"NCT04389580","https://ClinicalTrials.gov/show/NCT04389580",NA,"Egypt","Cairo","2020-May","2020-Jul","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","ICU","Mortality, ICU Admission, C-Reactive Protein, IL-1, IL-6, Tumor Necrosis Factor (Any), Interferon (Any), Lymphocyte Count, Erythrocyte Sedimentation Rate, D-Dimer","Hormone therapy, Hormone therapy + Other, SOC",160
"NCT04390503","https://ClinicalTrials.gov/show/NCT04390503",NA,"United States","New York","2020-May","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Healthy, Asymptomatic, Mild/Moderate","Healthy Exposed, Outpatient",NA,"Plasma based therapy, SOC",200
"NCT04363060","https://ClinicalTrials.gov/show/NCT04363060",NA,"France","Paris","2020-Apr","2020-Jul","Not Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events","Amoxicillin/clavulanate, AZT + Amoxicillin/clavulanate",104
"CHICTR2000029431","http://www.chictr.org.cn/showproj.aspx?proj=48907",NA,"China","Liaoning","2020-Feb","2021-Dec","Recruiting","Randomised","Unspecified",3,"Confirmed",NA,"Unclear","Pneumonia or ARDS, Radiographic Findings","Other, SOC",45
"IRCT20160706028815N5","http://en.irct.ir/trial/47682",NA,"Iran","Tehran","2020-May","2020-Jul","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Hospitalization","Antivirals, Other + Antivirals",40
"CHICTR2000029603","http://www.chictr.org.cn/showproj.aspx?proj=49075",NA,"China","Zhejiang","2020-Feb","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","ICU Admission, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, PaO2-FiO2, Respiratory Rate","LPV/r, Other",160
"NCT04363840","https://clinicaltrials.gov/show/NCT04363840",NA,"United States","Louisiana","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",1,"Confirmed","Unclear","Unclear","Hospitalization","Antihypertensive, Antihypertensive + Nutrition, SOC",1080
"NCT04359953","https://ClinicalTrials.gov/show/NCT04359953",NA,"France","Paris","2020-Apr","2021-Jun","Not Recruiting","Randomised","Open-Label",3,NA,NA,"Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea","ARBs, AZT, HCQ",1600
"NCT04329832","https://ClinicalTrials.gov/show/NCT04329832",NA,"United States","Utah","2020-Apr","2020-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed And Suspected",NA,"Hospital","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","AZT, HCQ",300
"IRCT20131129015584N3","http://en.irct.ir/trial/47665",NA,"Iran","Tehran","2020-May","2020-Jun","Recruiting","Randomised","Open-Label",2,"Suspected","Unclear","Hospital","Hospitalization, SpO2","Alternative therapy + AZT + LPV/r, AZT + LPV/r",68
"CHICTR2000030940","http://www.chictr.org.cn/showproj.aspx?proj=51061",NA,"China","Shanghai","2020-Mar","2020-Jun","Not Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Non-severe","Unclear","Clinical Improvement Score (Any), Pneumonia or ARDS, Cough, Fever, Dyspnea","TCM",76
"NCT04390464","https://ClinicalTrials.gov/show/NCT04390464",NA,"United Kingdom","Cambridgeshire","2020-May","2021-May","Recruiting","Randomised","Open-Label",3,"Suspected","Unclear","Hospital","Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Renal Outcome (Unspecified)","JAKi, mAb, SOC",1167
"NCT04358614","https://clinicaltrials.gov/show/NCT04358614",NA,"Italy","Rome","2020-Apr",NA,"Not Recruiting","Non-Randomised","Open-Label",2,NA,NA,"Hospital","ICU Admission, Hospital Discharge, Adverse Events, Serious Adverse Events","JAKi",12
"NL8609","https://trialregister.nl/trial/8609",NA,"Netherlands","Amsterdam","2020-Nov",NA,"Not Recruiting","Randomised","Open-Label",2,"Healthy","None","Healthy Unexposed","Monocyte Count","SOC, Vaccine, Vaccine + Bisphosphonate, Vaccine + Vaccine",100
"CHICTR2000029806","http://www.chictr.org.cn/showproj.aspx?proj=49161",NA,"China","Hubei","2020-Feb","2021-Jan","Recruiting","Randomised","Unspecified",3,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any)","mAb, Other, SOC",120
"NCT04365153","https://ClinicalTrials.gov/show/NCT04365153",NA,"United States","Ohio","2020-Apr","2020-Dec","Recruiting","Randomised","Quadruple",3,NA,NA,"Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any)","mAb, SOC",45
"NCT04333628","https://ClinicalTrials.gov/show/NCT04333628",NA,"Israel","Hazafon","2020-Apr","2021-Apr","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Non-severe","Outpatient","Clinical Improvement Score (Any), Viral Load or Clearance","HCQ, SOC",210
"CHICTR2000029988","http://www.chictr.org.cn/showproj.aspx?proj=49218",NA,"China","Hubei","2020-Feb","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","HCQ, SOC",80
"NCT04330586","https://ClinicalTrials.gov/show/NCT04330586",NA,"South Korea","Seoul","2020-Apr","2020-Jun","Not Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Non-severe","Outpatient","ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","Corticosteroids, HCQ + Corticosteroids, SOC",141
"NCT04384588","https://clinicaltrials.gov/show/NCT04384588",NA,"Chile","Santiago","2020-Apr",NA,"Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Severe","Unclear","Mortality","Plasma based therapy",100
"NCT04376034","https://ClinicalTrials.gov/show/NCT04376034",NA,"United States","West Virginia","2020-May","2021-Mar","Recruiting","Non-Randomised","Open-Label",3,"Confirmed","Severe","ICU",NA,"Plasma based therapy, SOC",240
"IRCT20200501047258N1","http://en.irct.ir/trial/47629",NA,"Iran","Tehran","2020-May","2021-May","Recruiting","Randomised","Open-Label",3,"Confirmed","Severe","Hospital",NA,"Plasma based therapy, SOC",120
"CHICTR2000030627","http://www.chictr.org.cn/showproj.aspx?proj=50727",NA,"China","Henan","2020-Mar","2020-May","Recruiting","Randomised","Unspecified",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","Plasma based therapy, SOC",30
"CHICTR2000029850","http://www.chictr.org.cn/showproj.aspx?proj=49533",NA,"China","Zhejiang","2020-Feb","2022-Feb","Recruiting","Non-Randomised","Unspecified",2,"Confirmed",NA,"ICU","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Anti SARS-COV-2 Titers, PaO2-FiO2","Plasma based therapy, SOC",20
"NCT04376788","https://ClinicalTrials.gov/show/NCT04376788",NA,"Egypt","Cairo","2020-May","2020-Jun","Not Recruiting","Randomised","Open-Label",3,"Confirmed","Severe","Unclear",NA,"Plasma based therapy, Plasma based therapy + Other, SOC",15
"NCT04354831","https://ClinicalTrials.gov/show/NCT04354831",NA,"United States","Wisconsin","2020-Apr","2022-May","Recruiting","Non-Randomised","Open-Label",2,NA,NA,"Hospital, ICU","Mortality, ICU Admission","Plasma based therapy",131
"NCT04393246","https://ClinicalTrials.gov/show/NCT04393246",NA,"United Kingdom","Cambridgeshire","2020-May","2021-Jan","Not Recruiting","Randomised","Open-Label",4,"Confirmed Or Suspected","Unclear","Hospital","Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Renal Outcome (Unspecified)","Other, SGLT2 + Other, SOC",1407
"CHICTR2000029541","http://www.chictr.org.cn/showproj.aspx?proj=48992",NA,"China","Hubei","2020-Feb","2020-Dec","Not Recruiting","Randomised","Unspecified",3,"Confirmed",NA,"Hospital","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Radiographic Findings","DRV/c + Other, LPV/r + Other, Other",100
"CHICTR2000030535","http://www.chictr.org.cn/showproj.aspx?proj=49790",NA,"China","Sichuan","2020-Mar","2020-Mar","Recruiting","Randomised","Unspecified",2,"Confirmed","Mixed","Unclear","Mortality, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings","LPV/r + IFN, LPV/r + IFN + Other",100
"NCT04365738","https://ClinicalTrials.gov/show/NCT04365738",NA,"Turkey","Istanbul","2020-Apr","2020-Apr","Completed","Randomised","Single",2,NA,NA,"Outpatient","Dyspnea, Other Mild Symptoms, Depression, Anxiety","Education, Non-invasive respiratory support",270
"CHICTR2000029601","http://www.chictr.org.cn/showproj.aspx?proj=48988",NA,"China","Hubei","2020-Feb","2020-Aug","Recruiting","Randomised","Unspecified",2,"Confirmed Or Suspected",NA,"Outpatient","Clinical Improvement Score (Any), Viral Load or Clearance, Fever","Education, Education + TCM",400
"2020-001891-14","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001891-14/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, SpO2, Respiratory Rate","Anticoagulants",NA
"NCT04322344","https://ClinicalTrials.gov/show/NCT04322344",NA,"Italy","Catanzaro","2020-Mar","2020-Jun","Recruiting","Non-Randomised","Double",2,"Confirmed",NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Alternative therapy, SOC",120
"NCT04326114","https://clinicaltrials.gov/show/NCT04326114",NA,"Spain","Madrid","2020-Mar",NA,"Not Recruiting","Randomised","Single",1,"Healthy",NA,"Healthy Unexposed","Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events","Non-invasive respiratory support, SOC",240
"NCT04387760","https://ClinicalTrials.gov/show/NCT04387760",NA,"Bahrain","Manama","2020-May","2020-Jul","Not Recruiting","Randomised","Open-Label",3,"Confirmed","Unclear","Unclear","Mortality, ICU Admission, Viral Load or Clearance, Ferritin, Lymphocyte Count, D-Dimer, Procalcitonin","FPV, HCQ, SOC",150
"CHICTR2000030987","http://www.chictr.org.cn/showproj.aspx?proj=51329",NA,"China","Beijing","2020-Mar","2020-Jun","Recruiting","Randomised","Unspecified",3,"Resolved",NA,"Resolved Discharged","Viral Load or Clearance, Pneumonia or ARDS, Cough, Dyspnea","FPV, FPV + HCQ, SOC",150
"NCT04264858","https://clinicaltrials.gov/show/NCT04264858",NA,"China","Beijing","2020-Aug",NA,"Not Recruiting","Non-Randomised","Open-Label",1,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Antibodies, PaO2-FiO2, Radiographic Findings","Igs",10
"CHICTR2000030003","http://www.chictr.org.cn/showproj.aspx?proj=49770",NA,"China","Sichuan","2020-Feb","2020-Jul","Not Recruiting","Randomised","Unspecified",3,"Confirmed","Non-severe","Hospital","Hospitalization, Hospital Discharge, Fever","TCM",480
"CHICTR2000030472","http://www.chictr.org.cn/showproj.aspx?proj=49753",NA,"China","Liaoning","2020-Mar","2020-Jun","Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Mixed","Hospital","Viral Load or Clearance, Adverse Events, Serious Adverse Events, PaO2-FiO2, Respiratory Rate","DAA, SOC",20
"CHICTR2000031090","http://www.chictr.org.cn/showproj.aspx?proj=51148",NA,"China","Zhejiang","2020-Mar","2022-Mar","Not Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Unclear","Quality of Life, Depression, Anxiety, Distress","Psychological therapy",60
"CHICTR2000030198","http://www.chictr.org.cn/showproj.aspx?proj=50066",NA,"China","Sichuan","2020-Feb","2020-Aug","Not Recruiting","Randomised","Unspecified",2,"Resolved","Severe","Resolved Discharged","Clinical Improvement Score (Any), PaO2-FiO2, Respiratory Rate, 6-Minute Walking Distance, Quality of Life, Depression, Anxiety","Psychological therapy, Respiratory + Education",60
"NCT04377997","https://ClinicalTrials.gov/show/NCT04377997",NA,"United States","Massachusetts","2020-May","2021-Jan","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital, ICU","Mortality, Deep Vein Thrombosis or Pulmonary Embolism, Shock, Cardiac Outcome (Unspecified)","Anticoagulants",300
"NCT04367831","https://ClinicalTrials.gov/show/NCT04367831",NA,"United States","New York","2020-Apr","2020-Nov","Recruiting","Randomised","Single",4,NA,NA,"ICU","ICU Admission, Renal Outcome (Unspecified)","Anticoagulants",100
"NCT04391140","https://ClinicalTrials.gov/show/NCT04391140",NA,"Spain","Barcelona","2020-May","2020-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed","Moderate/Severe","Hospital","Mortality","Positioning + Respiratory support, Respiratory support",248
"NCT04395807","https://clinicaltrials.gov/show/NCT04395807",NA,"Sweden","Stockholm","2020-May",NA,"Not Recruiting","Randomised","Single",1,"Confirmed","Moderate/Severe","Hospital",NA,"Non-invasive respiratory support",120
"CHICTR2000029954","http://www.chictr.org.cn/showproj.aspx?proj=49402",NA,"China","Hubei","2020-Feb","2020-Feb","Recruiting","Randomised","Open-Label",3,"Confirmed","Mixed","Outpatient, Hospital","ICU Admission, Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Other Mild Symptoms, Radiographic Findings","SOC, TCM",300
"CHICTR2000030545","http://www.chictr.org.cn/showproj.aspx?proj=50126",NA,"China","Hubei","2020-Mar","2020-Apr","Recruiting","Randomised","Unspecified",3,"Confirmed",NA,"Hospital","ICU Admission, Hospitalization, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, Radiographic Findings","SOC, TCM",300
"CHICTR2000029742","http://www.chictr.org.cn/showproj.aspx?proj=49297",NA,"China","Hubei","2020-Feb","2020-Dec","Recruiting","Randomised","Unspecified",5,"Confirmed Or Suspected","Mixed","Outpatient, Hospital","Viral Load or Clearance, Radiographic Findings","SOC, TCM",90
"NCT04381858","https://ClinicalTrials.gov/show/NCT04381858",NA,"Mexico","Aguascalientes","2020-May","2020-Aug","Recruiting","Randomised","Double",2,"Yes","Severe","ICU","Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO","Igs, Plasma based therapy",500
"2020-001696-32","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001696-32/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Mild/Moderate","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Blood Pressure, Heart Rate, SpO2, Distress, Cardiac Outcome (Unspecified)","Igs",NA
"EUCTR2020-001722-66-ES","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001722-66",NA,"Spain","Madrid","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","ICU","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Renal Outcome (Unspecified)","Igs, Plasma based therapy",116
"NCT04366115","https://ClinicalTrials.gov/show/NCT04366115",NA,"United States","Washington","2020-Apr","2022-Jun","Not Recruiting","Randomised","Open-Label",3,NA,NA,"ICU","Mortality","Corticosteroids, Corticosteroids + Other",126
"CTRI/2020/04/024904","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43130",NA,"India","New Delhi","2020-Apr",NA,"Not Recruiting","Randomised","Unspecified",NA,"Confirmed","Mild/Moderate/Severe","Unclear","Mortality, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ, HCQ + AZT",300
"NCT04363203","https://ClinicalTrials.gov/show/NCT04363203",NA,"United States","California","2020-Apr","2021-Mar","Not Recruiting","Single-Arm","Quadruple",1,"Confirmed","Mixed","Outpatient","Mortality, Hospitalization, Cough, Fever, Dyspnea","AZT, HCQ, SOC",300
"2020-001198-55","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001198-55/DK/",NA,"Denmark","Copenhagen","2020-Mar",NA,"Recruiting","Randomised","Double",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Visits or Returns to Emergency Department, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH, Quality of Life","AZT, HCQ, SOC",NA
"2020-001825-29","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001825-29/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","ICU","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, SpO2","Anakinra, AZT, HCQ, LPV/r",NA
"NCT04365582","https://clinicaltrials.gov/show/NCT04365582",NA,"France","Paris","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,NA,NA,"Outpatient",NA,"AZT, HCQ, LPV/r, SOC",640
"NCT04370262","https://ClinicalTrials.gov/show/NCT04370262",NA,"United States","New York","2020-Apr","2020-Sep","Recruiting","Randomised","Triple",2,NA,NA,"Hospital","Mortality","HCQ, HCQ + Other, SOC",1170
"NCT04377646","https://ClinicalTrials.gov/show/NCT04377646",NA,"Tunisia","Tunis","2020-May","2020-May","Not Recruiting","Randomised","Triple",4,"Healthy","None","Healthy Unexposed","Adverse Events","HCQ, HCQ + Zinc, SOC",660
"NCT04372082","https://ClinicalTrials.gov/show/NCT04372082",NA,"France","Nord","2020-May","2023-May","Not Recruiting","Randomised","Single",3,NA,NA,"Hospital","Mortality, Hospitalization, Non-invasive Ventilation","CCB + Other, HCQ, SOC",480
"NCT04307693","https://ClinicalTrials.gov/show/NCT04307693",NA,"South Korea","Seoul","2020-Mar","2020-Apr","Status Unclear","Randomised","Open-Label",2,"Confirmed","Non-severe","Outpatient","Mortality, ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate","HCQ, LPV/r, SOC",65
"CTRI/2020/03/024402","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42638",NA,"India","New Delhi","2020-Mar",NA,"Not Recruiting","Randomised","Open-Label",NA,NA,NA,"Healthcare Workers","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Other Mild Symptoms","HCQ",500
"NCT04390594","https://ClinicalTrials.gov/show/NCT04390594",NA,"Senegal","Dakar","2020-May","2020-Dec","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Hospitalization, Viral Load or Clearance, Organ Failure or Dysfunction (SOFA), Adverse Events","HCQ, HCQ + AZT",258
"2020-002123-11","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002123-11/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Mortality, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Adverse Events","HCQ, HCQ + Cyclosporine",NA
"IRCT20200403046926N1","http://en.irct.ir/trial/46926",NA,"Iran","Tehran","2020-Apr","2020-May","Completed","Randomised","Open-Label",2,NA,NA,"Outpatient","Hospitalization, C-Reactive Protein","HCQ, HCQ + LPV/r",60
"IRCT20200511047396N1","http://en.irct.ir/trial/48048",NA,"Iran","Tehran","2020-May","2020-Nov","Recruiting","Randomised","Double",2,"Confirmed","Mild/Moderate","Hospital","Mortality, Fever, SpO2","HCQ, HCQ + IFN",100
"NCT04390061","https://ClinicalTrials.gov/show/NCT04390061",NA,"Italy","Ancona","2020-May","2020-Sep","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Adverse Events","HCQ, HCQ + JAKi",116
"IRCT20200325046859N2","http://en.irct.ir/trial/47200",NA,"Iran","Tehran","2020-Apr","2020-Apr","Completed","Non-Randomised","Single",2,"Confirmed","Moderate","Hospital","Fever, C-Reactive Protein, White Blood Cell Count, LDH, Respiratory Rate, Radiographic Findings","HCQ, HCQ + Umifenovir",40
"2020-001635-27","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001635-27/FR/",NA,"France","Paris","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Moderate/Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Glucose, Radiographic Findings","Alternative therapy + Other, HCQ",NA
"NCT04363866","https://ClinicalTrials.gov/show/NCT04363866",NA,"United States","Oregon","2020-Apr","2020-Dec","Not Recruiting","Randomised","Single",2,"Confirmed And Suspected","Mixed","Unclear","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events, Serious Adverse Events, Quality of Life","HCQ, SOC",40
"CHICTR2000029559","http://www.chictr.org.cn/showproj.aspx?proj=48880","https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v1.full.pdf","China","Hubei","2020-Feb","2020-Feb","Completed w. Results","Randomised","Double",3,"Confirmed",NA,"Unclear","Viral Load or Clearance, CD4, CD8","HCQ, SOC",300
"CHICTR2000029803","http://www.chictr.org.cn/showproj.aspx?proj=49428",NA,"China","Hubei","2020-Feb","2021-Feb","Not Recruiting","Randomised","Open-Label",4,"Healthy (Exposed)",NA,"Healthy Exposed","Viral Load or Clearance, Cough, Fever, Serious Adverse Events, C-Reactive Protein, Radiographic Findings","HCQ, Umifenovir",320
"NCT04333732","https://ClinicalTrials.gov/show/NCT04333732",NA,"United States","Missouri","2020-Apr","2021-Feb","Not Recruiting","Randomised","Double",4,"Healthy (Exposed)","Healthy","Healthcare Workers",NA,"HCQ, SOC",55000
"NCT04333732","https://ClinicalTrials.gov/show/NCT04333732",NA,"Canada","Ontario","2020-Apr","2021-Feb","Not Recruiting","Randomised","Double",4,"Healthy (Exposed)","Healthy","Healthcare Workers",NA,"HCQ, SOC",55000
"NCT04333732","https://ClinicalTrials.gov/show/NCT04333732",NA,"Ireland","Dublin","2020-Apr","2021-Feb","Not Recruiting","Randomised","Double",4,"Healthy (Exposed)","Healthy","Healthcare Workers",NA,"HCQ, SOC",55000
"NCT04333732","https://ClinicalTrials.gov/show/NCT04333732",NA,"South Africa","Pretoria","2020-Apr","2021-Feb","Not Recruiting","Randomised","Double",4,"Healthy (Exposed)","Healthy","Healthcare Workers",NA,"HCQ, SOC",55000
"NCT04333732","https://ClinicalTrials.gov/show/NCT04333732",NA,"South Africa","Gauteng","2020-Apr","2021-Feb","Not Recruiting","Randomised","Double",4,"Healthy (Exposed)","Healthy","Healthcare Workers",NA,"HCQ, SOC",55000
"NCT04333732","https://ClinicalTrials.gov/show/NCT04333732",NA,"South Africa","Western Cape","2020-Apr","2021-Feb","Not Recruiting","Randomised","Double",4,"Healthy (Exposed)","Healthy","Healthcare Workers",NA,"HCQ, SOC",55000
"NCT04333732","https://ClinicalTrials.gov/show/NCT04333732",NA,"United Kingdom","London","2020-Apr","2021-Feb","Not Recruiting","Randomised","Double",4,"Healthy (Exposed)","Healthy","Healthcare Workers",NA,"HCQ, SOC",55000
"NCT04333732","https://ClinicalTrials.gov/show/NCT04333732",NA,"Zambia","Lusaka","2020-Apr","2021-Feb","Not Recruiting","Randomised","Double",4,"Healthy (Exposed)","Healthy","Healthcare Workers",NA,"HCQ, SOC",55000
"IRCT20200322046833N1","http://en.irct.ir/trial/46731",NA,"Iran","Tehran","2020-Apr","2020-Apr","Completed","Randomised","Double",2,NA,NA,"Hospital","Cough, Fever, Dyspnea, Adverse Events, Serious Adverse Events","HCQ + Antiretrovirals, HCQ + Antiretrovirals + Umifenovir",100
"NCT04374019","https://ClinicalTrials.gov/show/NCT04374019",NA,"United States","Kentucky","2020-May","2021-May","Recruiting","Randomised","Open-Label",4,"Confirmed","Unclear","Unclear","Mortality, ICU Admission, Viral Load or Clearance, Organ Failure or Dysfunction (SOFA), Adverse Events, Cardiac Outcome (Unspecified)","HCQ, HCQ + AZT, HCQ + Ivermectin, Other",240
"NCT04358081","https://ClinicalTrials.gov/show/NCT04358081",NA,"United States","California","2020-Apr","2020-Jun","Recruiting","Randomised","Quadruple",3,NA,NA,"Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events","HCQ, HCQ + AZT, SOC",444
"NCT04358081","https://ClinicalTrials.gov/show/NCT04358081",NA,"United States","Florida","2020-Apr","2020-Jun","Recruiting","Randomised","Quadruple",3,NA,NA,"Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events","HCQ, HCQ + AZT, SOC",444
"NCT04358081","https://ClinicalTrials.gov/show/NCT04358081",NA,"United States","Illinois","2020-Apr","2020-Jun","Recruiting","Randomised","Quadruple",3,NA,NA,"Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events","HCQ, HCQ + AZT, SOC",444
"NCT04358081","https://ClinicalTrials.gov/show/NCT04358081",NA,"United States","Louisiana","2020-Apr","2020-Jun","Recruiting","Randomised","Quadruple",3,NA,NA,"Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events","HCQ, HCQ + AZT, SOC",444
"NCT04358081","https://ClinicalTrials.gov/show/NCT04358081",NA,"United States","Maryland","2020-Apr","2020-Jun","Recruiting","Randomised","Quadruple",3,NA,NA,"Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events","HCQ, HCQ + AZT, SOC",444
"NCT04358081","https://ClinicalTrials.gov/show/NCT04358081",NA,"United States","Missouri","2020-Apr","2020-Jun","Recruiting","Randomised","Quadruple",3,NA,NA,"Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events","HCQ, HCQ + AZT, SOC",444
"NCT04358081","https://ClinicalTrials.gov/show/NCT04358081",NA,"United States","North Carolina","2020-Apr","2020-Jun","Recruiting","Randomised","Quadruple",3,NA,NA,"Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events","HCQ, HCQ + AZT, SOC",444
"NCT04358081","https://ClinicalTrials.gov/show/NCT04358081",NA,"United States","Washington","2020-Apr","2020-Jun","Recruiting","Randomised","Quadruple",3,NA,NA,"Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events","HCQ, HCQ + AZT, SOC",444
"NCT04347512","https://ClinicalTrials.gov/show/NCT04347512",NA,"France","Bas-Rhin","2020-Apr","2021-Aug","Not Recruiting","Randomised","Open-Label",3,NA,NA,"Unclear","Hypoxemia","HCQ, HCQ + AZT, SOC",405
"2020-001265-36","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001265-36/IE/",NA,"Ireland","Dublin","2020-Apr",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Non-critical","Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, PaO2-FiO2","HCQ, HCQ + AZT, SOC",267
"IRCT20200318046812N2","http://en.irct.ir/trial/46968",NA,"Iran","Tehran","2020-Apr","2021-Apr","Recruiting","Randomised","Open-Label",3,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Dyspnea, Adverse Events, Serious Adverse Events, C-Reactive Protein, Radiographic Findings","HCQ + AZT + Corticosteroids, HCQ + AZT + NSAIDs, HCQ + LPV/r",906
"NCT04366089","https://ClinicalTrials.gov/show/NCT04366089",NA,"Italy","Rome","2020-Apr","2020-Oct","Recruiting","Randomised","Single",4,NA,NA,"Hospital","Mortality, IL-6, IL-10, Tumor Necrosis Factor (Any), CD8","HCQ + AZT, HCQ + AZT + Non-invasive respiratory support + Nutrition",152
"EUCTR2020-001449-38-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001449-38",NA,"United Kingdom","London","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",3,"Confirmed, Suspected","Unclear","Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","FPV, HCQ + AZT + Zinc, SOC",450
"NCT04366245","https://ClinicalTrials.gov/show/NCT04366245",NA,"Spain","Sevilla","2020-Apr","2021-Dec","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, Antibodies, Radiographic Findings","HCQ + AZT or LPV/r + IFN, Plasma based therapy",72
"NCT04355052","https://clinicaltrials.gov/show/NCT04355052",NA,"Israel","Jerusalem","2020-Apr",NA,"Recruiting","Single-Arm","Open-Label",1,NA,NA,"Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, HCQ + Other, SOC",250
"IRCT20200318046812N1","http://en.irct.ir/trial/46783",NA,"Iran","Tehran","2020-Apr","2020-Jun","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Radiographic Findings","HCQ + FPV, HCQ + LPV/r",324
"NCT04376814","https://clinicaltrials.gov/show/NCT04376814",NA,"Iran","Tehran","2020-Mar",NA,"Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","ICU Admission","HCQ + FPV, HCQ + LPV/r",40
"IRCT20200406046968N3","http://en.irct.ir/trial/47152",NA,"Iran","East Azarbaijan","2020-May","2020-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Mortality","HCQ + LPV/r, HCQ + LPV/r + Other",60
"IRCT20200324046852N1","http://en.irct.ir/trial/46706",NA,"Iran","Tehran","2020-Apr","2020-Apr","Completed","Randomised","Double",2,NA,NA,"Hospital","Viral Load or Clearance, C-Reactive Protein, Radiographic Findings","Corticosteroids + Other + HCQ + LPV/r, HCQ + LPV/r",30
"IRCT20190804044429N1","http://en.irct.ir/trial/46741",NA,"Iran","Mazandaran","2020-Apr","2020-Jun","Recruiting","Unspecified","Open-Label",2,NA,NA,"Hospital","Mortality, Hospitalization, Cough, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, LDH","HCQ + LPV/r, IFN + HCQ + LPV/r",70
"NCT04380818","https://clinicaltrials.gov/show/NCT04380818",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Non-Randomised","Open-Label",7,"Confirmed","Moderate/severe","Hospital",NA,"HCQ + LPV/r + TCZ + AZT + Corticosteroids + Anticoagulants + Non-invasive respiratory support, Radiation therapy + HCQ + LPV/r + TCZ + AZT + Corticosteroids + Anticoagulants + Non-invasive respiratory support",106
"NCT04390152","https://ClinicalTrials.gov/show/NCT04390152",NA,"Colombia","Antioquia","2020-May","2020-Nov","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Moderate/Severe","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Ferritin, IL-1, IL-6, IL-8, Tumor Necrosis Factor (Any), Lymphocyte Count, D-Dimer","HCQ + LPV/r or AZT, Stem cells",40
"NCT04374903","https://ClinicalTrials.gov/show/NCT04374903",NA,"Jordan","Amman","2020-May","2020-Aug","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Unclear","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, HCQ + Other",58
"NCT04370782","https://ClinicalTrials.gov/show/NCT04370782",NA,"United States","New York","2020-May","2020-Sep","Recruiting","Randomised","Open-Label",4,NA,NA,"Outpatient","ICU Admission, Hospitalization, Adverse Events","HCQ + AZT + Zinc, HCQ + Zinc + Antibiotics",750
"ACTRN12620000557932","https://anzctr.org.au/ACTRN12620000557932.aspx",NA,"Australia","Canberra","2020-Nov",NA,"Not Recruiting","Randomised","Open-Label",NA,"Confirmed","Unclear","Hospital","Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO","HCQ + Zinc + Vitamins + AZT",200
"ACTRN12620000557932","https://anzctr.org.au/ACTRN12620000557932.aspx",NA,"United States","Washington, Dc","2020-Nov",NA,"Not Recruiting","Randomised","Open-Label",NA,"Confirmed","Unclear","Hospital","Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO","HCQ + Zinc + Vitamins + AZT",200
"ACTRN12620000557932","https://anzctr.org.au/ACTRN12620000557932.aspx",NA,"Germany","Berlin","2020-Nov",NA,"Not Recruiting","Randomised","Open-Label",NA,"Confirmed","Unclear","Hospital","Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO","HCQ + Zinc + Vitamins + AZT",200
"NCT04324996","https://ClinicalTrials.gov/show/NCT04324996",NA,"China","Chongqing","2020-Mar","2020-May","Recruiting","Randomised","Quadruple",2,"Confirmed",NA,"Unclear","Clinical Improvement Score (Any), Pneumonia or ARDS, Adverse Events, Treatment-emergent Adverse Events","Natural Killer Cells",90
"2020-001435-27","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001435-27/FR/",NA,"France","Paris","2020-Apr",NA,"Recruiting","Randomised","Open-Label",5,NA,NA,"Outpatient","Mortality, Hospitalization, Treatment-emergent Adverse Events","ARBs, FPV, HCQ, Imatinib",NA
"IRCT20200418047116N1","http://en.irct.ir/trial/47219",NA,"Iran","Tehran","2020-May","2020-May","Completed","Non-Randomised","Open-Label",2,"Confirmed","Severe","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Radiographic Findings","Igs, LPV/r",20
"CHICTR2000030262","http://www.chictr.org.cn/showproj.aspx?proj=50136",NA,"China","Shanghai","2020-Feb",NA,"Recruiting","Non-Randomised","Unspecified",4,"Confirmed",NA,"Unclear","Hospitalization, Viral Load or Clearance, Radiographic Findings","IFN, SOC",140
"NCT04360122","https://ClinicalTrials.gov/show/NCT04360122",NA,"Egypt","Cairo","2020-Apr","2020-Nov","Not Recruiting","Randomised","Open-Label",3,NA,NA,"Healthcare Workers","Viral Load or Clearance","Other",100
"NCT04361422","https://ClinicalTrials.gov/show/NCT04361422",NA,"Egypt","Cairo","2020-Apr","2020-Jun","Not Recruiting","Randomised","Open-Label",2,NA,NA,"Unclear","Clinical Improvement Score (Any), Viral Load or Clearance, Other Mild Symptoms","Other, SOC",300
"CTRI/2020/04/024948","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43364",NA,"India","New Delhi","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",NA,"Confirmed","Moderate","Unclear",NA,"Corticosteroids, HCQ, Ivermectin, SOC",120
"NCT04374279","https://ClinicalTrials.gov/show/NCT04374279",NA,"United States","Maryland","2020-May","2021-Jun","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events","Ivermectin, Other, SOC",60
"NCT04391127","https://ClinicalTrials.gov/show/NCT04391127",NA,"Mexico","Aguascalientes","2020-May","2020-Aug","Recruiting","Randomised","Double",3,"Confirmed","Unclear","Hospital","Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ + Ivermectin, Ivermectin",200
"NCT04382846","https://ClinicalTrials.gov/show/NCT04382846",NA,"Egypt","Cairo","2020-May","2030-Dec","Not Recruiting","Randomised","Open-Label",4,"Confirmed","Unclear","Unclear",NA,"Antivirals + AZT, Ivermectin + Antivirals, Ivermectin + Antivirals + AZT, Ivermectin + HCQ",80
"CHICTR2000032313","http://www.chictr.org.cn/showproj.aspx?proj=52916",NA,"China","Beijing","2020-Apr","2020-Dec","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear","Unclear","Clinical Improvement Score (Any), Radiographic Findings, Quality of Life","SOC, TCM",60
"NCT04357990","https://ClinicalTrials.gov/show/NCT04357990",NA,"Iceland","Reykjavik","2020-Apr","2020-Jul","Recruiting","Randomised","Triple",2,NA,NA,"Outpatient","Hospitalization, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events","Alternative therapy, SOC",81
"NCT04378920","https://ClinicalTrials.gov/show/NCT04378920",NA,"France","Paris","2020-May","2020-Jul","Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Mortality, PaO2-FiO2","Other",180
"CHICTR2000030471","http://www.chictr.org.cn/showproj.aspx?proj=50421",NA,"China","Guangdong","2020-Mar","2020-Apr","Recruiting","Randomised","Single",2,"Confirmed","Mixed","Outpatient, Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), C-Reactive Protein, Erythrocyte Sedimentation Rate","Nutrition, SOC",394
"IRCT20081019001369N5","http://en.irct.ir/trial/47141",NA,"Iran","Tehran","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,"Confirmed","Unclear","Outpatient","Clinical Improvement Score (Any), Cough, Fever, Other Mild Symptoms, C-Reactive Protein","Lithium, SOC",40
"PACTR202004893013257","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10981",NA,"Ghana","Accra","2020-Apr",NA,"Not Recruiting","Randomised","Unspecified",NA,"Healthy","None","Hospital","Mortality, Pneumonia or ARDS, Distress","HCQ, HCQ + LPV/r, LPV/r, SOC",6400
"CHICTR2000029496","http://www.chictr.org.cn/showproj.aspx?proj=48809",NA,"China","Hunan","2020-Feb","2021-Jan","Recruiting","Randomised","Open-Label",3,"Confirmed",NA,"Hospital","Viral Load or Clearance, Adverse Events","LPV/r, LPV/r + Other, Other",90
"NCT04295551","https://ClinicalTrials.gov/show/NCT04295551",NA,"China","Beijing","2020-Mar","2020-Jul","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Outpatient, Hospital","Cough, Fever, Dyspnea","LPV/r, LPV/r + TCM",80
"NCT04372628","https://ClinicalTrials.gov/show/NCT04372628",NA,"United States","Colorado","2020-May","2020-Dec","Not Recruiting","Randomised","Triple",3,"Confirmed",NA,"Outpatient","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Quality of Life","HCQ, LPV/r, SOC",900
"NCT04372628","https://ClinicalTrials.gov/show/NCT04372628",NA,"United States","Massachusetts","2020-May","2020-Dec","Not Recruiting","Randomised","Triple",3,"Confirmed",NA,"Outpatient","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Quality of Life","HCQ, LPV/r, SOC",900
"NCT04372628","https://ClinicalTrials.gov/show/NCT04372628",NA,"United States","Tennessee","2020-May","2020-Dec","Not Recruiting","Randomised","Triple",3,"Confirmed",NA,"Outpatient","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Quality of Life","HCQ, LPV/r, SOC",900
"NCT04364022","https://ClinicalTrials.gov/show/NCT04364022",NA,"Switzerland","Bern","2020-Apr","2020-Oct","Recruiting","Randomised","Open-Label",2,NA,NA,"Healthy Exposed",NA,"HCQ, LPV/r",420
"IRCT20151227025726N14","http://en.irct.ir/trial/46942",NA,"Iran","Tehran","2020-Apr","2020-Jul","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings","FPV, LPV/r",84
"NCT04276688","https://ClinicalTrials.gov/show/NCT04276688",NA,"China","Hong Kong","2020-Feb","2020-Mar","Completed","Randomised","Open-Label",3,"Confirmed",NA,"Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events, IL-6, Tumor Necrosis Factor (Any)","LPV/r, LPV/r + IFN",127
"NCT04261907","https://ClinicalTrials.gov/show/NCT04261907",NA,"China","Beijing","2020-Feb","2020-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Hospital","ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events, PaO2-FiO2, Respiratory Rate","LPV/r, Other",160
"IRCT20151227025726N15","http://en.irct.ir/trial/48018",NA,"Iran","Tehran","2020-May","2020-Jul","Recruiting","Randomised","Open-Label",2,"Confirmed","Moderate","Hospital","Invasive Mechanical Ventilation or ECMO, Dyspnea","LPV/r, Umifenovir",100
"CHICTR2000029468","http://www.chictr.org.cn/showproj.aspx?proj=48919",NA,"China","Sichuan","2020-Feb","2020-Jun","Not Recruiting","Non-Randomised","Unspecified",2,"Confirmed",NA,"Unclear","Mortality, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS","LPV/r",120
"CHICTR2000029609","http://www.chictr.org.cn/showproj.aspx?proj=49145",NA,"China","Guangdong","2020-Feb","2020-Dec","Not Recruiting","Non-Randomised","Open-Label",5,"Confirmed",NA,"Hospital","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance","HCQ, LPV/r, LPV/r + HCQ",205
"CHICTR2000029600","http://www.chictr.org.cn/showproj.aspx?proj=49042","https://reader.elsevier.com/reader/sd/pii/S2095809920300631?token=A28CA1B43E646EFBA54D61F15A05C13723D1BFA784EAC81E632C0FB769F1BD4BA964D4E304CB8D9EAA24DF528709668A","China","Guangdong","2020-Feb","2020-Apr","Completed w. Results","Non-Randomised","Unspecified",3,"Confirmed",NA,"Outpatient","Viral Load or Clearance, Radiographic Findings, Renal Outcome (Unspecified)","FPV + IFN, IFN, LPV/r + IFN",90
"CHICTR2000030117","http://www.chictr.org.cn/showproj.aspx?proj=49762",NA,"China","Beijing","2020-Feb","2021-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed","Non-severe","Unclear","Viral Load or Clearance, Fever","LPV/r + IFN, TCM",348
"NCT04275388","https://ClinicalTrials.gov/show/NCT04275388",NA,"China","Beijing","2020-Feb","2020-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Unclear","Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, PaO2-FiO2, Respiratory Rate","LPV/r + IFN, LPV/r + IFN + TCM",348
"IRCT20131129015584N2","http://en.irct.ir/trial/47639",NA,"Iran","Tehran","2020-May","2020-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Unclear","Hospitalization, SpO2","LPV/r + AZT, LPV/r + AZT + Alternative therapy",152
"JPRN-JRCTS031190227","https://jrct.niph.go.jp/latest-detail/jRCTs031190227",NA,"Japan","Gunma","2020-Feb",NA,"Recruiting","Single-Arm","Open-Label",1,"Confirmed",NA,"Hospital","Viral Load or Clearance, C-Reactive Protein","HCQ + LPV/r, Oseltamivir + HCQ + LPV/r",50
"CHICTR2000029387","http://www.chictr.org.cn/showproj.aspx?proj=48782",NA,"China","Chongqing","2020-Jan",NA,"Recruiting","Randomised","Unspecified",3,"Confirmed","Mixed","Outpatient","Mortality, Viral Load or Clearance, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","Antivirals + IFN, Antivirals + LPV/r + IFN, LPV/r + IFN",108
"CHICTR2000030218","http://www.chictr.org.cn/showproj.aspx?proj=50115",NA,"China","Jiangxi","2020-Feb","2020-Jun","Recruiting","Randomised","Unspecified",3,"Confirmed","Non-severe","Unclear","Viral Load or Clearance, Pneumonia or ARDS","LPV/r, LPV/r + TCM",80
"NCT04286503","https://ClinicalTrials.gov/show/NCT04286503",NA,"China","Beijing","2020-Feb","2021-Feb","Not Recruiting","Randomised","Open-Label",3,"Confirmed","Mixed","Outpatient, Hospital, ICU","Viral Load or Clearance, Fever, Radiographic Findings","Carrimycin, HCQ or LPV/r or Umifenovir",520
"CHICTR2000030946","http://www.chictr.org.cn/showproj.aspx?proj=51265",NA,"China","Guangdong","2020-Mar","2020-Apr","Recruiting","Non-Randomised","Unspecified",2,"Confirmed",NA,"Hospital",NA,"Anticoagulants, Other",120
"CHICTR2000032459","http://www.chictr.org.cn/showproj.aspx?proj=53003",NA,"China","Henan","2020-Apr",NA,"Recruiting","Randomised","Double",68,"Healthy","Healthy","Healthy Exposed",NA,"SOC, Vaccine",288
"NCT04383574","https://ClinicalTrials.gov/show/NCT04383574",NA,"China","Hebei","2020-May","2020-Jul","Not Recruiting","Randomised","Double",4,"Healthy","None","Healthy Unexposed","Adverse Events, Antibodies","SOC, Vaccine",422
"2020-001228-32","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001228-32/GB/",NA,"United Kingdom","London","2020-Apr",NA,"Recruiting","Randomised","Single",5,"Healthy","Healthy","Healthy Unexposed",NA,"SOC, Vaccine",10260
"IRCT20200516047468N1","http://en.irct.ir/trial/48176",NA,"Iran","Tehran","2020-May","2020-May","Completed","Randomised","Double",2,"Confirmed","Unclear","Hospital","Radiographic Findings","Antibiotics + AZT + LPV/r, Vitamins + Antibiotics + AZT + LPV/r",50
"NCT04389450","https://clinicaltrials.gov/show/NCT04389450",NA,"United States","Washington, Dc","2020-May",NA,"Not Recruiting","Randomised","Quadruple",1,"Confirmed","Unclear","Hospital",NA,"SOC, Stem cells",140
"NCT04389450","https://clinicaltrials.gov/show/NCT04389450",NA,"Israel","Jerusalem","2020-May",NA,"Not Recruiting","Randomised","Quadruple",1,"Confirmed","Unclear","Hospital",NA,"SOC, Stem cells",140
"NCT04400032","https://ClinicalTrials.gov/show/NCT04400032",NA,"Canada","Ontario","2020-May","2021-Jan","Not Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Adverse Events, Radiographic Findings","Stem cells",9
"CHICTR2000030116","http://www.chictr.org.cn/showproj.aspx?proj=49901",NA,"China","Jiangxi","2020-Feb","2020-Aug","Recruiting","Single-Arm","Unspecified",1,"Confirmed","Severe","Hospital","Invasive Mechanical Ventilation or ECMO","Stem cells",16
"NCT04371601","https://ClinicalTrials.gov/show/NCT04371601",NA,"China","Fujian","2020-May","2021-Dec","Not Recruiting","Randomised","Open-Label",4,NA,NA,"Unclear","C-Reactive Protein, IL-10, Tumor Necrosis Factor (Any), CD4, CD8, Blood Gas, PaO2-FiO2","Oseltamivir + Non-invasive respiratory support + Hormone therapy, Stem cells + Oseltamivir + Non-invasive respiratory support + Hormone therapy",60
"IRCT20120215009014N354","http://en.irct.ir/trial/48043",NA,"Iran","Hamadan","2020-May","2020-Aug","Not Recruiting","Randomised","Double",3,"Confirmed","Moderate/Severe","ICU","Mortality","Corticosteroids",81
"NCT04263402","https://clinicaltrials.gov/show/NCT04263402",NA,"China","Beijing","2020-Feb",NA,"Recruiting","Randomised","Single",1,"Confirmed","Severe","Unclear","ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), PaO2-FiO2, Radiographic Findings","Corticosteroids",100
"NCT04377503","https://ClinicalTrials.gov/show/NCT04377503",NA,"Brazil","Maranhao","2020-May","2020-Aug","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Unclear","ICU Admission, Invasive Mechanical Ventilation or ECMO, Radiographic Findings, Renal Outcome (Unspecified)","Corticosteroids, TCZ",40
"CTRI/2020/05/024981","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43374",NA,"India","New Delhi","2020-Feb",NA,"Not Recruiting","Randomised","Open-Label",NA,"Healthy","None","Healthy Unexposed",NA,"Alternative therapy, SOC",600
"IRCT20200324046850N1","http://en.irct.ir/trial/46732",NA,"Iran","Khuzestan","2020-Mar","2020-May","Completed","Randomised","Single",4,NA,NA,"Hospital","Cough, Fever, Dyspnea","Other, SOC, Vitamins, Vitamins + Other",100
"NCT04374461","https://ClinicalTrials.gov/show/NCT04374461",NA,"United States","New York","2020-May","2021-May","Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Severe","Hospital, ICU","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any)","Other",86
"NCT04365985","https://ClinicalTrials.gov/show/NCT04365985",NA,"United States","Michigan","2020-Apr","2020-May","Recruiting","Randomised","Triple",3,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Hospitalization, Renal Outcome (Unspecified)","Opiate antagonists, Opiate antagonists + Anesthetic, SOC",500
"IRCT20200410047009N1","http://en.irct.ir/trial/47052",NA,"Iran","Tehran","2020-Apr","2020-Jul","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Unclear","Mortality, Clinical Improvement Score (Any)","NSAIDs, SOC",101
"NCT04363346","https://ClinicalTrials.gov/show/NCT04363346",NA,"United States","Minnesota","2020-Apr","2022-Jan","Recruiting","Non-Randomised","Open-Label",2,NA,NA,"Hospital","Hospital Discharge, Non-invasive Ventilation, Stool Sample","Natural Killer Cells",12
"RPCEC00000309","http://rpcec.sld.cu/en/trials/RPCEC00000309-En",NA,"Mexico","Mexico","2020-May",NA,"Not Recruiting","Randomised","Double",NA,"Confirmed","Mild/Severe","Outpatient, Hospital, ICU","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","Other, SOC",50
"NCT04359810","https://ClinicalTrials.gov/show/NCT04359810",NA,"United States","New York","2020-Apr","2020-Dec","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation","Plasma based therapy, SOC",105
"CHICTR2000030539","http://www.chictr.org.cn/showproj.aspx?proj=50660",NA,"China","Guangdong","2020-Mar","2021-Mar","Not Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Non-severe","Outpatient","Viral Load or Clearance","Hygiene, SOC",40
"IRCT20090609002017N35","http://en.irct.ir/trial/48058",NA,"Iran","East Azarbaijan","2020-May","2020-Jun","Recruiting","Randomised","Double",4,"Confirmed","Unclear","Unclear","C-Reactive Protein","Other, SOC",40
"NCT04380519","https://ClinicalTrials.gov/show/NCT04380519",NA,"Russia","Moscow","2020-May","2020-Oct","Recruiting","Randomised","Double",3,"Confirmed","Severe","ICU","Mortality, Labor Absenteeism","mAb, Other, SOC",372
"CHICTR2000030033","http://www.chictr.org.cn/showproj.aspx?proj=49703",NA,"China","Guangdong","2020-Feb","2020-Jun","Not Recruiting","Randomised","Open-Label",3,"Healthy (Exposed)","Healthy","Healthy Exposed","Household Members with CoViD-19","SOC, TCM",828
"2020-001805-21","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001805-21/GB/",NA,"United Kingdom","London","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Moderate/Severe","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, Renal Outcome (Unspecified)","Oseltamivir, Oseltamivir + Other",120
"IRCT20200415047092N1","http://en.irct.ir/trial/47244",NA,"Iran","Tehran","2020-Apr","2020-May","Completed","Randomised","Open-Label",2,NA,NA,"Hospital","ICU Admission, Hospitalization, Fever","AZT + Oseltamivir + LPV/r + Antiretroviral + HCQ, Oseltamivir + LPV/r + Antiretroviral + HCQ",110
"CHICTR2000029974","http://www.chictr.org.cn/showproj.aspx?proj=49321",NA,"China","Shandong","2020-Feb","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Outpatient, Hospital","Mortality, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Serious or Seconday Infections, Radiographic Findings","SOC, TCM",300
"CHICTR2000029853","http://www.chictr.org.cn/showproj.aspx?proj=49532",NA,"China","Henan","2020-Feb","2020-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Hospital","Mortality, Hospitalization, Viral Load or Clearance, Cough, Fever, Other Mild Symptoms, CD4, Radiographic Findings","Antivirals, SOC",20
"CHICTR2000030165","http://www.chictr.org.cn/showproj.aspx?proj=49947",NA,"China","Tianjin","2020-Feb","2020-Dec","Recruiting","Randomised","Unspecified",3,"Confirmed","Mixed","Outpatient, Hospital","Viral Load or Clearance, Radiographic Findings","Respiratory support, SOC",60
"CHICTR2000029776","http://www.chictr.org.cn/showproj.aspx?proj=49342",NA,"China","Zhejiang","2020-Feb","2020-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed","Non-severe","Unclear","ICU Admission, Viral Load or Clearance, Cough, Fever, Other Mild Symptoms","Other, SOC",40
"CHICTR2000029972","http://www.chictr.org.cn/showproj.aspx?proj=49664",NA,"China","Hubei","2020-Feb","2020-May","Recruiting","Randomised","Unspecified",2,"Confirmed",NA,"Unclear","Viral Load or Clearance","Other, SOC",40
"NCT04333251","https://ClinicalTrials.gov/show/NCT04333251",NA,"United States","Texas","2020-Apr","2022-Dec","Not Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Hospital","Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Non-invasive respiratory support, Plasma based therapy",115
"NCT04386447","https://ClinicalTrials.gov/show/NCT04386447",NA,"France","Paris","2020-May","2020-Oct","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Mortality","Hormone therapy, SOC",145
"NCT04386447","https://ClinicalTrials.gov/show/NCT04386447",NA,"Italy","Parma","2020-May","2020-Oct","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Mortality","Hormone therapy, SOC",145
"NCT04381871","https://ClinicalTrials.gov/show/NCT04381871",NA,"Sudan","Khartoum","2020-May","2020-Aug","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear","Unclear","Mortality, Viral Load or Clearance","Other",110
"NCT04359251","https://ClinicalTrials.gov/show/NCT04359251",NA,"China","Jiangsu","2020-Apr","2020-Mar","Completed","Non-Randomised","Open-Label",3,NA,NA,"Hospital","PaO2-FiO2","Non-invasive respiratory support",20
"CHICTR2000029898","http://www.chictr.org.cn/showproj.aspx?proj=49482",NA,"China","Beijing","2020-Feb","2020-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, IgG, IgM or IgA","HCQ",100
"NCT04374149","https://ClinicalTrials.gov/show/NCT04374149",NA,"United States","South Carolina","2020-May","2020-Sep","Not Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Unclear","Hospital",NA,"Plasma based therapy, Plasma based therapy + JAKi",20
"NCT04382066","https://ClinicalTrials.gov/show/NCT04382066",NA,"Spain","Madrid","2020-May","2020-Nov","Recruiting","Randomised","Open-Label",3,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, Creatinine Phosphokinase, ALT, AST, Bilirubin, ECG","Other",27
"NCT04347954","https://ClinicalTrials.gov/show/NCT04347954",NA,"United States","California","2020-Apr","2020-Jul","Not Recruiting","Randomised","Double",3,NA,NA,"Unclear","Viral Load or Clearance, Fever, Adverse Events, Anti SARS-COV-2 Titers","Hygiene",45
"NCT04363463","https://clinicaltrials.gov/show/NCT04363463",NA,"France","Paris","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Positioning, SOC",400
"NCT04384900","https://ClinicalTrials.gov/show/NCT04384900",NA,"Denmark","Copenhagen","2020-May","2020-Nov","Recruiting","Randomised","Single",2,"Confirmed Or Suspected","Severe","ICU","Mortality, Invasive Mechanical Ventilation or ECMO, Renal Outcome (Unspecified)","Positioning",150
"NCT04325906","https://ClinicalTrials.gov/show/NCT04325906",NA,"United States","Illinois","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","ICU",NA,"Non-invasive respiratory support, Positioning + Non-invasive respiratory support",346
"NCT04359862","https://ClinicalTrials.gov/show/NCT04359862",NA,"Spain","Madrid","2020-Apr","2020-Aug","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital, Unclear","Mortality, IL-1, IL-6, IL-8, Tumor Necrosis Factor (Any), PaO2-FiO2","Anesthetic",50
"NCT04359862","https://ClinicalTrials.gov/show/NCT04359862",NA,"Spain","Valencia","2020-Apr","2020-Aug","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital, Unclear","Mortality, IL-1, IL-6, IL-8, Tumor Necrosis Factor (Any), PaO2-FiO2","Anesthetic",50
"NCT04377789","https://ClinicalTrials.gov/show/NCT04377789",NA,"Turkey","Istanbul","2020-May","2020-Jul","Recruiting","Non-Randomised","Open-Label",2,"Healthy","None","Healthy Unexposed","Mortality","Alternative therapy, SOC",50
"PACTR202005681895696","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10988",NA,"Kenya","Nairobi","2020-Apr",NA,"Not Recruiting","Randomised","Single",NA,"Healthy","None","Healthy Unexposed","Adverse Events, IgG, IgM or IgA, Antibodies","Vaccine",400
"NCT04381988","https://ClinicalTrials.gov/show/NCT04381988",NA,"United States","New Jersey","2020-May","2021-May","Recruiting","Randomised","Triple",3,"Healthy","None","Healthy Unexposed","Mortality","HCQ + Radiation therapy, Radiation therapy",132
"NCT04381988","https://ClinicalTrials.gov/show/NCT04381988",NA,"United States","New York","2020-May","2021-May","Recruiting","Randomised","Triple",3,"Healthy","None","Healthy Unexposed","Mortality","HCQ + Radiation therapy, Radiation therapy",132
"RPCEC00000308","http://rpcec.sld.cu/en/trials/RPCEC00000308-En",NA,"Cuba","Havana","2020-Mar",NA,"Not Recruiting","Randomised","Unspecified",NA,"Healthy","None","Healthy Unexposed",NA,"IFN",30
"NCT04320238","https://ClinicalTrials.gov/show/NCT04320238",NA,"China","Hubei","2020-Mar","2020-May","Recruiting","Non-Randomised","Open-Label",2,"Healthy (Exposed)","Healthy","Healthcare Workers","Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events, Treatment-emergent Adverse Events","IFN, IFN + Other",2944
"RPCEC00000307","http://rpcec.sld.cu/en/trials/RPCEC00000307-En",NA,"Cuba","Havana","2020-Apr",NA,"Recruiting","Randomised","Unspecified",NA,"Confirmed","Unclear","Unclear","Labor Absenteeism","IFN",120
"CHICTR2000029849","http://www.chictr.org.cn/showproj.aspx?proj=49530",NA,"China","Henan","2020-Feb","2021-Feb","Recruiting","Randomised","Unspecified",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Pneumonia or ARDS, Fever","SOC, TCM",60
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","California","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Colorado","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Connecticut","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Hawaii","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Illinois","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Indiana","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Iowa","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Louisiana","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Maine","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Maryland","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Massachusetts","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Michigan","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Minnesota","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Montana","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","New Hampshire","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","New Jersey","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","New York","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","North Carolina","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Ohio","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Oregon","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Pennsylvania","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Rhode Island","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","South Carolina","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Texas","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Utah","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Virginia","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Washington","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"China","Beijing","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"France","Paris","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Germany","Berlin","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Germany","Hamburg","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Germany","Schleswig-Holstein","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"China","Hong Kong","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Italy","Bergamo","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Italy","Brescia","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Italy","Cremona","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Italy","Milano","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Italy","Rome","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Italy","Padova","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Italy","Parma","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Italy","Pavia","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Italy","Piacenza","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Italy","Roma","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Japan","Kanagawa","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Japan","Tokyo","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"South Korea","Daegu","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"South Korea","Seoul","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Netherlands","Amsterdam","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Singapore","Singapore","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Spain","Asturias","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Spain","Madrid","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Spain","Barcelona","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Spain","Bizkaia","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Spain","Sevilla","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Sweden","Stockholm","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Switzerland","Bern","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Taiwan","Taipei","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Taiwan","Taipei City","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United Kingdom","London","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United Kingdom","Edinburgh","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United Kingdom","Glasgow","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United Kingdom","Liverpool","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United Kingdom","Manchester","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United Kingdom","Plymouth","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United Kingdom","Sheffield","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"2020-001784-88","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001784-88/FI/",NA,"Finland","Helsinki","2020-Apr",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Unclear","Hospital, ICU","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Platelet Count, eGFR, Quality of Life, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","HCQ, Remdesivir, SOC",NA
"NCT04377620","https://ClinicalTrials.gov/show/NCT04377620",NA,"United States","Pennsylvania","2020-May","2020-Jul","Recruiting","Randomised","Double",2,"Confirmed","Severe","ICU","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events","JAKi, SOC",500
"NCT04347538","https://ClinicalTrials.gov/show/NCT04347538",NA,"United States","Tennessee","2020-Apr","2021-Jun","Recruiting","Randomised","Open-Label",2,NA,NA,"Outpatient","Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Other Mild Symptoms","Hygiene, SOC",90
"NCT04323800","https://ClinicalTrials.gov/show/NCT04323800",NA,"United States","Maryland","2020-Mar","2022-Dec","Not Recruiting","Randomised","Triple",2,"Healthy (Exposed)","Healthy","Healthy Exposed","Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea","Plasma based therapy, SOC",150
"CHICTR2000033057","http://www.chictr.org.cn/showproj.aspx?proj=53529",NA,"China","Liaoning","2020-May","2020-Sep","Recruiting","Randomised","Unspecified",2,"Confirmed","Mild","Outpatient","Depression, Anxiety","Rehabilitation",160
"NCT04355676","https://ClinicalTrials.gov/show/NCT04355676",NA,"United States","Massachusetts","2020-Apr","2020-Aug","Not Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Other",80
"CHICTR2000029605","http://www.chictr.org.cn/showproj.aspx?proj=49051",NA,"China","Hubei","2020-Feb","2021-Feb","Recruiting","Randomised","Open-Label",4,"Confirmed",NA,"Unclear","ICU Admission, Viral Load or Clearance, Cough, Fever, Other Mild Symptoms","SOC, TCM",400
"NCT04371822","https://ClinicalTrials.gov/show/NCT04371822",NA,"Egypt","Cairo","2020-May","2020-Jun","Not Recruiting","Non-Randomised","Open-Label",3,NA,NA,"Healthy Unexposed, ICU","Mortality, ICU Admission, C-Reactive Protein, Ferritin, IL-1, IL-6, Tumor Necrosis Factor (Any), Interferon (Any), Lymphocyte Count, Erythrocyte Sedimentation Rate, D-Dimer","Other",56
"NCT04363827","https://ClinicalTrials.gov/show/NCT04363827",NA,"Italy","Rome","2020-Apr","2020-Sep","Not Recruiting","Randomised","Open-Label",2,NA,NA,"Healthy Exposed, Outpatient","Adverse Events, Quality of Life","HCQ, SOC",2300
"NCT04364802","https://ClinicalTrials.gov/show/NCT04364802",NA,"United States","Kentucky","2020-Apr","2021-May","Recruiting","Non-Randomised","Open-Label",2,NA,NA,"Healthcare Workers, Hospital",NA,"Hygiene, SOC",250
"NCT04386616","https://ClinicalTrials.gov/show/NCT04386616",NA,"United States","California","2020-May","2020-Sep","Recruiting","Randomised","Double",4,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Blood Pressure, Heart Rate, ECG, SpO2, Respiratory Rate, Radiographic Findings, Hypoxemia, Cardiac Outcome (Unspecified)","mAb, Other, SOC",300
"NCT04386616","https://ClinicalTrials.gov/show/NCT04386616",NA,"United States","Florida","2020-May","2020-Sep","Recruiting","Randomised","Double",4,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Blood Pressure, Heart Rate, ECG, SpO2, Respiratory Rate, Radiographic Findings, Hypoxemia, Cardiac Outcome (Unspecified)","mAb, Other, SOC",300
"NCT04386616","https://ClinicalTrials.gov/show/NCT04386616",NA,"United States","Louisiana","2020-May","2020-Sep","Recruiting","Randomised","Double",4,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Blood Pressure, Heart Rate, ECG, SpO2, Respiratory Rate, Radiographic Findings, Hypoxemia, Cardiac Outcome (Unspecified)","mAb, Other, SOC",300
"NCT04386616","https://ClinicalTrials.gov/show/NCT04386616",NA,"United States","Michigan","2020-May","2020-Sep","Recruiting","Randomised","Double",4,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Blood Pressure, Heart Rate, ECG, SpO2, Respiratory Rate, Radiographic Findings, Hypoxemia, Cardiac Outcome (Unspecified)","mAb, Other, SOC",300
"NCT04386616","https://ClinicalTrials.gov/show/NCT04386616",NA,"United States","Nevada","2020-May","2020-Sep","Recruiting","Randomised","Double",4,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Blood Pressure, Heart Rate, ECG, SpO2, Respiratory Rate, Radiographic Findings, Hypoxemia, Cardiac Outcome (Unspecified)","mAb, Other, SOC",300
"NCT04386616","https://ClinicalTrials.gov/show/NCT04386616",NA,"United States","New Jersey","2020-May","2020-Sep","Recruiting","Randomised","Double",4,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Blood Pressure, Heart Rate, ECG, SpO2, Respiratory Rate, Radiographic Findings, Hypoxemia, Cardiac Outcome (Unspecified)","mAb, Other, SOC",300
"NCT04386616","https://ClinicalTrials.gov/show/NCT04386616",NA,"United States","New York","2020-May","2020-Sep","Recruiting","Randomised","Double",4,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Blood Pressure, Heart Rate, ECG, SpO2, Respiratory Rate, Radiographic Findings, Hypoxemia, Cardiac Outcome (Unspecified)","mAb, Other, SOC",300
"NCT04386616","https://ClinicalTrials.gov/show/NCT04386616",NA,"United States","Ohio","2020-May","2020-Sep","Recruiting","Randomised","Double",4,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Blood Pressure, Heart Rate, ECG, SpO2, Respiratory Rate, Radiographic Findings, Hypoxemia, Cardiac Outcome (Unspecified)","mAb, Other, SOC",300
"NCT04386616","https://ClinicalTrials.gov/show/NCT04386616",NA,"United States","Pennsylvania","2020-May","2020-Sep","Recruiting","Randomised","Double",4,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Blood Pressure, Heart Rate, ECG, SpO2, Respiratory Rate, Radiographic Findings, Hypoxemia, Cardiac Outcome (Unspecified)","mAb, Other, SOC",300
"NCT04386616","https://ClinicalTrials.gov/show/NCT04386616",NA,"United States","Texas","2020-May","2020-Sep","Recruiting","Randomised","Double",4,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Blood Pressure, Heart Rate, ECG, SpO2, Respiratory Rate, Radiographic Findings, Hypoxemia, Cardiac Outcome (Unspecified)","mAb, Other, SOC",300
"NCT04386616","https://ClinicalTrials.gov/show/NCT04386616",NA,"United States","Virginia","2020-May","2020-Sep","Recruiting","Randomised","Double",4,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Blood Pressure, Heart Rate, ECG, SpO2, Respiratory Rate, Radiographic Findings, Hypoxemia, Cardiac Outcome (Unspecified)","mAb, Other, SOC",300
"NCT04386616","https://ClinicalTrials.gov/show/NCT04386616",NA,"United States","Washington","2020-May","2020-Sep","Recruiting","Randomised","Double",4,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Blood Pressure, Heart Rate, ECG, SpO2, Respiratory Rate, Radiographic Findings, Hypoxemia, Cardiac Outcome (Unspecified)","mAb, Other, SOC",300
"NCT04382586","https://ClinicalTrials.gov/show/NCT04382586",NA,"United States","Illinois","2020-May","2020-Jul","Not Recruiting","Randomised","Double",3,"Confirmed","Severe","Hospital, ICU","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2","Other, SOC",52
"NCT04382586","https://ClinicalTrials.gov/show/NCT04382586",NA,"United States","Massachusetts","2020-May","2020-Jul","Not Recruiting","Randomised","Double",3,"Confirmed","Severe","Hospital, ICU","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2","Other, SOC",52
"NCT04382586","https://ClinicalTrials.gov/show/NCT04382586",NA,"United States","New Jersey","2020-May","2020-Jul","Not Recruiting","Randomised","Double",3,"Confirmed","Severe","Hospital, ICU","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2","Other, SOC",52
"NCT04382586","https://ClinicalTrials.gov/show/NCT04382586",NA,"United States","Wisconsin","2020-May","2020-Jul","Not Recruiting","Randomised","Double",3,"Confirmed","Severe","Hospital, ICU","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2","Other, SOC",52
"NCT04392778","https://ClinicalTrials.gov/show/NCT04392778",NA,"Turkey","Istanbul","2020-May","2020-Jul","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","ICU","Clinical Improvement Score (Any)","SOC, Stem cells",30
"CHICTR2000029956","http://www.chictr.org.cn/showproj.aspx?proj=49618",NA,"China","Sichuan","2020-Feb","2020-Jul","Not Recruiting","Randomised","Unspecified",2,"Resolved",NA,"Resolved Discharged","Cough, Fever, Dyspnea, Other Mild Symptoms, Quality of Life, Depression, Anxiety, Distress","SOC, TCM",120
"CTRI/2020/04/024729","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42933",NA,"India","New Delhi","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",NA,"Confirmed","None","Unclear",NA,"HCQ, SOC",60
"NCT04303507","https://ClinicalTrials.gov/show/NCT04303507",NA,"Thailand","Nan","2020-Mar","2021-Apr","Recruiting","Randomised","Double",2,"Healthy (Exposed)","Healthy","Healthcare Workers","Viral Load or Clearance, Pneumonia or ARDS","HCQ, SOC",40000
"NCT04331600","https://ClinicalTrials.gov/show/NCT04331600",NA,"Poland","Warsaw","2020-Apr","2020-Sep","Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Outpatient","Mortality, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Serious or Seconday Infections","HCQ, SOC",400
"NCT04394442","https://ClinicalTrials.gov/show/NCT04394442",NA,"Saudi Arabia","Riyadh","2020-May","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Mortality, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","HCQ, SOC",200
"NCT04329611","https://ClinicalTrials.gov/show/NCT04329611",NA,"Canada","Alberta","2020-Apr","2020-Aug","Recruiting","Single-Arm","Triple",1,"Confirmed",NA,"Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","HCQ, SOC",1660
"NCT04389359","https://ClinicalTrials.gov/show/NCT04389359",NA,"United Kingdom","Cambridgeshire","2020-May","2021-Aug","Not Recruiting","Randomised","Open-Label",2,"Healthy","None","Healthy Unexposed","Mortality","HCQ, SOC",1500
"NCT04385264","https://ClinicalTrials.gov/show/NCT04385264",NA,"Switzerland","Vaud","2020-May","2020-Aug","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear","Outpatient","Pneumonia or ARDS, Adverse Events, Distress","HCQ, SOC",800
"NCT04379492","https://ClinicalTrials.gov/show/NCT04379492",NA,"United States","New York","2020-May","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Unclear","Hospital","Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO","HCQ, SOC",120
"NCT04384380","https://ClinicalTrials.gov/show/NCT04384380",NA,"Taiwan","Taoyuan","2020-May","2020-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Mild/Moderate","Unclear","Adverse Events, Radiographic Findings","HCQ, SOC",45
"NCT04384458","https://ClinicalTrials.gov/show/NCT04384458",NA,"Brazil","Brasilia","2020-May","2020-Oct","Not Recruiting","Non-Randomised","Open-Label",2,"Healthy","Healthy","Healthcare Workers","Adverse Events, Heart Rate, ECG, Cardiac Outcome (Unspecified)","HCQ, SOC",400
"NCT04382625","https://ClinicalTrials.gov/show/NCT04382625",NA,"United States","Idaho","2020-May","2022-Jan","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Moderate","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Cardiac Outcome (Unspecified)","HCQ, SOC",120
"NCT04374942","https://ClinicalTrials.gov/show/NCT04374942",NA,"Canada","Ontario","2020-May","2020-Aug","Recruiting","Randomised","Quadruple",2,NA,NA,"Healthcare Workers","Mortality, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Other Mild Symptoms, Adverse Events, Quality of Life, Distress","HCQ, SOC",988
"NCT04370015","https://ClinicalTrials.gov/show/NCT04370015",NA,"Pakistan","Punjab","2020-Apr","2020-Jun","Not Recruiting","Randomised","Quadruple",2,NA,NA,"Healthcare Workers","Labor Absenteeism, Adverse Events","HCQ, SOC",374
"NCT04364815","https://ClinicalTrials.gov/show/NCT04364815",NA,"Philippines","Quezon","2020-Apr","2021-May","Not Recruiting","Randomised","Double",2,NA,NA,"Healthcare Workers",NA,"HCQ, SOC",960
"NCT04333225","https://ClinicalTrials.gov/show/NCT04333225",NA,"United States","Texas","2020-Apr","2020-Jul","Not Recruiting","Non-Randomised","Open-Label",2,"Exposed","Healthy","Healthcare Workers","Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Dyspnea, C-Reactive Protein, IL-6, Tumor Necrosis Factor (Any), Radiographic Findings","HCQ, SOC",228
"CHICTR2000031174","http://www.chictr.org.cn/showproj.aspx?proj=51437",NA,"China","Shanghai","2020-Mar","2020-Sep","Not Recruiting","Single-Arm","Unspecified",1,"Healthy",NA,"Healthy Unexposed",NA,"HCQ, SOC",1000
"NCT04369742","https://ClinicalTrials.gov/show/NCT04369742",NA,"United States","New York","2020-Apr","2020-Jun","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Fever, C-Reactive Protein, IL-6, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Glucose, LDH","HCQ, SOC",626
"NCT04308668","https://ClinicalTrials.gov/show/NCT04308668",NA,"United States","Minnesota","2020-Mar","2020-May","Recruiting","Randomised","Quadruple",2,"Mixed","Mixed","Healthy Exposed, Healthcare Workers, Outpatient","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, PaO2-FiO2, Blood pH","HCQ, SOC",3000
"NCT04308668","https://ClinicalTrials.gov/show/NCT04308668",NA,"United States","New York","2020-Mar","2020-May","Recruiting","Randomised","Quadruple",2,"Mixed","Mixed","Healthy Exposed, Healthcare Workers, Outpatient","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, PaO2-FiO2, Blood pH","HCQ, SOC",3000
"NCT04308668","https://ClinicalTrials.gov/show/NCT04308668",NA,"Canada","Alberta","2020-Mar","2020-May","Recruiting","Randomised","Quadruple",2,"Mixed","Mixed","Healthy Exposed, Healthcare Workers, Outpatient","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, PaO2-FiO2, Blood pH","HCQ, SOC",3000
"NCT04308668","https://ClinicalTrials.gov/show/NCT04308668",NA,"Canada","Manitoba","2020-Mar","2020-May","Recruiting","Randomised","Quadruple",2,"Mixed","Mixed","Healthy Exposed, Healthcare Workers, Outpatient","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, PaO2-FiO2, Blood pH","HCQ, SOC",3000
"NCT04308668","https://ClinicalTrials.gov/show/NCT04308668",NA,"Canada","Quebec","2020-Mar","2020-May","Recruiting","Randomised","Quadruple",2,"Mixed","Mixed","Healthy Exposed, Healthcare Workers, Outpatient","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, PaO2-FiO2, Blood pH","HCQ, SOC",3000
"NCT04363450","https://ClinicalTrials.gov/show/NCT04363450",NA,"United States","Louisiana","2020-Apr","2020-Jul","Recruiting","Randomised","Quadruple",2,NA,NA,"Healthcare Workers","Labor Absenteeism","HCQ, SOC",1700
"CHICTR2000032487","http://www.chictr.org.cn/showproj.aspx?proj=52394",NA,"China","Shanghai","2020-Apr","2020-Sep","Not Recruiting","Randomised","Unspecified",2,NA,NA,"Healthy Unexposed","Antibodies","HCQ, SOC",2000
"NCT04353271","https://ClinicalTrials.gov/show/NCT04353271",NA,"United States","Alabama","2020-Apr","2020-Jul","Not Recruiting","Randomised","Quadruple",2,NA,NA,"Outpatient","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Anti SARS-COV-2 Titers, Antibodies","HCQ, SOC",58
"NCT04318444","https://ClinicalTrials.gov/show/NCT04318444",NA,"United States","New York","2020-Mar","2021-Mar","Recruiting","Randomised","Quadruple",2,"Healthy (Exposed)","Healthy","Healthy Exposed","Viral Load or Clearance","HCQ, SOC",1600
"NCT04315896","https://ClinicalTrials.gov/show/NCT04315896",NA,"Mexico","Mexico","2020-Mar","2020-Oct","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events","HCQ, SOC",500
"NCT04318015","https://ClinicalTrials.gov/show/NCT04318015",NA,"Mexico","Mexico","2020-Mar","2020-Dec","Recruiting","Randomised","Quadruple",2,"Healthy (Exposed)","Healthy","Healthcare Workers","Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms","HCQ, SOC",400
"NCT04323631","https://ClinicalTrials.gov/show/NCT04323631",NA,"Israel","Haifa","2020-Mar","2020-Dec","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Unclear","Mortality, Serious or Seconday Infections","HCQ, SOC",1116
"2020-001257-51","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001257-51/DK/",NA,"Denmark","Copenhagen","2020-Mar",NA,"Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","HCQ, SOC",NA
"2020-001697-30","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001697-30/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Healthy","None","Healthcare Workers","ICU Admission, Pneumonia or ARDS, Cough, Fever, Other Mild Symptoms, ECG","HCQ, SOC",NA
"2020-001441-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001441-39/GB/",NA,"United Kingdom","London","2020-Apr",NA,"Recruiting","Randomised","Double",2,"Healthy","None","Healthcare Workers",NA,"HCQ, SOC",40000
"2020-001704-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001704-42/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Double",2,"Healthy","None","Healthcare Workers",NA,"HCQ, SOC",NA
"2020-002287-31","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002287-31/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Unspecified",2,"Healthy","None","Healthy Unexposed","Mortality, Cough, Fever, Dyspnea, Other Mild Symptoms","HCQ, SOC",1930
"IRCT20200405046958N1","http://en.irct.ir/trial/46946",NA,"Iran","Tehran","2020-Apr","2020-Jun","Recruiting","Randomised","Triple",2,NA,NA,"Healthy Unexposed","Viral Load or Clearance","HCQ, SOC",60
"IRCT20190122042450N4","http://en.irct.ir/trial/47090",NA,"Iran","Tehran","2020-Apr","2020-Jun","Recruiting","Randomised","Open-Label",2,NA,NA,"Healthy Exposed","Viral Load or Clearance, Radiographic Findings","HCQ, SOC",1000
"NCT04346329","https://clinicaltrials.gov/show/NCT04346329",NA,"Colombia","Bogota","2020-Oct",NA,"Not Recruiting","Randomised","Double",1,NA,NA,"Healthcare Workers","Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events","HCQ, SOC",86
"ACTRN12620000457943","https://anzctr.org.au/ACTRN12620000457943.aspx",NA,"New Zealand","Wellington","2020-Aug",NA,"Not Recruiting","Randomised","Double",NA,NA,NA,"Outpatient","Mortality, Clinical Improvement Score (Any), Fever, Adverse Events","HCQ, SOC",70
"ACTRN12620000501943","https://anzctr.org.au/ACTRN12620000501943.aspx",NA,"Australia","Canberra","2020-Apr",NA,"Not Recruiting","Randomised","Unspecified",NA,"Healthy","Healthy","Healthcare Workers",NA,"HCQ, SOC",2250
"NCT04352946","https://clinicaltrials.gov/show/NCT04352946",NA,"United States","Washington, Dc","2020-Apr",NA,"Not Recruiting","Randomised","Quadruple",1,NA,NA,"Healthcare Workers","Mortality, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Adverse Events, Anti SARS-COV-2 Titers","HCQ, SOC",374
"ACTRN12620000566932","https://anzctr.org.au/ACTRN12620000566932.aspx",NA,"Australia","Canberra","2020-May",NA,"Not Recruiting","Randomised","Unspecified",NA,"Confirmed Or Suspected","Unclear","Hospital","Mortality","HCQ, SOC",3000
"CTRI/2020/05/025067","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43019",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",NA,"Healthy (Exposed)","None","Healthcare Workers",NA,"HCQ, SOC",10990
"CTRI/2020/05/025022","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43183",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Randomised","Open-Label",NA,"Confirmed","Mild","Unclear",NA,"HCQ, SOC",166
"ISRCTN88057279","http://isrctn.com/ISRCTN88057279",NA,"United Kingdom","London","2020-May",NA,"Recruiting","Randomised","Open-Label",NA,"Healthy","None","Hospital",NA,"HCQ, SOC",500
"ISRCTN86534580","http://isrctn.com/ISRCTN86534580",NA,"United Kingdom","London","2020-Mar",NA,"Recruiting","Randomised","Unspecified",NA,"Suspected",NA,"Outpatient","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ, SOC",3000
"NCT04316377","https://ClinicalTrials.gov/show/NCT04316377",NA,"Norway","Oslo","2020-Mar","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance","HCQ, SOC",202
"CHICTR2000029868","http://www.chictr.org.cn/showproj.aspx?proj=49524",NA,"China","Shanghai","2020-Feb","2020-Jun","Completed","Randomised","Open-Label",2,"Confirmed","Mixed","Unclear","Viral Load or Clearance, Adverse Events","HCQ, SOC",360
"2020-001010-38","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001010-38/NO/",NA,"Norway","Oslo","2020-Mar",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ, SOC",NA
"NCT04324463","https://ClinicalTrials.gov/show/NCT04324463",NA,"Canada","Ontario","2020-Mar","2020-Sep","Recruiting","Randomised","Open-Label",3,"Confirmed",NA,"Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, SOC",1500
"NCT04354597","https://ClinicalTrials.gov/show/NCT04354597",NA,"Jordan","Amman","2020-Apr","2020-Aug","Not Recruiting","Randomised","Open-Label",2,NA,NA,"Healthcare Workers","Mortality, ICU Admission, Viral Load or Clearance, Non-invasive Ventilation, Adverse Events","HCQ + AZT, SOC",200
"NCT04374552","https://ClinicalTrials.gov/show/NCT04374552",NA,"United States","New Jersey","2020-May","2020-Nov","Not Recruiting","Randomised","Quadruple",2,"Confirmed","None","Unclear","Viral Load or Clearance","HCQ + AZT, SOC",140
"NCT04365231","https://ClinicalTrials.gov/show/NCT04365231",NA,"France","Paris","2020-Apr","2020-Jun","Not Recruiting","Randomised","Open-Label",2,NA,NA,"Outpatient","ICU Admission, Hospitalization","HCQ + AZT, SOC",50
"NCT04392973","https://ClinicalTrials.gov/show/NCT04392973",NA,"Saudi Arabia","Riyadh","2020-May","2021-Nov","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Moderate/Severe","Hospital","Clinical Improvement Score (Any)","HCQ + FPV, SOC",520
"2020-001644-25","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001644-25/ES/",NA,"France","Paris","2020-May",NA,"Recruiting","Randomised","Open-Label",4,"Confirmed","Severe","ICU","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2","Acalabrutinib, SOC",260
"2020-001644-25","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001644-25/ES/",NA,"Italy","Rome","2020-May",NA,"Recruiting","Randomised","Open-Label",4,"Confirmed","Severe","ICU","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2","Acalabrutinib, SOC",260
"2020-001644-25","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001644-25/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Open-Label",4,"Confirmed","Severe","ICU","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2","Acalabrutinib, SOC",260
"2020-001644-25","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001644-25/ES/",NA,"United States","Washington, Dc","2020-May",NA,"Recruiting","Randomised","Open-Label",4,"Confirmed","Severe","ICU","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2","Acalabrutinib, SOC",260
"NCT04355429","https://ClinicalTrials.gov/show/NCT04355429",NA,"France","Paris","2020-Apr","2020-Jul","Not Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, Invasive Mechanical Ventilation or ECMO","ACEi, SOC",230
"IRCT20140907019073N4","http://en.irct.ir/trial/46736",NA,"Iran","Fars","2020-Mar","2020-Jul","Recruiting","Randomised","Double",2,"Suspected",NA,"Hospital","Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein","Alternative therapy, SOC",60
"IRCT20200413047053N1","http://en.irct.ir/trial/47139",NA,"Iran","Tehran","2020-Apr","2020-Jul","Recruiting","Randomised","Double",3,NA,NA,"Outpatient","C-Reactive Protein","Alternative therapy, SOC",60
"CTRI/2020/05/025166","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43553",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Randomised","Open-Label",NA,"Healthy","None","Healthy Unexposed",NA,"Alternative therapy, SOC",1200
"CTRI/2020/05/025156","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43590",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Randomised","Open-Label",NA,"Confirmed","Mild","Unclear","Viral Load or Clearance","Alternative therapy, SOC",60
"CTRI/2020/04/024882","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42899",NA,"India","Haryana","2020-Apr",NA,"Not Recruiting","Non-Randomised","Unspecified",NA,"Confirmed","Mild/Moderate","Unclear","Hospital Discharge","Alternative therapy, SOC",60
"IRCT20081019001369N2","http://en.irct.ir/trial/46868",NA,"Iran","Tehran","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,NA,NA,"Outpatient","Clinical Improvement Score (Any), Fever, C-Reactive Protein","Alternative therapy, SOC",40
"IRCT20200316046792N1","http://en.irct.ir/trial/46554",NA,"Iran","Tehran","2020-Mar","2020-May","Completed","Randomised","Double",3,"Confirmed",NA,"Hospital","Mortality, Hospitalization, Cough, Fever, Treatment-emergent Adverse Events, Respiratory Rate","Alternative therapy, SOC",150
"IRCT20081019001369N3","http://en.irct.ir/trial/46978",NA,"Iran","Tehran","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,NA,NA,"Outpatient","Clinical Improvement Score (Any), Fever, C-Reactive Protein","Alternative therapy, SOC",40
"IRCT20200324046851N1","http://en.irct.ir/trial/46712",NA,"Iran","East Azarbaijan","2020-Apr","2020-Apr","Completed","Non-Randomised","Double",2,NA,NA,"ICU","Viral Load or Clearance","Alternative therapy, SOC",86
"IRCT20200509047373N1","http://en.irct.ir/trial/48001",NA,"Iran","Fars","2020-May","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Moderate","Hospital","Hospitalization, Hospital Discharge, Fever, SpO2","Alternative therapy, SOC",60
"IRCT20200415047089N1","http://en.irct.ir/trial/47234",NA,"Iran","Markazi","2020-Apr","2020-May","Completed","Randomised","Single",0,NA,NA,"Outpatient","Hospitalization, Other Mild Symptoms","Alternative therapy, SOC",100
"IRCT20200406046965N1","http://en.irct.ir/trial/46958",NA,"Iran","Tehran","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,NA,NA,"Outpatient","Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein","Alternative therapy, SOC",40
"CTRI/2020/05/025088","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43555",NA,"India","New Delhi","2020-Sep",NA,"Not Recruiting","Randomised","Open-Label",NA,"Healthy","None","Healthy Unexposed, Healthy Exposed",NA,"Alternative therapy, SOC",1200
"IRCT20200404046934N1","http://en.irct.ir/trial/46913",NA,"Iran","Qom","2020-Apr","2020-Apr","Completed","Randomised","Triple",2,NA,NA,"Unclear","Fever, Blood Pressure, Respiratory Rate","Alternative therapy, SOC",130
"CTRI/2020/05/025161","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43442",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Randomised","Unspecified",NA,"Confirmed","Mild/Moderate","Hospital","Hospital Discharge, Cough, Fever, Dyspnea","Alternative therapy, SOC",120
"IRCT20160131026298N3","http://en.irct.ir/trial/47019",NA,"Iran","Tehran","2020-Apr","2020-May","Completed","Randomised","Double",2,"Confirmed","Unclear","Unclear","Cough, Dyspnea, Radiographic Findings, Quality of Life","Alternative therapy, SOC",80
"CTRI/2020/05/024969","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43393",NA,"India","Delhi","2020-Jan",NA,"Not Recruiting","Randomised","Open-Label",NA,"Confirmed","Unclear","Unclear","Mortality","Alternative therapy, SOC",100
"IRCT20171213037866N2","http://en.irct.ir/trial/47684",NA,"Iran","Semnan","2020-May","2020-Aug","Recruiting","Randomised","Single",2,"Confirmed","Unclear","Unclear","Hospital Discharge, Radiographic Findings","Alternative therapy, SOC",68
"IRCT20200404046933N1","http://en.irct.ir/trial/46893",NA,"Iran","Tehran","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,NA,NA,"Outpatient","Clinical Improvement Score (Any), C-Reactive Protein","Alternative therapy, SOC",40
"IRCT20200404046937N1","http://en.irct.ir/trial/46903",NA,"Iran","Tehran","2020-Apr","2020-Jun","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Viral Load or Clearance, Cough, Fever, Dyspnea, C-Reactive Protein, Radiographic Findings","Alternative therapy, SOC",60
"IRCT20200115046144N2","http://en.irct.ir/trial/47645",NA,"Iran","Semnan","2020-May","2020-Nov","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Other Mild Symptoms","Alternative therapy, SOC",40
"IRCT20200404046937N2","http://en.irct.ir/trial/47016",NA,"Iran","Tehran","2020-Apr","2020-Jun","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Viral Load or Clearance, Cough, Fever, C-Reactive Protein, Radiographic Findings","Alternative therapy, SOC",60
"IRCT20200416047104N1","http://en.irct.ir/trial/47251",NA,"Iran","Tehran","2020-Apr","2020-Jun","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Cough, Dyspnea, Other Mild Symptoms, C-Reactive Protein, Ferritin, Creatinine Phosphokinase, LDH, Blood Pressure, Respiratory Rate","Alternative therapy, SOC",66
"IRCT20200326046868N1","http://en.irct.ir/trial/47934",NA,"Iran","Khuzestan","2020-May","2020-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Unclear","Unclear","Platelet Count","Alternative therapy, SOC",88
"CTRI/2020/05/025171","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43487",NA,"India","Delhi","2020-May",NA,"Not Recruiting","Randomised","Open-Label",NA,"Healthy","None","Healthy Unexposed, Healthy Exposed",NA,"Alternative therapy, SOC",50000
"CTRI/2020/05/025178","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43557",NA,"India","Delhi","2020-May",NA,"Not Recruiting","Randomised","Open-Label",NA,"Healthy","Unclear","Healthy Exposed",NA,"Alternative therapy, SOC",140
"ISRCTN13311119","http://isrctn.com/ISRCTN13311119",NA,"India","New Delhi","2020-Apr",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed","Mild/Moderate","Outpatient",NA,"Alternative therapy, SOC",116
"NCT04394208","https://ClinicalTrials.gov/show/NCT04394208",NA,"Egypt","Cairo","2020-May","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Mild/Moderate/Severe","Hospital","Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events","Alternative therapy, SOC",50
"IRCT20080901001165N48","http://en.irct.ir/trial/47318",NA,"Iran","Tehran","2020-Apr","2020-Jul","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Cough, Fever","Alternative therapy, SOC",100
"NCT04363541","https://ClinicalTrials.gov/show/NCT04363541",NA,"Mexico","Mexico","2020-Apr","2020-Sep","Not Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","ICU Admission, Hospitalization","Alternative therapy, SOC",298
"IRCT20180923041093N5","http://en.irct.ir/trial/47018",NA,"Iran","Tehran","2020-Apr","2020-May","Completed","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, Hospitalization, Cough, Fever, Other Mild Symptoms, C-Reactive Protein, Respiratory Rate, Radiographic Findings, Anxiety","Alternative therapy, SOC",60
"CTRI/2020/05/025093","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43539",NA,"India","New Delhi","2020-Nov",NA,"Not Recruiting","Randomised","Open-Label",NA,"Healthy","None","Healthy Unexposed, Healthy Exposed",NA,"Alternative therapy, SOC",1200
"IRCT20081011001323N25","http://en.irct.ir/trial/47935",NA,"Iran","Tehran","2020-May","2020-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed","Moderate/Severe","Hospital","Radiographic Findings","Alternative therapy, SOC",80
"CTRI/2020/04/024883","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43168",NA,"India","New Delhi","2020-Apr",NA,"Recruiting","Randomised","Single",NA,"Confirmed","Unclear","Hospital",NA,"Alternative therapy, SOC",112
"IRCT20200516047462N1","http://en.irct.ir/trial/48141",NA,"Iran","Tehran","2020-May","2020-Jun","Recruiting","Randomised","Double",2,"Suspected","Moderate","Outpatient","Cough, Dyspnea","Alternative therapy + Other, SOC",50
"NCT04362111","https://ClinicalTrials.gov/show/NCT04362111",NA,"United States","Alabama","2020-Apr","2020-Jul","Not Recruiting","Randomised","Triple",2,NA,NA,"Hospital","Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, D-Dimer, LDH","Anakinra, SOC",20
"EUCTR2020-001734-36-FR","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001734-36",NA,"France","Paris","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2","Anakinra, SOC",240
"NCT04366232","https://ClinicalTrials.gov/show/NCT04366232",NA,"France","Paris","2020-Apr","2020-Aug","Not Recruiting","Randomised","Open-Label",3,NA,NA,"Hospital","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA)","Anakinra with/without Ruxolitinib, SOC",54
"NCT04366232","https://ClinicalTrials.gov/show/NCT04366232",NA,"France","Var","2020-Apr","2020-Aug","Not Recruiting","Randomised","Open-Label",3,NA,NA,"Hospital","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA)","Anakinra with/without Ruxolitinib, SOC",54
"NCT04389840","https://ClinicalTrials.gov/show/NCT04389840",NA,"United States","North Carolina","2020-May","2021-Feb","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO","Anticoagulants, SOC",524
"CHICTR2000030701","http://www.chictr.org.cn/showproj.aspx?proj=50795",NA,"China","Guangdong","2020-Mar","2020-Sep","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Respiratory Rate","Anticoagulants, SOC",60
"CHICTR2000030700","http://www.chictr.org.cn/showproj.aspx?proj=50786",NA,"China","Hubei","2020-Mar","2020-Sep","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Respiratory Rate","Anticoagulants, SOC",60
"NCT04372589","https://clinicaltrials.gov/show/NCT04372589",NA,"Canada","Ottawa","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cardiac Outcome (Unspecified)","Anticoagulants, SOC",3000
"NCT04352400","https://ClinicalTrials.gov/show/NCT04352400",NA,"Italy","Padova","2020-Apr","2021-Dec","Not Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), PaO2-FiO2, Cardiac Outcome (Unspecified)","Anticoagulants, SOC",256
"KCT0005003","http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=16635",NA,"South Korea","Seoul","2020-May",NA,"Not Recruiting","Randomised","Open-Label",NA,"Confirmed","Moderate/Severe","Hospital","Hospital Discharge, Clinical Improvement Score (Any)","Anticoagulants, SOC",84
"ACTRN12620000517976","https://anzctr.org.au/ACTRN12620000517976.aspx",NA,"Australia","Canberra","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",NA,"Confirmed Or Suspected","Severe","Hospital",NA,"Anticoagulants, SOC",172
"NCT04332666","https://ClinicalTrials.gov/show/NCT04332666",NA,"Belgium","Brussels","2020-Apr","2020-May","Not Recruiting","Randomised","Triple",2,"Confirmed Or Suspected",NA,"ICU","ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Serious Adverse Events, IL-1, IL-2, IL-6, IL-7, IL-8, IL-10, Tumor Necrosis Factor (Any), Interferon (Any), Angiotensins, PaO2-FiO2, Radiographic Findings","Antihypertensive, SOC",60
"NCT04375124","https://ClinicalTrials.gov/show/NCT04375124",NA,"Turkey","Istanbul","2020-May","2020-Aug","Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Mortality","Antihypertensive, SOC",20
"NCT04365309","https://ClinicalTrials.gov/show/NCT04365309",NA,"China","Shaanxi","2020-Apr","2020-Apr","Recruiting","Randomised","Open-Label",2,NA,NA,"Unclear",NA,"Antihypertensive, SOC",128
"NCT04354389","https://ClinicalTrials.gov/show/NCT04354389",NA,"Italy","Milano","2020-Apr","2020-Jun","Not Recruiting","Randomised","Triple",2,NA,NA,"Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance","Antivirals, SOC",82
"NCT04354389","https://ClinicalTrials.gov/show/NCT04354389",NA,"Italy","Modena","2020-Apr","2020-Jun","Not Recruiting","Randomised","Triple",2,NA,NA,"Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance","Antivirals, SOC",82
"NCT04381884","https://ClinicalTrials.gov/show/NCT04381884",NA,"Argentina","Ciudad De Buenos Aires","2020-May","2020-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Viral Load or Clearance, Adverse Events, Antibodies","Ivermectin, SOC",45
"NCT04390022","https://ClinicalTrials.gov/show/NCT04390022",NA,"Spain","Navarra","2020-May","2020-Aug","Recruiting","Randomised","Double",2,"Confirmed","Unclear","Outpatient","Viral Load or Clearance, Cough, Fever, Adverse Events, IgG, IgM or IgA, CD4, CD8","Ivermectin, SOC",24
"CTRI/2020/05/025068","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43449",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Open-Label",NA,"Confirmed","Unclear","Hospital","Viral Load or Clearance","Ivermectin, SOC",50
"CTRI/2020/04/024858","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43236",NA,"India","Delhi","2020-Apr",NA,"Not Recruiting","Non-Randomised","Open-Label",NA,"Confirmed","Unclear","Hospital","Viral Load or Clearance","Ivermectin, SOC",50
"NCT04392713","https://clinicaltrials.gov/show/NCT04392713",NA,"Pakistan","Islamabad","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","None/Mild/Moderate",NA,NA,"Ivermectin, SOC",100
"NCT04392427","https://ClinicalTrials.gov/show/NCT04392427",NA,"Egypt","Cairo","2020-May","2022-May","Not Recruiting","Randomised","Single",2,"Confirmed","Unclear","Unclear",NA,"Ivermectin + Antivirals, SOC",100
"NCT04394117","https://ClinicalTrials.gov/show/NCT04394117",NA,"Australia","New South Wales","2020-May","2021-Jan","Not Recruiting","Randomised","Single",2,"Confirmed","Unclear","Outpatient, Hospital","Mortality, ICU Admission, Renal Outcome (Unspecified)","ARBs, SOC",605
"NCT04364893","https://ClinicalTrials.gov/show/NCT04364893",NA,"Brazil","Brasilia","2020-Apr","2020-Oct","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Cardiac Outcome (Unspecified)","ARBs + ACEi, SOC",500
"NCT04381962","https://ClinicalTrials.gov/show/NCT04381962",NA,"United Kingdom","Oxford","2020-May","2020-Sep","Not Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Unclear","Outpatient","Mortality, Pneumonia or ARDS","AZT, SOC",800
"NCT04369365","https://ClinicalTrials.gov/show/NCT04369365",NA,"Austria","Vienna","2020-Apr","2020-Aug","Recruiting","Randomised","Single",2,NA,NA,"Outpatient","Adverse Events","AZT, SOC",200
"2020-001752-17","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001752-17/FR/",NA,"France","Paris","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Mild/Moderate","Outpatient","Hospitalization, Viral Load or Clearance, Antibodies","AZT, SOC",NA
"EUCTR2020-001740-26-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001740-26",NA,"United Kingdom","London","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,"Suspected","Unclear","Outpatient","Mortality, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Adverse Events","AZT, SOC",800
"NCT04371107","https://ClinicalTrials.gov/show/NCT04371107",NA,"France","Paris","2020-May","2020-Jun","Not Recruiting","Randomised","Open-Label",2,NA,NA,"Outpatient",NA,"AZT, SOC",64
"NCT04380376","https://ClinicalTrials.gov/show/NCT04380376",NA,"Russia","Moscow","2020-May","2020-Oct","Recruiting","Non-Randomised","Single",2,"Confirmed Or Suspected","Moderate/Severe","Unclear","C-Reactive Protein, IL-6, Lymphocyte Count, D-Dimer","Chemotherapy, SOC",60
"NCT04355143","https://ClinicalTrials.gov/show/NCT04355143",NA,"United States","California","2020-Apr","2021-Apr","Recruiting","Randomised","Open-Label",2,NA,NA,"Unclear","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, D-Dimer, Troponin, Cardiac Outcome (Unspecified)","Colchicine, SOC",150
"NCT04322565","https://ClinicalTrials.gov/show/NCT04322565",NA,"Italy","Parma","2020-Mar","2020-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Outpatient","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever","Colchicine, SOC",310
"NCT04363437","https://ClinicalTrials.gov/show/NCT04363437",NA,"United States","New York","2020-Apr","2020-May","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, Non-invasive Ventilation, C-Reactive Protein, Troponin","Colchicine, SOC",70
"NCT04375202","https://ClinicalTrials.gov/show/NCT04375202",NA,"Italy","Rome","2020-May","2020-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Organ Failure or Dysfunction (SOFA), Ferritin, White Blood Cell Count, ALT","Colchicine, SOC",308
"NCT04328480","https://ClinicalTrials.gov/show/NCT04328480",NA,"Argentina","Santa Fe","2020-Mar","2020-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Severe","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO","Colchicine, SOC",2500
"NCT04322682","https://ClinicalTrials.gov/show/NCT04322682",NA,"United States","California","2020-Mar","2020-Sep","Recruiting","Randomised","Single",2,"Confirmed",NA,"Outpatient","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH","Colchicine, SOC",6000
"NCT04322682","https://ClinicalTrials.gov/show/NCT04322682",NA,"United States","New York","2020-Mar","2020-Sep","Recruiting","Randomised","Single",2,"Confirmed",NA,"Outpatient","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH","Colchicine, SOC",6000
"NCT04322682","https://ClinicalTrials.gov/show/NCT04322682",NA,"Canada","Quebec","2020-Mar","2020-Sep","Recruiting","Randomised","Single",2,"Confirmed",NA,"Outpatient","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH","Colchicine, SOC",6000
"NCT04322682","https://ClinicalTrials.gov/show/NCT04322682",NA,"Spain","Madrid","2020-Mar","2020-Sep","Recruiting","Randomised","Single",2,"Confirmed",NA,"Outpatient","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH","Colchicine, SOC",6000
"2020-001603-16","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001603-16/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Outpatient","Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Colchicine, SOC",NA
"NCT04392141","https://ClinicalTrials.gov/show/NCT04392141",NA,"Iran","Kermanshah","2020-May","2020-Jun","Recruiting","Randomised","Double",2,"Confirmed","Mild/Moderate/Severe","Unclear","Mortality, Hospitalization, C-Reactive Protein, IL-6, Lymphocyte Count, Erythrocyte Sedimentation Rate","Colchicine + Alternative therapy, SOC",200
"NCT04355637","https://ClinicalTrials.gov/show/NCT04355637",NA,"Spain","Barcelona","2020-Apr","2020-Aug","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, C-Reactive Protein, Ferritin, White Blood Cell Count, D-Dimer, LDH, Cardiac Outcome (Unspecified)","Corticosteroids, SOC",300
"2020-001667-85","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001667-85/FR/",NA,"France","Paris","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Mild/Moderate","Unclear","Adverse Events, Serious Adverse Events","Corticosteroids, SOC",NA
"NCT04361474","https://clinicaltrials.gov/show/NCT04361474",NA,"France","Paris","2020-Apr",NA,"Recruiting","Randomised","Single",1,NA,NA,"Unclear","Clinical Improvement Score (Any), Blood Pressure, Heart Rate, Respiratory Rate","Corticosteroids, SOC",120
"NCT04381364","https://ClinicalTrials.gov/show/NCT04381364",NA,"Sweden","Stockholm","2020-May","2020-Dec","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Dyspnea","Corticosteroids, SOC",446
"NCT04395105","https://ClinicalTrials.gov/show/NCT04395105",NA,"Argentina","Buenos Aires","2020-May","2020-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Mortality, Organ Failure or Dysfunction (SOFA), C-Reactive Protein","Corticosteroids, SOC",284
"NCT04360876","https://ClinicalTrials.gov/show/NCT04360876",NA,"United States","Colorado","2020-Apr","2020-Sep","Not Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, Quality of Life, Renal Outcome (Unspecified)","Corticosteroids, SOC",90
"EUCTR2020-001395-15-DK","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001395-15",NA,"Denmark","Copenhagen","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Invasive Mechanical Ventilation or ECMO, Hypoxia, Renal Outcome (Unspecified)","Corticosteroids, SOC",1000
"NCT04323592","https://ClinicalTrials.gov/show/NCT04323592",NA,"Italy","Trieste","2020-Mar","2020-May","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein","Corticosteroids, SOC",104
"2020-001934-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001934-37/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), PaO2-FiO2, Shock","Corticosteroids, SOC",NA
"IRCT20200406046963N1","http://en.irct.ir/trial/47088",NA,"Iran","Tehran","2020-Apr","2020-May","Completed","Randomised","Open-Label",2,NA,NA,"ICU","Mortality, ICU Admission, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Radiographic Findings","Corticosteroids, SOC",40
"IRCT20200204046369N1","http://en.irct.ir/trial/46776",NA,"Iran","Tehran","2020-Apr","2020-Jun","Recruiting","Non-Randomised","Open-Label",2,NA,NA,"Hospital","Fever, Blood Urea Nitrogen, PaO2-FiO2, Respiratory Rate, Radiographic Findings","Corticosteroids, SOC",48
"IRCT20080901001165N52","http://en.irct.ir/trial/47641",NA,"Iran","Tehran","2020-May","2020-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Moderate/Severe","Hospital","ICU Admission, Hospitalization, Hospital Discharge, Shock, Hypoxemia","Corticosteroids, SOC",50
"NCT04359511","https://ClinicalTrials.gov/show/NCT04359511",NA,"France","Paris","2020-Apr","2020-Nov","Not Recruiting","Randomised","Single",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Quality of Life","Corticosteroids, SOC",210
"NCT04392531","https://ClinicalTrials.gov/show/NCT04392531",NA,"Spain","Madrid","2020-May","2020-Jul","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Viral Load or Clearance, Adverse Events, C-Reactive Protein, Ferritin, IL-6, D-Dimer, Creatinine Phosphokinase, LDH, Antibodies","Cyclosporine, SOC",120
"NCT04392531","https://ClinicalTrials.gov/show/NCT04392531",NA,"Spain","Navarra","2020-May","2020-Jul","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Viral Load or Clearance, Adverse Events, C-Reactive Protein, Ferritin, IL-6, D-Dimer, Creatinine Phosphokinase, LDH, Antibodies","Cyclosporine, SOC",120
"IRCT20200328046886N1","http://en.irct.ir/trial/46885",NA,"Iran","Mazandaran","2020-Apr","2020-Mar","Completed","Randomised","Double",2,NA,NA,"Hospital","Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","DAA + Antiviral, SOC",48
"NCT04382391","https://ClinicalTrials.gov/show/NCT04382391",NA,"United States","Pennsylvania","2020-May","2020-Sep","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Unclear","Mortality, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Device, SOC",20
"NCT04386694","https://ClinicalTrials.gov/show/NCT04386694",NA,"Brazil","Brasilia","2020-May","2020-Jul","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","ICU","Hospital Discharge, C-Reactive Protein, Platelet Count, D-Dimer, IgG, IgM or IgA, PaO2-FiO2","Device, SOC",30
"NCT04371952","https://ClinicalTrials.gov/show/NCT04371952",NA,"France","Paris","2020-May","2020-Dec","Not Recruiting","Randomised","Double",2,NA,NA,"Outpatient","Mortality, ICU Admission, Hospitalization","Antibiotics, SOC",330
"2020-001643-13","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001643-13/GB/",NA,"United Kingdom","London","2020-Apr",NA,"Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Platelet Count, Hemoglobin, ALT, AST, Bilirubin","DPP1 inhibitor, SOC",300
"NCT04365517","https://ClinicalTrials.gov/show/NCT04365517",NA,"Italy","Rome","2020-Apr","2020-Jun","Not Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Clinical Improvement Score (Any)","DPP-4i, SOC",170
"CHICTR2000030744","http://www.chictr.org.cn/showproj.aspx?proj=50910",NA,"China","Shandong","2020-Mar","2020-Aug","Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Severe","ICU","Mortality, ICU Admission, Hospitalization","ECMO, SOC",30
"CHICTR2000032456","http://www.chictr.org.cn/showproj.aspx?proj=53048",NA,"China","Shanghai","2020-Apr","2020-May","Completed","Randomised","Open-Label",2,"Confirmed Or Suspected",NA,"Hospital","Quality of Life, Depression, Anxiety","Education + Non-invasive respiratory support, SOC",100
"CHICTR2000032367","http://www.chictr.org.cn/showproj.aspx?proj=52972",NA,"China","Shanghai","2020-Apr","2020-Jul","Recruiting","Randomised","Unspecified",2,"Confirmed","Mild","Hospital","Hospitalization, Dyspnea, Other Mild Symptoms","Exercise, SOC",186
"CHICTR2000029460","http://www.chictr.org.cn/showproj.aspx?proj=48930",NA,"China","Hubei","2020-Feb","2021-Dec","Not Recruiting","Randomised","Open-Label",2,"Resolved",NA,"Resolved Discharged","Adverse Events, 6-Minute Walking Distance, Quality of Life","Exercise, SOC",100
"NCT04358549","https://ClinicalTrials.gov/show/NCT04358549",NA,"United States","Massachusetts","2020-Apr","2020-Aug","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Clinical Improvement Score (Any), Viral Load or Clearance","FPV, SOC",50
"NCT04333589","https://ClinicalTrials.gov/show/NCT04333589",NA,"China","Anhui","2020-Apr","2020-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Unclear","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","FPV, SOC",210
"NCT04333589","https://ClinicalTrials.gov/show/NCT04333589",NA,"China","Hubei","2020-Apr","2020-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Unclear","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","FPV, SOC",210
"NCT04333589","https://ClinicalTrials.gov/show/NCT04333589",NA,"China","Zhejiang","2020-Apr","2020-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Unclear","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","FPV, SOC",210
"2020-001904-41","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001904-41/GB/",NA,"United Kingdom","London","2020-Apr",NA,"Status Unclear","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital",NA,"FPV, SOC",302
"TCTR20200514001","http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=6236",NA,"Thailand","Nan","2020-Dec",NA,"Not Recruiting","Randomised","Open-Label",NA,"Confirmed","Unclear","Unclear","Fever, SpO2","FPV, SOC",96
"CTRI/2020/05/025114","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43504",NA,"India","New Delhi","2020-Dec",NA,"Not Recruiting","Randomised","Open-Label",NA,"Confirmed","Mild/Moderate","Hospital",NA,"FPV, SOC",150
"NCT04346628","https://clinicaltrials.gov/show/NCT04346628",NA,"United States","Washington, Dc","2020-Oct",NA,"Not Recruiting","Randomised","Open-Label",1,NA,NA,"Outpatient","Clinical Improvement Score (Any), Viral Load or Clearance, Other Mild Symptoms, Anti SARS-COV-2 Titers","FPV, SOC",120
"JPRN-JRCTS041190120","https://jrct.niph.go.jp/latest-detail/jRCTs041190120",NA,"Japan","Aichi","2020-Feb",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed",NA,"Outpatient","Viral Load or Clearance","FPV, SOC",86
"NCT04365127","https://ClinicalTrials.gov/show/NCT04365127",NA,"United States","California","2020-Apr","2020-Sep","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Hormone therapy, SOC",40
"NCT04348513","https://ClinicalTrials.gov/show/NCT04348513",NA,"Greece","Athens","2020-Apr","2021-May","Not Recruiting","Randomised","Triple",2,"Yes","Severe","ICU","Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever, Deep Vein Thrombosis or Pulmonary Embolism, C-Reactive Protein, White Blood Cell Count, Erythrocyte Sedimentation Rate, D-Dimer, Creatinine Phosphokinase, Fibrinogen, ALT, Bilirubin, Urine Sample, Blood Pressure, PaO2-FiO2, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Hormone therapy, SOC",60
"NCT04352959","https://ClinicalTrials.gov/show/NCT04352959",NA,"France","Lyonnais","2020-Apr","2020-May","Not Recruiting","Randomised","Triple",2,NA,NA,"Unclear","Viral Load or Clearance","Hygiene, SOC",178
"NCT04393792","https://ClinicalTrials.gov/show/NCT04393792",NA,"United Kingdom","Hampshire","2020-May","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed Or Healthy Or Suspected","None","Healthy Exposed, Healthcare Workers","Viral Load or Clearance","Hygiene, SOC",40
"NCT04371965","https://ClinicalTrials.gov/show/NCT04371965",NA,"France","Paris","2020-May","2020-Jul","Not Recruiting","Randomised","Open-Label",2,NA,NA,"Unclear","ICU Admission, Hospitalization, Viral Load or Clearance, Cough, Other Mild Symptoms, Distress","Hygiene, SOC",24
"EUCTR2020-001721-31-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001721-31",NA,"United Kingdom","London","2020-Apr",NA,"Not Recruiting","Randomised","Double",3,"Confirmed Or Suspected","Unclear","Unclear","Viral Load or Clearance","Hygiene, SOC",40
"CTRI/2020/05/024962","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43237",NA,"India","New Delhi","2020-Jan",NA,"Not Recruiting","Randomised","Unspecified",NA,"Confirmed","Unclear","Unclear","Viral Load or Clearance","Hygiene, SOC",96
"CTRI/2020/04/024806","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42843",NA,"India","New Delhi","2020-Apr",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed","Mild","Hospital",NA,"Imatinib, SOC",100
"NCT04261426","https://clinicaltrials.gov/show/NCT04261426",NA,"China","Beijing","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",1,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events","Igs, SOC",80
"NCT04381377","https://ClinicalTrials.gov/show/NCT04381377",NA,"Russia","Moscow","2020-May","2021-Apr","Recruiting","Randomised","Triple",2,"Confirmed","Unclear","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO","Immunomodulators, SOC",394
"NCT04381377","https://ClinicalTrials.gov/show/NCT04381377",NA,"Russia","Novgorod","2020-May","2021-Apr","Recruiting","Randomised","Triple",2,"Confirmed","Unclear","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO","Immunomodulators, SOC",394
"NCT04381377","https://ClinicalTrials.gov/show/NCT04381377",NA,"Russia","Orenburg","2020-May","2021-Apr","Recruiting","Randomised","Triple",2,"Confirmed","Unclear","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO","Immunomodulators, SOC",394
"NCT04381377","https://ClinicalTrials.gov/show/NCT04381377",NA,"Russia","Vladimir","2020-May","2021-Apr","Recruiting","Randomised","Triple",2,"Confirmed","Unclear","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO","Immunomodulators, SOC",394
"NCT04280588","https://ClinicalTrials.gov/show/NCT04280588",NA,"China","Beijing","2020-Feb","2020-Jul","Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Pneumonia or ARDS","Immunomodulators, SOC",30
"NCT04273581","https://ClinicalTrials.gov/show/NCT04273581",NA,"China","Beijing","2020-Feb","2020-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, IL-1, IL-2, IL-6, IL-7, IL-8, IL-10, Tumor Necrosis Factor (Any), Granulocyte Stimulaiting Factor, IP-10, MCP-1, MIP-1","Immunomodulators, SOC",40
"NCT04273529","https://ClinicalTrials.gov/show/NCT04273529",NA,"China","Zhejiang","2020-Feb","2020-May","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Mixed","Unclear","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Serious Adverse Events, IL-1, IL-2, IL-6, IL-7, IL-8, IL-10, Tumor Necrosis Factor (Any), Granulocyte Stimulaiting Factor, IP-10, MCP-1, PaO2-FiO2, Respiratory Rate","Immunomodulators, SOC",100
"NCT04360096","https://ClinicalTrials.gov/show/NCT04360096",NA,"United States","Florida","2020-Apr","2020-Aug","Not Recruiting","Randomised","Quadruple",2,NA,NA,"Hospital","Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Dyspnea, PaO2-FiO2, 6-Minute Walking Distance","Inhaled solution, SOC",144
"NCT04359654","https://ClinicalTrials.gov/show/NCT04359654",NA,"United Kingdom","London","2020-Apr","2020-Aug","Not Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, PaO2-FiO2","Inhaled solution, SOC",50
"NCT04333420","https://ClinicalTrials.gov/show/NCT04333420",NA,"Netherlands","Amsterdam","2020-Apr","2020-Oct","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Viral Load or Clearance, PaO2-FiO2","IFN, SOC",130
"NCT04385095","https://ClinicalTrials.gov/show/NCT04385095",NA,"United Kingdom","Belfast","2020-May","2020-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed Or Suspected","Mixed","Outpatient, Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Cough, Adverse Events, Blood Pressure, Heart Rate, SpO2, Respiratory Rate, Cardiac Outcome (Unspecified)","IFN, SOC",400
"NCT04385095","https://ClinicalTrials.gov/show/NCT04385095",NA,"United Kingdom","Birmingham","2020-May","2020-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed Or Suspected","Mixed","Outpatient, Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Cough, Adverse Events, Blood Pressure, Heart Rate, SpO2, Respiratory Rate, Cardiac Outcome (Unspecified)","IFN, SOC",400
"NCT04385095","https://ClinicalTrials.gov/show/NCT04385095",NA,"United Kingdom","Bradford","2020-May","2020-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed Or Suspected","Mixed","Outpatient, Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Cough, Adverse Events, Blood Pressure, Heart Rate, SpO2, Respiratory Rate, Cardiac Outcome (Unspecified)","IFN, SOC",400
"NCT04385095","https://ClinicalTrials.gov/show/NCT04385095",NA,"United Kingdom","York","2020-May","2020-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed Or Suspected","Mixed","Outpatient, Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Cough, Adverse Events, Blood Pressure, Heart Rate, SpO2, Respiratory Rate, Cardiac Outcome (Unspecified)","IFN, SOC",400
"NCT04385095","https://ClinicalTrials.gov/show/NCT04385095",NA,"United Kingdom","Leicester","2020-May","2020-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed Or Suspected","Mixed","Outpatient, Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Cough, Adverse Events, Blood Pressure, Heart Rate, SpO2, Respiratory Rate, Cardiac Outcome (Unspecified)","IFN, SOC",400
"NCT04385095","https://ClinicalTrials.gov/show/NCT04385095",NA,"United Kingdom","Manchester","2020-May","2020-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed Or Suspected","Mixed","Outpatient, Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Cough, Adverse Events, Blood Pressure, Heart Rate, SpO2, Respiratory Rate, Cardiac Outcome (Unspecified)","IFN, SOC",400
"NCT04385095","https://ClinicalTrials.gov/show/NCT04385095",NA,"United Kingdom","Nottingham","2020-May","2020-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed Or Suspected","Mixed","Outpatient, Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Cough, Adverse Events, Blood Pressure, Heart Rate, SpO2, Respiratory Rate, Cardiac Outcome (Unspecified)","IFN, SOC",400
"NCT04385095","https://ClinicalTrials.gov/show/NCT04385095",NA,"United Kingdom","London","2020-May","2020-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed Or Suspected","Mixed","Outpatient, Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Cough, Adverse Events, Blood Pressure, Heart Rate, SpO2, Respiratory Rate, Cardiac Outcome (Unspecified)","IFN, SOC",400
"NCT04385095","https://ClinicalTrials.gov/show/NCT04385095",NA,"United Kingdom","Southampton","2020-May","2020-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed Or Suspected","Mixed","Outpatient, Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Cough, Adverse Events, Blood Pressure, Heart Rate, SpO2, Respiratory Rate, Cardiac Outcome (Unspecified)","IFN, SOC",400
"IRCT20100228003449N28","http://en.irct.ir/trial/46538",NA,"Iran","Tehran","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",2,"Confirmed Or Suspected",NA,"Hospital","Hospitalization, Clinical Improvement Score (Any), Adverse Events","IFN, SOC",30
"IRCT20100228003449N27","http://en.irct.ir/trial/46545",NA,"Iran","Tehran","2020-Mar","2020-May","Completed","Randomised","Open-Label",2,"Confirmed Or Suspected",NA,"Hospital","Hospitalization, Clinical Improvement Score (Any), Adverse Events","IFN, SOC",30
"IRCT20080901001165N53","http://en.irct.ir/trial/48066",NA,"Iran","Tehran","2020-May","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed","Moderate","Hospital","Mortality, Fever","IFN, SOC",100
"NCT04388709","https://ClinicalTrials.gov/show/NCT04388709",NA,"United States","New York","2020-May","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","ICU Admission, Hospital Discharge, Fever, Adverse Events, Hypoxia","IFN, SOC",66
"NCT04331899","https://ClinicalTrials.gov/show/NCT04331899",NA,"United States","California","2020-Apr","2021-May","Recruiting","Randomised","Single",2,"Confirmed","Non-severe","Outpatient","Viral Load or Clearance","IFN, SOC",120
"CHICTR2000030480","http://www.chictr.org.cn/showproj.aspx?proj=50470",NA,"China","Hubei","2020-Mar","2020-Jul","Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Unclear","Treatment-emergent Adverse Events","IFN, SOC",328
"NCT04293887","https://ClinicalTrials.gov/show/NCT04293887",NA,"China","Hebei","2020-Mar","2020-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Hospital","ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Treatment-emergent Adverse Events, Respiratory Rate","IFN, SOC",328
"NCT04373824","https://clinicaltrials.gov/show/NCT04373824",NA,"India","New Delhi","2020-Apr",NA,"Recruiting","Non-Randomised","Open-Label",1,"Confirmed","Unclear","Hospital",NA,"Ivermectin, SOC",50
"NCT04393051","https://ClinicalTrials.gov/show/NCT04393051",NA,"Italy","Pisa","2020-May","2020-Jun","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","JAKi, SOC",126
"NCT04320277","https://clinicaltrials.gov/show/NCT04320277",NA,"Italy","Rome","2020-Mar",NA,"Not Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Mixed","Unclear","ICU Admission, Adverse Events, C-Reactive Protein, IL-6, Tumor Necrosis Factor (Any)","JAKi, SOC",200
"EUCTR2020-001662-11-DE","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001662-11",NA,"United States","Washington, Dc","2020-Apr",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Unclear","Hospital","ICU Admission, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, SpO2","JAKi, SOC",402
"EUCTR2020-001662-11-DE","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001662-11",NA,"France","Paris","2020-Apr",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Unclear","Hospital","ICU Admission, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, SpO2","JAKi, SOC",402
"EUCTR2020-001662-11-DE","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001662-11",NA,"Spain","Madrid","2020-Apr",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Unclear","Hospital","ICU Admission, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, SpO2","JAKi, SOC",402
"EUCTR2020-001662-11-DE","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001662-11",NA,"Germany","Berlin","2020-Apr",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Unclear","Hospital","ICU Admission, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, SpO2","JAKi, SOC",402
"EUCTR2020-001662-11-DE","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001662-11",NA,"United Kingdom","London","2020-Apr",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Unclear","Hospital","ICU Admission, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, SpO2","JAKi, SOC",402
"EUCTR2020-001662-11-DE","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001662-11",NA,"Italy","Rome","2020-Apr",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Unclear","Hospital","ICU Admission, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, SpO2","JAKi, SOC",402
"NCT04321174","https://ClinicalTrials.gov/show/NCT04321174",NA,"Canada","British Columbia","2020-Mar","2021-Mar","Recruiting","Randomised","Single",2,"Healthy (Exposed)","Healthy","Healthy Exposed","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Cough, Fever, Other Mild Symptoms, Adverse Events, Quality of Life, Distress","LPV/r, SOC",1220
"NCT04321174","https://ClinicalTrials.gov/show/NCT04321174",NA,"Canada","Ontario","2020-Mar","2021-Mar","Recruiting","Randomised","Single",2,"Healthy (Exposed)","Healthy","Healthy Exposed","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Cough, Fever, Other Mild Symptoms, Adverse Events, Quality of Life, Distress","LPV/r, SOC",1220
"CHICTR2000029308","http://www.chictr.org.cn/showproj.aspx?proj=48684","https://www.nejm.org/doi/pdf/10.1056/NEJMoa2001282?articleTools=true","China","Hubei","2020-Jan","2021-Jan","Completed w. Results","Randomised","Open-Label",2,"Confirmed",NA,"Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events","LPV/r, SOC",160
"CHICTR2000031196","http://www.chictr.org.cn/showproj.aspx?proj=51112",NA,"China","Beijing","2020-Mar","2020-Dec","Recruiting","Non-Randomised","Unspecified",2,"Confirmed",NA,"Unclear","Viral Load or Clearance, Adverse Events","LPV/r + IFN, SOC",90
"NCT04371367","https://clinicaltrials.gov/show/NCT04371367",NA,"France","Paris","2020-Apr",NA,"Recruiting","Randomised","Double",3,NA,NA,"ICU","Hospitalization","mAb, SOC",108
"NCT04305106","https://ClinicalTrials.gov/show/NCT04305106",NA,"China","Shandong","2020-Mar","2020-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any)","mAb, SOC",140
"NCT04347226","https://ClinicalTrials.gov/show/NCT04347226",NA,"United States","New York","2020-Apr","2021-Sep","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any)","mAb, SOC",138
"EUCTR2020-001370-30-DE","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001370-30",NA,"United States","Washington, Dc","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Unclear","Hospital","Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO","mAb, SOC",450
"EUCTR2020-001370-30-DE","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001370-30",NA,"France","Paris","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Unclear","Hospital","Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO","mAb, SOC",450
"EUCTR2020-001370-30-DE","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001370-30",NA,"Spain","Madrid","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Unclear","Hospital","Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO","mAb, SOC",450
"EUCTR2020-001370-30-DE","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001370-30",NA,"Germany","Berlin","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Unclear","Hospital","Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO","mAb, SOC",450
"EUCTR2020-001370-30-DE","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001370-30",NA,"United Kingdom","London","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Unclear","Hospital","Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO","mAb, SOC",450
"EUCTR2020-001370-30-DE","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001370-30",NA,"Italy","Rome","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Unclear","Hospital","Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO","mAb, SOC",450
"EUCTR2020-001370-30-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001370-30",NA,"United States","Washington, Dc","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Unclear","Hospital","Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO","mAb, SOC",450
"EUCTR2020-001370-30-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001370-30",NA,"France","Paris","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Unclear","Hospital","Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO","mAb, SOC",450
"EUCTR2020-001370-30-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001370-30",NA,"Spain","Madrid","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Unclear","Hospital","Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO","mAb, SOC",450
"EUCTR2020-001370-30-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001370-30",NA,"Germany","Berlin","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Unclear","Hospital","Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO","mAb, SOC",450
"EUCTR2020-001370-30-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001370-30",NA,"Italy","Rome","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Unclear","Hospital","Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO","mAb, SOC",450
"EUCTR2020-001370-30-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001370-30",NA,"United Kingdom","London","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Unclear","Hospital","Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO","mAb, SOC",450
"NCT04381052","https://ClinicalTrials.gov/show/NCT04381052",NA,"United States","New York","2020-May","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","ICU","ICU Admission, Adverse Events, C-Reactive Protein, Renal Outcome (Unspecified)","mAb, SOC",30
"NCT04363502","https://clinicaltrials.gov/show/NCT04363502",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Randomised","Triple",1,"Confirmed","Severe","ICU","C-Reactive Protein","mAb, SOC",30
"CTRI/2020/05/024959","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42878",NA,"India","New Delhi","2020-Jan",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed","Moderate/Severe","Hospital","Mortality","mAb, SOC",30
"NCT04347239","https://ClinicalTrials.gov/show/NCT04347239",NA,"United States","California","2020-Apr","2020-Dec","Recruiting","Randomised","Quadruple",2,NA,NA,"Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","mAb, SOC",390
"NCT04347239","https://ClinicalTrials.gov/show/NCT04347239",NA,"United States","Connecticut","2020-Apr","2020-Dec","Recruiting","Randomised","Quadruple",2,NA,NA,"Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","mAb, SOC",390
"NCT04347239","https://ClinicalTrials.gov/show/NCT04347239",NA,"United States","Massachusetts","2020-Apr","2020-Dec","Recruiting","Randomised","Quadruple",2,NA,NA,"Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","mAb, SOC",390
"NCT04347239","https://ClinicalTrials.gov/show/NCT04347239",NA,"United States","New Jersey","2020-Apr","2020-Dec","Recruiting","Randomised","Quadruple",2,NA,NA,"Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","mAb, SOC",390
"NCT04347239","https://ClinicalTrials.gov/show/NCT04347239",NA,"United States","New York","2020-Apr","2020-Dec","Recruiting","Randomised","Quadruple",2,NA,NA,"Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","mAb, SOC",390
"NCT04347239","https://ClinicalTrials.gov/show/NCT04347239",NA,"United States","North Carolina","2020-Apr","2020-Dec","Recruiting","Randomised","Quadruple",2,NA,NA,"Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","mAb, SOC",390
"NCT04347239","https://ClinicalTrials.gov/show/NCT04347239",NA,"United States","Ohio","2020-Apr","2020-Dec","Recruiting","Randomised","Quadruple",2,NA,NA,"Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","mAb, SOC",390
"NCT04347239","https://ClinicalTrials.gov/show/NCT04347239",NA,"United States","Oregon","2020-Apr","2020-Dec","Recruiting","Randomised","Quadruple",2,NA,NA,"Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","mAb, SOC",390
"NCT04347239","https://ClinicalTrials.gov/show/NCT04347239",NA,"United States","Texas","2020-Apr","2020-Dec","Recruiting","Randomised","Quadruple",2,NA,NA,"Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","mAb, SOC",390
"NCT04399980","https://ClinicalTrials.gov/show/NCT04399980",NA,"United States","Ohio","2020-May","2021-May","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital",NA,"mAb, SOC",60
"NCT04369469","https://ClinicalTrials.gov/show/NCT04369469",NA,"United States","Massachusetts","2020-Apr","2020-Nov","Not Recruiting","Randomised","Open-Label",2,NA,NA,"ICU","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), PaO2-FiO2, SpO2","mAb, SOC",270
"2020-001497-30","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001497-30/FR/",NA,"France","Paris","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), PaO2-FiO2, SpO2","mAb, SOC",270
"2020-001497-30","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001497-30/FR/",NA,"Germany","Berlin","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), PaO2-FiO2, SpO2","mAb, SOC",270
"2020-001497-30","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001497-30/FR/",NA,"Italy","Rome","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), PaO2-FiO2, SpO2","mAb, SOC",270
"2020-001497-30","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001497-30/FR/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), PaO2-FiO2, SpO2","mAb, SOC",270
"2020-001497-30","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001497-30/FR/",NA,"United Kingdom","London","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), PaO2-FiO2, SpO2","mAb, SOC",270
"2020-001497-30","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001497-30/FR/",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), PaO2-FiO2, SpO2","mAb, SOC",270
"NCT04380961","https://ClinicalTrials.gov/show/NCT04380961",NA,"United States","Illinois","2020-May","2020-Jun","Recruiting","Randomised","Quadruple",3,"Confirmed","Severe/Critical","Hospital","Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Adverse Events, ALT, Bilirubin","mAb, SOC",270
"NCT04380961","https://ClinicalTrials.gov/show/NCT04380961",NA,"United States","Louisiana","2020-May","2020-Jun","Recruiting","Randomised","Quadruple",3,"Confirmed","Severe/Critical","Hospital","Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Adverse Events, ALT, Bilirubin","mAb, SOC",270
"NCT04380961","https://ClinicalTrials.gov/show/NCT04380961",NA,"United States","Michigan","2020-May","2020-Jun","Recruiting","Randomised","Quadruple",3,"Confirmed","Severe/Critical","Hospital","Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Adverse Events, ALT, Bilirubin","mAb, SOC",270
"NCT04380961","https://ClinicalTrials.gov/show/NCT04380961",NA,"United States","Missouri","2020-May","2020-Jun","Recruiting","Randomised","Quadruple",3,"Confirmed","Severe/Critical","Hospital","Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Adverse Events, ALT, Bilirubin","mAb, SOC",270
"NCT04380961","https://ClinicalTrials.gov/show/NCT04380961",NA,"United States","Montana","2020-May","2020-Jun","Recruiting","Randomised","Quadruple",3,"Confirmed","Severe/Critical","Hospital","Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Adverse Events, ALT, Bilirubin","mAb, SOC",270
"NCT04380961","https://ClinicalTrials.gov/show/NCT04380961",NA,"United States","New Jersey","2020-May","2020-Jun","Recruiting","Randomised","Quadruple",3,"Confirmed","Severe/Critical","Hospital","Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Adverse Events, ALT, Bilirubin","mAb, SOC",270
"NCT04380961","https://ClinicalTrials.gov/show/NCT04380961",NA,"United States","Texas","2020-May","2020-Jun","Recruiting","Randomised","Quadruple",3,"Confirmed","Severe/Critical","Hospital","Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Adverse Events, ALT, Bilirubin","mAb, SOC",270
"NCT04365101","https://ClinicalTrials.gov/show/NCT04365101",NA,"United States","New Jersey","2020-Apr","2020-Nov","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Cough, Organ Failure or Dysfunction (SOFA), Adverse Events","Natural Killer Cells, SOC",86
"NCT04365101","https://ClinicalTrials.gov/show/NCT04365101",NA,"United States","Washington","2020-Apr","2020-Nov","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Cough, Organ Failure or Dysfunction (SOFA), Adverse Events","Natural Killer Cells, SOC",86
"NCT04390191","https://ClinicalTrials.gov/show/NCT04390191",NA,"United States","New York","2020-May","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Mild","Outpatient, Hospital","Mortality, ICU Admission, Household Members with CoViD-19, Invasive Mechanical Ventilation or ECMO, SpO2","Non-invasive respiratory support, SOC",200
"NCT04326075","https://clinicaltrials.gov/show/NCT04326075",NA,"Italy","Milan","2020-Mar",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected",NA,"Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO","Non-invasive respiratory support, SOC",900
"NCT04378712","https://ClinicalTrials.gov/show/NCT04378712",NA,"China","Guangdong","2020-May","2020-Mar","Completed","Non-Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Hospital Discharge, Cough, Dyspnea, SpO2, Distress","Non-invasive respiratory support, SOC",90
"CTRI/2020/05/025071","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43447",NA,"India","New Delhi","2020-Aug",NA,"Not Recruiting","Randomised","Unspecified",NA,"Confirmed","Moderate/Severe","Hospital","ICU Admission, Invasive Mechanical Ventilation or ECMO","Non-invasive respiratory support, SOC",40
"NCT04306393","https://ClinicalTrials.gov/show/NCT04306393",NA,"United States","Alabama","2020-Mar","2021-Mar","Recruiting","Randomised","Single",2,"Confirmed","Severe","ICU",NA,"Non-invasive respiratory support, SOC",200
"NCT04306393","https://ClinicalTrials.gov/show/NCT04306393",NA,"United States","Louisiana","2020-Mar","2021-Mar","Recruiting","Randomised","Single",2,"Confirmed","Severe","ICU",NA,"Non-invasive respiratory support, SOC",200
"NCT04306393","https://ClinicalTrials.gov/show/NCT04306393",NA,"United States","Massachusetts","2020-Mar","2021-Mar","Recruiting","Randomised","Single",2,"Confirmed","Severe","ICU",NA,"Non-invasive respiratory support, SOC",200
"NCT04388683","https://ClinicalTrials.gov/show/NCT04388683",NA,"United States","Massachusetts","2020-May","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital, ICU","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), D-Dimer, Fibrinogen, PaO2-FiO2","Non-invasive respiratory support, SOC",42
"NCT04383002","https://ClinicalTrials.gov/show/NCT04383002",NA,"Canada","Ontario","2020-May","2020-Dec","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","ICU",NA,"Non-invasive respiratory support, SOC",20
"NCT04312243","https://ClinicalTrials.gov/show/NCT04312243",NA,"China","Beijing","2020-Mar","2021-Mar","Not Recruiting","Randomised","Open-Label",2,"Healthy (Exposed)","Healthy","Healthcare Workers","Viral Load or Clearance, Labor Absenteeism","Non-invasive respiratory support, SOC",470
"NCT04368923","https://ClinicalTrials.gov/show/NCT04368923",NA,"Egypt","Cairo","2020-Apr","2020-May","Not Recruiting","Randomised","Single",2,NA,NA,"Outpatient","Blood Gas, Blood Pressure, Heart Rate, SpO2, Respiratory Rate, Blood pH, Cardiac Outcome (Unspecified)","Non-invasive respiratory support, SOC",60
"NCT04370223","https://ClinicalTrials.gov/show/NCT04370223",NA,"Spain","Madrid","2020-Apr","2020-Oct","Not Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Ferritin, Lymphocyte Count, Neutrophils","Non-invasive respiratory support, SOC",208
"NCT04370223","https://ClinicalTrials.gov/show/NCT04370223",NA,"Spain","Asturias","2020-Apr","2020-Oct","Not Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Ferritin, Lymphocyte Count, Neutrophils","Non-invasive respiratory support, SOC",208
"NCT04370223","https://ClinicalTrials.gov/show/NCT04370223",NA,"Spain","Valencia","2020-Apr","2020-Oct","Not Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Ferritin, Lymphocyte Count, Neutrophils","Non-invasive respiratory support, SOC",208
"NCT04370223","https://ClinicalTrials.gov/show/NCT04370223",NA,"Spain","Valladolid","2020-Apr","2020-Oct","Not Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Ferritin, Lymphocyte Count, Neutrophils","Non-invasive respiratory support, SOC",208
"NCT04368845","https://ClinicalTrials.gov/show/NCT04368845",NA,"Greece","Athens","2020-Apr","2020-Jul","Recruiting","Randomised","Single",2,NA,NA,"Resolved Discharged","Dyspnea, Other Mild Symptoms, Quality of Life, Depression, Anxiety","Non-invasive respiratory support, SOC",100
"CHICTR2000031271","http://www.chictr.org.cn/showproj.aspx?proj=51194",NA,"China","Guangdong","2020-Mar","2021-Mar","Not Recruiting","Randomised","Unspecified",2,"Confirmed",NA,"Unclear","Mortality, ICU Admission, Hospitalization, Organ Failure or Dysfunction (SOFA), Quality of Life","Nutrition, SOC",80
"PACTR202005599385499","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10971",NA,"Egypt","Cairo","2020-Apr",NA,"Not Recruiting","Randomised","Unspecified",NA,"Confirmed Or Healthy Or Suspected","Unclear","Healthy Exposed, Healthcare Workers",NA,"Nutrition, SOC",60
"NCT04390477","https://ClinicalTrials.gov/show/NCT04390477",NA,"Spain","Alicante","2020-May","2020-Jul","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Hospital Discharge, Adverse Events","Nutrition, SOC",40
"NCT04366180","https://ClinicalTrials.gov/show/NCT04366180",NA,"Spain","Granada","2020-Apr","2020-Jun","Recruiting","Randomised","Quadruple",2,NA,NA,"Healthcare Workers","ICU Admission, Pneumonia or ARDS, Cough, Other Mild Symptoms","Nutrition, SOC",314
"2020-001498-63","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001498-63/BE/",NA,"France","Paris","2020-May",NA,"Recruiting","Randomised","Double",2,"Confirmed","Severe","Outpatient, Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, SpO2","Other, SOC",545
"2020-001498-63","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001498-63/BE/",NA,"United States","Washington, Dc","2020-May",NA,"Recruiting","Randomised","Double",2,"Confirmed","Severe","Outpatient, Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, SpO2","Other, SOC",545
"NCT04393038","https://ClinicalTrials.gov/show/NCT04393038",NA,"France","Paris","2020-May","2020-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Unclear","Outpatient, Hospital","Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, D-Dimer, Troponin","Other, SOC",1034
"EUCTR2020-001571-32-FR","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001571-32",NA,"France","Aude","2020-Jul",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), IL-2, PaO2-FiO2, Patient Positioning","Other, SOC",30
"NCT04385836","https://ClinicalTrials.gov/show/NCT04385836",NA,"Saudi Arabia","Riyadh","2020-May","2020-Sep","Recruiting","Randomised","Single",2,"Confirmed","Unclear","Hospital","Clinical Improvement Score (Any)","Other, SOC",150
"2020-001953-36","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001953-36/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Blood Pressure, Heart Rate, SpO2, Distress, Cardiac Outcome (Unspecified)","Other, SOC",NA
"NCT04382040","https://ClinicalTrials.gov/show/NCT04382040",NA,"Israel","Haifa","2020-May","2020-Jul","Recruiting","Randomised","Quadruple",2,"Confirmed","Moderate","Hospital","ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, SpO2","Other, SOC",50
"NCT04382040","https://ClinicalTrials.gov/show/NCT04382040",NA,"Israel","Jerusalem","2020-May","2020-Jul","Recruiting","Randomised","Quadruple",2,"Confirmed","Moderate","Hospital","ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, SpO2","Other, SOC",50
"NCT04387240","https://ClinicalTrials.gov/show/NCT04387240",NA,"Saudi Arabia","Riyadh","2020-May","2020-Oct","Not Recruiting","Randomised","Triple",2,"Confirmed","Mild/Moderate","Unclear","ICU Admission","Other, SOC",22
"CHICTR2000032915","http://www.chictr.org.cn/showproj.aspx?proj=53658",NA,"China","Heilongjiang","2020-May","2020-Dec","Recruiting","Randomised","Unspecified",2,"Confirmed","Mild","Unclear","Viral Load or Clearance, Fever, Urine Sample, Blood Pressure, ECG, Radiographic Findings, Renal Outcome (Unspecified)","Other, SOC",240
"NCT04365699","https://ClinicalTrials.gov/show/NCT04365699",NA,"United States","New York","2020-Apr","2020-Dec","Recruiting","Single-Arm","Open-Label",1,NA,NA,"Hospital","Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events, Cardiac Outcome (Unspecified)","Other, SOC",500
"2020-001886-35","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001886-35/GB/",NA,"United Kingdom","London","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Moderate/Severe","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Glucose, Surfactant Factor Protein, PaO2-FiO2","Other, SOC",20
"NCT04375735","https://ClinicalTrials.gov/show/NCT04375735",NA,"Canada","Ontario","2020-May","2021-Jan","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","ICU","Mortality, ICU Admission, Hospitalization, Adverse Events, IL-1, IL-4, IL-6, IL-10, Tumor Necrosis Factor (Any), Granulocyte Stimulaiting Factor, MCP-1","Other, SOC",20
"IRCT20200317046797N4","http://en.irct.ir/trial/46969",NA,"Iran","East Azarbaijan","2020-Apr","2020-May","Completed","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","Other, SOC",60
"NCT04353284","https://ClinicalTrials.gov/show/NCT04353284",NA,"United States","Massachusetts","2020-Apr","2021-May","Not Recruiting","Randomised","Quadruple",2,NA,NA,"Outpatient","Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Other Mild Symptoms","Other, SOC",114
"NCT04366739","https://ClinicalTrials.gov/show/NCT04366739",NA,"France","Paris","2020-Apr","2020-Aug","Not Recruiting","Randomised","Single",2,NA,NA,"Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Adverse Events, C-Reactive Protein, Lymphocyte Count, Creatinine Phosphokinase, ECG, Radiographic Findings, Anxiety","Other, SOC",40
"NCT04354805","https://ClinicalTrials.gov/show/NCT04354805",NA,"Egypt","Cairo","2020-Apr","2020-Aug","Not Recruiting","Randomised","Triple",2,NA,NA,"Hospital","LDH","Other, SOC",60
"NCT04362059","https://clinicaltrials.gov/show/NCT04362059",NA,"United States","New Hampshire","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",1,NA,NA,"Hospital","Adverse Events, Serious Adverse Events, PaO2-FiO2","Other, SOC",24
"CHICTR2000030540","http://www.chictr.org.cn/showproj.aspx?proj=50658",NA,"China","Hubei","2020-Mar","2020-Jun","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Severe","ICU","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Erythrocyte Sedimentation Rate, Radiographic Findings","Other, SOC",152
"2020-001786-36","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001786-36/GB/",NA,"Belgium","Brussels","2020-Apr",NA,"Recruiting","Randomised","Double",2,"Confirmed","Moderate/Severe","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Serious or Seconday Infections, Adverse Events, C-Reactive Protein, Ferritin, Monocyte Count, Lymphocyte Count, D-Dimer, CD4, CD8, Radiographic Findings","Other, SOC",200
"2020-001786-36","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001786-36/GB/",NA,"France","Paris","2020-Apr",NA,"Recruiting","Randomised","Double",2,"Confirmed","Moderate/Severe","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Serious or Seconday Infections, Adverse Events, C-Reactive Protein, Ferritin, Monocyte Count, Lymphocyte Count, D-Dimer, CD4, CD8, Radiographic Findings","Other, SOC",200
"2020-001786-36","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001786-36/GB/",NA,"Italy","Rome","2020-Apr",NA,"Recruiting","Randomised","Double",2,"Confirmed","Moderate/Severe","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Serious or Seconday Infections, Adverse Events, C-Reactive Protein, Ferritin, Monocyte Count, Lymphocyte Count, D-Dimer, CD4, CD8, Radiographic Findings","Other, SOC",200
"2020-001786-36","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001786-36/GB/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Double",2,"Confirmed","Moderate/Severe","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Serious or Seconday Infections, Adverse Events, C-Reactive Protein, Ferritin, Monocyte Count, Lymphocyte Count, D-Dimer, CD4, CD8, Radiographic Findings","Other, SOC",200
"2020-001786-36","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001786-36/GB/",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Randomised","Double",2,"Confirmed","Moderate/Severe","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Serious or Seconday Infections, Adverse Events, C-Reactive Protein, Ferritin, Monocyte Count, Lymphocyte Count, D-Dimer, CD4, CD8, Radiographic Findings","Other, SOC",200
"NCT04389801","https://ClinicalTrials.gov/show/NCT04389801",NA,"Egypt","Cairo","2020-May","2020-Sep","Not Recruiting","Randomised","Single",2,"Confirmed","Moderate","Hospital","Mortality","Other, SOC",200
"NCT04379479","https://ClinicalTrials.gov/show/NCT04379479",NA,"Mexico","Mexico","2020-May","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Severe","Unclear",NA,"Other, SOC",562
"NCT04391179","https://ClinicalTrials.gov/show/NCT04391179",NA,"United States","Michigan","2020-May","2020-Dec","Recruiting","Randomised","Single",2,"Confirmed","Unclear","Outpatient, Hospital","D-Dimer","Other, SOC",80
"NCT04355364","https://ClinicalTrials.gov/show/NCT04355364",NA,"France","Paris","2020-Apr","2020-Aug","Recruiting","Randomised","Single",2,NA,NA,"ICU","Clinical Improvement Score (Any)","Inhaled solution, SOC",100
"ISRCTN40580903","http://isrctn.com/ISRCTN40580903",NA,"United Kingdom","London","2020-May",NA,"Recruiting","Randomised","Open-Label",NA,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Hospital Discharge, PaO2-FiO2, SpO2","Other, SOC",588
"NCT04375397","https://ClinicalTrials.gov/show/NCT04375397",NA,"United States","Illinois","2020-May","2020-Jul","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, PaO2-FiO2","Other, SOC",46
"2020-001296-33","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001296-33/DK/",NA,"Denmark","Copenhagen","2020-Apr",NA,"Recruiting","Randomised","Double",2,"Confirmed","Severe","ICU","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Renal Outcome (Unspecified)","Other, SOC",80
"IRCT20200427047215N1","http://en.irct.ir/trial/47520",NA,"Iran","Tehran","2020-May","2020-Jul","Recruiting","Randomised","Single",2,"Confirmed","Unclear","Hospital","Hospitalization, Hospital Discharge, SpO2","Other, SOC",60
"NCT04379076","https://ClinicalTrials.gov/show/NCT04379076",NA,"United Kingdom","London","2020-May","2020-Oct","Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Serious or Seconday Infections, C-Reactive Protein, Ferritin, Lymphocyte Count, D-Dimer, CD4, CD8","Other, SOC",48
"NCT04390217","https://ClinicalTrials.gov/show/NCT04390217",NA,"United States","California","2020-May","2020-Dec","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Moderate/Severe","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","Other, SOC",120
"NCT04361643","https://ClinicalTrials.gov/show/NCT04361643",NA,"Spain","Madrid","2020-Apr","2020-Aug","Not Recruiting","Randomised","Quadruple",2,NA,NA,"Unclear","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Neutrophils","Immunomodulators, SOC",120
"IRCT20131215015805N2","http://en.irct.ir/trial/46887",NA,"Iran","Tehran","2020-May","2020-Jun","Recruiting","Randomised","Double",2,"Confirmed","Mixed","Unclear","Mortality, Hospitalization, Pneumonia or ARDS, Radiographic Findings","Other, SOC",50
"NCT04374032","https://ClinicalTrials.gov/show/NCT04374032",NA,"Bosnia & Herzegovina","Sarajevo","2020-May","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed","Moderate/Severe","Hospital","Hospitalization, Adverse Events, Radiographic Findings","Other, SOC",120
"IRCT20081019001369N4","http://en.irct.ir/trial/46977",NA,"Iran","Tehran","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,NA,NA,"Outpatient","Clinical Improvement Score (Any), Fever, C-Reactive Protein","Antibiotics, SOC",40
"NCT04389411","https://ClinicalTrials.gov/show/NCT04389411",NA,"Canada","Quebec","2020-May","2021-Feb","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear","Unclear","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department","Other, SOC",600
"NCT04391712","https://ClinicalTrials.gov/show/NCT04391712",NA,"United States","Massachusetts","2020-May","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Unclear","C-Reactive Protein, IL-6, Radiographic Findings","Other, SOC",20
"CTRI/2020/05/024967","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43338",NA,"India","New Delhi","2020-Jan",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Suspected","None/Mild","Healthy Exposed","Cough, Fever, Dyspnea","Other, SOC",30
"NCT04385849","https://ClinicalTrials.gov/show/NCT04385849",NA,"United States","California","2020-May","2020-Jul","Not Recruiting","Randomised","Triple",2,"Confirmed","Unclear","Unclear","Adverse Events, White Blood Cell Count, Lymphocyte Count, Platelet Count, Hemoglobin","Other, SOC",30
"IRCT20120215009014N355","http://en.irct.ir/trial/48039",NA,"Iran","Hamadan","2020-May","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Mild/Moderate","Hospital","Mortality","Other, SOC",92
"IRCT20080901001165N55","http://en.irct.ir/trial/48061",NA,"Iran","Tehran","2020-May","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed","Moderate","Hospital","Fever","Other, SOC",72
"NCT04356833","https://clinicaltrials.gov/show/NCT04356833",NA,"United Kingdom","London","2020-Apr",NA,"Recruiting","Non-Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, Fibrinogen, PaO2-FiO2","Other, SOC",24
"CTRI/2020/04/024949","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43400",NA,"India","New Delhi","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",NA,"Confirmed","Mild","Outpatient",NA,"Other, SOC",48
"2020-001860-27","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001860-27/GB/",NA,"United Kingdom","London","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Mild/Moderate/Severe","Outpatient, Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Platelet Count, Hemoglobin, ALT, PaO2-FiO2, SpO2, Radiographic Findings","Other, SOC",40
"IRCT20160625028622N1","http://en.irct.ir/trial/46576",NA,"Iran","Tehran","2020-Mar","2020-Apr","Completed","Non-Randomised","Double",2,"Confirmed",NA,"Outpatient, Hospital","Cough, Radiographic Findings","Other, SOC",125
"ACTRN12620000473965","https://anzctr.org.au/ACTRN12620000473965.aspx",NA,"Australia","Canberra","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",NA,NA,NA,"Healthcare Workers","Viral Load or Clearance, Other Mild Symptoms, Serious or Seconday Infections, Anti SARS-COV-2 Titers","Other, SOC",1000
"NCT04384445","https://ClinicalTrials.gov/show/NCT04384445",NA,"United States","Florida","2020-May","2020-Sep","Not Recruiting","Randomised","Double",2,"Confirmed","Moderate/Severe","Hospital","Mortality, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, D-Dimer","Other, SOC",20
"NCT04384445","https://ClinicalTrials.gov/show/NCT04384445",NA,"United States","Georgia","2020-May","2020-Sep","Not Recruiting","Randomised","Double",2,"Confirmed","Moderate/Severe","Hospital","Mortality, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, D-Dimer","Other, SOC",20
"CHICTR2000030006","http://www.chictr.org.cn/showproj.aspx?proj=49737",NA,"China","Hubei","2020-Feb","2020-May","Recruiting","Randomised","Unspecified",2,"Confirmed",NA,"Hospital","Mortality, Viral Load or Clearance, Fever, Radiographic Findings, Lung Inflamation","Other, SOC",60
"CHICTR2000030892","http://www.chictr.org.cn/showproj.aspx?proj=51118",NA,"China","Guangdong","2020-Mar","2020-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Unclear","Hospitalization, Hospital Discharge, Treatment-emergent Adverse Events, Radiographic Findings","Other, SOC",40
"NCT04384731","https://ClinicalTrials.gov/show/NCT04384731",NA,"France","Paris","2020-May","2020-Nov","Not Recruiting","Randomised","Single",2,"Confirmed","Severe","ICU","Mortality, ICU Admission, Hospital Discharge, PaO2-FiO2, SpO2","Other, SOC",20
"NCT04365257","https://ClinicalTrials.gov/show/NCT04365257",NA,"United States","Maryland","2020-Apr","2020-Dec","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events","Other, SOC",220
"IRCT20200414047070N1","http://en.irct.ir/trial/47169",NA,"Iran","Tehran","2020-Apr","2020-Sep","Recruiting","Randomised","Open-Label",2,NA,NA,"Unclear","Viral Load or Clearance","Other, SOC",50
"IRCT20200508047346N1","http://en.irct.ir/trial/47953",NA,"Iran","Tehran","2020-May","2021-Mar","Recruiting","Randomised","Open-Label",2,"Confirmed","Moderate/Severe","Hospital","Mortality, Fever, PaO2-FiO2","Other, SOC",124
"NCT04366050","https://ClinicalTrials.gov/show/NCT04366050",NA,"United States","California","2020-Apr","2021-Apr","Not Recruiting","Randomised","Triple",2,NA,NA,"Hospital","Mortality, ICU Admission","ACEi, SOC",560
"NCT04382950","https://clinicaltrials.gov/show/NCT04382950",NA,"Egypt","Cairo","2020-Aug",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Unclear","Fever","Other, SOC",24
"EUCTR2020-001411-25-AT","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"United States","Washington, Dc","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, SOC",230
"EUCTR2020-001411-25-AT","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Spain","Madrid","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, SOC",230
"EUCTR2020-001411-25-AT","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Austria","Vienna","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, SOC",230
"EUCTR2020-001411-25-AT","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Israel","Jerusalem","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, SOC",230
"EUCTR2020-001411-25-AT","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Italy","Rome","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, SOC",230
"EUCTR2020-001411-25-AT","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"United Kingdom","London","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, SOC",230
"EUCTR2020-001411-25-AT","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"India","New Delhi","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, SOC",230
"EUCTR2020-001411-25-AT","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"France","Paris","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, SOC",230
"EUCTR2020-001411-25-AT","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Canada","Ottawa","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, SOC",230
"EUCTR2020-001411-25-AT","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Belgium","Brussels","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, SOC",230
"EUCTR2020-001411-25-AT","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Malaysia","Kuala Lumpur","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, SOC",230
"EUCTR2020-001411-25-AT","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Australia","Canberra","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, SOC",230
"EUCTR2020-001411-25-AT","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Germany","Berlin","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, SOC",230
"NCT04355962","https://ClinicalTrials.gov/show/NCT04355962",NA,"Switzerland","Zurich","2020-Apr","2021-Mar","Recruiting","Randomised","Double",2,NA,NA,"ICU","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, IL-6, MCP-1, Procalcitonin, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Anesthetic, SOC",64
"NCT04371640","https://ClinicalTrials.gov/show/NCT04371640",NA,"United States","Pennsylvania","2020-May","2020-Jul","Recruiting","Randomised","Quadruple",2,NA,NA,"Hospital","Adverse Events","Other, SOC",40
"NCT04364763","https://ClinicalTrials.gov/show/NCT04364763",NA,"United States","Texas","2020-Apr","2021-Jun","Not Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Fever, Organ Failure or Dysfunction (SOFA), Distress, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Other, SOC",252
"NCT04308317","https://ClinicalTrials.gov/show/NCT04308317",NA,"China","Zhejiang","2020-Mar","2021-Mar","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Unclear","Mortality, Fever","Other, SOC",60
"CTRI/2020/05/025167","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43378",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Non-Randomised","Open-Label",NA,"Confirmed","None/Mild","Outpatient",NA,"Other, SOC",32
"NCT04326426","https://ClinicalTrials.gov/show/NCT04326426",NA,"United States","New York","2020-Mar","2020-Aug","Recruiting","Randomised","Triple",2,"Confirmed","Severe","Hospital","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Other Mild Symptoms, IL-6","Other, SOC",300
"CHICTR2000030002","http://www.chictr.org.cn/showproj.aspx?proj=49738",NA,"China","Anhui","2020-Feb","2020-Jul","Recruiting","Randomised","Unspecified",2,"Confirmed","Mixed","Outpatient, Hospital","Mortality, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","Other, SOC",60
"NCT04393311","https://ClinicalTrials.gov/show/NCT04393311",NA,"United States","California","2020-May","2020-Dec","Not Recruiting","Randomised","Double",2,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, SpO2","Other, SOC",150
"CHICTR2000032737","http://www.chictr.org.cn/showproj.aspx?proj=53458",NA,"China","Guangdong","2020-May","2021-Jun","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear","Unclear","Pneumonia or ARDS, C-Reactive Protein, IL-2, IL-6, Tumor Necrosis Factor (Any), Interferon (Any), Lymphocyte Count, Erythrocyte Sedimentation Rate, D-Dimer, Myoglobin, Procalcitonin, Electrolytes, Glucose, Blood Gas, Renal Outcome (Unspecified)","Other, SOC",60
"NCT04385186","https://ClinicalTrials.gov/show/NCT04385186",NA,"Colombia","Bogota","2020-May","2020-Nov","Not Recruiting","Randomised","Single",2,"Confirmed","Moderate/Severe","Hospital","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), IL-6, Hemoglobin, D-Dimer, Procalcitonin, AST, Bilirubin, Antibodies, Radiographic Findings","Plasma based therapy, SOC",60
"NCT04385186","https://ClinicalTrials.gov/show/NCT04385186",NA,"Colombia","Cundinamarca","2020-May","2020-Nov","Not Recruiting","Randomised","Single",2,"Confirmed","Moderate/Severe","Hospital","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), IL-6, Hemoglobin, D-Dimer, Procalcitonin, AST, Bilirubin, Antibodies, Radiographic Findings","Plasma based therapy, SOC",60
"NCT04385186","https://ClinicalTrials.gov/show/NCT04385186",NA,"Colombia","Risaralda","2020-May","2020-Nov","Not Recruiting","Randomised","Single",2,"Confirmed","Moderate/Severe","Hospital","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), IL-6, Hemoglobin, D-Dimer, Procalcitonin, AST, Bilirubin, Antibodies, Radiographic Findings","Plasma based therapy, SOC",60
"NCT04374526","https://ClinicalTrials.gov/show/NCT04374526",NA,"Italy","Roma","2020-May","2020-Sep","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital",NA,"Plasma based therapy, SOC",182
"NCT04374526","https://ClinicalTrials.gov/show/NCT04374526",NA,"Italy","Chieti","2020-May","2020-Sep","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital",NA,"Plasma based therapy, SOC",182
"NCT04374526","https://ClinicalTrials.gov/show/NCT04374526",NA,"Italy","Rome","2020-May","2020-Sep","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital",NA,"Plasma based therapy, SOC",182
"NCT04391101","https://ClinicalTrials.gov/show/NCT04391101",NA,"Colombia","Antioquia","2020-May","2021-Jun","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","ICU","Mortality, Hospitalization, Fever, Adverse Events","Plasma based therapy, SOC",231
"NCT04388410","https://ClinicalTrials.gov/show/NCT04388410",NA,"Mexico","Mexico","2020-May","2020-Oct","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Severe","Hospital","Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Antibodies","Plasma based therapy, SOC",250
"NCT04385199","https://ClinicalTrials.gov/show/NCT04385199",NA,"United States","Michigan","2020-May","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Unclear","ICU Admission, Radiographic Findings","Plasma based therapy, SOC",30
"NCT04364737","https://ClinicalTrials.gov/show/NCT04364737",NA,"United States","New York","2020-Apr","2023-Jan","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Clinical Improvement Score (Any)","Plasma based therapy, SOC",300
"NCT04377568","https://ClinicalTrials.gov/show/NCT04377568",NA,"Canada","Alberta","2020-May","2021-Dec","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, SOC",100
"NCT04377568","https://ClinicalTrials.gov/show/NCT04377568",NA,"Canada","British Columbia","2020-May","2021-Dec","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, SOC",100
"NCT04377568","https://ClinicalTrials.gov/show/NCT04377568",NA,"Canada","Manitoba","2020-May","2021-Dec","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, SOC",100
"NCT04377568","https://ClinicalTrials.gov/show/NCT04377568",NA,"Canada","Nova Scotia","2020-May","2021-Dec","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, SOC",100
"NCT04377568","https://ClinicalTrials.gov/show/NCT04377568",NA,"Canada","Ontario","2020-May","2021-Dec","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, SOC",100
"NCT04377568","https://ClinicalTrials.gov/show/NCT04377568",NA,"Canada","Quebec","2020-May","2021-Dec","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, SOC",100
"NCT04377568","https://ClinicalTrials.gov/show/NCT04377568",NA,"Canada","Saskatchewan","2020-May","2021-Dec","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, SOC",100
"NCT04374487","https://ClinicalTrials.gov/show/NCT04374487",NA,"India","Delhi","2020-May","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital, ICU","Mortality, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever, Dyspnea, Other Mild Symptoms, Organ Failure or Dysfunction (SOFA), Adverse Events, PaO2-FiO2","Plasma based therapy, SOC",100
"NCT04362176","https://ClinicalTrials.gov/show/NCT04362176",NA,"United States","Tennessee","2020-Apr","2021-Apr","Recruiting","Randomised","Triple",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Quality of Life, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, SOC",500
"CHICTR2000030702","http://www.chictr.org.cn/showproj.aspx?proj=50537",NA,"China","Beijing","2020-Mar","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Dyspnea, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","Plasma based therapy, SOC",50
"IRCT20151228025732N53","http://en.irct.ir/trial/46931",NA,"Iran","Semnan","2020-Apr","2020-Jun","Recruiting","Non-Randomised","Open-Label",2,NA,NA,"Hospital","Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, White Blood Cell Count, CD4, CD8","Plasma based therapy, SOC",12
"IRCT20150808023559N21","http://en.irct.ir/trial/47594",NA,"Iran","Tehran","2020-May","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Mortality, Hospitalization, Hospital Discharge","Plasma based therapy, SOC",60
"CTRI/2020/04/024775","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43149",NA,"India","Delhi","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",NA,"Confirmed","Moderate","Hospital","Mortality, Pneumonia or ARDS, PaO2-FiO2","Plasma based therapy, SOC",452
"CTRI/2020/04/024804","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42849",NA,"India","Karnataka","2020-Apr",NA,"Not Recruiting","Single-Arm","Unspecified",1,"Confirmed","Severe","ICU","Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Organ Failure or Dysfunction (SOFA), Antibodies, PaO2-FiO2, SpO2, Radiographic Findings","Plasma based therapy, SOC",10
"CTRI/2020/04/024915","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43332",NA,"India","Delhi","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",NA,"Confirmed","Moderate/Severe","Hospital","Mortality, Pneumonia or ARDS, PaO2-FiO2","Plasma based therapy, SOC",100
"ISRCTN85216856","http://isrctn.com/ISRCTN85216856",NA,"Ecuador","Quito","2020-Nov",NA,"Recruiting","Randomised","Triple",NA,"Confirmed","Unclear","Hospital",NA,"Plasma based therapy, SOC",200
"CHICTR2000029757","http://www.chictr.org.cn/showproj.aspx?proj=49081",NA,"China","Beijing","2020-Feb","2021-Feb","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","Plasma based therapy, SOC",200
"2020-002482-34","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002482-34/3rd/",NA,"United States","Washington, Dc","2020-May",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Adverse Events, Serious Adverse Events, SpO2, Respiratory Rate, Radiographic Findings, Quality of Life","Plasma based therapy, SOC",54
"NCT04385043","https://ClinicalTrials.gov/show/NCT04385043",NA,"Italy","Catanzaro","2020-May","2020-Oct","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Mortality, Clinical Improvement Score (Any), Lymphocyte Count","Plasma based therapy, SOC",400
"NCT04385043","https://ClinicalTrials.gov/show/NCT04385043",NA,"Italy","Cosenza","2020-May","2020-Oct","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Mortality, Clinical Improvement Score (Any), Lymphocyte Count","Plasma based therapy, SOC",400
"NCT04385043","https://ClinicalTrials.gov/show/NCT04385043",NA,"Italy","Rome","2020-May","2020-Oct","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Mortality, Clinical Improvement Score (Any), Lymphocyte Count","Plasma based therapy, SOC",400
"NCT04385043","https://ClinicalTrials.gov/show/NCT04385043",NA,"Italy","Reggio Calabria","2020-May","2020-Oct","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Mortality, Clinical Improvement Score (Any), Lymphocyte Count","Plasma based therapy, SOC",400
"NCT04385043","https://ClinicalTrials.gov/show/NCT04385043",NA,"Italy","Vibo Valentia","2020-May","2020-Oct","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Mortality, Clinical Improvement Score (Any), Lymphocyte Count","Plasma based therapy, SOC",400
"CHICTR2000030179","http://www.chictr.org.cn/showproj.aspx?proj=50059",NA,"China","Jiangxi","2020-Feb","2020-Apr","Recruiting","Randomised","Unspecified",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Viral Load or Clearance","Plasma based therapy, SOC",100
"NCT04395144","https://ClinicalTrials.gov/show/NCT04395144",NA,"Canada","Quebec","2020-May","2020-Oct","Recruiting","Randomised","Open-Label",2,"Confirmed","Moderate/Severe","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","Positioning, SOC",346
"NCT04383613","https://ClinicalTrials.gov/show/NCT04383613",NA,"Canada","Ontario","2020-May","2020-Dec","Recruiting","Randomised","Single",2,"Confirmed Or Suspected","Unclear","Hospital","Mortality, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Adverse Events, PaO2-FiO2, Patient Positioning","Positioning, SOC",350
"NCT04368000","https://ClinicalTrials.gov/show/NCT04368000",NA,"United States","Utah","2020-Apr","2020-Dec","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, SpO2","Positioning, SOC",60
"NCT04366856","https://clinicaltrials.gov/show/NCT04366856",NA,"France","Paris","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",1,NA,NA,"Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO","Positioning, SOC",500
"NL8538","https://trialregister.nl/trial/8538",NA,"Netherlands","Amsterdam","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital",NA,"Positioning, SOC",342
"CHICTR2000030084","http://www.chictr.org.cn/showproj.aspx?proj=49952",NA,"China","Shanxi","2020-Feb","2022-Feb","Recruiting","Randomised","Unspecified",2,"Confirmed",NA,"Outpatient","Depression, Anxiety","Psychological therapy, SOC",180
"CHICTR2000029459","http://www.chictr.org.cn/showproj.aspx?proj=48929",NA,"China","Hubei","2020-Feb","2021-Dec","Not Recruiting","Randomised","Unspecified",2,"Resolved",NA,"Resolved Discharged","Adverse Events, Serious Adverse Events, PaO2-FiO2, Respiratory Rate, 6-Minute Walking Distance, Quality of Life","Psychological therapy, SOC",100
"NCT04385901","https://ClinicalTrials.gov/show/NCT04385901",NA,"United States","Missouri","2020-May","2022-Apr","Not Recruiting","Non-Randomised","Double",2,"Confirmed","Unclear","Outpatient","6-Minute Walking Distance","Rehabilitation, SOC",72
"NCT04381338","https://ClinicalTrials.gov/show/NCT04381338",NA,"Italy","Padova","2020-May","2020-Sep","Not Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Severe","ICU","ICU Admission, Hospitalization","Rehabilitation, SOC",92
"NCT04381338","https://ClinicalTrials.gov/show/NCT04381338",NA,"Italy","Verona","2020-May","2020-Sep","Not Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Severe","ICU","ICU Admission, Hospitalization","Rehabilitation, SOC",92
"NCT04357457","https://ClinicalTrials.gov/show/NCT04357457",NA,"France","Paris","2020-Apr","2020-Jul","Not Recruiting","Randomised","Quadruple",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","Respiratory stimulant, SOC",212
"EUCTR2020-001909-22-FR","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001909-22",NA,"France","Aude","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,"Confirmed, Suspected","Unclear","Hospital","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO","Respiratory stimulant, SOC",212
"NCT04388514","https://ClinicalTrials.gov/show/NCT04388514",NA,"Italy","Udine","2020-May","2020-Oct","Recruiting","Randomised","Single",2,"Confirmed","Mild/Moderate","Unclear","ICU Admission, Hospitalization","Respiratory support, SOC",90
"CHICTR2000030418","http://www.chictr.org.cn/showproj.aspx?proj=50341",NA,"China","Fujian","2020-Mar","2021-Mar","Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Unclear","IL-6, Quality of Life, Distress","Respiratory support, SOC",80
"CHICTR2000030432","http://www.chictr.org.cn/showproj.aspx?proj=50268",NA,"China","Fujian","2020-Mar","2020-Aug","Not Recruiting","Randomised","Open-Label",2,"Healthy (Exposed)","Healthy","Healthcare Workers","Quality of Life","Respiratory support, SOC",80
"CHICTR2000030578","http://www.chictr.org.cn/showproj.aspx?proj=50690",NA,"China","Shandong","2020-Mar","2021-Feb","Not Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Hospital","Quality of Life","Respiratory support, SOC",40
"NCT04324073","https://ClinicalTrials.gov/show/NCT04324073",NA,"France","Paris","2020-Mar","2021-Mar","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH","Sarilumab, SOC",239
"NCT04359901","https://clinicaltrials.gov/show/NCT04359901",NA,"United States","Washington, Dc","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, Non-invasive Ventilation","Sarilumab, SOC",120
"2020-001379-34","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001379-34/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,NA,"Unclear","Mortality, Non-invasive Ventilation, IL-1, IL-6, IL-8, Tumor Necrosis Factor (Any), PaO2-FiO2","Anesthetic, SOC",NA
"2020-001473-79","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001473-79/GB/",NA,"Italy","Rome","2020-Apr",NA,"Recruiting","Randomised","Double",2,"Confirmed","Mild/Moderate","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","SGLT2, SOC",900
"2020-001473-79","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001473-79/GB/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Double",2,"Confirmed","Mild/Moderate","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","SGLT2, SOC",900
"2020-001473-79","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001473-79/GB/",NA,"United Kingdom","London","2020-Apr",NA,"Recruiting","Randomised","Double",2,"Confirmed","Mild/Moderate","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","SGLT2, SOC",900
"2020-001473-79","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001473-79/GB/",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Randomised","Double",2,"Confirmed","Mild/Moderate","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","SGLT2, SOC",900
"NCT04377308","https://ClinicalTrials.gov/show/NCT04377308",NA,"United States","Ohio","2020-May","2021-Apr","Recruiting","Non-Randomised","Open-Label",2,"Confirmed Or Suspected","Unclear","Outpatient, Hospital","Mortality, Hospitalization, Depression, Anxiety","SOC, SSRIs",2000
"NCT04380402","https://ClinicalTrials.gov/show/NCT04380402",NA,"United States","Massachusetts","2020-May","2021-Dec","Not Recruiting","Randomised","Open-Label",2,"Suspected","Unclear","Hospital","Mortality, ICU Admission, Visits or Returns to Emergency Department, Clinical Improvement Score (Any)","SOC, Statins",300
"IRCT20190727044343N2","http://en.irct.ir/trial/46639",NA,"Iran","Tehran","2020-Apr","2020-Apr","Completed","Randomised","Double",2,NA,NA,"Hospital","Mortality, Hospital Discharge, C-Reactive Protein","SOC, Statins",100
"IRCT20200413047062N1","http://en.irct.ir/trial/47146",NA,"Iran","Tehran","2020-May","2020-May","Completed","Non-Randomised","Single",2,"Confirmed","Unclear","Hospital","Mortality","SOC, Statins",76
"2020-001319-26","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001319-26/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Resolved Discharged","Mortality, Cardiac Outcome (Unspecified)","SOC, Statins",NA
"CHICTR2000031319","http://www.chictr.org.cn/showproj.aspx?proj=51647",NA,"China","Hubei","2020-Mar","2020-Jul","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Severe","Hospital","Viral Load or Clearance, Fever, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Neutrophils, Creatinine Phosphokinase, CK-MB, Troponin, Procalcitonin, ALT, LDH, CD4, CD8, Respiratory Rate, Radiographic Findings","SOC, Stem cells",20
"NCT04377334","https://ClinicalTrials.gov/show/NCT04377334",NA,"Germany","Berlin","2020-May","2020-Nov","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Lymphocyte Count, D-Dimer, Antibodies","SOC, Stem cells",40
"NCT04366323","https://ClinicalTrials.gov/show/NCT04366323",NA,"Spain","Sevilla","2020-Apr","2021-Oct","Not Recruiting","Randomised","Open-Label",2,NA,NA,"ICU","Adverse Events","SOC, Stem cells",26
"CHICTR2000029580","http://www.chictr.org.cn/showproj.aspx?proj=49088",NA,"China","Hubei","2020-Feb","2020-Dec","Recruiting","Randomised","Single",2,"Confirmed","Severe","Hospital","Adverse Events","SOC, Stem cells",70
"CHICTR2000030173","http://www.chictr.org.cn/showproj.aspx?proj=49229",NA,"China","Hunan","2020-Feb","2020-Apr","Not Recruiting","Randomised","Unspecified",2,"Confirmed",NA,"Unclear","Viral Load or Clearance, Radiographic Findings","SOC, Stem cells",60
"CHICTR2000030088","http://www.chictr.org.cn/showproj.aspx?proj=49902",NA,"China","Beijing","2020-Feb","2021-Dec","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Severe","Outpatient, Hospital","Viral Load or Clearance, Radiographic Findings","SOC, Stem cells",40
"IRCT20140528017891N8","http://en.irct.ir/trial/46623",NA,"Iran","Tehran","2020-Mar","2020-Apr","Completed","Randomised","Double",2,"Confirmed","Unclear","ICU","Mortality, Pneumonia or ARDS, C-Reactive Protein, Procalcitonin, CD4, CD8, Radiographic Findings","SOC, Stem cells",10
"IRCT20200418047121N2","http://en.irct.ir/trial/47275",NA,"Iran","Tehran","2020-May","2020-Sep","Recruiting","Non-Randomised","Double",2,"Confirmed","Severe","Hospital, Unclear","Radiographic Findings","SOC, Stem cells",6
"IRCT20200421047150N1","http://en.irct.ir/trial/47964",NA,"Iran","Tehran","2020-May","2020-Oct","Recruiting","Randomised","Triple",2,"Confirmed","Unclear","Hospital","Mortality, Pneumonia or ARDS, Radiographic Findings","SOC, Stem cells",90
"NCT04366271","https://clinicaltrials.gov/show/NCT04366271",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",1,NA,NA,"Hospital","Mortality","SOC, Stem cells",106
"NCT04371393","https://clinicaltrials.gov/show/NCT04371393",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Randomised","Triple",1,NA,NA,"ICU","Mortality","SOC, Stem cells",300
"NCT04367077","https://ClinicalTrials.gov/show/NCT04367077",NA,"United States","Ohio","2020-Apr","2021-Sep","Recruiting","Randomised","Quadruple",2,NA,NA,"Hospital","Mortality, Adverse Events, Radiographic Findings","SOC, Stem cells",400
"CHICTR2000030007","http://www.chictr.org.cn/showproj.aspx?proj=49619",NA,"China","Guangdong","2020-Feb","2020-Apr","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Mixed","Unclear","Viral Load or Clearance, Radiographic Findings","SOC, Stem cells",200
"NCT04299152","https://ClinicalTrials.gov/show/NCT04299152",NA,"China","Beijing","2020-Mar","2020-Oct","Not Recruiting","Randomised","Single",2,"Confirmed",NA,"Unclear","Viral Load or Clearance, Other Mild Symptoms, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Natural Killer Cell Count, Radiographic Findings","SOC, Stem cells",20
"NCT04390139","https://ClinicalTrials.gov/show/NCT04390139",NA,"Spain","Barcelona","2020-May","2020-Oct","Recruiting","Randomised","Quadruple",2,"Confirmed","Moderate","ICU","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Ferritin, Neutrophils, D-Dimer, LDH, PaO2-FiO2","SOC, Stem cells",30
"CHICTR2000030944","http://www.chictr.org.cn/showproj.aspx?proj=50199",NA,"China","Jiangxi","2020-Mar","2020-Aug","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","ICU","Mortality, Treatment-emergent Adverse Events","SOC, Stem cells + Natural Killer Cells",20
"IRCT20200312046749N1","http://en.irct.ir/trial/46551",NA,"Iran","Tehran","2020-Mar","2020-Sep","Recruiting","Non-Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Radiographic Findings","SOC, TNF inhibitor",80
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United States","California","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United States","Colorado","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United States","Florida","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United States","Illinois","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United States","Louisiana","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United States","Massachusetts","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United States","Minnesota","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United States","New Jersey","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United States","New York","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United States","North Carolina","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United States","Ohio","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United States","Pennsylvania","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United States","Texas","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United States","Utah","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United States","Washington","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"Canada","Ontario","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"Canada","Quebec","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"Denmark","Copenhagen","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"France","Vendee","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"France","Paris","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"Germany","Berlin","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"Italy","Napoli","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"Italy","Roma","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"Italy","Bergamo","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"Italy","Milano","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"Italy","Rome","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"Italy","Pavia","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"Netherlands","Amsterdam","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"Netherlands","Utrecht","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"Spain","Barcelona","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"Spain","Madrid","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United Kingdom","Glasgow","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United Kingdom","Leeds","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United Kingdom","London","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United Kingdom","Manchester","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United Kingdom","Salford","2020-Mar","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","SOC, TCZ",450
"NCT04372186","https://ClinicalTrials.gov/show/NCT04372186",NA,"United States","Arizona","2020-May","2020-Aug","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, SpO2, Respiratory Rate, Renal Outcome (Unspecified)","SOC, TCZ",379
"NCT04372186","https://ClinicalTrials.gov/show/NCT04372186",NA,"United States","California","2020-May","2020-Aug","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, SpO2, Respiratory Rate, Renal Outcome (Unspecified)","SOC, TCZ",379
"NCT04372186","https://ClinicalTrials.gov/show/NCT04372186",NA,"United States","Connecticut","2020-May","2020-Aug","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, SpO2, Respiratory Rate, Renal Outcome (Unspecified)","SOC, TCZ",379
"NCT04372186","https://ClinicalTrials.gov/show/NCT04372186",NA,"United States","District Of Columbia","2020-May","2020-Aug","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, SpO2, Respiratory Rate, Renal Outcome (Unspecified)","SOC, TCZ",379
"NCT04372186","https://ClinicalTrials.gov/show/NCT04372186",NA,"United States","Florida","2020-May","2020-Aug","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, SpO2, Respiratory Rate, Renal Outcome (Unspecified)","SOC, TCZ",379
"NCT04372186","https://ClinicalTrials.gov/show/NCT04372186",NA,"United States","Georgia","2020-May","2020-Aug","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, SpO2, Respiratory Rate, Renal Outcome (Unspecified)","SOC, TCZ",379
"NCT04372186","https://ClinicalTrials.gov/show/NCT04372186",NA,"United States","Kansas","2020-May","2020-Aug","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, SpO2, Respiratory Rate, Renal Outcome (Unspecified)","SOC, TCZ",379
"NCT04372186","https://ClinicalTrials.gov/show/NCT04372186",NA,"United States","Louisiana","2020-May","2020-Aug","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, SpO2, Respiratory Rate, Renal Outcome (Unspecified)","SOC, TCZ",379
"NCT04372186","https://ClinicalTrials.gov/show/NCT04372186",NA,"United States","Maryland","2020-May","2020-Aug","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, SpO2, Respiratory Rate, Renal Outcome (Unspecified)","SOC, TCZ",379
"NCT04372186","https://ClinicalTrials.gov/show/NCT04372186",NA,"United States","Michigan","2020-May","2020-Aug","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, SpO2, Respiratory Rate, Renal Outcome (Unspecified)","SOC, TCZ",379
"NCT04372186","https://ClinicalTrials.gov/show/NCT04372186",NA,"United States","Nevada","2020-May","2020-Aug","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, SpO2, Respiratory Rate, Renal Outcome (Unspecified)","SOC, TCZ",379
"NCT04372186","https://ClinicalTrials.gov/show/NCT04372186",NA,"United States","New Jersey","2020-May","2020-Aug","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, SpO2, Respiratory Rate, Renal Outcome (Unspecified)","SOC, TCZ",379
"NCT04372186","https://ClinicalTrials.gov/show/NCT04372186",NA,"United States","New Mexico","2020-May","2020-Aug","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, SpO2, Respiratory Rate, Renal Outcome (Unspecified)","SOC, TCZ",379
"NCT04372186","https://ClinicalTrials.gov/show/NCT04372186",NA,"United States","New York","2020-May","2020-Aug","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, SpO2, Respiratory Rate, Renal Outcome (Unspecified)","SOC, TCZ",379
"NCT04372186","https://ClinicalTrials.gov/show/NCT04372186",NA,"United States","Pennsylvania","2020-May","2020-Aug","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, SpO2, Respiratory Rate, Renal Outcome (Unspecified)","SOC, TCZ",379
"NCT04372186","https://ClinicalTrials.gov/show/NCT04372186",NA,"United States","South Dakota","2020-May","2020-Aug","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, SpO2, Respiratory Rate, Renal Outcome (Unspecified)","SOC, TCZ",379
"NCT04372186","https://ClinicalTrials.gov/show/NCT04372186",NA,"United States","Wisconsin","2020-May","2020-Aug","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, SpO2, Respiratory Rate, Renal Outcome (Unspecified)","SOC, TCZ",379
"NCT04377750","https://ClinicalTrials.gov/show/NCT04377750",NA,"Israel","Jerusalem","2020-May","2020-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","ICU",NA,"SOC, TCZ",500
"NCT04361552","https://ClinicalTrials.gov/show/NCT04361552",NA,"United States","Georgia","2020-Apr","2022-May","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","SOC, TCZ",180
"NCT04356937","https://ClinicalTrials.gov/show/NCT04356937",NA,"United States","Massachusetts","2020-Apr","2020-Jun","Not Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Renal Outcome (Unspecified)","SOC, TCZ",300
"CHICTR2000029765","http://www.chictr.org.cn/showproj.aspx?proj=49409",NA,"China","Anhui","2020-Feb","2020-May","Recruiting","Randomised","Unspecified",2,"Confirmed","Mixed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","SOC, TCZ",188
"IRCT20200406046968N1","http://en.irct.ir/trial/47021",NA,"Iran","Tehran","2020-Apr","2020-Jun","Recruiting","Single-Arm","Open-Label",1,NA,NA,"ICU","Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","SOC, TCZ",10
"IRCT20200510047383N1","http://en.irct.ir/trial/48024",NA,"Iran","Tehran","2020-May","2020-Aug","Recruiting","Randomised","Double",2,"Confirmed","Severe","ICU","Mortality, SpO2","SOC, TCZ",100
"CHICTR2000029994","http://www.chictr.org.cn/showproj.aspx?proj=49309",NA,"China","Shanghai","2020-Feb","2020-Aug","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Unclear","Hospitalization, Natural Killer Cell Count, Radiographic Findings, Renal Outcome (Unspecified)","SOC, TCM",200
"CHICTR2000030225","http://www.chictr.org.cn/showproj.aspx?proj=49945",NA,"China","Shanghai","2020-Feb","2020-Dec","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Unclear","Hospitalization, Hospital Discharge, Clinical Improvement Score (Any)","SOC, TCM",186
"CHICTR2000029769","http://www.chictr.org.cn/showproj.aspx?proj=49415",NA,"China","Zhejiang","2020-Feb","2020-Apr","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Severe","Hospital","Mortality","SOC, TCM",40
"CHICTR2000030704","http://www.chictr.org.cn/showproj.aspx?proj=50778",NA,"China","Jiangsu","2020-Mar","2020-Mar","Suspended","Randomised","Unspecified",2,"Confirmed",NA,"Hospital","Non-invasive Ventilation, White Blood Cell Count, Creatinine Phosphokinase, CK-MB, ALT, PaO2-FiO2, Respiratory Rate","SOC, TCM",50
"CHICTR2000030324","http://www.chictr.org.cn/showproj.aspx?proj=50231",NA,"China","Hubei","2020-Feb","2020-May","Not Recruiting","Single-Arm","Unspecified",1,"Confirmed",NA,"Outpatient","Cough, Fever, Dyspnea","SOC, TCM",40
"CHICTR2000029978","http://www.chictr.org.cn/showproj.aspx?proj=49702",NA,"China","Shanghai","2020-Feb","2020-Jul","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Mixed","Hospital","Hospitalization, Cough, Fever, Dyspnea, PD-1, Weight, Height or BMI, Creatinine Phosphokinase, CK-MB, ALT, CD4, CD8, Respiratory Rate, Radiographic Findings, Depression, Anxiety, Distress","SOC, TCM",186
"CHICTR2000030804","http://www.chictr.org.cn/showproj.aspx?proj=51018",NA,"China","Guangdong","2020-Mar","2021-Mar","Recruiting","Randomised","Unspecified",2,"Confirmed","Non-severe","Outpatient","Hospitalization, Cough, C-Reactive Protein","SOC, TCM",128
"CHICTR2000030937","http://www.chictr.org.cn/showproj.aspx?proj=51240",NA,"China","Guangdong","2020-Mar","2020-Aug","Recruiting","Randomised","Open-Label",2,"Resolved",NA,"Resolved Discharged","Other Mild Symptoms","SOC, TCM",144
"CHICTR2000031944","http://www.chictr.org.cn/showproj.aspx?proj=52414",NA,"China","Beijing","2020-Apr","2020-Dec","Recruiting","Randomised","Unspecified",2,NA,NA,"Healthy Exposed","Viral Load or Clearance, Fever, Other Mild Symptoms","SOC, TCM",2000
"CHICTR2000029822","http://www.chictr.org.cn/showproj.aspx?proj=49502",NA,"China","Hebei","2020-Feb","2020-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Hospital","Hospitalization, Viral Load or Clearance, Fever, Respiratory Rate","SOC, TCM",110
"NCT04291053","https://ClinicalTrials.gov/show/NCT04291053",NA,"China","Beijing","2020-Mar","2020-Aug","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Non-severe","Outpatient","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, PaO2-FiO2, Respiratory Rate","SOC, TCM",550
"CHICTR2000029479","http://www.chictr.org.cn/showproj.aspx?proj=48773",NA,"China","Sichuan","2020-Feb","2020-May","Completed","Randomised","Open-Label",2,"Healthy","Healthy","Healthy Unexposed","Pneumonia or ARDS","SOC, TCM",20000
"CHICTR2000029781","http://www.chictr.org.cn/showproj.aspx?proj=49138",NA,"China","Hubei","2020-Feb","2020-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Fever","SOC, TCM",160
"CHICTR2000029433","http://www.chictr.org.cn/showproj.aspx?proj=48898",NA,"China","Hebei","2020-Feb","2020-Dec","Completed","Randomised","Open-Label",2,"Suspected",NA,"Unclear","Viral Load or Clearance, Cough, Fever, Other Mild Symptoms, Radiographic Findings","SOC, TCM",240
"CHICTR2000029434","http://www.chictr.org.cn/showproj.aspx?proj=48889",NA,"China","Hebei","2020-Feb","2020-Dec","Completed","Randomised","Open-Label",2,"Confirmed","Non-severe","Unclear","Viral Load or Clearance, Cough, Fever, Other Mild Symptoms, Radiographic Findings","SOC, TCM",240
"CHICTR2000032919","http://www.chictr.org.cn/showproj.aspx?proj=53274",NA,"China","Hubei","2020-May","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Unclear","Unclear","Other Mild Symptoms, Stool Sample","SOC, TCM",200
"CHICTR2000031203","http://www.chictr.org.cn/showproj.aspx?proj=51030",NA,"China","Henan","2020-Mar","2022-Feb","Recruiting","Randomised","Unspecified",2,"Resolved",NA,"Resolved Discharged","Anxiety","SOC, TCM",28
"CHICTR2000030043","http://www.chictr.org.cn/showproj.aspx?proj=49866",NA,"China","Beijing","2020-Feb","2020-Dec","Not Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Severe","Hospital","ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","SOC, TCM",300
"CHICTR2000032205","http://www.chictr.org.cn/showproj.aspx?proj=52662",NA,"China","Hubei","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Unclear","Unclear",NA,"SOC, TCM",200
"CHICTR2000029780","http://www.chictr.org.cn/showproj.aspx?proj=49220",NA,"China","Hubei","2020-Feb","2020-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Non-severe","Outpatient","Viral Load or Clearance, Dyspnea, Other Mild Symptoms, Adverse Events, Serious Adverse Events","SOC, TCM",160
"CHICTR2000033133","http://www.chictr.org.cn/showproj.aspx?proj=53925",NA,"China","Zhejiang","2020-May","2020-Apr","Completed","Randomised","Open-Label",2,"Confirmed","Unclear","Unclear","ICU Admission, Viral Load or Clearance, Cough, Fever, Other Mild Symptoms","SOC, TCM",60
"CHICTR2000032214","http://www.chictr.org.cn/showproj.aspx?proj=52781",NA,"China","Hubei","2020-Apr","2020-Jul","Not Recruiting","Randomised","Double",2,NA,NA,"Unclear","Other Mild Symptoms","SOC, TCM",200
"CHICTR2000030720","http://www.chictr.org.cn/showproj.aspx?proj=50793",NA,"China","Hubei","2020-Mar","2020-Aug","Recruiting","Randomised","Unspecified",2,"Recovering",NA,"Resolved Discharged","Clinical Improvement Score (Any), Fever, Antibodies, Radiographic Findings","SOC, TCM",120
"CHICTR2000029549","http://www.chictr.org.cn/showproj.aspx?proj=49014",NA,"China","Sichuan","2020-Feb","2020-May","Recruiting","Randomised","Unspecified",2,"Confirmed Or Suspected",NA,"Unclear","Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Radiographic Findings","SOC, TCM",400
"CHICTR2000029960","http://www.chictr.org.cn/showproj.aspx?proj=49639",NA,"China","Hunan","2020-Feb","2020-May","Not Recruiting","Non-Randomised","Unspecified",2,"Confirmed Or Suspected",NA,"Unclear",NA,"SOC, TCM",100
"CHICTR2000029947","http://www.chictr.org.cn/showproj.aspx?proj=49599",NA,"China","Shanghai","2020-Feb","2020-Jun","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Severe","Hospital","Viral Load or Clearance, Serious or Seconday Infections, Adverse Events, Quality of Life","SOC, TCM",200
"CHICTR2000029941","http://www.chictr.org.cn/showproj.aspx?proj=49596",NA,"China","Shanghai","2020-Feb","2020-Jun","Not Recruiting","Randomised","Unspecified",2,"Confirmed And Suspected","Mixed","Outpatient, Hospital","Hospitalization, Viral Load or Clearance, Fever, Adverse Events, Serious Adverse Events, Radiographic Findings","SOC, TCM",200
"CHICTR2000029763","http://www.chictr.org.cn/showproj.aspx?proj=49408",NA,"China","Beijing","2020-Feb","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Hospital","Fever, Radiographic Findings, Quality of Life","SOC, TCM",408
"CHICTR2000029790","http://www.chictr.org.cn/showproj.aspx?proj=49453",NA,"China","Shanghai","2020-Feb","2020-Oct","Recruiting","Randomised","Unspecified",2,"Confirmed",NA,"Unclear","Hospitalization, Viral Load or Clearance, Fever","SOC, TCM",120
"CHICTR2000029461","http://www.chictr.org.cn/showproj.aspx?proj=48927",NA,"China","Hubei","2020-Feb","2021-Dec","Not Recruiting","Randomised","Unspecified",2,"Confirmed",NA,"Outpatient","Viral Load or Clearance, Cough, Fever, Adverse Events, 6-Minute Walking Distance, Quality of Life","SOC, TCM",100
"CHICTR2000029439","http://www.chictr.org.cn/showproj.aspx?proj=48904",NA,"China","Beijing","2020-Feb","2021-Dec","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Non-severe","Outpatient","Viral Load or Clearance, Pneumonia or ARDS, Fever, Adverse Events, Serious Adverse Events, PaO2-FiO2, Respiratory Rate","SOC, TCM",120
"CHICTR2000029493","http://www.chictr.org.cn/showproj.aspx?proj=48931",NA,"China","Hubei","2020-Feb","2021-Dec","Not Recruiting","Randomised","Unspecified",2,"Resolved",NA,"Resolved Discharged","Adverse Events, 6-Minute Walking Distance, Quality of Life","SOC, TCM",100
"CHICTR2000029777","http://www.chictr.org.cn/showproj.aspx?proj=49380",NA,"China","Hubei","2020-Feb","2020-Jun","Recruiting","Randomised","Unspecified",2,"Confirmed","Severe","Hospital","Mortality, Clinical Improvement Score (Any), Organ Failure or Dysfunction (SOFA), Coagulation Test, Radiographic Findings","SOC, TCM",160
"CHICTR2000030936","http://www.chictr.org.cn/showproj.aspx?proj=51100",NA,"China","Sichuan","2020-Mar","2020-May","Recruiting","Non-Randomised","Unspecified",2,"Confirmed Or Suspected",NA,"Outpatient, Hospital","Fever","SOC, TCM",2840
"CHICTR2000029381","http://www.chictr.org.cn/showproj.aspx?proj=48768",NA,"China","Guangdong","2020-Jan",NA,"Not Recruiting","Non-Randomised","Unspecified",2,"Confirmed",NA,"Hospital","ICU Admission, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, White Blood Cell Count, Creatinine Phosphokinase, CK-MB, eGFR, Myoglobin, Troponin, ALT, Albumin, Bilirubin, IgG, IgM or IgA, PaO2-FiO2, Respiratory Rate, Radiographic Findings","SOC, TCM",400
"CHICTR2000029993","http://www.chictr.org.cn/showproj.aspx?proj=49435",NA,"China","Guangdong","2020-Feb","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Unclear","Mortality, Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Serious or Seconday Infections, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","SOC, TCM + Umifenovir",40
"IRCT20080901001165N46","http://en.irct.ir/trial/47087",NA,"Iran","Tehran","2020-Apr","2020-Aug","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, Cough, Fever, Adverse Events, IL-1, IL-6, Tumor Necrosis Factor (Any)","SOC, Umifenovir",200
"NCT04379336","https://ClinicalTrials.gov/show/NCT04379336",NA,"South Africa","Western Cape","2020-May","2021-Apr","Recruiting","Randomised","Quadruple",2,"Healthy","None","Healthcare Workers","Mortality, ICU Admission, Hospitalization, Labor Absenteeism, Adverse Events","SOC, Vaccine",500
"NCT04328441","https://ClinicalTrials.gov/show/NCT04328441",NA,"Netherlands","Amsterdam","2020-Mar","2020-Oct","Recruiting","Randomised","Quadruple",2,"Healthy",NA,"Healthcare Workers","Mortality, ICU Admission, Hospitalization, Labor Absenteeism, Fever, Other Mild Symptoms, Anti SARS-COV-2 Titers, IgG, IgM or IgA, Antibodies","SOC, Vaccine",1500
"NCT04328441","https://ClinicalTrials.gov/show/NCT04328441",NA,"Netherlands","Gelderland","2020-Mar","2020-Oct","Recruiting","Randomised","Quadruple",2,"Healthy",NA,"Healthcare Workers","Mortality, ICU Admission, Hospitalization, Labor Absenteeism, Fever, Other Mild Symptoms, Anti SARS-COV-2 Titers, IgG, IgM or IgA, Antibodies","SOC, Vaccine",1500
"NCT04328441","https://ClinicalTrials.gov/show/NCT04328441",NA,"Netherlands","Zuid-Holland","2020-Mar","2020-Oct","Recruiting","Randomised","Quadruple",2,"Healthy",NA,"Healthcare Workers","Mortality, ICU Admission, Hospitalization, Labor Absenteeism, Fever, Other Mild Symptoms, Anti SARS-COV-2 Titers, IgG, IgM or IgA, Antibodies","SOC, Vaccine",1500
"NCT04328441","https://ClinicalTrials.gov/show/NCT04328441",NA,"Netherlands","Utrecht","2020-Mar","2020-Oct","Recruiting","Randomised","Quadruple",2,"Healthy",NA,"Healthcare Workers","Mortality, ICU Admission, Hospitalization, Labor Absenteeism, Fever, Other Mild Symptoms, Anti SARS-COV-2 Titers, IgG, IgM or IgA, Antibodies","SOC, Vaccine",1500
"NCT04362124","https://ClinicalTrials.gov/show/NCT04362124",NA,"Colombia","Antioquia","2020-Apr","2021-Jun","Not Recruiting","Randomised","Quadruple",2,NA,NA,"Healthcare Workers","Mortality, Viral Load or Clearance, Adverse Events, Serious Adverse Events","SOC, Vaccine",1000
"2020-001888-90","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001888-90/DK/",NA,"Denmark","Copenhagen","2020-Apr",NA,"Recruiting","Randomised","Single",2,"Healthy","None","Healthcare Workers","Mortality, ICU Admission, Labor Absenteeism, Fever","SOC, Vaccine",NA
"2020-001783-28","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001783-28/HU/",NA,"Hungary","Budapest","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Healthy","None","Healthcare Workers","Mortality, ICU Admission, Labor Absenteeism, Fever","SOC, Vaccine",NA
"NCT04369794","https://clinicaltrials.gov/show/NCT04369794",NA,"Brazil","Brasilia","2020-Apr",NA,"Not Recruiting","Randomised","Quadruple",1,NA,NA,"Healthy Exposed",NA,"SOC, Vaccine",1000
"NCT04373291","https://clinicaltrials.gov/show/NCT04373291",NA,"Denmark","Copenhagen","2020-Jan",NA,"Not Recruiting","Randomised","Double",3,"Healthy",NA,"Healthcare Workers","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Viral Load or Clearance, Labor Absenteeism, Fever, Other Mild Symptoms","SOC, Vaccine",1500
"CTRI/2020/04/024833","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43105",NA,"India","New Delhi","2020-Apr",NA,"Not Recruiting","Randomised","Double",NA,"Healthy (Exposed)","None","Healthcare Workers","Cough, Fever, Dyspnea, Antibodies, Distress","SOC, Vaccine",1826
"CTRI/2020/05/025013","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42858",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Non-Randomised","Unspecified",NA,"Confirmed","Unclear","Hospital","Hospitalization, Hospital Discharge, Distress","SOC, Vaccine",60
"NCT04384549","https://clinicaltrials.gov/show/NCT04384549",NA,"France","Paris","2020-Jun",NA,"Not Recruiting","Randomised","Single",1,"Healthy","Healthy","Healthy Exposed, Healthcare Workers",NA,"SOC, Vaccine",1120
"NL8547","https://trialregister.nl/trial/8547",NA,"Netherlands","Amsterdam","2020-Apr",NA,"Recruiting","Randomised","Single",2,"Healthy","None","Healthy Unexposed",NA,"SOC, Vaccine",1600
"PACTR202004693933092","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10953",NA,"Egypt","Cairo","2020-Dec",NA,"Not Recruiting","Randomised","Unspecified",NA,NA,NA,"Healthcare Workers","Hospitalization, Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms","SOC, Vaccine",200
"CTRI/2020/04/024846","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43004",NA,"India","New Delhi","2020-Apr",NA,"Recruiting","Randomised","Unspecified",NA,"Confirmed","Severe","ICU","ICU Admission, Organ Failure or Dysfunction (SOFA)","SOC, Vaccine",40
"CTRI/2020/04/024749","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42972",NA,"India","New Delhi","2020-Apr",NA,"Not Recruiting","Randomised","Double",NA,"Healthy","None","Healthy Unexposed, Healthy Exposed, Healthcare Workers",NA,"SOC, Vaccine",5946
"NCT04366908","https://ClinicalTrials.gov/show/NCT04366908",NA,"Spain","Cordoba","2020-Apr","2020-Jul","Not Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Dyspnea, Adverse Events, PaO2-FiO2","SOC, Vitamins",1008
"IRCT20180520039738N2","http://en.irct.ir/trial/46974",NA,"Iran","Markazi","2020-Apr","2020-Apr","Completed","Randomised","Double",2,NA,NA,"Unclear","Cough, Fever, C-Reactive Protein, Erythrocyte Sedimentation Rate, Creatinine Phosphokinase, LDH, Respiratory Rate, Blood pH","SOC, Vitamins",140
"NCT04363216","https://ClinicalTrials.gov/show/NCT04363216",NA,"United States","Pennsylvania","2020-Apr","2021-May","Not Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Fever","SOC, Vitamins",66
"NCT04334005","https://ClinicalTrials.gov/show/NCT04334005",NA,"Spain","Granada","2020-Apr","2020-Jun","Not Recruiting","Randomised","Double",2,"Confirmed","Non-severe","Outpatient","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms","SOC, Vitamins",200
"IRCT20200319046819N1","http://en.irct.ir/trial/46838",NA,"Iran","Tehran","2020-Apr","2020-Jul","Recruiting","Randomised","Single",2,NA,NA,"ICU","Mortality, Hospitalization, C-Reactive Protein, IL-6, Tumor Necrosis Factor (Any), Interferon (Any), White Blood Cell Count, Erythrocyte Sedimentation Rate","SOC, Vitamins",60
"CHICTR2000030138","http://www.chictr.org.cn/showproj.aspx?proj=50004",NA,"China","Beijing","2020-Feb","2020-May","Not Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Severe","Unclear","Clinical Improvement Score (Any)","SOC, Stem cells",60
"NCT04371926","https://ClinicalTrials.gov/show/NCT04371926",NA,"United States","Texas","2020-May","2021-Jun","Not Recruiting","Randomised","Single",2,NA,NA,"Healthcare Workers, Hospital","Fever","HCQ, SOC",64
"NCT04371523","https://ClinicalTrials.gov/show/NCT04371523",NA,"Canada","Ontario","2020-May","2020-Jul","Not Recruiting","Randomised","Quadruple",2,NA,NA,"Healthcare Workers","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Adverse Events","HCQ, SOC",1100
"NCT04354870","https://ClinicalTrials.gov/show/NCT04354870",NA,"United States","New York","2020-Apr","2020-Aug","Recruiting","Non-Randomised","Open-Label",2,NA,NA,"Healthcare Workers","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Other Mild Symptoms, Adverse Events, Serious Adverse Events, Anti SARS-COV-2 Titers","HCQ, SOC",350
"NCT04359329","https://clinicaltrials.gov/show/NCT04359329",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,NA,"Outpatient","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","Estrogen steroid hormone, SOC",110
"NCT04353128","https://ClinicalTrials.gov/show/NCT04353128",NA,"Spain","Madrid","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,NA,NA,"Healthcare Workers","Viral Load or Clearance","Melatonin, SOC",450
"IRCT20200328046882N1","http://en.irct.ir/trial/46784",NA,"Iran","Tehran","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","DAA",60
"IRCT20130812014333N147","http://en.irct.ir/trial/46853",NA,"Iran","Tehran","2020-Apr","2020-Jun","Recruiting","Randomised","Single",4,NA,NA,"Hospital","Hospitalization","DAA, HCQ, Lithium, Other",80
"2020-001766-11","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001766-11/FR/",NA,"France","Paris","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","ICU","Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Blood Pressure, Heart Rate, PaO2-FiO2, Cardiac Outcome (Unspecified)","ARBs, Other",NA
"NCT04392414","https://ClinicalTrials.gov/show/NCT04392414",NA,"Russia","Moscow","2020-May","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed","Moderate/Severe","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Fever, C-Reactive Protein, Antibodies","Plasma based therapy, SOC",60
"NCT04373460","https://ClinicalTrials.gov/show/NCT04373460",NA,"United States","Maryland","2020-May","2022-Dec","Not Recruiting","Randomised","Triple",2,"Confirmed","Mild","Outpatient","Mortality, Hospitalization, Adverse Events, Antibodies","Plasma based therapy, SOC",1344
"NCT04355767","https://ClinicalTrials.gov/show/NCT04355767",NA,"United States","California","2020-Apr","2022-Dec","Not Recruiting","Randomised","Double",2,NA,NA,"Outpatient","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Fever, Dyspnea, Other Mild Symptoms","Plasma based therapy, SOC",206
"NCT04361253","https://clinicaltrials.gov/show/NCT04361253",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Randomised","Double",1,NA,NA,"Hospital, ICU","Mortality, Clinical Improvement Score (Any)","Plasma based therapy, SOC",220
"NCT04393415","https://clinicaltrials.gov/show/NCT04393415",NA,"Egypt","Cairo","2020-May",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Unclear","Hospital",NA,"SOC, Stem cells",100
"EUCTR2020-001206-35-AT","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001206-35",NA,"Austria","Vienna","2020-Mar",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Unclear","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Angiotensins, ACE, ACE-II, PaO2-FiO2","ACEi + ARBs, Other",798
"NCT04359797","https://ClinicalTrials.gov/show/NCT04359797",NA,"United States","Tennessee","2020-Apr","2021-Apr","Recruiting","Randomised","Single",2,NA,NA,"Hospital","Mortality, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2","Positioning",300
"CHICTR2000030093","http://www.chictr.org.cn/showproj.aspx?proj=49932",NA,"China","Shanxi","2020-Feb","2021-Mar","Not Recruiting","Non-Randomised","Unspecified",2,"Healthy (Exposed)",NA,"Healthcare Workers","Anxiety","Psychological therapy",60
"CHICTR2000030288","http://www.chictr.org.cn/showproj.aspx?proj=50202",NA,"China","Beijing","2020-Feb","2020-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Unclear","Clinical Improvement Score (Any), Viral Load or Clearance","SOC, TCM",204
"CHICTR2000029814","http://www.chictr.org.cn/showproj.aspx?proj=49387",NA,"China","Shanghai","2020-Feb","2020-Dec","Recruiting","Non-Randomised","Unspecified",2,"Confirmed",NA,"Unclear","Viral Load or Clearance, Cough, Fever, Dyspnea","SOC, TCM",30
"CHICTR2000029517","http://www.chictr.org.cn/showproj.aspx?proj=48861",NA,"China","Zhejiang","2020-Feb","2020-Apr","Recruiting","Randomised","Double",2,"Suspected",NA,"Unclear","Mortality, Pneumonia or ARDS","SOC, TCM",100
"CHICTR2000029755","http://www.chictr.org.cn/showproj.aspx?proj=49301",NA,"China","Hubei","2020-Feb","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Clinical Improvement Score (Any)","SOC, TCM",120
"CHICTR2000029855","http://www.chictr.org.cn/showproj.aspx?proj=49543",NA,"China","Zhejiang","2020-Feb",NA,"Recruiting","Randomised","Unspecified",3,"Confirmed","Non-severe","Outpatient","Clinical Improvement Score (Any), Viral Load or Clearance, Fever","SOC, TCM",180
"CHICTR2000029819","http://www.chictr.org.cn/showproj.aspx?proj=49490",NA,"China","Zhejiang","2020-Feb","2020-Aug","Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Severe","Unclear","Viral Load or Clearance, Radiographic Findings","SOC, TCM",80
"CHICTR2000030034","http://www.chictr.org.cn/showproj.aspx?proj=49647",NA,"China","Zhejiang","2020-Feb","2020-Jun","Recruiting","Randomised","Unspecified",2,"Confirmed",NA,"Unclear","Viral Load or Clearance, Pneumonia or ARDS, Fever","SOC, TCM",132
"2020-001709-21","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001709-21/FR/",NA,"France","Paris","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Unclear","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Dyspnea, Deep Vein Thrombosis or Pulmonary Embolism, Hemoglobin, Radiographic Findings, Renal Outcome (Unspecified)","Anticoagulants",NA
"NCT04377659","https://ClinicalTrials.gov/show/NCT04377659",NA,"United States","New York","2020-May","2021-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital, ICU","Mortality","TCZ",40
"CHICTR2000030580","http://www.chictr.org.cn/showproj.aspx?proj=50693",NA,"China","Shanghai","2020-Mar","2020-Apr","Recruiting","Randomised","Unspecified",2,"Confirmed","Severe","Hospital","Viral Load or Clearance, IL-6, IL-10, Tumor Necrosis Factor (Any), Radiographic Findings","SOC, TCZ + Adalimumab",60
"CHICTR2000029495","http://www.chictr.org.cn/showproj.aspx?proj=48971",NA,"China","Hubei","2020-Feb","2021-Dec","Not Recruiting","Randomised","Open-Label",3,"Resolved",NA,"Resolved Discharged","Quality of Life, Depression, Anxiety","Psychological therapy, TCM, TCM + Psychological therapy",90
"CHICTR2000030001","http://www.chictr.org.cn/showproj.aspx?proj=49723",NA,"China","Heilongjiang","2020-Feb","2020-May","Recruiting","Randomised","Double",2,"Confirmed",NA,"Hospital","Mortality, Viral Load or Clearance, Fever, Radiographic Findings, Lung Inflamation","Other, SOC",240
"NCT04252885","https://ClinicalTrials.gov/show/NCT04252885","https://www.medrxiv.org/content/medrxiv/early/2020/03/23/2020.03.19.20038984.full.pdf","China","Guangdong","2020-Feb","2020-May","Completed w. Results","Randomised","Open-Label",2,"Confirmed",NA,"Unclear","Mortality, Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, Tumor Necrosis Factor (Any), Interferon (Any), Creatinine Phosphokinase, CK-MB, eGFR, Myoglobin, ALT, Bilirubin, Blood Pressure, Heart Rate, PaO2-FiO2, Respiratory Rate, Radiographic Findings","LPV/r, SOC, Umifenovir",125
"CHICTR2000030254","http://www.chictr.org.cn/showproj.aspx?proj=50137","https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v1.full.pdf","China","Hubei","2020-Feb",NA,"Completed w. Results","Randomised","Unspecified",2,"Confirmed",NA,"Hospital","Mortality, ICU Admission, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Organ Failure or Dysfunction (SOFA), Serious Adverse Events","FPV, Umifenovir",240
"CHICTR2000029759","http://www.chictr.org.cn/showproj.aspx?proj=49352",NA,"China","Chongqing","2020-Feb","2020-May","Suspended","Randomised","Open-Label",3,"Confirmed","Mixed","Hospital","ICU Admission, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea","IFN + Other, LPV/r + IFN, Umifenovir + IFN",60
"NCT04273763","https://ClinicalTrials.gov/show/NCT04273763",NA,"China","Zhejiang","2020-Feb","2020-May","Not Recruiting","Randomised","Open-Label",3,"Confirmed Or Suspected","Non-severe","Outpatient","Mortality, ICU Admission, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, PaO2-FiO2, Respiratory Rate","IFN + Umifenovir, IFN + Umifenovir + Other",18
"CHICTR2000030922","http://www.chictr.org.cn/showproj.aspx?proj=51141",NA,"China","Guangdong","2020-Mar","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed","Non-severe","Outpatient","Mortality, Viral Load or Clearance, Pneumonia or ARDS, ALT","IFN + Other, Umifenovir + IFN",30
"NCT04368988","https://ClinicalTrials.gov/show/NCT04368988",NA,"Australia","Queensland","2020-Apr","2020-Dec","Recruiting","Randomised","Triple",3,NA,NA,"Healthy Exposed","IgG, IgM or IgA, Antibodies","SOC, Vaccine",131
"NCT04368988","https://ClinicalTrials.gov/show/NCT04368988",NA,"Australia","Victoria","2020-Apr","2020-Dec","Recruiting","Randomised","Triple",3,NA,NA,"Healthy Exposed","IgG, IgM or IgA, Antibodies","SOC, Vaccine",131
"NCT04368728","https://ClinicalTrials.gov/show/NCT04368728",NA,"United States","Maryland","2020-Apr","2021-Aug","Recruiting","Randomised","Triple",5,NA,NA,"Healthy Unexposed","Adverse Events, Serious Adverse Events, Antibodies","SOC, Vaccine",7600
"NCT04368728","https://ClinicalTrials.gov/show/NCT04368728",NA,"United States","New York","2020-Apr","2021-Aug","Recruiting","Randomised","Triple",5,NA,NA,"Healthy Unexposed","Adverse Events, Serious Adverse Events, Antibodies","SOC, Vaccine",7600
"NCT04368728","https://ClinicalTrials.gov/show/NCT04368728",NA,"United States","Ohio","2020-Apr","2021-Aug","Recruiting","Randomised","Triple",5,NA,NA,"Healthy Unexposed","Adverse Events, Serious Adverse Events, Antibodies","SOC, Vaccine",7600
"ISRCTN90906759","http://isrctn.com/ISRCTN90906759",NA,"United Kingdom","London","2020-Jul",NA,"Recruiting","Randomised","Single",NA,"Healthy","None","Healthy Unexposed","Adverse Events","Vaccine",10260
"CHICTR2000032716","http://www.chictr.org.cn/showproj.aspx?proj=53389",NA,"China","Shanghai","2020-May","2020-Apr","Completed","Unspecified","Unspecified",2,"Confirmed","Severe","Hospital","C-Reactive Protein, Lymphocyte Count, CD4, PaO2-FiO2","Vitamins",12
"NCT04372017","https://ClinicalTrials.gov/show/NCT04372017",NA,"United States","South Dakota","2020-May","2022-Apr","Recruiting","Randomised","Double",2,NA,NA,"Healthy Exposed, Healthcare Workers",NA,"HCQ, Vitamins",1739
"NCT04385940","https://ClinicalTrials.gov/show/NCT04385940",NA,"Canada","Alberta","2020-May","2020-Aug","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear","Unclear","ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Platelet Count","Vitamins",64
"NCT04385771","https://ClinicalTrials.gov/show/NCT04385771",NA,"Germany","Berlin","2020-May","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","ICU","ICU Admission, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, IL-6, D-Dimer, Urine Sample","ECMO, ECMO + Cytokine removal",80
"NCT04373707","https://clinicaltrials.gov/show/NCT04373707",NA,"France","Paris","2020-Jan",NA,"Recruiting","Randomised","Single",1,"Confirmed, Suspected","Unclear","Hospital, ICU",NA,"Anticoagulants",602
"CHICTR2000032399","http://www.chictr.org.cn/showproj.aspx?proj=52942",NA,"China","Hubei","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,"Confirmed","Unclear","Unclear",NA,"SOC, TCM",200
"NCT04351191","https://ClinicalTrials.gov/show/NCT04351191",NA,"Pakistan","Punjab","2020-Apr","2020-May","Recruiting","Randomised","Quadruple",4,"Yes","Non-severe","Outpatient","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance","HCQ, SOC",400
"NCT04346667","https://ClinicalTrials.gov/show/NCT04346667",NA,"Pakistan","Punjab","2020-Apr","2020-May","Recruiting","Randomised","Double",4,NA,NA,"Outpatient","Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Dyspnea, Adverse Events","HCQ, SOC",400
"NCT04352933","https://ClinicalTrials.gov/show/NCT04352933",NA,"United Kingdom","London","2020-Apr","2020-Oct","Recruiting","Randomised","Quadruple",3,NA,NA,"Healthcare Workers","Hospitalization, Viral Load or Clearance, Other Mild Symptoms","HCQ, SOC",1000
"NCT04362332","https://ClinicalTrials.gov/show/NCT04362332",NA,"Netherlands","Utrecht","2020-Apr","2021-Apr","Recruiting","Randomised","Open-Label",3,NA,NA,"Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Treatment-emergent Adverse Events","HCQ, SOC",950
"NCT04354428","https://ClinicalTrials.gov/show/NCT04354428",NA,"United States","Illinois","2020-Apr","2020-Jul","Recruiting","Randomised","Double",4,NA,NA,"Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Serious or Seconday Infections, Adverse Events, Serious Adverse Events","HCQ, HCQ + AZT, SOC",630
"NCT04354428","https://ClinicalTrials.gov/show/NCT04354428",NA,"United States","Louisiana","2020-Apr","2020-Jul","Recruiting","Randomised","Double",4,NA,NA,"Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Serious or Seconday Infections, Adverse Events, Serious Adverse Events","HCQ, HCQ + AZT, SOC",630
"NCT04354428","https://ClinicalTrials.gov/show/NCT04354428",NA,"United States","Massachusetts","2020-Apr","2020-Jul","Recruiting","Randomised","Double",4,NA,NA,"Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Serious or Seconday Infections, Adverse Events, Serious Adverse Events","HCQ, HCQ + AZT, SOC",630
"NCT04354428","https://ClinicalTrials.gov/show/NCT04354428",NA,"United States","New York","2020-Apr","2020-Jul","Recruiting","Randomised","Double",4,NA,NA,"Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Serious or Seconday Infections, Adverse Events, Serious Adverse Events","HCQ, HCQ + AZT, SOC",630
"NCT04354428","https://ClinicalTrials.gov/show/NCT04354428",NA,"United States","Washington","2020-Apr","2020-Jul","Recruiting","Randomised","Double",4,NA,NA,"Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Serious or Seconday Infections, Adverse Events, Serious Adverse Events","HCQ, HCQ + AZT, SOC",630
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Madrid","2020-Apr","2020-Jun","Recruiting","Randomised","Double",4,"Healthy","Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/Tenofovir, HCQ, HCQ + Emtricitabine/Tenofovir, SOC",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Alicante","2020-Apr","2020-Jun","Recruiting","Randomised","Double",4,"Healthy","Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/Tenofovir, HCQ, HCQ + Emtricitabine/Tenofovir, SOC",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Asturias","2020-Apr","2020-Jun","Recruiting","Randomised","Double",4,"Healthy","Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/Tenofovir, HCQ, HCQ + Emtricitabine/Tenofovir, SOC",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Barcelona","2020-Apr","2020-Jun","Recruiting","Randomised","Double",4,"Healthy","Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/Tenofovir, HCQ, HCQ + Emtricitabine/Tenofovir, SOC",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Las Palmas","2020-Apr","2020-Jun","Recruiting","Randomised","Double",4,"Healthy","Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/Tenofovir, HCQ, HCQ + Emtricitabine/Tenofovir, SOC",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","La Rioja","2020-Apr","2020-Jun","Recruiting","Randomised","Double",4,"Healthy","Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/Tenofovir, HCQ, HCQ + Emtricitabine/Tenofovir, SOC",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Murcia","2020-Apr","2020-Jun","Recruiting","Randomised","Double",4,"Healthy","Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/Tenofovir, HCQ, HCQ + Emtricitabine/Tenofovir, SOC",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Navarra","2020-Apr","2020-Jun","Recruiting","Randomised","Double",4,"Healthy","Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/Tenofovir, HCQ, HCQ + Emtricitabine/Tenofovir, SOC",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Valencia","2020-Apr","2020-Jun","Recruiting","Randomised","Double",4,"Healthy","Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/Tenofovir, HCQ, HCQ + Emtricitabine/Tenofovir, SOC",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Alava","2020-Apr","2020-Jun","Recruiting","Randomised","Double",4,"Healthy","Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/Tenofovir, HCQ, HCQ + Emtricitabine/Tenofovir, SOC",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Albacete","2020-Apr","2020-Jun","Recruiting","Randomised","Double",4,"Healthy","Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/Tenofovir, HCQ, HCQ + Emtricitabine/Tenofovir, SOC",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Burgos","2020-Apr","2020-Jun","Recruiting","Randomised","Double",4,"Healthy","Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/Tenofovir, HCQ, HCQ + Emtricitabine/Tenofovir, SOC",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Cuenca","2020-Apr","2020-Jun","Recruiting","Randomised","Double",4,"Healthy","Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/Tenofovir, HCQ, HCQ + Emtricitabine/Tenofovir, SOC",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Granada","2020-Apr","2020-Jun","Recruiting","Randomised","Double",4,"Healthy","Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/Tenofovir, HCQ, HCQ + Emtricitabine/Tenofovir, SOC",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Palencia","2020-Apr","2020-Jun","Recruiting","Randomised","Double",4,"Healthy","Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/Tenofovir, HCQ, HCQ + Emtricitabine/Tenofovir, SOC",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Salamanca","2020-Apr","2020-Jun","Recruiting","Randomised","Double",4,"Healthy","Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/Tenofovir, HCQ, HCQ + Emtricitabine/Tenofovir, SOC",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Segovia","2020-Apr","2020-Jun","Recruiting","Randomised","Double",4,"Healthy","Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/Tenofovir, HCQ, HCQ + Emtricitabine/Tenofovir, SOC",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Sevilla","2020-Apr","2020-Jun","Recruiting","Randomised","Double",4,"Healthy","Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/Tenofovir, HCQ, HCQ + Emtricitabine/Tenofovir, SOC",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Valladolid","2020-Apr","2020-Jun","Recruiting","Randomised","Double",4,"Healthy","Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/Tenofovir, HCQ, HCQ + Emtricitabine/Tenofovir, SOC",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Zaragoza","2020-Apr","2020-Jun","Recruiting","Randomised","Double",4,"Healthy","Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/Tenofovir, HCQ, HCQ + Emtricitabine/Tenofovir, SOC",4000
"NCT04346147","https://ClinicalTrials.gov/show/NCT04346147",NA,"Spain","Madrid","2020-Apr","2020-Aug","Recruiting","Randomised","Open-Label",4,"Yes","Unspecified","Hospital","Clinical Improvement Score (Any), Treatment-emergent Adverse Events, Serious Adverse Events","HCQ + Imatinib, HCQ + JAKi, HCQ + LPV/r",165
"NCT04344379","https://ClinicalTrials.gov/show/NCT04344379",NA,"France","Paris","2020-Apr","2020-Jul","Recruiting","Randomised","Double",3,"No","Healthy","Healthcare Workers","Viral Load or Clearance","AZT, HCQ, SOC",900
"NCT04351347","https://clinicaltrials.gov/show/NCT04351347",NA,"Egypt","Cairo","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,"Yes","Unspecified","Unclear","Viral Load or Clearance","HCQ, Ivermectin, Nitazoxanide",60
"NCT04347031","https://ClinicalTrials.gov/show/NCT04347031",NA,"Russia","Moscow","2020-Apr","2020-Aug","Recruiting","Randomised","Open-Label",4,NA,NA,"Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Other Mild Symptoms, Adverse Events, Serious Adverse Events, C-Reactive Protein","HCQ, Other, TCZ + AZT + HCQ",320
"NCT04356495","https://ClinicalTrials.gov/show/NCT04356495",NA,"France","Paris","2020-Apr","2020-Jul","Not Recruiting","Randomised","Open-Label",5,NA,NA,"Outpatient","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, Creatinine Phosphokinase, Procalcitonin, Prothrombin, ALT, LDH, Bicarbonates, Quality of Life","Antihypertensive, FPV, HCQ, Other, SOC",1057
"NCT04349592","https://ClinicalTrials.gov/show/NCT04349592",NA,"Qatar","Doha","2020-Apr","2020-May","Not Recruiting","Randomised","Quadruple",3,"Yes","Non-severe","Hospital","Viral Load or Clearance","HCQ, HCQ + AZT, SOC",456
"NCT04344444","https://ClinicalTrials.gov/show/NCT04344444",NA,"United States","Louisiana","2020-Apr","2021-Apr","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital",NA,"HCQ, HCQ + AZT, SOC",600
"CHICTR2000032011","http://www.chictr.org.cn/showproj.aspx?proj=52142",NA,"China","Beijing","2020-Apr","2020-May","Not Recruiting","Randomised","Unspecified",3,"Yes","Severe","Hospital","C-Reactive Protein, IL-6, PaO2-FiO2, Radiographic Findings","Non-invasive respiratory support, SOC",45
"NCT04351763","https://ClinicalTrials.gov/show/NCT04351763",NA,"Poland","Warsaw","2020-Apr","2021-Mar","Recruiting","Randomised","Single",2,"Confirmed","Mixed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Fever, PaO2-FiO2, Cardiac Outcome (Unspecified)","Amiodarone, SOC, Verapamil",804
"NCT04350281","https://clinicaltrials.gov/show/NCT04350281",NA,"China","Hong Kong","2020-Apr",NA,"Recruiting","Randomised","Open-Label",1,"Yes","Severe","Hospital, ICU","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events","HCQ, IFN",80
"NCT04361461","https://ClinicalTrials.gov/show/NCT04361461",NA,"Brazil","Brasilia","2020-Apr","2020-Nov","Not Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital, ICU","Mortality, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","HCQ, HCQ + AZT",500
"NCT04355026","https://ClinicalTrials.gov/show/NCT04355026",NA,"Slovenia","Celje","2020-Apr","2020-Jun","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","ICU Admission, Hospitalization, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ, HCQ + Bromhexine",90
"NCT04359680","https://ClinicalTrials.gov/show/NCT04359680",NA,"United States","Florida","2020-Apr","2020-Aug","Recruiting","Randomised","Triple",3,NA,NA,"Healthcare Workers","Viral Load or Clearance","Antivirals, SOC",800
"NCT04359680","https://ClinicalTrials.gov/show/NCT04359680",NA,"United States","New York","2020-Apr","2020-Aug","Recruiting","Randomised","Triple",3,NA,NA,"Healthcare Workers","Viral Load or Clearance","Antivirals, SOC",800
"NCT04359680","https://ClinicalTrials.gov/show/NCT04359680",NA,"United States","Texas","2020-Apr","2020-Aug","Recruiting","Randomised","Triple",3,NA,NA,"Healthcare Workers","Viral Load or Clearance","Antivirals, SOC",800
"2020-001406-27","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001406-27/FR/",NA,"France","Paris","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, PaO2-FiO2, Respiratory Rate, Radiographic Findings","AZT, HCQ",NA
"NCT04347915","https://ClinicalTrials.gov/show/NCT04347915",NA,"South Korea","Seoul","2020-Apr","2020-Sep","Recruiting","Randomised","Open-Label",2,"Confirmed","Non-severe","Unclear","Viral Load or Clearance, Non-invasive Ventilation","Clevudine, HCQ",60
"NCT04341870","https://ClinicalTrials.gov/show/NCT04341870",NA,"France","Paris","2020-Apr","2020-May","Suspended","Randomised","Open-Label",3,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ + AZT + Sarilumab, Sarilumab",27
"NCT04334148","https://ClinicalTrials.gov/show/NCT04334148",NA,"United States","Florida","2020-Apr","2020-Jul","Recruiting","Randomised","Triple",2,"Healthy","Healthy","Healthcare Workers","Viral Load or Clearance, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","HCQ, SOC",15000
"NCT04334148","https://ClinicalTrials.gov/show/NCT04334148",NA,"United States","Kansas","2020-Apr","2020-Jul","Recruiting","Randomised","Triple",2,"Healthy","Healthy","Healthcare Workers","Viral Load or Clearance, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","HCQ, SOC",15000
"NCT04334148","https://ClinicalTrials.gov/show/NCT04334148",NA,"United States","Louisiana","2020-Apr","2020-Jul","Recruiting","Randomised","Triple",2,"Healthy","Healthy","Healthcare Workers","Viral Load or Clearance, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","HCQ, SOC",15000
"NCT04334148","https://ClinicalTrials.gov/show/NCT04334148",NA,"United States","Maryland","2020-Apr","2020-Jul","Recruiting","Randomised","Triple",2,"Healthy","Healthy","Healthcare Workers","Viral Load or Clearance, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","HCQ, SOC",15000
"NCT04334148","https://ClinicalTrials.gov/show/NCT04334148",NA,"United States","Minnesota","2020-Apr","2020-Jul","Recruiting","Randomised","Triple",2,"Healthy","Healthy","Healthcare Workers","Viral Load or Clearance, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","HCQ, SOC",15000
"NCT04334148","https://ClinicalTrials.gov/show/NCT04334148",NA,"United States","Missouri","2020-Apr","2020-Jul","Recruiting","Randomised","Triple",2,"Healthy","Healthy","Healthcare Workers","Viral Load or Clearance, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","HCQ, SOC",15000
"NCT04334148","https://ClinicalTrials.gov/show/NCT04334148",NA,"United States","New York","2020-Apr","2020-Jul","Recruiting","Randomised","Triple",2,"Healthy","Healthy","Healthcare Workers","Viral Load or Clearance, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","HCQ, SOC",15000
"NCT04334148","https://ClinicalTrials.gov/show/NCT04334148",NA,"United States","North Carolina","2020-Apr","2020-Jul","Recruiting","Randomised","Triple",2,"Healthy","Healthy","Healthcare Workers","Viral Load or Clearance, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","HCQ, SOC",15000
"NCT04334148","https://ClinicalTrials.gov/show/NCT04334148",NA,"United States","Tennessee","2020-Apr","2020-Jul","Recruiting","Randomised","Triple",2,"Healthy","Healthy","Healthcare Workers","Viral Load or Clearance, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","HCQ, SOC",15000
"NCT04334148","https://ClinicalTrials.gov/show/NCT04334148",NA,"United States","Texas","2020-Apr","2020-Jul","Recruiting","Randomised","Triple",2,"Healthy","Healthy","Healthcare Workers","Viral Load or Clearance, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","HCQ, SOC",15000
"NCT04334148","https://ClinicalTrials.gov/show/NCT04334148",NA,"United States","Washington","2020-Apr","2020-Jul","Recruiting","Randomised","Triple",2,"Healthy","Healthy","Healthcare Workers","Viral Load or Clearance, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","HCQ, SOC",15000
"NCT04334148","https://ClinicalTrials.gov/show/NCT04334148",NA,"United States","Wisconsin","2020-Apr","2020-Jul","Recruiting","Randomised","Triple",2,"Healthy","Healthy","Healthcare Workers","Viral Load or Clearance, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","HCQ, SOC",15000
"NCT04342156","https://ClinicalTrials.gov/show/NCT04342156",NA,"Singapore","Singapore","2020-Apr","2020-Aug","Not Recruiting","Randomised","Open-Label",2,NA,NA,"Healthy Exposed","Mortality, Hospitalization, Visits or Returns to Emergency Department, Invasive Mechanical Ventilation or ECMO","HCQ, SOC",1200
"NCT04341441","https://clinicaltrials.gov/show/NCT04341441",NA,"United States","Washington, Dc","2020-Jul",NA,"Recruiting","Randomised","Triple",6,NA,NA,"Healthcare Workers","Hospitalization, Viral Load or Clearance, Other Mild Symptoms, Adverse Events, Serious Adverse Events, IgG, IgM or IgA","HCQ, SOC",3000
"PACTR202004801273802","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10928",NA,"Nigeria","Niger","2020-Feb",NA,"Not Recruiting","Randomised","Double",NA,NA,NA,"Hospital","Clinical Improvement Score (Any), Viral Load or Clearance","HCQ, SOC",600
"TCTR20200404004","http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=5995",NA,"Thailand","Nan","2020-Mar",NA,"Not Recruiting","Randomised","Unspecified",NA,NA,NA,"Healthy Exposed","Hospitalization, Anti SARS-COV-2 Titers","HCQ, SOC",400
"NCT04351516","https://clinicaltrials.gov/show/NCT04351516",NA,"Germany","Berlin","2020-Apr",NA,"Recruiting","Randomised","Quadruple",1,"Yes","Mixed","Outpatient","Mortality, Hospitalization","HCQ, SOC",350
"NCT04349228","https://ClinicalTrials.gov/show/NCT04349228",NA,"Tunisia","Tunis","2020-Apr","2020-Jul","Recruiting","Randomised","Single",2,"No","Healthy","Healthcare Workers","Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Renal Outcome (Unspecified)","HCQ, SOC",530
"PACTR202004761408382","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10957",NA,"Nigeria","Niger","2020-Apr",NA,"Not Recruiting","Randomised","Unspecified",NA,NA,NA,"Hospital","Hospital Discharge, Viral Load or Clearance, Cough, Other Mild Symptoms, Adverse Events, Anti SARS-COV-2 Titers, Creatinine Phosphokinase, Electrolytes, ALT, CD4, CD8, Blood Urea Nitrogen","Alternative therapy, SOC",72
"NCT04355936","https://ClinicalTrials.gov/show/NCT04355936",NA,"Argentina","Ciudad De Buenos Aires","2020-Apr","2020-Oct","Recruiting","Randomised","Open-Label",2,NA,NA,"Unclear","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Troponin, LDH, Urine Sample","Antihypertensive, SOC",400
"NCT04345406","https://clinicaltrials.gov/show/NCT04345406",NA,"Egypt","Cairo","2020-Nov",NA,"Not Recruiting","Randomised","Open-Label",1,NA,NA,"Unclear","Viral Load or Clearance, Radiographic Findings","Antihypertensive, SOC",60
"NCT04348500","https://ClinicalTrials.gov/show/NCT04348500",NA,"United States","California","2020-Apr","2020-Dec","Not Recruiting","Randomised","Quadruple",2,"Yes","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation","Clazakizumab, SOC",60
"NCT04350320","https://ClinicalTrials.gov/show/NCT04350320",NA,"Spain","Murcia","2020-Apr","2020-Oct","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, Ferritin, IL-1, IL-6, Tumor Necrosis Factor (Any), Granulocyte Stimulaiting Factor, White Blood Cell Count, D-Dimer, LDH","Colchicine, SOC",102
"NCT04348305","https://ClinicalTrials.gov/show/NCT04348305",NA,"Denmark","Copenhagen","2020-Apr","2021-Mar","Recruiting","Randomised","Quadruple",2,"Yes","Severe","Hospital, ICU","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Quality of Life","Corticosteroids, SOC",1000
"NCT04343729","https://ClinicalTrials.gov/show/NCT04343729",NA,"Brazil","Amazonas","2020-Apr","2020-Sep","Recruiting","Randomised","Quadruple",2,NA,NA,"Unclear","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Corticosteroids, SOC",420
"NCT04351295","https://clinicaltrials.gov/show/NCT04351295",NA,"Egypt","Cairo","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",1,"Yes","Unspecified","Unclear","Viral Load or Clearance","FPV, SOC",40
"NCT04342663","https://ClinicalTrials.gov/show/NCT04342663",NA,"United States","Illinois","2020-Apr","2020-Aug","Recruiting","Randomised","Triple",2,NA,NA,"Outpatient","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Troponin","Fluvoxamine, SOC",152
"NCT04342663","https://ClinicalTrials.gov/show/NCT04342663",NA,"United States","Missouri","2020-Apr","2020-Aug","Recruiting","Randomised","Triple",2,NA,NA,"Outpatient","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Troponin","Fluvoxamine, SOC",152
"NCT04344600","https://ClinicalTrials.gov/show/NCT04344600",NA,"United States","Maryland","2020-Apr","2020-Dec","Not Recruiting","Randomised","Single",2,NA,NA,"Healthy Exposed","Viral Load or Clearance","IFN, SOC",164
"NCT04343248","https://ClinicalTrials.gov/show/NCT04343248",NA,"United States","Florida","2020-Apr","2020-Aug","Recruiting","Randomised","Triple",3,"Not Specified","Unspecified","Hospital","Mortality, Clinical Improvement Score (Any), PaO2-FiO2","Nitazoxanide, SOC",800
"NCT04343248","https://ClinicalTrials.gov/show/NCT04343248",NA,"United States","Georgia","2020-Apr","2020-Aug","Recruiting","Randomised","Triple",3,"Not Specified","Unspecified","Hospital","Mortality, Clinical Improvement Score (Any), PaO2-FiO2","Nitazoxanide, SOC",800
"NCT04343248","https://ClinicalTrials.gov/show/NCT04343248",NA,"United States","Louisiana","2020-Apr","2020-Aug","Recruiting","Randomised","Triple",3,"Not Specified","Unspecified","Hospital","Mortality, Clinical Improvement Score (Any), PaO2-FiO2","Nitazoxanide, SOC",800
"NCT04343248","https://ClinicalTrials.gov/show/NCT04343248",NA,"United States","Texas","2020-Apr","2020-Aug","Recruiting","Randomised","Triple",3,"Not Specified","Unspecified","Hospital","Mortality, Clinical Improvement Score (Any), PaO2-FiO2","Nitazoxanide, SOC",800
"NCT04348409","https://ClinicalTrials.gov/show/NCT04348409",NA,"Brazil","Brasilia","2020-Apr","2020-May","Recruiting","Randomised","Quadruple",2,"Yes","Mixed","Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Nitazoxanide, SOC",50
"NCT04334629","https://ClinicalTrials.gov/show/NCT04334629",NA,"United Kingdom","London","2020-Apr","2020-Sep","Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2","NSAIDs, SOC",230
"NCT04388826","https://ClinicalTrials.gov/show/NCT04388826",NA,"United States","Arizona","2020-May","2020-Jul","Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear","Hospital","Hospital Discharge, Clinical Improvement Score (Any), Fever","Other, SOC",40
"NCT04388826","https://ClinicalTrials.gov/show/NCT04388826",NA,"United States","Minnesota","2020-May","2020-Jul","Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear","Hospital","Hospital Discharge, Clinical Improvement Score (Any), Fever","Other, SOC",40
"NCT04388826","https://ClinicalTrials.gov/show/NCT04388826",NA,"United States","Nevada","2020-May","2020-Jul","Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear","Hospital","Hospital Discharge, Clinical Improvement Score (Any), Fever","Other, SOC",40
"NCT04388826","https://ClinicalTrials.gov/show/NCT04388826",NA,"United States","New Jersey","2020-May","2020-Jul","Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear","Hospital","Hospital Discharge, Clinical Improvement Score (Any), Fever","Other, SOC",40
"IRCT20170210032478N3","http://en.irct.ir/trial/47173",NA,"Iran","Tehran","2020-Apr","2020-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Unclear","Visits or Returns to Emergency Department, Clinical Improvement Score (Any), Pneumonia or ARDS, C-Reactive Protein","Other, SOC",50
"NCT04348656","https://ClinicalTrials.gov/show/NCT04348656",NA,"Canada","Alberta","2020-Apr","2020-Oct","Recruiting","Randomised","Open-Label",2,"Yes","Mixed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, SOC",1200
"NCT04348656","https://ClinicalTrials.gov/show/NCT04348656",NA,"Canada","British Columbia","2020-Apr","2020-Oct","Recruiting","Randomised","Open-Label",2,"Yes","Mixed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, SOC",1200
"NCT04348656","https://ClinicalTrials.gov/show/NCT04348656",NA,"Canada","Manitoba","2020-Apr","2020-Oct","Recruiting","Randomised","Open-Label",2,"Yes","Mixed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, SOC",1200
"NCT04348656","https://ClinicalTrials.gov/show/NCT04348656",NA,"Canada","Ontario","2020-Apr","2020-Oct","Recruiting","Randomised","Open-Label",2,"Yes","Mixed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, SOC",1200
"NCT04348656","https://ClinicalTrials.gov/show/NCT04348656",NA,"Canada","Quebec","2020-Apr","2020-Oct","Recruiting","Randomised","Open-Label",2,"Yes","Mixed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, SOC",1200
"NCT04356534","https://ClinicalTrials.gov/show/NCT04356534",NA,"Bahrain","Manama","2020-Apr","2020-May","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Ferritin, White Blood Cell Count, D-Dimer, Troponin, Procalcitonin, LDH, Radiographic Findings","Plasma based therapy, SOC",40
"NCT04374539","https://ClinicalTrials.gov/show/NCT04374539",NA,"Spain","Barcelona","2020-May","2021-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","ICU","Mortality, Invasive Mechanical Ventilation or ECMO","Plasma based therapy, SOC",116
"NCT04344535","https://clinicaltrials.gov/show/NCT04344535",NA,"United States","Washington, Dc","2020-Oct",NA,"Recruiting","Randomised","Quadruple",1,"Mixed","Mixed","Hospital","Clinical Improvement Score (Any), Distress","Plasma based therapy, SOC",500
"NCT04346446","https://clinicaltrials.gov/show/NCT04346446",NA,"India","New Delhi","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Yes","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), PaO2-FiO2","Plasma based therapy, SOC",40
"NCT04343963","https://ClinicalTrials.gov/show/NCT04343963",NA,"Mexico","Mexico","2020-Apr","2020-Sep","Recruiting","Randomised","Quadruple",2,NA,NA,"Hospital","Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, IL-6","Pyridostigmine, SOC",436
"NCT04348695","https://ClinicalTrials.gov/show/NCT04348695",NA,"Spain","Madrid","2020-Apr","2020-May","Recruiting","Randomised","Open-Label",2,"Yes","Mixed","Hospital","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","Ruxolitinib + Simvastatin, SOC",94
"NCT04357808","https://ClinicalTrials.gov/show/NCT04357808",NA,"Spain","Madrid","2020-Apr","2020-Jun","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","Sarilumab, SOC",30
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United States","California","2020-Apr","2020-Aug","Recruiting","Randomised","Single",2,"Yes","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Selinexor, SOC",230
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United States","Florida","2020-Apr","2020-Aug","Recruiting","Randomised","Single",2,"Yes","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Selinexor, SOC",230
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United States","Georgia","2020-Apr","2020-Aug","Recruiting","Randomised","Single",2,"Yes","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Selinexor, SOC",230
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United States","Illinois","2020-Apr","2020-Aug","Recruiting","Randomised","Single",2,"Yes","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Selinexor, SOC",230
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United States","Kansas","2020-Apr","2020-Aug","Recruiting","Randomised","Single",2,"Yes","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Selinexor, SOC",230
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United States","Kentucky","2020-Apr","2020-Aug","Recruiting","Randomised","Single",2,"Yes","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Selinexor, SOC",230
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United States","Massachusetts","2020-Apr","2020-Aug","Recruiting","Randomised","Single",2,"Yes","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Selinexor, SOC",230
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United States","Michigan","2020-Apr","2020-Aug","Recruiting","Randomised","Single",2,"Yes","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Selinexor, SOC",230
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United States","New York","2020-Apr","2020-Aug","Recruiting","Randomised","Single",2,"Yes","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Selinexor, SOC",230
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United States","North Carolina","2020-Apr","2020-Aug","Recruiting","Randomised","Single",2,"Yes","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Selinexor, SOC",230
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United States","Pennsylvania","2020-Apr","2020-Aug","Recruiting","Randomised","Single",2,"Yes","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Selinexor, SOC",230
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United States","Texas","2020-Apr","2020-Aug","Recruiting","Randomised","Single",2,"Yes","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Selinexor, SOC",230
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United States","Washington","2020-Apr","2020-Aug","Recruiting","Randomised","Single",2,"Yes","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Selinexor, SOC",230
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"Austria","Vienna","2020-Apr","2020-Aug","Recruiting","Randomised","Single",2,"Yes","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Selinexor, SOC",230
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"France","Paris","2020-Apr","2020-Aug","Recruiting","Randomised","Single",2,"Yes","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Selinexor, SOC",230
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"Israel","Jerusalem","2020-Apr","2020-Aug","Recruiting","Randomised","Single",2,"Yes","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Selinexor, SOC",230
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"Spain","Barcelona","2020-Apr","2020-Aug","Recruiting","Randomised","Single",2,"Yes","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Selinexor, SOC",230
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"Spain","Salamanca","2020-Apr","2020-Aug","Recruiting","Randomised","Single",2,"Yes","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Selinexor, SOC",230
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United Kingdom","Kent","2020-Apr","2020-Aug","Recruiting","Randomised","Single",2,"Yes","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Selinexor, SOC",230
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United Kingdom","London","2020-Apr","2020-Aug","Recruiting","Randomised","Single",2,"Yes","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Selinexor, SOC",230
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United Kingdom","Plymouth","2020-Apr","2020-Aug","Recruiting","Randomised","Single",2,"Yes","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Selinexor, SOC",230
"NCT04345887","https://clinicaltrials.gov/show/NCT04345887",NA,"Turkey","Ankara","2020-Oct",NA,"Not Recruiting","Randomised","Triple",1,"Yes","Severe","ICU","Organ Failure or Dysfunction (SOFA), PaO2-FiO2","SOC, Spironolactone",60
"NCT04361942","https://ClinicalTrials.gov/show/NCT04361942",NA,"Spain","Valladolid","2020-Apr","2020-Nov","Recruiting","Randomised","Triple",2,NA,NA,"ICU","Mortality, Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO","SOC, Stem cells",24
"NCT04348461","https://clinicaltrials.gov/show/NCT04348461",NA,"Spain","Madrid","2020-Oct",NA,"Not Recruiting","Randomised","Quadruple",2,"Yes","Severe","ICU","Adverse Events","SOC, Stem cells",100
"NCT04361032","https://ClinicalTrials.gov/show/NCT04361032",NA,"Tunisia","Tunis","2020-Apr","2020-Sep","Not Recruiting","Randomised","Open-Label",2,NA,NA,"ICU","Mortality","SOC, TCZ + Pembrolizumab",260
"NCT04358809","https://ClinicalTrials.gov/show/NCT04358809",NA,"India","Chandigarh","2020-Apr","2021-Feb","Not Recruiting","Randomised","Quadruple",2,NA,NA,"Hospital","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Other Mild Symptoms, Adverse Events, Serious Adverse Events","SOC, Treated mycobacterium",480
"NCT04348370","https://ClinicalTrials.gov/show/NCT04348370",NA,"United States","California","2020-Apr","2021-May","Recruiting","Randomised","Double",2,"No","Healthy","Healthcare Workers","Clinical Improvement Score (Any), Viral Load or Clearance","SOC, Vaccine",1800
"NCT04348370","https://ClinicalTrials.gov/show/NCT04348370",NA,"United States","Texas","2020-Apr","2021-May","Recruiting","Randomised","Double",2,"No","Healthy","Healthcare Workers","Clinical Improvement Score (Any), Viral Load or Clearance","SOC, Vaccine",1800
"NCT04350931","https://ClinicalTrials.gov/show/NCT04350931",NA,"Egypt","Cairo","2020-Apr","2020-Oct","Not Recruiting","Randomised","Single",2,"No","Healthy","Healthcare Workers","Viral Load or Clearance","SOC, Vaccine",900
"NCT04351490","https://ClinicalTrials.gov/show/NCT04351490",NA,"France","Paris","2020-Apr","2020-Jul","Not Recruiting","Randomised","Open-Label",2,"Yes","Severe","Hospital","Mortality, Viral Load or Clearance","SOC, Zinc + Vitamins",3140
"NCT04347889","https://ClinicalTrials.gov/show/NCT04347889",NA,"United States","New York","2020-Apr","2020-Dec","Not Recruiting","Randomised","Single",2,"Negative","Healthy","Healthcare Workers","Hospitalization, Anti SARS-COV-2 Titers","HCQ, Vitamins",1212
"NCT04353336","https://ClinicalTrials.gov/show/NCT04353336",NA,"Egypt","Cairo","2020-Apr","2030-Dec","Not Recruiting","Randomised","Open-Label",2,NA,NA,"Unclear","Viral Load or Clearance","HCQ",40
"ACTRN12620000417987","https://anzctr.org.au/ACTRN12620000417987.aspx",NA,"Australia","Canberra","2020-Mar",NA,"Recruiting","Randomised","Open-Label",NA,"Healthy (Exposed)","Healthy","Healthcare Workers","Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Cough, Fever, Dyspnea, Other Mild Symptoms","HCQ",680
"NCT04330144","https://ClinicalTrials.gov/show/NCT04330144",NA,"South Korea","Seoul","2020-Apr","2021-Mar","Not Recruiting","Randomised","Single",2,"Healthy (Exposed)",NA,"Healthy Exposed","Viral Load or Clearance","HCQ",2486
"2020-000890-25","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000890-25/FR/","https://www.sciencedirect.com/science/article/pii/S0924857920300996","France","Paris","2020-Mar",NA,"Completed w. Results","Unspecified","Unspecified",NA,"Confirmed",NA,"Hospital","Mortality, Hospitalization, Viral Load or Clearance, Fever, Respiratory Rate","HCQ",NA
"2020-001417-21","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001417-21/BE/",NA,"Belgium","Brussels","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Mild","Hospital","Hospitalization, Viral Load or Clearance, Other Mild Symptoms, Adverse Events, Serious Adverse Events","HCQ",NA
"NCT04351919","https://ClinicalTrials.gov/show/NCT04351919",NA,"Tunisia","Tunis","2020-Apr","2020-Jul","Not Recruiting","Single-Arm","Open-Label",1,"Yes","Non-severe","Unclear","Other Mild Symptoms","HCQ",400
"NCT04351620","https://ClinicalTrials.gov/show/NCT04351620",NA,"United States","Illinois","2020-Apr","2020-Jun","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Non-severe","Outpatient","Hospitalization, Fever, Other Mild Symptoms, Adverse Events","HCQ",20
"NCT04345653","https://ClinicalTrials.gov/show/NCT04345653",NA,"United States","New Jersey","2020-Apr","2021-Apr","Recruiting","Single-Arm","Open-Label",1,"No","Healthy","Healthcare Workers","Viral Load or Clearance, Adverse Events, Serious Adverse Events","HCQ",45
"NCT04348474","https://ClinicalTrials.gov/show/NCT04348474",NA,"Brazil","Brasilia","2020-Apr","2020-Jun","Suspended","Single-Arm","Open-Label",1,"Yes","Non-severe","Outpatient","Mortality, Hospitalization, Clinical Improvement Score (Any)","HCQ + AZT",200
"IRCT20100228003449N30","http://en.irct.ir/trial/46536",NA,"Iran","Tehran","2020-Mar","2020-May","Completed","Single-Arm","Open-Label",1,"Confirmed Or Suspected",NA,"Hospital","Hospitalization, Clinical Improvement Score (Any), Adverse Events, Treatment-emergent Adverse Events","HCQ + LPV/r",50
"IRCT20151227025726N12","http://en.irct.ir/trial/46561",NA,"Iran","Tehran","2020-Mar","2020-Apr","Completed","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","Hospitalization, Cough, Fever, Dyspnea, Other Mild Symptoms, Treatment-emergent Adverse Events, Radiographic Findings","HCQ + Oseltamivir + LPV/r + IFN",20
"CTRI/2020/04/024731","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42912",NA,"India","New Delhi","2020-Apr",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Healthy (Exposed)","None","Healthy Exposed","Cough, Other Mild Symptoms","Alternative therapy",50
"IRCT20200405046960N1","http://en.irct.ir/trial/46961",NA,"Iran","Tehran","2020-Apr","2020-Apr","Completed","Single-Arm","Open-Label",1,NA,NA,"Hospital","C-Reactive Protein, White Blood Cell Count, Respiratory Rate","Alternative therapy",15
"CTRI/2020/04/024857","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43212",NA,"India","New Delhi","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",NA,"Confirmed","Mild","Outpatient","ICU Admission","Alternative therapy",100
"CTRI/2020/04/024947","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43259",NA,"India","New Delhi","2020-Apr",NA,"Not Recruiting","Randomised","Unspecified",NA,"Confirmed","Mild/Moderate","Hospital",NA,"Alternative therapy",100
"CTRI/2020/05/025049","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43313",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",NA,"Confirmed Or Suspected","Unclear","Unclear","Mortality","Alternative therapy",100
"CTRI/2020/05/024986","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43455",NA,"India","Delhi","2020-Apr",NA,"Not Recruiting","Single-Arm","Unspecified",1,"Suspected","None","Healthy Exposed",NA,"Alternative therapy",10000
"CTRI/2020/05/025069","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43522",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Healthy","None","Healthy Exposed",NA,"Alternative therapy",1324
"CTRI/2020/04/024659","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42967",NA,"India","New Delhi","2020-Apr",NA,"Not Recruiting","Single-Arm","Open-Label",1,NA,NA,"Healthy Exposed","Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea","Alternative therapy",30
"IRCT20200408046990N1","http://en.irct.ir/trial/47061",NA,"Iran","Tehran","2020-Apr","2020-Sep","Recruiting","Non-Randomised","Open-Label",2,NA,NA,"Outpatient","Hospitalization, Cough, Fever, Other Mild Symptoms, Adverse Events, Radiographic Findings","Alternative therapy",60
"EUCTR2020-001466-11-GR","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001466-11",NA,"Greece","Athens","2020-Apr",NA,"Not Recruiting","Non-Randomised","Open-Label",1,NA,NA,"Unclear","Other Mild Symptoms, Organ Failure or Dysfunction (SOFA)","Anakinra + Cotrimoxazole",100
"EUCTR2020-001882-36-GR","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001882-36",NA,"Greece","Athens","2020-Apr",NA,"Not Recruiting","Unspecified","Open-Label",NA,"Confirmed Or Suspected","Unclear","Unclear","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Cough, Dyspnea","Antibiotics",90
"NCT04352985","https://ClinicalTrials.gov/show/NCT04352985",NA,"Canada","Ontario","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",NA,NA,NA,"ICU",NA,"Antibiotics",NA
"NCT04354155","https://clinicaltrials.gov/show/NCT04354155",NA,"United States","Washington, Dc","2020-Apr",NA,"Not Recruiting","Single-Arm","Open-Label",1,NA,NA,"Hospital","Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, D-Dimer","Anticoagulants",38
"NCT04355247","https://ClinicalTrials.gov/show/NCT04355247",NA,"Puerto Rico","Puerto Rico","2020-Apr","2020-Jul","Recruiting","Single-Arm","Open-Label",1,NA,NA,"Hospital","Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Ferritin, IL-6, D-Dimer, LDH, Radiographic Findings","Corticosteroids",20
"ACTRN12620000500954","https://anzctr.org.au/ACTRN12620000500954.aspx",NA,"Australia","Canberra","2020-Apr",NA,"Not Recruiting","Non-Randomised","Open-Label",NA,"Confirmed","Unclear","Outpatient, Hospital, ICU","Mortality, Hospitalization, Adverse Events","Device",20
"NCT04379037","https://ClinicalTrials.gov/show/NCT04379037",NA,"United States","Arizona","2020-May","2020-Oct","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Moderate/Severe","Hospital","Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO","Device",50
"NCT04369599","https://clinicaltrials.gov/show/NCT04369599",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Single-Arm","Open-Label",1,"Unclear","Severe","ICU",NA,"Device",24
"NCT04368156","https://ClinicalTrials.gov/show/NCT04368156",NA,"Spain","Valencia","2020-Apr","2020-Jul","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Device",90
"NCT04361214","https://ClinicalTrials.gov/show/NCT04361214",NA,"United States","Illinois","2020-Apr","2020-Jul","Recruiting","Single-Arm","Open-Label",1,NA,NA,"Outpatient","Hospitalization, Clinical Improvement Score (Any), Fever, Other Mild Symptoms, Adverse Events","DMARD",20
"NCT04351906","https://clinicaltrials.gov/show/NCT04351906",NA,"Germany","Berlin","2020-Sep",NA,"Recruiting","Single-Arm","Open-Label",1,"Yes","Severe","ICU","Adverse Events","ECCO2R",20
"JPRN-JRCTS031190226","https://jrct.niph.go.jp/latest-detail/jRCTs031190226",NA,"Japan","Gunma","2020-Feb",NA,"Recruiting","Single-Arm","Open-Label",1,"Confirmed",NA,"Hospital","Viral Load or Clearance, C-Reactive Protein","FPV",50
"TCTR20200409006","http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=6016",NA,"Thailand","Nan","2020-Mar",NA,"Not Recruiting","Randomised","Unspecified",NA,NA,NA,"ICU","Mortality, ICU Admission, Non-invasive Ventilation, IL-6","Hemoperfusion",206
"ACTRN12620000470998","https://anzctr.org.au/ACTRN12620000470998.aspx",NA,"Australia","Canberra","2020-Apr",NA,"Not Recruiting","Non-Randomised","Unspecified",NA,NA,NA,"Unclear","Viral Load or Clearance","Hygiene",20
"NCT04383548","https://ClinicalTrials.gov/show/NCT04383548",NA,"Egypt","Asyut","2020-May","2020-Dec","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed, Healthy","Unclear, Healthy","Healthy Exposed, Unclear","Adverse Events, IgG, IgM or IgA","Igs",100
"NCT04343976","https://ClinicalTrials.gov/show/NCT04343976",NA,"United States","Massachusetts","2020-Apr","2020-Oct","Not Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Respiratory Rate","IFN",20
"NCT04379518","https://ClinicalTrials.gov/show/NCT04379518",NA,"United States","New York","2020-May","2021-Apr","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Mild/Moderate","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Adverse Events, Distress","IFN + Rintatolimod",80
"SLCTR/2020/011","https://slctr.lk/trials/slctr-2020-011",NA,"Sri Lanka","Western Province","2020-May",NA,"Not Recruiting","Randomised","Unspecified",NA,"Healthy","None","Healthy Exposed","Cough, Fever, Dyspnea, Other Mild Symptoms","HCQ, SOC",400
"CHICTR2000030170","http://www.chictr.org.cn/showproj.aspx?proj=50017",NA,"China","Shanghai","2020-Feb","2020-Jul","Recruiting","Randomised","Unspecified",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any)","JAKi",16
"2020-001459-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001459-42/DK/",NA,"Denmark","Copenhagen","2020-Apr",NA,"Recruiting","Unspecified","Open-Label",NA,NA,NA,"Hospital","Mortality","JAKi",NA
"NCT04359290","https://clinicaltrials.gov/show/NCT04359290",NA,"Germany","Hessen","2020-Apr",NA,"Not Recruiting","Single-Arm","Open-Label",1,NA,NA,"Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Anti SARS-COV-2 Titers, C-Reactive Protein, Ferritin, IL-6, Radiographic Findings","JAKi",15
"NCT04332042","https://ClinicalTrials.gov/show/NCT04332042",NA,"Italy","Ancona","2020-Apr","2020-Jun","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed",NA,"Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","JAKi",50
"NCT04355494","https://ClinicalTrials.gov/show/NCT04355494",NA,"France","Paris","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",NA,NA,NA,"Hospital",NA,"mAb",NA
"NCT04288713","https://ClinicalTrials.gov/show/NCT04288713",NA,"United States","New York","2020-Feb",NA,"Recruiting","Unspecified","Unspecified",NA,"Confirmed","Severe","ICU",NA,"mAb",NA
"RPCEC00000311","http://rpcec.sld.cu/en/trials/RPCEC00000311-En",NA,"Cuba","Havana","2020-Dec",NA,"Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","PaO2-FiO2","mAb",80
"2020-002472-12","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002472-12/NL/",NA,"Netherlands","Amsterdam","2020-May",NA,"Status Unclear","Single-Arm","Open-Label",1,"Confirmed","Unclear","Hospital","Adverse Events","mAb",80
"NCT04275245","https://clinicaltrials.gov/show/NCT04275245","https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1.full.pdf","China","Beijing","2020-Jun",NA,"Completed w. Results","Single-Arm","Open-Label",1,"Confirmed",NA,"Unclear","Viral Load or Clearance, Pneumonia or ARDS, Fever, C-Reactive Protein, D-Dimer, PaO2-FiO2, Respiratory Rate, Radiographic Findings","mAb",20
"NCT04358588","https://ClinicalTrials.gov/show/NCT04358588",NA,"United States","New Jersey","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",NA,NA,NA,"Unclear",NA,"Non-invasive respiratory support",NA
"2020-001329-30","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001329-30/AT/",NA,"China","Beijing","2020-Apr",NA,"Recruiting","Randomised","Single",2,NA,NA,"ICU","PaO2-FiO2","Non-invasive respiratory support",200
"2020-001329-30","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001329-30/AT/",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Randomised","Single",2,NA,NA,"ICU","PaO2-FiO2","Non-invasive respiratory support",200
"IRCT20191125045492N2","http://en.irct.ir/trial/47149",NA,"Iran","Mazandaran","2020-Apr","2020-May","Completed","Randomised","Open-Label",2,NA,NA,"Unclear","Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein","Non-invasive respiratory support",80
"NCT04337918","https://ClinicalTrials.gov/show/NCT04337918",NA,"Canada","British Columbia","2020-Apr","2020-Jul","Recruiting","Randomised","Single",2,"Confirmed","Mixed","Healthy Unexposed, Outpatient","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Non-invasive respiratory support",200
"NCT04382768","https://ClinicalTrials.gov/show/NCT04382768",NA,"Argentina","Buenos Aires","2020-May","2021-Jan","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed Or Suspected","Unclear","Unclear","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Organ Failure or Dysfunction (SOFA), Adverse Events, Lymphocyte Count","NSAIDs",40
"RPCEC00000313","http://rpcec.sld.cu/en/trials/RPCEC00000313-En",NA,"Cuba","Havana","2020-May",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","ICU","Mortality, ICU Admission, Hospital Discharge","Other",16
"NCT04389385","https://ClinicalTrials.gov/show/NCT04389385",NA,"Turkey","Kayseri","2020-May","2020-Sep","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear","Unclear",NA,"Other",60
"CHICTR2000030761","http://www.chictr.org.cn/showproj.aspx?proj=50956",NA,"China","Shanghai","2020-Mar","2020-Apr","Not Recruiting","Single-Arm","Unspecified",1,"Confirmed","Severe","ICU","C-Reactive Protein, IL-6, IL-8, Tumor Necrosis Factor (Any)","Other",20
"NCT04378244","https://ClinicalTrials.gov/show/NCT04378244",NA,"United States","California","2020-May","2021-Jan","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear","Hospital","ICU Admission, Hospitalization","Other",18
"CHICTR2000033003","http://www.chictr.org.cn/showproj.aspx?proj=53790",NA,"China","Beijing","2020-May","2022-Apr","Not Recruiting","Single-Arm","Unspecified",1,"Healthy","None","Healthy Unexposed","Adverse Events","Other",25
"CHICTR2000030773","http://www.chictr.org.cn/showproj.aspx?proj=50934",NA,"China","Shanghai","2020-Mar","2020-Jul","Recruiting","Single-Arm","Unspecified",1,"Confirmed",NA,"ICU","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Other",20
"ACTRN12620000472976","https://anzctr.org.au/ACTRN12620000472976.aspx",NA,"Australia","Canberra","2020-Apr",NA,"Not Recruiting","Non-Randomised","Open-Label",NA,NA,NA,"Hospital","Other Mild Symptoms","Other",100
"NCT04319731","https://ClinicalTrials.gov/show/NCT04319731",NA,"United States","Utah","2020-Mar","2021-Mar","Recruiting","Single-Arm","Open-Label",1,"Confirmed",NA,"Hospital","Mortality, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, IL-6","Other",10
"NCT04389671","https://ClinicalTrials.gov/show/NCT04389671",NA,"United States","Pennsylvania","2020-May","2020-Oct","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","ICU","PaO2-FiO2, SpO2","Other",30
"CHICTR2000030477","http://www.chictr.org.cn/showproj.aspx?proj=50458",NA,"China","Beijing","2020-Mar","2020-Jun","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, IL-6, IL-10, Tumor Necrosis Factor (Any)","Other",19
"NCT04374591","https://ClinicalTrials.gov/show/NCT04374591",NA,"Egypt","Cairo","2020-May","2020-Jun","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Moderate","Hospital",NA,"Other",40
"CHICTR2000030029","http://www.chictr.org.cn/showproj.aspx?proj=49824",NA,"China","Zhejiang","2020-Feb","2020-May","Not Recruiting","Single-Arm","Unspecified",1,"Confirmed",NA,"Unclear","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","Other",20
"NCT04368377","https://ClinicalTrials.gov/show/NCT04368377",NA,"Italy","Milano","2020-Apr","2020-Apr","Completed","Single-Arm","Open-Label",1,NA,NA,"ICU","Hemoglobin, PaO2-FiO2","Other",5
"CHICTR2000029636","http://www.chictr.org.cn/showproj.aspx?proj=49215",NA,"China","Hubei","2020-Feb","2020-Jul","Recruiting","Single-Arm","Unspecified",1,"Confirmed",NA,"Hospital","Viral Load or Clearance, Cough, Fever, Other Mild Symptoms","Other",40
"NCT04370236","https://ClinicalTrials.gov/show/NCT04370236",NA,"United States","California","2020-Apr","2021-Jan","Not Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any)","Other",150
"CHICTR2000030503","http://www.chictr.org.cn/showproj.aspx?proj=49632",NA,"China","Zhejiang","2020-Mar",NA,"Recruiting","Non-Randomised","Unspecified",2,NA,NA,"ICU","Mortality, ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, IL-6, PaO2-FiO2","Other",60
"CHICTR2000029573","http://www.chictr.org.cn/showproj.aspx?proj=49065",NA,"China","Zhejiang","2020-Feb",NA,"Recruiting","Randomised","Unspecified",4,NA,NA,"Outpatient, Hospital","Mortality, Viral Load or Clearance, Pneumonia or ARDS, Radiographic Findings","Other",480
"NCT04388527","https://ClinicalTrials.gov/show/NCT04388527",NA,"United States","Pennsylvania","2020-May","2020-Aug","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Glucose","Plasma based therapy",50
"NCT04397757","https://ClinicalTrials.gov/show/NCT04397757",NA,"United States","Pennsylvania","2020-May","2020-Sep","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Glucose","Plasma based therapy",80
"NCT04321421","https://ClinicalTrials.gov/show/NCT04321421",NA,"Italy","Pavia","2020-Mar","2020-Apr","Completed","Single-Arm","Open-Label",1,"Confirmed","Severe","ICU","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Antibodies","Plasma based therapy",49
"NCT04321421","https://ClinicalTrials.gov/show/NCT04321421",NA,"Italy","Mantova","2020-Mar","2020-Apr","Completed","Single-Arm","Open-Label",1,"Confirmed","Severe","ICU","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Antibodies","Plasma based therapy",49
"NCT04384497","https://ClinicalTrials.gov/show/NCT04384497",NA,"Sweden","Stockholm","2020-May","2020-Jun","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","Fever, Adverse Events, Antibodies","Plasma based therapy",50
"NCT04397523","https://ClinicalTrials.gov/show/NCT04397523",NA,"Macedonia","Skopje","2020-May","2021-Apr","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","ICU","Mortality, ICU Admission, Adverse Events","Plasma based therapy",20
"NCT04355897","https://ClinicalTrials.gov/show/NCT04355897",NA,"United States","Ohio","2020-Apr","2020-Jul","Recruiting","Single-Arm","Open-Label",1,NA,NA,"Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy",100
"NCT04392232","https://ClinicalTrials.gov/show/NCT04392232",NA,"United States","Ohio","2020-May","2020-Dec","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital",NA,"Plasma based therapy",100
"NCT04347681","https://ClinicalTrials.gov/show/NCT04347681",NA,"Saudi Arabia","Riyadh","2020-Apr","2020-Dec","Recruiting","Non-Randomised","Open-Label",2,NA,NA,"Hospital, ICU","Mortality, ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events","Plasma based therapy",40
"NCT04390178","https://ClinicalTrials.gov/show/NCT04390178",NA,"Sweden","Stockholm","2020-May","2020-Jun","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Mild/Moderate","Hospital","Fever, Adverse Events, Antibodies","Plasma based therapy",10
"NCT04389710","https://ClinicalTrials.gov/show/NCT04389710",NA,"United States","Pennsylvania","2020-May","2021-Apr","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","ICU","ICU Admission, Hospitalization, Hospital Discharge, Adverse Events, C-Reactive Protein, Platelet Count, D-Dimer, Prothrombin, Fibrinogen","Plasma based therapy",100
"NCT04389944","https://ClinicalTrials.gov/show/NCT04389944",NA,"Switzerland","Bern","2020-May","2020-Jun","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Hospital Discharge, Adverse Events","Plasma based therapy",15
"NCT04377672","https://ClinicalTrials.gov/show/NCT04377672",NA,"United States","Maryland","2020-May","2021-May","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed Or Healthy","Healthy or unclear","Healthy Exposed, Unclear","Adverse Events, Antibodies","Plasma based therapy",30
"NCT04374565","https://ClinicalTrials.gov/show/NCT04374565",NA,"United States","Virginia","2020-May","2021-Apr","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Antibodies, Renal Outcome (Unspecified)","Plasma based therapy",29
"NCT04375098","https://ClinicalTrials.gov/show/NCT04375098",NA,"Chile","Santiago","2020-May","2020-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever","Plasma based therapy",30
"NCT04372368","https://ClinicalTrials.gov/show/NCT04372368",NA,"United States","Colorado","2020-May",NA,"Recruiting","Unspecified","Unspecified",NA,"Confirmed",NA,"Hospital",NA,"Plasma based therapy",NA
"NCT04363034","https://ClinicalTrials.gov/show/NCT04363034",NA,"United States","Arkansas","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",NA,NA,NA,"ICU",NA,"Plasma based therapy",NA
"NCT04356482","https://ClinicalTrials.gov/show/NCT04356482",NA,"Mexico","Jalisco","2020-Apr","2020-Nov","Not Recruiting","Single-Arm","Open-Label",1,NA,NA,"Hospital","ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Adverse Events","Plasma based therapy",90
"NCT04356482","https://ClinicalTrials.gov/show/NCT04356482",NA,"Mexico","Sonora","2020-Apr","2020-Nov","Not Recruiting","Single-Arm","Open-Label",1,NA,NA,"Hospital","ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Adverse Events","Plasma based therapy",90
"NCT04356482","https://ClinicalTrials.gov/show/NCT04356482",NA,"Mexico","Mexico","2020-Apr","2020-Nov","Not Recruiting","Single-Arm","Open-Label",1,NA,NA,"Hospital","ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Adverse Events","Plasma based therapy",90
"NCT04360486","https://ClinicalTrials.gov/show/NCT04360486",NA,"United States","Virginia","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",NA,NA,NA,"Hospital",NA,"Plasma based therapy",NA
"NCT04358211","https://ClinicalTrials.gov/show/NCT04358211",NA,"United States","Louisiana","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",NA,NA,NA,"ICU",NA,"Plasma based therapy",NA
"NCT04357106","https://ClinicalTrials.gov/show/NCT04357106",NA,"Mexico","Puebla","2020-Apr","2020-Jul","Recruiting","Single-Arm","Open-Label",1,NA,NA,"ICU","Mortality, Adverse Events, PaO2-FiO2","Plasma based therapy",10
"IRCT20200406046968N2","http://en.irct.ir/trial/47115",NA,"Iran","East Azarbaijan","2020-Apr","2020-Jul","Recruiting","Single-Arm","Open-Label",1,NA,NA,"Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Plasma based therapy",30
"NCT04365439","https://clinicaltrials.gov/show/NCT04365439",NA,"Switzerland","Ticino","2020-Apr",NA,"Not Recruiting","Single-Arm","Open-Label",1,NA,NA,"Hospital","Viral Load or Clearance, IL-6, Antibodies","Plasma based therapy",10
"NCT04393727","https://clinicaltrials.gov/show/NCT04393727",NA,"Italy","Rome","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Moderate","Hospital","Invasive Mechanical Ventilation or ECMO","Plasma based therapy",126
"NCT04358003","https://clinicaltrials.gov/show/NCT04358003",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Single-Arm","Open-Label",1,NA,NA,"ICU","Mortality, Organ Failure or Dysfunction (SOFA)","Plasma based therapy",2000
"IRCT20200414047072N1","http://en.irct.ir/trial/47163",NA,"Iran","Tehran","2020-Apr","2021-Apr","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital, ICU","Viral Load or Clearance, Fever, Dyspnea, Organ Failure or Dysfunction (SOFA), Respiratory Rate, Radiographic Findings","Plasma based therapy",357
"NCT04352751","https://ClinicalTrials.gov/show/NCT04352751",NA,"Pakistan","Sind","2020-Apr","2021-Apr","Recruiting","Single-Arm","Open-Label",1,NA,NA,"Hospital, ICU","Clinical Improvement Score (Any), Dyspnea, Other Mild Symptoms","Plasma based therapy",2000
"CHICTR2000030849","http://www.chictr.org.cn/showproj.aspx?proj=51086",NA,"China","Henan","2020-Mar","2021-Mar","Not Recruiting","Single-Arm","Unspecified",1,"Confirmed",NA,"Outpatient","Depression, Anxiety","Psychological therapy",81
"NCT04394793","https://ClinicalTrials.gov/show/NCT04394793",NA,"India","Delhi","2020-May","2021-Jan","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Moderate/Severe","Hospital","Mortality, ICU Admission, Hospitalization","Radiation therapy",10
"NCT04366791","https://ClinicalTrials.gov/show/NCT04366791",NA,"United States","Georgia","2020-Apr","2020-Jun","Recruiting","Single-Arm","Open-Label",1,NA,NA,"Hospital","C-Reactive Protein, Ferritin, IL-6, Hemoglobin, D-Dimer, eGFR, Myoglobin, Troponin, Procalcitonin, Fibrinogen, Triglycerides, ALT, AST, Albumin, Bilirubin, LDH, Blood Gas, Blood Pressure, Heart Rate, PaO2-FiO2, Radiographic Findings, Blood pH, Cardiac Outcome (Unspecified)","Radiation therapy",10
"NCT04390412","https://ClinicalTrials.gov/show/NCT04390412",NA,"Iran","Tehran","2020-May","2020-Aug","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Unclear","ICU Admission, Hospitalization, C-Reactive Protein, IL-6, Platelet Count, Erythrocyte Sedimentation Rate, Radiographic Findings","Radiation therapy",5
"IRCT20170211032494N3","http://en.irct.ir/trial/47735",NA,"Iran","Tehran","2020-May","2020-Jun","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","IL-1, SpO2","Radiation therapy",10
"NCT04377477","https://ClinicalTrials.gov/show/NCT04377477",NA,"Italy","Brescia","2020-May","2021-May","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear","Unclear","ICU Admission, Hospitalization, Adverse Events, Radiographic Findings","Radiation therapy",30
"NCT04394182","https://clinicaltrials.gov/show/NCT04394182",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Single-Arm","Open-Label",1,"Confirmed","Moderate","Hospital","SpO2","Radiation therapy + Non-invasive respiratory support + LPV/r + HCQ + AZT + Other + Anticoagulants + Corticosteroids + TCZ",15
"NCT04302766","https://ClinicalTrials.gov/show/NCT04302766",NA,"United States","Virginia","2020-Mar",NA,"Recruiting","Unspecified","Unspecified",NA,"Confirmed","Mixed","Unclear",NA,"Remdesivir",NA
"CHICTR2000030433","http://www.chictr.org.cn/showproj.aspx?proj=50273",NA,"China","Fujian","2020-Mar","2020-Oct","Not Recruiting","Single-Arm","Unspecified",1,"Recovered",NA,"Resolved Discharged","Quality of Life","Respiratory support",80
"NCT04395716","https://ClinicalTrials.gov/show/NCT04395716",NA,"United States","California","2020-May","2021-May","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","ECG, SpO2","Respiratory support",50
"NCT04360837","https://ClinicalTrials.gov/show/NCT04360837",NA,"Hungary","Szeged","2020-Apr","2021-Jun","Recruiting","Single-Arm","Open-Label",1,NA,NA,"Hospital","Clinical Improvement Score (Any), PaO2-FiO2","Respiratory support",10
"NCT04338958","https://ClinicalTrials.gov/show/NCT04338958",NA,"Germany","Berlin","2020-Apr","2021-Jan","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","Viral Load or Clearance, Antibodies","Ruxolitinib",200
"NCT04386239","https://ClinicalTrials.gov/show/NCT04386239",NA,"Italy","Milano","2020-May","2020-Dec","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","Viral Load or Clearance, Fever, Tumor Necrosis Factor (Any)","Sarilumab",40
"NCT04352803","https://ClinicalTrials.gov/show/NCT04352803",NA,"United States","Massachusetts","2020-Apr","2024-Apr","Not Recruiting","Non-Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Stem cells",20
"NCT04313322","https://ClinicalTrials.gov/show/NCT04313322",NA,"Jordan","Amman","2020-Mar","2020-Jun","Recruiting","Single-Arm","Open-Label",1,"Confirmed",NA,"Unclear","Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, Radiographic Findings","Stem cells",5
"NCT04302519","https://ClinicalTrials.gov/show/NCT04302519",NA,"China","Beijing","2020-Mar","2021-Jun","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","PaO2-FiO2, Radiographic Findings, Hypoxia, Hypoxemia","Stem cells",24
"IRCT20140911019125N6","http://en.irct.ir/trial/46668",NA,"Iran","Kerman","2020-Apr","2020-Oct","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear","Unclear","Viral Load or Clearance","Stem cells",10
"IRCT20190717044241N2","http://en.irct.ir/trial/47110",NA,"Iran","Tehran","2020-Apr","2020-Jul","Recruiting","Single-Arm","Open-Label",1,NA,NA,"ICU","PaO2-FiO2","Stem cells",10
"NCT04370834","https://ClinicalTrials.gov/show/NCT04370834",NA,"United States","New York","2020-May","2022-Jan","Not Recruiting","Single-Arm","Open-Label",1,NA,NA,"Hospital",NA,"TCZ",200
"NCT04363736","https://ClinicalTrials.gov/show/NCT04363736",NA,"United States","Massachusetts","2020-Apr","2020-Jun","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, C-Reactive Protein, Ferritin, IL-6","TCZ",100
"2020-001995-13","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001995-13/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Unspecified","Open-Label",NA,"Confirmed","Moderate/Severe","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, D-Dimer, Procalcitonin, PaO2-FiO2, SpO2, Radiographic Findings, Renal Outcome (Unspecified)","TCZ",NA
"NCT04315480","https://clinicaltrials.gov/show/NCT04315480",NA,"Italy","Rome","2020-Mar",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2","TCZ",38
"JPRN-JAPICCTI-205270","https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-205270",NA,"Japan","Tokyo","2020-Apr",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6","TCZ",10
"NL8504","https://trialregister.nl/trial/8504",NA,"Netherlands","Amsterdam","2020-Mar",NA,"Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Anti SARS-COV-2 Titers, C-Reactive Protein, Ferritin, IL-6, IL-8, Radiographic Findings","TCZ",354
"IRCT20151227025726N13","http://en.irct.ir/trial/46681",NA,"Iran","Tehran","2020-Mar","2020-May","Completed","Single-Arm","Open-Label",1,"Confirmed","Mixed","Hospital","Hospitalization, Viral Load or Clearance, Cough, Fever, Dyspnea, Treatment-emergent Adverse Events, Radiographic Findings","TCZ + LPV/r + HCQ",40
"CHICTR2000032098","http://www.chictr.org.cn/showproj.aspx?proj=52477",NA,"China","Hubei","2020-Apr","2020-Jul","Recruiting","Single-Arm","Unspecified",1,NA,NA,"Unclear","Viral Load or Clearance, C-Reactive Protein, Radiographic Findings","TCM",300
"CHICTR2000030490","http://www.chictr.org.cn/showproj.aspx?proj=50487",NA,"China","Hubei","2020-Mar","2020-Mar","Recruiting","Single-Arm","Unspecified",1,"Confirmed Or Suspected","Severe","Unclear","Viral Load or Clearance","TCM",100
"JPRN-UMIN000040407","https://rctportal.niph.go.jp/en/detail?trial_id=UMIN000040407",NA,"Japan","Tokyo","2020-May",NA,"Completed","Single-Arm","Open-Label",NA,"Confirmed","Unclear","Unclear",NA,"TCM",15
"CHICTR2000030314","http://www.chictr.org.cn/showproj.aspx?proj=50248",NA,"China","Hubei","2020-Feb","2020-Apr","Not Recruiting","Single-Arm","Unspecified",1,"Confirmed",NA,"Unclear","Cough, Fever, Dyspnea","TCM",40
"CHICTR2000030386","http://www.chictr.org.cn/showproj.aspx?proj=50323",NA,"China","Hunan","2020-Feb","2020-Dec","Not Recruiting","Single-Arm","Unspecified",1,"Healthy (Exposed Or Unexposed)","Healthy","Healthy Exposed","Quality of Life","TCM",1000
"JPRN-UMIN000040341","https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046023",NA,"Japan","Tokyo","2020-Sep",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear","Unclear",NA,"TCM",15
"CHICTR2000030864","http://www.chictr.org.cn/showproj.aspx?proj=50662",NA,"China","Hubei","2020-Mar","2020-Jul","Recruiting","Single-Arm","Unspecified",1,"Confirmed",NA,"Unclear","Viral Load or Clearance, Pneumonia or ARDS, White Blood Cell Count, Monocyte Count, Natural Killer Cell Count, Creatinine Phosphokinase, CK-MB, eGFR, ALT, Albumin, Bilirubin, Glucose, Radiographic Findings","TCM",50
"CHICTR2000030896","http://www.chictr.org.cn/showproj.aspx?proj=51028",NA,"China","Henan","2020-Mar","2021-Mar","Recruiting","Single-Arm","Unspecified",1,"Confirmed","Non-severe","Unclear","Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, Radiographic Findings","TCM",24
"CHICTR2000030219","http://www.chictr.org.cn/showproj.aspx?proj=50110",NA,"China","Tianjin","2020-Feb","2020-Dec","Recruiting","Single-Arm","Unspecified",1,"Confirmed",NA,"Unclear","Viral Load or Clearance, C-Reactive Protein, Radiographic Findings","TCM",120
"NCT04353518","https://ClinicalTrials.gov/show/NCT04353518",NA,"India","Chandigarh","2020-Apr","2021-Mar","Not Recruiting","Randomised","Quadruple",2,NA,NA,"Healthy Unexposed","Serious or Seconday Infections, Adverse Events, Serious Adverse Events","Treated mycobacterium",4000
"NCT04299724","https://ClinicalTrials.gov/show/NCT04299724",NA,"China","Guangdong","2020-Mar","2023-Jul","Recruiting","Single-Arm","Open-Label",1,"Confirmed And Healthy",NA,"Healthy Unexposed, Healthy Exposed, Outpatient","Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Treatment-emergent Adverse Events, C-Reactive Protein","Vaccine",100
"IRCT20140428017469N1","http://en.irct.ir/trial/47989",NA,"Iran","Fars","2020-May","2020-Jul","Not Recruiting","Single-Arm","Open-Label",1,"Healthy","None","Healthy Exposed",NA,"Vaccine",130000
"NCT04276896","https://ClinicalTrials.gov/show/NCT04276896",NA,"China","Guangdong","2020-Feb","2023-Jul","Recruiting","Single-Arm","Open-Label",1,"Confirmed",NA,"Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Radiographic Findings","Vaccine",100
"NCT04380532","https://ClinicalTrials.gov/show/NCT04380532",NA,"Canada","British Columbia","2020-May","2021-May","Not Recruiting","Single-Arm","Open-Label",1,"Healthy","None","Healthy Unexposed","Adverse Events, Platelet Count, Radiographic Findings","Vaccine",20
"NCT04380532","https://ClinicalTrials.gov/show/NCT04380532",NA,"Mongolia","Ulaanbaatar","2020-May","2021-May","Not Recruiting","Single-Arm","Open-Label",1,"Healthy","None","Healthy Unexposed","Adverse Events, Platelet Count, Radiographic Findings","Vaccine",20
"NCT04323514","https://ClinicalTrials.gov/show/NCT04323514",NA,"Italy","Palermo","2020-Mar","2021-Mar","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Peak RRadiographic Findings","Vitamins",500
"NCT04324489","https://ClinicalTrials.gov/show/NCT04324489",NA,"China","Hubei","2020-Mar","2020-Apr","Completed","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation",NA,4
"CHICTR2000030041","http://www.chictr.org.cn/showproj.aspx?proj=49891",NA,"China","Hubei","2020-Feb","2020-Jun","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Mixed","Hospital","Viral Load or Clearance",NA,40
"NCT04334967","https://ClinicalTrials.gov/show/NCT04334967",NA,"United States","Oregon","2020-Apr","2020-May","Suspended","Randomised","Single",2,"Confirmed","Non-severe","Outpatient","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea",NA,13
"NCT04338126","https://ClinicalTrials.gov/show/NCT04338126",NA,"United States","Alabama","2020-Apr","2020-Oct","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Unspecified","Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms",NA,60
"NCT04338828","https://ClinicalTrials.gov/show/NCT04338828",NA,"United States","Massachusetts","2020-Apr","2021-Apr","Recruiting","Randomised","Triple",2,"Suspected","Mixed","Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events",NA,260
"NCT04381936","https://ClinicalTrials.gov/show/NCT04381936",NA,"United Kingdom","London","2020-May","2020-Dec","Recruiting","Randomised","Open-Label",5,"Confirmed","Mixed","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Renal Outcome (Unspecified)",NA,12000
"NCT04344951","https://ClinicalTrials.gov/show/NCT04344951",NA,"Greece","Athens","2020-Apr","2021-Apr","Recruiting","Single-Arm","Open-Label",1,NA,NA,"Outpatient, Hospital","Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, PaO2-FiO2",NA,60
"NCT04343144","https://ClinicalTrials.gov/show/NCT04343144",NA,"France","Paris","2020-Apr","2020-Jul","Not Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events, Serious Adverse Events",NA,92
"NCT04338698","https://ClinicalTrials.gov/show/NCT04338698",NA,"Pakistan","Islamabad","2020-Apr","2020-Sep","Not Recruiting","Randomised","Double",3,"Confirmed","Mixed","Unclear","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO",NA,500
"NCT04340557","https://ClinicalTrials.gov/show/NCT04340557",NA,"United States","California","2020-Apr","2020-Oct","Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6",NA,200
"NCT04337541","https://ClinicalTrials.gov/show/NCT04337541",NA,"Denmark","Copenhagen","2020-Apr","2020-Jul","Recruiting","Randomised","Open-Label",2,"Healthy","Healthy","Healthcare Workers, Outpatient","Viral Load or Clearance, Antibodies",NA,6000
"NCT04336254","https://ClinicalTrials.gov/show/NCT04336254",NA,"China","Hubei","2020-Apr","2020-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Severe","Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Treatment-emergent Adverse Events, C-Reactive Protein, Respiratory Rate, Radiographic Findings",NA,20
"NCT04335201","https://ClinicalTrials.gov/show/NCT04335201",NA,"Italy","Milano","2020-Apr","2020-Sep","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Mixed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, IL-6, IL-10, Tumor Necrosis Factor (Any), Interferon (Any), LDH",NA,50
"CHICTR2000031630","http://www.chictr.org.cn/showproj.aspx?proj=50474",NA,"China","Guangdong","2020-Apr","2020-Jun","Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Unspecified","Unclear",NA,NA,60
"CHICTR2000031494","http://www.chictr.org.cn/showproj.aspx?proj=51904",NA,"China","Hubei","2020-Apr","2020-Dec","Recruiting","Single-Arm","Unspecified",2,"Confirmed","Severe","Unclear","Radiographic Findings",NA,36
"2020-001243-15","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001243-15/BE/",NA,"Belgium","Brussels","2020-Mar",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO",NA,NA
"2020-001156-18","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001156-18/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",3,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO",NA,NA
"2020-001271-33","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001271-33/FR/",NA,"France","Paris","2020-Mar",NA,"Recruiting","Randomised","Double",2,"Confirmed","Unspecified","Hospital","Mortality, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, C-Reactive Protein, IL-1, IL-2, IL-4, IL-6, IL-8, Tumor Necrosis Factor (Any), IgG, IgM or IgA, Antibodies",NA,NA
"2020-001194-69","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001194-69/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Double",2,"Healthy","Healthy","Healthy Exposed","Mortality, Viral Load or Clearance",NA,NA
"2020-001307-16","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001307-16/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO",NA,NA
"2020-001606-33","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001606-33/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Non-severe","Unclear","Mortality, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Fever, Adverse Events, Treatment-emergent Adverse Events, Ferritin, D-Dimer, LDH, PaO2-FiO2, Respiratory Rate",NA,NA
"IRCT20200321046828N1","http://en.irct.ir/trial/46624",NA,"Iran","Tehran","2020-Mar","2020-Mar","Completed","Non-Randomised","Open-Label",6,NA,NA,"Hospital","Fever, Radiographic Findings",NA,30
"IRCT20140617018126N2","http://en.irct.ir/trial/46637",NA,"Iran","East Azarbaijan","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",2,"Confirmed","Unspecified","Hospital","C-Reactive Protein, White Blood Cell Count, Respiratory Rate",NA,60
"IRCT20160316027081N1","http://en.irct.ir/trial/46678",NA,"Iran","Fars","2020-Mar","2020-Apr","Completed","Randomised","Double",2,"Confirmed","Unspecified","Hospital","Mortality, Hospital Discharge, Respiratory Rate",NA,374
"IRCT20200323046841N1","http://en.irct.ir/trial/46715",NA,"Iran","Tehran","2020-Mar","2020-May","Completed","Randomised","Triple",2,"Confirmed","Unspecified","Hospital","Clinical Improvement Score (Any)",NA,60
"IRCT20180923041093N3","http://en.irct.ir/trial/46721",NA,"Iran","Tehran","2020-Mar","2020-May","Completed","Randomised","Open-Label",2,"Confirmed","Unspecified","Outpatient","Mortality, Hospitalization, Cough, Fever, Other Mild Symptoms, Respiratory Rate",NA,100
"IRCT20200324046850N5","http://en.irct.ir/trial/46751",NA,"Iran","Tehran","2020-Apr","2020-May","Completed","Randomised","Double",2,"Confirmed","Unspecified","Hospital","Mortality, Hospitalization, Cough, Fever, Respiratory Rate",NA,40
"IRCT20200325046860N1","http://en.irct.ir/trial/46759",NA,"Iran","Tehran","2020-Mar","2020-Aug","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital","Respiratory Rate",NA,200
"IRCT20200317046797N2","http://en.irct.ir/trial/46786",NA,"Iran","Tehran","2020-Apr","2020-May","Completed","Randomised","Open-Label",2,"Confirmed","Unspecified","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Cough, Dyspnea",NA,40
"IRCT20180802040678N4","http://en.irct.ir/trial/46824",NA,"Iran","Tehran","2020-Apr","2020-Apr","Completed","Randomised","Open-Label",2,"Confirmed","Unspecified","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any)",NA,100
"IRCT20150704023055N2","http://en.irct.ir/trial/46837",NA,"Iran","Mazandaran","2020-Apr","2020-Apr","Completed","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospital, ICU","Clinical Improvement Score (Any), IL-6",NA,10
"NCT04338802","https://clinicaltrials.gov/show/NCT04338802",NA,"China","Hubei","2020-Jan",NA,"Not Recruiting","Randomised","Open-Label",1,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO",NA,96
"NCT04340414","https://clinicaltrials.gov/show/NCT04340414",NA,"China","Beijing","2020-Mar",NA,"Recruiting","Single-Arm","Open-Label",1,NA,NA,"Hospital","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6",NA,10
"NCT04344548","https://clinicaltrials.gov/show/NCT04344548",NA,"Colombia","Bogota","2020-Oct",NA,"Not Recruiting","Single-Arm","Open-Label",1,NA,NA,"Outpatient","ICU Admission, Hospitalization, Hospital Discharge, Viral Load or Clearance, Household Members with CoViD-19, Labor Absenteeism, Adverse Events, Treatment-emergent Adverse Events",NA,10
"JPRN-JRCTS031190269","https://jrct.niph.go.jp/latest-detail/jRCTs031190269",NA,"Japan","Toyama","2020-Mar",NA,"Recruiting","Randomised","Open-Label",NA,"Yes","Unspecified","Outpatient","Viral Load or Clearance, Pneumonia or ARDS, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events",NA,90
"NL8490","https://trialregister.nl/trial/8490",NA,"Netherlands","Amsterdam","2020-Mar",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events",NA,950
"NL8491","https://trialregister.nl/trial/8491",NA,"Netherlands","Amsterdam","2020-Mar",NA,"Recruiting","Randomised","Double",2,"Confirmed","Severe","Hospital","Mortality, ICU Admission, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, Albumin, PaO2-FiO2",NA,386
"NCT04336748","https://ClinicalTrials.gov/show/NCT04336748",NA,"Austria","Vienna","2020-Apr","2020-Jul","Not Recruiting","Randomised","Triple",2,"Healthy","Healthy","Healthcare Workers","Viral Load or Clearance, Labor Absenteeism",NA,440
